Do abnormalities in dynamic cerebral auto-regulation

underlie the pathophysiological processes behind syncope in older people? by Ong, Alice
  
 
 
Do abnormalities in dynamic 
cerebral auto-regulation 
underlie the 
pathophysiological processes 
behind syncope in older 
people? 
Alice C. L. Ong 
Faculty of Medicine & Health Sciences 
PhD Thesis  2014 
This copy of the thesis has been supplied on condition that anyone who consults it is 
understood to recognize that its copyright rests with the author and that use of any 
information derived there from must be in accordance with current UK Copyright Law. In 
addition, any quotation or extract must include full attribution. 
 
 
 i 
 
Abstract 
Do abnormalities in dynamic cerebral auto-regulation underlie the 
pathophysiological processes behind syncope in older people? 
Introduction: The aim of this thesis was to investigate whether abnormalities in 
dynamic cerebral auto-regulation (dCA) explain the symptoms associated with 
orthostatic (OH) and post-prandial hypotension (PPH).  
Methods: Based on clinical symptoms and signs for the OH study: 4 Groups: 
Asymptomatic No OH (control), Symptomatic No OH, Asymptomatic OH, and 
Symptomatic OH. PPH study: double-blind placebo controlled cross-over study of 
glucose (50g) drink.  2 Groups: No PPH (control) and PPH. Baseline and head-up-tilt 
(HUT, for OH maximum 30 minutes study or to symptoms; PPH study maximum 60 
minutes per visit).  All had Transcranial Doppler ultrasound, beat-to-beat BP, ECG and 
CO2 monitoring. Baseline autonomic function, arterial stiffness, cardiac baroreceptor 
sensitivity (BRS) were calculated and dynamic cerebral auto-regulation (as the auto-
regulatory index ARI) assessed before and during tilt.  
Results: OH: n=85, mean age 73.9±7.1 years; PPH: n= 40, mean age 73.4±7.3 years 
Baseline: No significant differences were found between groups for cardiac BRS, 
arterial stiffness, cerebral blood flow velocity (CBFV) or dCA in either study. HUT 
both studies: falls in BP, CO2 and CBFV, increases in HR, and fall in ARI amongst 
symptomatic subjects prior to the end of HUT (maximum duration or symptom onset) 
compared to pre-HUT values. PPH study: fall in ARI with HUT irrespective of 
whether glucose or placebo phase. 
Conclusions: The development of symptoms during tilt in both studies was related to a 
fall in CBFV and impaired cerebral auto-regulation.  Abnormalities in cerebral auto-
regulation may explain the symptoms of OH and PPH although these changes can only 
be detected during head-up-tilt. 
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1 Introduction 
Syncope can be defined as a “transient loss of consciousness due to transient global 
cerebral hypoperfusion characterised by rapid onset, short duration, and spontaneous 
complete recovery”(Moya et al., 2009). Although some may be familiar with the 
following: “The only difference between syncope and sudden death is that in one you 
wake up.” (Engel, 1978) 
 
Syncope has many causes, and some, but not all, are associated with reduced survival 
as illustrated by Figure 1 (Soteriades et al., 2002). Orthostatic hypotension (OH) and 
post-prandial hypotension (PPH) are common causes of syncope in older populations, 
and are associated with significant morbidity (Vaitkevicius et al., 1991) and in the case 
of orthostatic hypotension can increase mortality (Fedorowski et al., 2010, Rose et al., 
2006). However some people can experience symptoms of OH or PPH without 
necessarily having a fall in systemic BP levels whilst others can have a systemic BP 
drop but no symptoms (Moya et al., 2009, Mader et al., 1987). The pathophysiological 
reasons for why some experience symptoms and others do not is unclear and less well 
researched despite its potential importance, as this knowledge may assist in the future 
development of new therapeutic pathways.   
 
This thesis aims to explore firstly, whether abnormalities in dynamic cerebral auto-
regulation explain the symptoms of post-prandial and orthostatic hypotension, and 
secondly to systematically review the effects of pharmacological treatment for OH and 
PPH which may potentially highlight the underlying pathophysiological mechanisms 
for symptom production.  
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Figure 1 Reduced probability of survival with syncope of differing aetiology over a 25 year period (Adapted 
from Figure 2 in Soteriades et al, 2002)[The Kaplan Meier survival curves demonstrate that those with 
cardiac syncope have a lower survival than those without syncope] 
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2 Background 
2.1 Orthostatic Hypotension and Post-Prandial Hypotension in 
the context of Syncope 
Syncope can be classified according to three primary categories related to causation: 1) 
those which are neurally-mediated, 2) those due to orthostatic hypotension, and 3) 
those with a cardiac basis for syncope (Moya et al., 2009). Neurally-mediated syncope 
relates to conditions where there is an inappropriate vasodilatation and/or bradycardia, 
resulting in a fall in systemic blood pressure (BP) and presumably a resulting decrease 
in cerebral blood flow (CBF) in response to a trigger or carotid sinus hypersensitivity. 
It is considered to be, 1) vasodepressor where there is a fall in BP as a result in a 
reduction in the vasoconstrictor tone, 2) cardio-inhibitory where bradycardia or 
asystole is more prominent and 3) mixed if both vasodepressor and cardio-inhibitory 
signs are present. Neurally-mediated (or reflex) syncope includes vasovagal syncope 
which can be due to both emotional stress e.g. pain or orthostatic stress, as well as that 
directly related to a specific situation e.g. coughing, post-prandial hypotension, post-
voiding of urine (i.e. post-micturition syncope). Orthostatic hypotension (OH) has a 
complex underlying pathophysiology and can be related to primary autonomic failure, 
and secondary autonomic failure, as shown in Table 1. However the complex nature of 
OH means there are many other causes including drugs e.g. diuretics, and volume 
depletion e.g. due to diarrhoea. The current classification recommended by the 
European Society of Cardiology is shown in Table 1 (Moya et al., 2009).  
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Neurally-
mediated 
(reflex) syncope 
Vasovagal Emotional e.g. fear, pain 
Orthostatic  
Situational Cough, sneeze 
Gastrointestinal stimulation e.g. swallow, 
defaecation, visceral pain 
Micturition (post-voiding) 
Post-exercise 
Post-prandial 
Others e.g. laughter, playing brass 
instruments, weightlifting 
Carotid sinus syncope 
Atypical 
Orthostatic 
hypotension 
Primary autonomic failure Pure autonomic failure 
Multiple system atrophy 
Parkinson’s disease with autonomic failure 
Lewy body dementia 
Secondary autonomic failure Diabetes mellitus 
Amyloidosis 
Uraemia 
Spinal cord injury 
Drug-induced Alcohol 
Vasodilators 
Diuretics 
Phenothiazines 
Anti-depressants 
Volume depletion e.g. haemorrhage, diarrhoea, vomiting 
Cardiac syncope Primary 
arrhythmia 
Bradycardia Sinus node dysfunction 
Atrioventricular conduction system disease 
Implanted device malfunction 
Tachycardia Supraventricular 
Ventricular  Idiopathic 
Secondary to 
structural heart 
disease 
Channelopathies  
Drug induced bradycardia or tachyarrhythmia 
Structural 
disease 
Cardiac Valvular disease 
Acute myocardial infarction or ischaemia 
Hypertrophic cardiomyopathy 
Cardiac mass e.g. atrial myxoma 
Pericardial disease or tamponade 
Congenital anomalies of coronary arteries 
Prosthetic valve disease 
Others  Pulmonary embolus 
Acute aortic dissection 
Pulmonary hypertension 
Table 1 The Classification of Syncope by the European Society of Cardiology (2009)(Moya et al., 2009) 
   
 5 
 
Figure 1 in the previous section illustrates the reduced survival associated with some 
causes of syncope. In particular a cardiac cause of syncope confers a large reduction in 
survival, with a survival probability of 0.4 at 10 years compared to 0.8 for no syncope 
or vasovagal and other causes (Soteriades et al., 2002). From the Framingham study 
cohort (n=7814, mean age 51.1 ±14.4 years), the incidence of a the first report of 
syncope (n=822, n=727 in outcome analysis, mean age 65.8 years) has been estimated 
at 6.2 per 1000 person-years, with 36.6% of cases having an unknown cause, 21.2% 
vasovagal, 9.5% cardiac and 9.4% orthostatic (Soteriades et al., 2002). Thus it can be 
seen that the classification of syncope can have a significant impact on an individual 
person’s life expectancy. 
 
2.2 Orthostatic Hypotension (OH) 
2.2.1 Definition 
The many types of OH, as described by the European Society of Cardiology (ESC), 
reflect the complex nature of orthostatic hypotension with its multi-factorial 
underlying pathophysiological origins (Moya et al., 2009). On the one hand it defines 
OH as “an abnormal decrease in systolic BP upon standing”, the magnitude of BP fall 
dependent on the sub-type of OH. However the associated signs and symptoms are 
described simply as “orthostatic intolerance”.  
 
Some individuals lack symptoms despite a postural fall in systemic BP (usually 
measured in the brachial artery) defined as “Classical OH” by the European Society of 
Cardiology. This is simply described as a systolic blood pressure (SBP) reduction of 
≥20mmHg and/or a diastolic blood pressure (DBP) reduction of ≥10mmHg within a 
 6 
 
period of 3 minutes of standing from a supine position, symptoms are not considered 
as a necessary component in this definition. However the ESC definition of “Initial 
OH” requires a fall in SBP of ≥40mmHg accompanied by transient symptoms lasting 
less than 30 seconds. The entity of “Delayed OH” is characterised by the progressive 
fall in SBP alone, after standing for several minutes and may include the presence or 
absence of symptoms (Moya et al., 2009). There has been the suggestion that because 
OH is likely to represent a wide range of underlying causes, it could be classified using 
modelflow measures of total peripheral resistance (TPR) and cardiac output (CO) to 
produce physiological types (Deegan et al., 2007). Where there is a large drop in TPR 
then it would be calssified as “arteriolar”, where the drop was mostly in terms of CO, 
then it could be classed as “venular”, and if both TPR and CO were involved, it would 
be classed as  “mixed”(Deegan et al., 2007).  
 
However, the complexity of orthostatic hypotension is further burdened by whether the 
falls in SBP and DBP should include changes associated in beat-to-beat measurments 
of BP, which is often done in research, and can therefore provide a higher estimate of 
the prevalence of OH within a population than cuff measurements(van der Velde et al., 
2007, Cooke et al., 2013). The consensus statement published during the period of this 
thesis also takes into account the use of beat-to-beat monitoring, by considering initial 
OH to be that which occurs within 15 seconds of standing, or passive tilting, and is the 
result of conflicting CO and TPR (Freeman et al., 2011). The 2011 consensus also 
recgonises delayed OH in both active standing and passive tilting, as that which occurs 
after 3 minutes (Freeman et al., 2011). 
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More recently, there has been a suggestion for dividing OH into morphological types 
depending on the slope of SBP and DBP decay, and their proportionate recovery from 
baseline i.e. “small drop, overshoot”, “medium drop, slow recovery” and “large drop, 
nonrecovery (Cooke et al., 2013). Of course, there is the ongoing debate, as to how 
long should a fall in BP last when using beat-to-beat monitoring be considered as 
significant, although it has been suggested that less than 30 seconds would not be 
enough to cause symptoms (Romero-Ortuno et al., 2010). 
 
2.2.2 Epidemiology 
The multiple underlying aetiologies of OH has resulted it in being a common condition 
in community, hospital or care home environments. As might be expected the 
prevalence of OH varies between studies, depending on many factors, in particular the 
age and population type that are included. It should be noted that there is some 
variation in the definition of OH and older studies may not always include a fall in 
DBP in the study definition. The actual incidence of OH is unknown, although the 
incidence of first reports of orthostatic syncope is 0.58 per 1000 person-years 
(Soteriades et al., 2002) it has been suggested that for initial OH it is around 3.6% 
where it is the primary diagnosis of transient loss of consciousness (Wieling et al., 
2007). Although some studies have defined OH as a postural fall in SBP of ≥30mmHg 
(Low et al., 1995), most studies generally refer to a fall in SBP of ≥20mmHg 
(Applegate et al., 1991a, Hiitola et al., 2009). Thus amongst hospital patients and the 
general population over the age of 65 years, the reported prevalence rates vary between 
6.4% (excluding those who had any risk factors for OH) and 65% (Vloet et al., 2005, 
Soteriades et al., 2002, Poon and Braun, 2005, Applegate et al., 1991a, Mader et al., 
1987, Caird et al., 1973, Räihä et al., 1995, Luukinen et al., 1999, de la Iglesia B. et al., 
 8 
 
2013, Rutan et al., 1992, Weiss et al., 2002, Kamaruzzaman et al., 2010, Valbusa et al., 
2012). However it should be noted that Cooke et al (2013), compared beat-to-beat BP 
changes during HUT with sit to stand BP, with a reported prevalence of 58.6% versus 
17.3% in community dwelling adults over the age of 65 years. Furthermore it has been 
suggested that subtypes of OH will need to be considered in addition to the overall 
prevalence, with arteriolar OH accounting for 47%, 33% venular, and 9% mixed 
(Cooke et al., 2013). Data collected from community Norfolk patients attending a 
Transient Ischemic Attack (TIA) clinic, where 43.8% were classed as non-TIA, OH 
was found to have a prevalence of 22.3% (de la Iglesia B. et al., 2013).  It has been 
shown that
 
even after excluding those with primary autonomic dysfunction and 
Parkinson’s disease the prevalence can remain high at 55% in the population studied 
(Poon and Braun, 2005).  
 
Furthermore studies have shown that not all those with a postural fall in BP associated 
with OH are symptomatic.  Even amongst those over the age of 75 years, only 33% 
reported symptoms associated with the BP fall, and this included those with a history 
of falls (Poon and Braun, 2005).  The prevalence of OH has been observed to increase 
as the number of potentially causative medications increased from zero (prevalence of 
35%) to three or more (65%) (Poon and Braun, 2005). One study found that a fall in 
SBP of at least 20mmHg after 1 minute of standing was present in only 10.7% of 
independently living older poeople (mean age of 69.8 years, range 56-93 years), and in 
the population studied only 21.9% of those with a fall in BP had symptoms on standing 
(Mader et al., 1987). Furthermore 18.3% had symptoms on standing, but did not have a 
significant fall in systemic BP (Mader et al., 1987). There was no significant difference 
in the frequency of  postural symptoms on standing between those with or without a 
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fall in BP, but a higher proportion of those with a postural fall, compared to those with 
no postural fall, had hypertension (31.3% vs. 14.6%, p=0.016) (Mader et al., 1987).  
Elsewhere it has been shown that applying diagnostic BP criteria of OH without 
necessarily including postural symptoms for OH amongst unselected community 
dwelling older people the prevalence of OH is higher than the previous study (Mader 
et al., 1987),  at  28% (Räihä et al., 1995), and 34% in those over the age of 75 years 
(Hiitola et al., 2009). Of course it is recognised that the prevalence will vary with the 
differing criteria applied for the diagnosis of OH over the years (Frith et al., 2014). 
Table 2 summarises selected studies on the prevalence of OH in older adults. 
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Study (Author, 
Year, Country) 
Study Population Prevalence 
of OH 
(% of study 
population) 
N Age (years) 
(Mean ± SD 
unless otherwise 
specified) 
Sex  
M:F 
(%)  
Population Group 
Applegate et al, 
1991, USA 
4736 ≥60  
(72.1 ±6.6; n=817 
OH) 
40.3:59.7 Systolic 
hypertension  
17.3 
Caird et al, 1972, 
UK 
494 45.7% ≥75 36.2:63.8 Home dwelling ≥ 
65 years of age 
24.0 
Hiitola et al, 2009, 
Finland 
653 81 (range 75-99) 30:70 Home dwelling 
≥75 years of age 
34.0 
Kamaruzzaman et 
al, 2010, UK 
3775 Range 60 to 80  
(69.4 ±5.5, 
n=1059 OH) 
0:100 Community 
dwelling older 
women 
28.0 
Luukinen et al, 
1999, Finland 
792 76 ±4.9 38:62 Community 
dwelling older 
people 
30.0 
Mader et al, 1987, 
USA 
300 69.8 (range 56 to 
93) 
33:77 Community 
dwelling older 
people ≥55 years 
of age 
10.7 
(overall) 
13.7 (OH 
risk 
factors*) 
6.4 (no OH 
risk factors) 
Ooi et al, 2000, 
USA 
844 73.8% ≥80  19.7:80.3 Nursing home 
residents ≥60 
years of age 
50.0 
Poon et al, 2005, 
USA 
342 82 ±4.7 96:4 Veterans 
attending geriatric 
clinic 
55.0 
(overall) 
35.0 (no 
causative 
medication) 
Räihä et al, 1995, 
Finland 
329 ≥65 53:47 Community 
dwelling older 
people ≥65 years 
of age 
28.3 
Rutan et al, 1992, 
USA 
4931 ≥65 43.5:56.5 Community 
dwelling older 
people ≥65 years 
of age 
16.2 
Valbusa et al, 
2011, France and 
Italy 
994 88±5 33:77 Older people in 
nursing homes 
18.0 
Vloet et al, 2005, 
Netherlands 
85 80± 7 51.7:48.3 Geriatric Ward in-
patients 
52.0 
Weiss et al, 2002, 
Israel 
502 81.6 ±7.0 48:52 Geriatric in-
patients 
67.9 
Table 2 The prevalence of orthostatic hypotension in various populations of older adults  
(* OH risk factors include e.g. diabetes mellitus, hypertension, medication) 
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In terms of predictors of OH,  Mader et al (1987) found a significant difference 
between those with and without a postural BP fall in terms of the proportion having at 
least one risk factor for OH (75% versus 56.3%, p = 0.04), this could include various 
medications e.g. anti-hypertensives, as well as active medical conditions e.g. cardiac 
disease, clinical findings of e.g. varicose veins and laboratory findings e.g. low 
haematorcrit (Mader et al., 1987). Another study (Ensrud et al., 1992) found that whilst 
Parkinsonism was strongly associated with a postural fall in BP as well as postural 
dizziness, the relationship with diuretics was weaker for both postural BP and postural 
symptom. Both systolic and diastolic hypertension was found to be associated with 
postural hypotension (Ensrud et al., 1992). 
 
2.2.3 Morbidity and Mortality 
Orthostatic hypotension is not a benign condition, being frequently associated with 
recurrent falls and their complications e.g. fracture. (Graafmans et al., 1996). In 
addition OH is associated with a significant increased mortality (Fedorowski et al., 
2010). This increasing mortality over time associated with cardiac syncope is much 
greater than other causes and is illustrated in Table 1. For example even amongst 
community dwellers with OH there is an increased risk of vascular death (Caird et al., 
1973, Räihä et al., 1995) and in a population of the Atherosclerosis Risk in 
Communities (ARIC) Study involving nearly 12,000 middle-aged adults, OH has been 
shown to be predictive of ischaemic stroke even after adjustment for stroke factors 
(HR: 2.0, 95% CI 1.2 to 3.2) (Eigenbrodt et al., 2000). However OH is also associated 
with an increased risk of all-cause mortality (HR 2.4, 95% CI 2.1 to 2.8), even after 
adjusting for the presence of cardiovascular disease (HR 2.0, 95% CI 1.6 to 2.7) in 
around 13,000 middle age participants (mean age 57 years) of the ARIC cohort over a 
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13 year period (Rose et al., 2006). On the one hand the presence of a postural BP fall 
in those with  hypertension increases the risk of cerebrovascular disease in older adults 
(Kario et al., 2002). Conversely an increase in cerebrovascular disease is also seen in 
older adults with hypertension who have an increase in SBP of ≥20mmHg on head-up 
tilt. Thus there is a U-shaped relation between postural BP change and cerebrovascular 
disease, whereby a fall or rise in BP is associated with cerebrovascular disease (Kario 
et al., 2002).  In both of these instances the presence of cerebrovascular disease may be 
related to alterations in not only systemic BP, but also changes in cerebral auto-
regulation (CA). For example an abnormal localised cerebral vasoconstriction would 
result in reduced perfusion of brain tissue and hence an infarct. 
 
2.2.4 Clinical Presentation 
There are a variety of symptoms associated with orthostatic intolerance (which does 
not necessarily relate to a corresponding postural drop in BP) and OH (diagnosed by 
the postural drop in BP), which include dizziness, general loss of strength, the sense of 
instability, nausea and a tendency to fall
 
(Vloet et al., 2005). However as stated 
previously not all older people with OH are symptomatic; only between 23-59% of 
older adults with OH have symptoms associated with a fall in systemic BP (Soteriades 
et al., 2002, Ensrud et al., 1992, Graafmans et al., 1996). Furthermore it has been 
demonstrated that there are some who have postural dizziness but no postural fall in 
systemic SBP levels (18.9% of those with no postural fall in BP) (Ensrud et al., 1992). 
It should also be noted that a history of falls has been shown to be more closely 
associated with the symptom of dizziness rather than the postural reduction in BP per 
se (Soteriades et al., 2002, Ensrud et al., 1992, Graafmans et al., 1996).  The most 
common symptoms of orthostatic hypotension amongst those with autonomic 
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dysfunction (i.e. pure autonomic failure, multisystem atrophy, autonomic neuropathy, 
diabetic autonomic neuropathy) and a postural BP fall reported by older subjects are 
“light-headedness” or “dizziness” in 88% of cases, “weakness” or “tiredness”  in 72%, 
with reduced cognition in terms of thinking or concentrating as common as “blurred 
vision” in 47%. Other symptoms include “tremulousness” (38%), “vertigo” (37%), 
“pallor” (31%), “anxiety” (29%), “tachycardia” or “palpitations” (26%), “clammy 
feeling” (19%) and “nausea” (18%) (Low et al., 1995). However there is evidence that 
OH is not simply explained by autonomic dysfunction (Lagro et al., 2013). 
 
Low et al (1995) used the composite autonomic symptom score (CASS) (Low, 1993) 
and a composite symptom score based on the frequency of orthostatic intolerance (0 = 
never, 1 = uncommon, 2 = at least once a week, 3 = more often than not, 4 = 
consistently present), standing time to develop orthostatic symptoms (0 = never, 1 = 
more than 5 minutes, 2 = within 2 to 5 minutes, 4 = less than 1 minute) and frequency 
of syncope (0 = never, 2 = less than once per month, 4 = at least once per week). It was 
found that by analysing the regression between the CASS and the composite symptom 
score, the best correlation was amongst those with symptomatic OH (y = 3.612 + 
0.331x, where y = symptom score, x= CASS, p = 0.00513, r = 0.3009) or all groups 
combined, but not with asymptomatic OH or those with a negative head-up tilt (HUT) 
but with a history of symptoms of OH (Low et al., 1995). The variation in types of 
symptoms may be related to the underlying aetiology of OH (Low et al., 1995), but 
whether an individual with a postural drop in BP has symptoms may potentially reflect 
control of cerebral blood flow rather than maintenance of systemic BP levels through 
cardiovascular autonomic function (Lagro et al., 2013). 
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2.3 Post-prandial Hypotension (PPH) 
2.3.1 Definition 
Post-prandial hypotension (PPH) has be defined as a reduction in the SBP of 
≥20mmHg within 2 hours of the start of a meal or when SBP falls to ≤90mmHg within 
this period where the pre-prandial SBP was ≥100mmHg (Jansen and Lipsitz, 1995). 
Like OH it may not always be associated with symptoms (Jansen and Lipsitz, 1995), 
conversely symptoms are not always accompanied by a low BP (Vloet et al., 2003). 
 
2.3.2 Epidemiology 
Post-prandial falls in BP are common in older community dwelling adults. However 
the incidence of PPH is unknown, although the incidence of first reports of other 
causes of syncope is 0.47 per 1000 person-years (Soteriades et al., 2002); and the 
prevalence rates of PPH has been reported to be up to 36% of those residing in care 
homes (Vaitkevicius et al., 1991, Aronow and Ahn, 1994) and as high as 67% in the 
older hospital population (Vloet et al., 2005). However although post-prandial falls in 
BP is  prevalent amongst community dwelling healthy older people, the actual fall in 
SBP is smaller, with SBP changes of -11±9mmHg by 60 minutes after a meal 
compared to 1±7mmHg in similar conditions without a meal (Lipsitz and Fullerton, 
1986, Heseltine et al., 1991a). Amongst those in care home facilities it was found that 
24% of residents (mean age 80±9 years) had a SBP fall of over 20mmHg after a meal 
(Aronow and Ahn, 1994). The fall in post-prandial SBP amongst those in long-term 
care is larger in those with a history of syncope in the previous 6 months (24±5mmHg) 
compared to those without such a history (14±5mmHg) (Aronow and Ahn, 1994). 
Thus amongst those without a history of syncope, it is similar to healthy older people 
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living within the community. Table 3 summarises the prevalence rates of PPH amongst 
various groups of older people. 
Study (Author, Year, 
Country) 
Study Population  Prevalence 
of PPH 
(% of study 
population) 
N Age (years) 
(Mean ± SD unless 
otherwise specified) 
Sex Ratio 
M:F 
(%)  
Population 
Group 
Aronow et al, 1994, 
USA 
499 80 ±9 29:71 Long-term 
health care 
residents 
24.0 
Maurer et al, 2000, 
USA 
50 78 (range 61 to 96) 32:68 Older persons 
from 
community 
and inpatients 
22.0 
Vaitkevicius et al, 
1991, USA 
113 78 ±9 27:73 Nursing home 
residents 
36.0 
Vloet et al, 2005, 
Netherlands 
85 80 ±7 51.7:48.3 Geriatric 
Ward in-
patients 
67.0 
Table 3 The prevalence of post-prandial hypotension in populations of older adults 
 
2.3.3 Morbidity & Mortality 
PPH has been found to be present in half of those with unexplained syncope (Jansen 
and Lipsitz, 1995) and is associated with acute vascular events such as stroke and 
angina (Vaitkevicius et al., 1991, Kohara et al., 1999). It has been suggested that 
amongst older patients with hypertension, the extent of the post-prandial SBP pressure 
fall (categorised as SBP fall <5mmHg, 5-9mmHg, ≥10mmHg) correlates with 
magnetic resonance imaging (MRI) evidence  of cerebrovascular damage in terms of 
the number of lacunar infarcts present and degree of advanced leukoaraiosis. Those 
shown to have a larger SBP fall post-meal had more damage despite the fact that there 
were no significant differences in mean daytime or night-time BP levels (Kohara et al., 
1999).  It has been suggested that the more severe cerebrovascular changes are likely 
to be a reflection of the relative change between pre and post-prandial BP, and not 
merely the post-prandial BP (Kohara et al., 1999).  
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2.3.4 Clinical Presentation 
PPH has been shown to be independent of a history of syncope (Lipsitz et al., 1983) 
and can be asymptomatic (Heseltine et al., 1991a) in around a third of cases (Vloet et 
al., 2005). Older people within institutionalised care (mean age 87.8 years, SEM±1.0 
years), regardless of whether they have a history of syncope or not, can have large 
asymptomatic post-prandial falls in SBP (mean 15mmHg, SEM±2mmHg; and mean 
11mmHg, SEM±4mmHg) within 35 minutes after the start of a meal (Lipsitz et al., 
1983). Maximal falls in SBP can reach a mean of 25mmHg, SEM±5mmHg amongst 
those with a history of syncope, and 24±9mmHg in those without a history (p<0.03) 
(Lipsitz et al., 1983).  Symptomatic post-prandial hypotension can result in a poor 
quality of life, often presenting with dizziness, falls, visual disturbances, nausea, 
yawning and tiredness (Vloet et al., 2005, Jansen and Lipsitz, 1995, Vloet et al., 2003). 
 
The fall in SBP after standardised meal ingestion amongst care home residents (n=113, 
mean age 78±9 years) has been shown to be greater than the response to head-up tilt 
(HUT) alone, with symptoms present in 22% after a meal versus 12% with HUT alone 
(Maurer et al., 2000). Furthermore the time to symptoms occurred sooner after meal 
ingestion than HUT alone (Maurer et al., 2000). However it should be noted that 
although there was a high prevalence of hypertension (44%), and half were on BP 
lowering medication (Maurer et al., 2000), there was no sub-group analysis to 
determine whether a history of hypertension or anti-hypertensive medications (in terms 
of drug class and the number of drugs used) influenced whether or not participants had 
symptomatic falls in post-prandial BP. Furthermore it has been suggested that PPH, 
like OH in older adults is not fully explained by abnormalities in cardiovascular 
autonomic function (Lagro et al., 2013). 
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In older patients it has been shown that there is variation in the post-prandial BP 
response depending on the time of day, with falls decreasing over the course of the day 
with the greatest fall in SBP at breakfast. The fall in SBP with the evening meal was 
significantly smaller than that at breakfast (p<0.0001) and at lunch (p<0.0004), with 
only 57% of patients having PPH (defined as a decrease in SBP ≥20mmHg) after the 
evening meal (Vloet et al., 2003). However this greater fall in BP after breakfast may 
simply be related to the prolonged supine position assumed for sleeping or perhaps 
reflects the composition of the meal as it is known that a high simple carbohydrate 
meals result in a greater fall in SBP than a complex carbohydrate meal (Heseltine et 
al., 1991a). The varying effects of meal composition and the type and volume of drinks 
ingested on BP, and is discussed further in Section 2.10. 
 
2.4 The relationship between the pathophysiology of OH, PPH 
and symptoms 
2.4.1 The case of OH 
The relationship between OH, hypertension and antihypertensive drugs is complex but 
may provide insight into the relationship between OH, cerebral auto-regulation (CA), 
arterial BP (ABP), arterial stiffness and symptoms. There are many associations with 
OH including drugs especially some anti-psychotic agents and anti-hypertensives, and 
diseases such as diabetes (Mader et al., 1987). The possible causal relationship 
between anti-hypertensive medication and orthostatic hypotension is supported by the 
fact that withdrawal of anti-hypertensive medication has been shown to reduce the 
prevalence of OH (Fotherby and Potter, 1994). However normalising supine BP levels 
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with treatment also reduces OH (Räihä et al., 1995). Those with postural hypotension 
were more likely to have supine hypertension defined as SBP >160mmHg or DBP 
>90mmHg (31.3% vs. 14.6%, p=0.016) (Mader et al., 1987). In addition regardless of 
whether participants had or had no postural hypotension, similar proportions had 
postural symptoms on examination (21.9% vs. 18.3%, p>0.05) (Mader et al., 1987). 
This would support the possibility that symptoms may be related to the ability of a 
person’s CA to maintain cerebral blood flow. 
 
Although OH amongst those with autonomic failure is associated with supine 
hypertension (Goldstein et al., 2003), the variable association of OH with isolated 
supine hypertension is shown in the placebo phase of the Syst-Eur trial. Only 21% of 
the 2716 included in the study showed at least one episode of a fall in SBP of at least 
20mmHg with only 2.5% showing this on three occasions. For a DBP fall of at least 
10mmHg, 9.7% has at least one occurrence and 0.4% had three occurrences. The 
supine SBP was 175±13mmHg and DBP was 86±6mmHg (Vanhanen et al., 1996). 
Other studies also show that supine SBP, DBP and mean BP are significantly higher 
amongst those with a SBP fall of at least 20mmHg (Räihä et al., 1995). Even in studies 
where the prevalence of OH was reported to be lower (Mader et al., 1987) supine SBP 
and DBP was significantly higher. In addition, recent evidence suggests cardiac 
autonomic function is similar in older adults with and without OH (Lagro et al., 2013). 
 
However on the other hand the prevalence of OH is significantly lower amongst those 
where hypertension was treated (13% vs. untreated 23%, p<0.001), and pulse pressure 
was higher amongst those with OH (Valbusa et al., 2012). Thus although baroreceptor 
sensitivity (BRS) declines with hypertension (Parati et al., 1988), treating hypertension 
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with antihypertensive agents improves BRS (Berdeaux and Giudicelli, 1987). Thus a 
difficult paradox remains to be solved for the older hypertensive patient. Where does 
the role of anti-hypertensive agents fit in with OH (whether symptomatic or 
asymptomatic) and perhaps CA?  
 
2.4.2 The case of PPH 
For post-prandial hypotension the most significant reduction in BP in those over 65 
years of age occurs within 90 minutes of ingestion of a high in simple carbohydrate 
substrate e.g. glucose, and is independent of the presence or absence of systemic 
hypertension (Visvanathan et al., 2005, Jansen et al., 1987, Potter JF, 1989) even after 
medication withdrawal (Lipsitz et al., 1983).
 
Caffeine (an adenosine antagonist) when 
given after meals can reduce post-prandial symptoms and BP reduction (Heseltine et 
al., 1991c, Heseltine et al., 1991b) and thus suggesting adenosine may have an 
underlying pathophysiological role by inducing splanchnic vasodilatation resulting in 
the reduction in BP. Other studies have shown that the cardiac baroreflex in older 
people is impaired as HR does not increase enough to compensate for a lowering of BP 
after meals (Lipsitz et al., 1983) which may contribute further to post-prandial falls in 
BP. However recent evidence does suggest that there is little difference in cardiac 
autonomic dysfunction in older adults with PPH compared to those without (Lagro et 
al., 2013). 
 
Research has shown that the post-meal reduction in BP relates to glucose levels 
(Jansen et al., 1987) rather than the direct insulin effect of impairing baroreceptor 
sensitivity (BRS). This impairment is thought to be due to the lack of a compensatory 
increase in HR after meals (Lipsitz et al., 1983). Furthermore peripheral 
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vasoconstriction appears to be absent in the presence of hypotension after a meal  in 
older participants with a history of syncope compared to older adult controls (Jansen et 
al., 1995). Therefore it may be that PPH reflects the failure to maintain systemic 
vascular resistance in order to compensate for blood diverted into the splanchnic 
circulation (Jansen and Lipsitz, 1995). This has been supported by the fact that BP is 
maintained in the same way in both healthy younger and older adults; by increasing 
HR and forearm vascular resistance associated with an increased plasma 
norepinephrine. In contrast those with autonomic dysfunction due to a variety of 
causes, the lack of adequately maintained vascular resistance observed suggests this 
may be the pathophysiological basis for PPH (Lipsitz et al., 1993).  
 
2.5 The physiological processes 
There are several physiological parameters important to the understanding of the 
relationship between systemic arterial blood pressure (ABP) and cerebral blood flow 
(CBF) control by cerebral auto-regulation (CA) in OH and PPH. This includes the 
normal response to active standing and how this differs from head-up-tilt in the 
laboratory environment, as well as the differences in the physiological response 
between younger and older adults; and the normal physiology associated with the 
ingestion of meals in terms of the effect on arterial blood pressure, as previously 
discussed. Central to these ideas is the haemostatic control of arterial blood pressure in 
response to posture and digestion, and the changes in ability of baroreceptors 
(essentially sensors of a feedback loop) to provide an adequate feedback mechanism in 
the presence of increasing arterial stiffness with age. This is described in detail in the 
following section. Key to understanding CA is its primary purpose to maintain 
adequate cerebral blood flow (CBF) for perfusion of brain tissue despite normal 
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physiological fluctuations in arterial blood pressure during routine day to day 
activities. The question remains as to why some people with systemic falls in BP to 
standing or after meals have symptoms whilst others do not. Furthermore some people 
have no systemic BP changes following standing or post-meal but may have symptoms 
suggestive of PPH.  Are there differences in CA to account for this? Are there 
differences in arterial stiffness? 
 
2.6 Cerebral auto-regulation 
2.6.1 Physiology 
Cerebral blood flow (CBF) is controlled via several different mechanisms including 
those reliant on metabolic, myogenic and neurogenic processes. Normally CBF is 
maintained at approximately 50ml/100g min
-1
 where PaCO2 (arterial partial pressure of 
carbon dioxide) remains constant. However PaCO2 will vary regionally and thus there 
is increased CBF to regions of the brain that are metabolically active (Lassen, 1974). 
In terms of chemical control a high PaCO2 results in cerebral vasodilatation, and low 
levels cause vasoconstriction causing relative hypoxia. PaCO2 is further influenced by 
the pH of the cerebrospinal fluid (CSF) around arterioles and the bicarbonate levels in 
the CSF. Unlike PaCO2, PaO2 (arterial partial pressure of oxygen) only has a major 
effect on CBF if significantly low and is at the level at which lactic acidosis of brain 
tissue occurs (approximately less than 50mmHg). The neurogenic control of CBF is in 
part due to the innervation of the pial arteries which run across the surface of the brain. 
The smooth muscle within the arteries will result in vasoconstriction and 
vasodilatation according to whether the stimulus is norepinephrine or acetylcholine 
respectively (Lassen, 1974). The brain can tolerate a small reduction in CBF before 
symptoms develop, but when CBF drops by more than 30% of normal levels, the O2 
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requirements can no longer be met by increasing its extraction from the blood. At this 
point symptoms such dizziness, light-headedness etc. will appear (Paulson et al., 
1990). 
 
Cerebral auto-regulation (CA) refers to the intrinsic mechanisms by which CBF is 
maintained despite variations in cerebral perfusion pressure i.e. the pressure difference 
between the venous and arterial systems of the brain (Lassen, 1974, Blaha et al., 2007). 
Static CA relates to the changes in CBF over a longer period of time which occurs as a 
result with gradual changes in systemic BP. This is likely due to smooth muscle 
response in the arteriolar wall and can be affected for example by the partial pressure 
of carbon dioxide in arterial blood (Lassen, 1974, Blaha et al., 2007) as well as nitric 
oxide (Dawson et al., 2009). On the other hand dynamic CA (dCA) relates to the rapid 
changes of CBF that occur in response to  quick (occurring over a few seconds)  
changes in arterial BP within the range of static CA (van Beek et al., 2008).  
 
The rapid changes in CBF, which can be within seconds, can be non-invasively 
assessed with Transcranial Doppler ultrasound (TCD) using the cerebral blood flow 
velocities (CBFV) e.g. of the middle cerebral artery, as a surrogate marker of CBF. 
(Aaslid et al., 1982 , Aaslid et al., 1989) Using TCD to record cerebral blood flow 
velocity (CBFV) of the MCA allows exploration of its relationship with real-time 
systemic BP and CO2 changes. Although this allows CA to be assessed using CBFV as 
a surrogate marker for CBF it does assume that the arterial diameter is constant, this 
has been shown to be the case (Newell et al., 1994, Berlowitz et al., 2011, Wilkinson et 
al., 2000). The use of static CA is limited by the fact that in the semi-steady state 
measures of CBFV and the associated cerebrovascular resistance is the outcome of the 
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stable BP level. In addition as static CA is reflected by average long-term changes in 
BP, its use is limited by the need for sustained changes in BP induced by 
pharmacologically active agents. As dynamic CA reflects the changes in CBFV in 
response to rapid changes in BP it can provide information on beat-to-beat changes in 
BP (van Beek et al., 2008). However CBF will only be maintained across a particular 
range of perfusion pressures, and this range will vary according to PaCO2 (Lassen, 
1974). However recent MRI (magnetic resonance imaging) study showed that in 
conscious participants, the diameter of the MCA is constant across a range of PETCO2 
(end-tidal partial pressure of carbon dioxide) (Serrador et al., 2000). Thus under stable 
conditions CA is able to maintain constant CBF between a MAP of around 60mmHg 
to 150mmHg as shown by Figure 2 (Paulson et al., 1990) and CA is rarely absent, but 
can be found to be impaired. The underlying mechanisms of static and dynamic CA 
differ, as it has been shown that by inducing a response from either component by 
chemically invoking a sustained increase in BP or by reducing BP with lower body 
negative pressure respectively, the resultant response would be vasoconstriction and 
vasodilatation respectively. However as both of methods of measuring CA have the 
same result, i.e. maintain CBF, then it is likely that the processes causing 
vasoconstriction would differ from those resulting in vasodilatation (Tiecks et al., 
1995). 
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Cerebral perfusion fails when the cerebral perfusion pressure falls to less than 
approximately 40mmHg, which triggers an increase in SNSA response resulting in an 
increase in systemic ABP (Lassen, 1974). Studies using 
133
Xe and correlating blood 
flow and symptoms of hypoxia have shown that the critical level of CBF, or that at 
which ischaemia occurs, is approximately 18-20ml/100 min
-1
 (Lassen, 1974). 
Furthermore it has been shown that CA is impaired if associated with cerebral 
ischaemia (Symon et al., 1973). A recent study in healthy female volunteers, looking at 
the relationship between cardiac output and dCA, not only showed that these were 
independent but has also shown that there is a significant difference in the auto-
regulatory index (ARI) dependent on whether the participant is supine or seated 
(Deegan et al., 2010). The ARI is a constant based on a mathematical model which 
allows us to compare how well an individual’s CA compares to normal, and is 
discussed below. 
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Figure 2 Cerebral Auto-regulation Curve under stable conditions 
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To assess dynamic CA a stimulus a rapid step change in ABP (of ≥15mmHg) is 
necessary in order to allow the response in ABP and CBFV to be simultaneously 
analysed, this can be done using several methods e.g.  thigh-cuff deflation, head-up-tilt 
(HUT). The time it takes for CBFV to recover and attain its original level will vary 
according to the state of CA.  
 
A classical mathematically derived model of assessing  cerebral auto-regulation, 
defined as  an auto-regulatory index (ARI), was developed by Asalid and is measured 
on  a scale from 0 to 9 (as shown in Figure 16) to indicate whether cerebral auto-
regulation is perfect (score 9) or markedly impaired (score 0). It uses the CBFV and 
ABP after thigh-cuff release to attain a change in CVR per second relative to changes 
in ABP. The ARI relies on computer modelling based on the actual recorded ABP 
from the moment of thigh-cuff release over 30 seconds, from which a theoretical or 
hypothetical CBFV response based on no cerebral auto-regulation would be created. 
Within this model of zero CA a linear relationship between ABP and CBFV is 
assumed with falls CBFV following a similar percentage fall in ABP. A further nine 
models of other possible CBFV responses are made with an increase in the ability of 
CA being assumed. Thus an actual CBFV response can be matched against these 
models in order to determine best fitting model and thus the ARI value (Tiecks et al., 
1995). Thus from Figure 3 it can be seen that normal cerebral auto-regulation will have 
an ARI of around 5. 
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Figure 3 The Auto-regulatory Index (ARI), adapted from Tiecks et al. (2005) 
 
Other methods to assess CA include using spontaneous fluctuations in BP and CBFV 
(Panerai et al., 1998) and considering the frequency domain (versus the time domain of 
the previous method) transfer function analysis whereby the power spectra of the 
oscillations in BP and CBFV are assessed in terms of gain, phase and coherence, i.e. 
spectral analysis (Panerai, 2009, van Beek et al., 2008). These methods shall be 
discussed further in the Methodology section. 
 
In addition it has also been suggested that there is a sex difference in terms of the 
effectiveness of CA, with females being better able to maintain CBFV with changes in 
posture during assessment of sit-to-stand, as well as showing better CO2 reactivity and 
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higher ARI (Deegan et al., 2011b). It should also be noted that there is little difference 
in the regional cerebral vascular response to hypercapnia and hypocapnia between 
healthy young and older men using positron emission tomography (PET), although a 
reduction in the total vascular response was noted amongst older men to indicate 
sclerotic changes in both the cerebral and medullary arteries (Ito et al., 2002). ARI is 
further discussed in the Methodology Chapter. 
 
2.7 The physiological response to standing 
2.7.1 Systemic BP and standing 
Blood pressure (BP) is maintained via a negative feedback mechanism and is 
summarised in Figure 4 and 5. Activation of these components is dependent on 
whether it relates to short or long-term control, and include high and low pressure 
baroreceptors (which include cardiac stretch receptors and the great vessel  pressure 
receptors) and chemoreceptors (which detect pH, CO2 levels, endothelin peptides, 
nitrous oxide and other factors) strategically located along the vasculature (Kohan et 
al., 2011). Thus when the body assumes an upright posture from a physiologically 
stable supine position, the resultant peripheral venous pooling causes a fall in arterial 
BP (ABP). This is due to a decrease in the filling pressure within the heart and the 
subsequent fall in stroke volume. This triggers the feedback loop as shown in Figure 4. 
This triggers signals (mechanical and chemical) via the afferent limb of the reflex arc 
from the arterial baroreceptors found in the carotid sinus and aortic arch, as well as the 
cardiac mechanoreceptors, to the brainstem via the autonomic nervous system (Borst et 
al., 1982) The arterial (high pressure) baroreceptors (discussed later) are 
predominantly found in the carotid sinus at the bifurcation of the internal and external 
carotid artery and the aortic arch, but can also be found within the common carotid 
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artery (around the thyroid artery). These mechanoreceptors detect arterial wall stretch 
in response to intravascular pressure. Afferent signals are conveyed via both 
myelinated and unmyelinated fibres of the sinus nerve (conveying rapid changes in BP 
via the glossopharyngeal nerve) from the carotid sinus and via the vagus nerve 
(conveying more sustained changes in BP) from the aortic arch, to the nucleus tractus 
solitarius (NTS) in the medulla.  
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Figure 4 Normal control of BP 
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The brainstem component of the feedback mechanism is illustrated in Figure 5. From 
the NTS there are pathways leading to the origins of the efferent parasympathetic 
component of vagus nerve in the nucleus ambigus (NA) and dorsal vagal motonucleus 
(DVM) within the medulla; but also another which connects to the anterior 
hypothalamus before synapsing with the NA and DVM. The sympathetic efferent 
component of the baroreflex is relayed via the intermediolateral column of the spinal 
cord from the rostral ventrolateral medulla (RVLM), which in turn receives 
information from the NTS via the caudal ventrolateral medulla (Kirkman and Sawdon, 
2010, Ackermann, 2004). This results in signals via the efferent limb to adjust for the 
fall in ABP by increasing the sympathetic drive and reducing the parasympathetic 
response in order to increase the heart rate transiently for around 10 seconds (Borst et 
al., 1982). With this there is also peripheral vasoconstriction to help increase the 
cardiac filling pressure and therefore together with the increase in heart rate assists in 
maintaining the ABP (Borst et al., 1984). Thus it can be seen that an abnormality of 
either the afferent or efferent limb of the BP control arc can result in failure of a 
compensatory BP rise, and therefore BP remains low. 
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Figure 5 Brainstem control of BP [Key: AH=anterior hypothalamus, CVM=caudal ventrolateral medulla, 
DVN=dorsal vagal motonucleus, NA=nucleus ambigus, NTS=nucleus tractus solitarius, RVM=rostral 
ventrolateral  medulla]   
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2.8 The baroreceptor reflex arc 
Arterial baroreceptors are stretch receptors innervated by 9
th
 and 10
th
 cranial nerves 
and are important in the control of BP (See Figure 4 and 6). Those found in the carotid 
artery and aorta are arterial or high-pressure baroreceptors, whilst those found in 
cardiopulmonary areas are low pressure baroreceptors. The reflex arc is a negative 
feedback loop which is initiated when baroreceptors are triggered to a point less or 
greater than the stable set point of baroreceptor firing or discharge. This is illustrated in 
Figure 6, adapted from (Berdeaux and Giudicelli, 1987).  
 
 
 
 
 
 
 
Figure 6 Baroreceptor discharge and mean arterial pressure (MAP) (adapted from Berdeaux and Giudicelli, 
1987) 
 
Thus it can be seen from Figure 6 that there will be an associated reduction in afferent 
signals from the baroreceptors as a result of a fall in BP. This in turn via the reflex arc 
will result in an efferent response consisting of an increase in sympathetic and decrease 
in the parasympathetic activity resulting in a compensatory increase in BP to within 
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the less able they are to provide a correct discharge or firing rate in response to the BP 
level, and the less able they are to control BP. 
 
2.8.1 About baroreceptor sensitivity 
Baroreceptor mechanisms which help maintain systemic BP levels at a set level in 
response to acute haemodynamic challenges, via the baroreceptor reflex arc, and 
require an intact autonomic nervous system (Monahan, 2007).  Cardiac baroreceptor 
sensitivity (BRS) can be measured non-invasively (Dawson et al., 1997)  by assessing 
the change in the duration of the inter-beat interval (R to R interval in milliseconds on 
the ECG) in relation to an acute change in systemic SBP (units of msec/mmHg) 
(Bothová et al., 2010). There are various mathematical methods of calculating cardiac 
BRS (Davos et al., 2002) using either spontaneous variations in BP (Eveson et al., 
2005) or by inducing BP changes by a particular stimulus, e.g. Valsalva (Palmero et 
al., 1981) or pharmacologically e.g. phenylephrine infusions (Robbe et al., 1987),  to 
induce BP changes. An example of normal BRS where a stimulus causes an increase in 
the change SBP and R-R interval is demonstrated in Figure 7 with the corresponding 
ideal regression line showing good correlation in Figure 8. One example of an 
abnormal BRS is shown in Figure 9 where there is little change in the R-R interval 
after a stimulus induces an increase in SBP, and the associated regression line is shown 
in Figure 10. 
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Figure 7 Normal BRS. SBP (solid line) and corresponding RR interval (dotted line) for consecutive beats. 
 
 
 
 
 
 
 
Figure 8 Normal BRS. Correlation of regression line between SBP and RR interval. 
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Figure 9 Abnormal BRS. SBP (solid line) and corresponding RR interval (dotted line) for consecutive 
beats. 
 
 
 
 
 
 
 
 
 
 
Figure 10 Abnormal BRS. Correlation of regression line between SBP and RR interval. 
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2.9 Active versus passive upright posture 
2.9.1 Younger adults 
There are important physiological differences between the haemodynamic responses to 
active and passive attainment of the upright posture. It has been shown that in healthy 
young adults (mean age  30 years, range 24-41 years) there are differences between 
active standing and passive head-up-tilt in the first 30 seconds,  active standing 
producing a greater reduction in SBP and DBP (Borst et al., 1984, Tanaka et al., 1996), 
albeit transient, and a higher elevation in heart rate (Tanaka et al., 1996, Borst et al., 
1982) probably as a result of a greater fall in total peripheral resistance (TPR) without 
a compensatory increase in cardiac output (Sprangers et al., 1991) with active standing 
(Tanaka et al., 1996).  
 
Another difference associated with active standing is that there appears to be an 
increase in intra-abdominal pressure, absent with passive tilt. With no significant 
changes between passive and active standing after this initial period (<1 minute) of 
assuming the upright posture, it has been concluded that the greater fall in ABP with 
active standing is due to reduced TPR, as a result of vasodilation, which is not fully 
compensated for by cardiopulmonary baroreflex activation. The shift of blood flow 
from the splanchnic circulation as a result of increased intra-abdominal pressure is also 
thought to contribute in the distension of the right atrium and activation of the 
cardiopulmonary baroreflex (Tanaka et al., 1996). Of note later in the upright position 
(1-7 minutes), HR, SBP and DBP are higher in active standing than passive tilt, likely 
because of sustained muscular contraction in active standing providing ongoing 
positive chronotropic action (Tanaka et al., 1996). The differences in haemodynamic 
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parameters between active and passive upright posture in younger and older healthy 
adults are summarised in Table 4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4 Summary of haemodynamic changes in younger and older adults during active and passive upright 
posture (Key:  small increase,  larger increase,  small decrease,  larger decrease, = equilibrium 
reached, / blunted response) 
 
2.9.2 Older adults 
Differences in the haemodynamic responses between active standing and passive head-
up-tilt to assume an upright posture have also been observed in older adults above the 
age of 70 years. Like their younger counterparts there is a transient BP fall in the first 
10 seconds to posture change followed by an increase around 20 seconds after standing 
with an accompanying transient increase in heart rate. However these features were not 
observed during head-up tilt in reasonably healthy older adults who were not on any 
medication that may negatively affect postural BP control or with systemic disease 
(with the exception of anti-hypertensive medications). The response of SBP to 
Posture Age 
Group 
Haemodynamic 
parameter 
Initial 
response  
(0-10secs) 
Intermediate 
response  
(10-30secs) 
Later  
(after 30 secs) 
Active 
Upright 
Young 
adult 
HR   = 
BP   = 
TPR   = 
Older 
adult 
HR  = = 
BP   = 
TPR   = 
Passive 
Upright 
Young 
adult 
HR  = = 
BP   = 
TPR   = 
Older 
adult 
HR = = = 
BP   = 
TPR    
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standing also depended on whether participants were in the upper or lower quartile of 
supine BP, with a higher but not significant fall associated in those who were in the 
upper quartile of supine BP (Imholz et al., 1990). Thus increasing systemic BP levels 
appear to influence an effect on the BP response to tilt in older persons. 
 
It has been suggested that when a subject actively stands from a supine or sitting 
position, this only alters  the diastolic component of BP (DBP) with no significant 
change in HR or SBP  responses (Ten Harkel et al., 1990). However, earlier work 
using invasive electrophysiological studies in adults with a mean age of 50 years 
(range 18-72 years) confirms that with HUT there is an increase in HR, with 
significant increases in both systemic blood norepinephrine and epinephrine levels, and 
a lower increase in dopamine indicating an increase in sympathetic nervous system 
activation (SNSA) (Hermiller et al., 1984). Although there are some differences 
between the BP response to assuming active and passive upright posture, for practical 
reasons and for standardisation of assessment of the physiological response, HUT is 
commonly used in the research setting, as well as to aid assessment of syncope in the 
clinical setting. 
 
2.9.3 The Haemodynamic response to tilt  
Healthy older adults physiologically respond differently to passive HUT compared to 
younger adults. A tilt angle of >60º is usually used, although it has been suggested that 
the changes associated with passive tilt can be seen from as little as 20º (Hainsworth 
and Al-Shamma, 1988). In young adults the main adaptations to a fall in BP with 60º  
HUT are an increase in HR and reduction in end-systolic volume to maintain cardiac 
output and the mean arterial pressure (Shannon et al., 1991). To maintain mean arterial 
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pressure, the main response in older adults is an increase in peripheral vascular 
resistance (PVR) with a reduced ability to decrease the end-systolic volume (Shannon 
et al., 1991) as marked by a blunted HR response with sit to stand and with supine to 
60º  upright tilt with increasing age (Goldstein and Shapiro, 1990, Hainsworth and Al-
Shamma, 1988), and a reduced cardiac output with 60◦ HUT (Hainsworth and Al-
Shamma, 1988). More recently it has been found that although there is an increase in 
the systemic vascular resistance with age, this is not significant once confounders (e.g. 
waist and hip circumference, cholesterol, haematocrit etc.) were adjusted for 
(Tahvanainen et al., 2007). However the increased PWV associated with increasing 
age remained significant (p<0.05) (Tahvanainen et al., 2007). Thus the differences in 
how BP is maintained with HUT, and the increasing PWV with age, probably accounts 
in part, the rising prevalence of OH and PPH with age. 
 
2.9.4 Cerebral blood flow and postural change 
A change in posture from the supine to the upright position requires cerebral blood 
flow to adapt to maintain adequate cerebral perfusion; this is known as cerebral auto-
regulation (CA) and shall be discussed in detail later. 
 
CBF can be assessed at the macrovascular level with transcranial Doppler ultrasound 
(TCD) which measures cerebral blood flow velocity (CBFV) and also at the 
microvascular level. By using diffuse correlation and near-infrared spectroscopy to 
measure blood flow directly at the microvascular level, no significant changes to the 
relative cerebral blood flow in the frontal lobe cortex can be seen when moving from 
supine to standing in healthy older adults (Edlow et al., 2010). However there were 
significant declines in the relative cerebral blood flow across all age groups on 
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standing (Edlow et al., 2010). The initial fall in BP on assuming the upright posture in 
the first 15 seconds or so can be associated with transient symptoms of light-
headedness, dizziness and nausea. However this and its associated transient reduction 
in cerebral hypoperfusion as evidenced by a fall in the middle cerebral artery (MCA) 
velocities, detected by TCD  ultrasound, is not related to pre-syncope or orthostatic 
tolerance in young healthy volunteers (mean age 25±5 years) (Thomas et al., 2009). 
Nevertheless, the transient reductions in cerebral blood flow velocities do occur with 
the assumption of the upright posture, and the fact that these can sometimes cause 
symptoms of orthostatic intolerance, may be a clue to potential underlying changes 
associated with OH and PPH. 
 
2.10 The physiological response to eating 
The normal physiological response to meal consumption includes diversion of blood to 
the splanchnic circulation (Sidery et al., 1993) resulting in a reduction in the systemic 
vascular resistance and thus the maintenance of blood pressure requires this to be 
counteracted by haemodynamic and humoral responses (Jansen and Lipsitz, 1995, 
Fagan et al., 1986). Amongst adults (without OH) a small post-prandial decline in 
supine mean ABP of 2-5mmHg is present and does not significantly differ in groups of 
young, middle-aged or older adults (over the age of 60 years) (Oberman et al., 2000). 
Furthermore healthy older people have been shown to consistently have some 
asymptomatic reduction in BP after meals (Lipsitz and Fullerton, 1986).  
 
Forearm vascular resistance, as a surrogate marker of systemic vascular resistance, 
falls in all age groups to a similar degree, despite the higher baseline level in middle-
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aged and older adults (Oberman et al., 2000). Neurohumoral responses can be 
evaluated by determining changes in plasma levels of vasoactive peptides such as 
norepinephrine, renin, endothelin and aldosterone (Oberman et al., 2000). 
Accompanying this is a small increase in heart rate as a result of increased sympathetic 
nervous system activation (SNSA) as reflected by the increase  in plasma 
norepinephrine levels which is present in all ages (albeit greater with age) (Oberman et 
al., 2000). Plasma renin activity (also an indicator of SNSA) and renin peptides 
increase within 30 minutes post-ingestion, and subsequently declines in all groups. 
Endothelin, a vasoconstrictor, shows an age related plasma endothelin response, in 
older adults as 30 minutes after a meal the levels fall, whereas this does not occur in 
adults less than 40 years of age. Furthermore the decline in endothelin in older adults 
continues even at an hour after the meal, whereas it increased in younger adults and is 
associated with no significant change in middle-aged adults (Oberman et al., 2000). 
  
Adenosine is a vasodilator in the splanchnic circulation (Granger et al., 1978) and thus 
in part explains why caffeine as an adenosine receptor blocker (as well as associated 
sympathetic stimulation and renin-angiotensin system) can increase systemic post-
prandial BP in seated older adults.(Heseltine et al., 1991c) A rise in plasma insulin 
(which may also stimulate SNSA and thus noradrenaline (NA)) accompanies the rise 
in plasma glucose after a carbohydrate or mixed meal or oral glucose ingestion, with a 
much flatter response to oral fructose (Jansen et al., 1987, Potter JF, 1989). 
Carbohydrate and lipid dense meals both have been shown to significantly reduce the 
total peripheral index in older adults with hypertension compared to a pure protein-rich 
meal within a one hour period (Ferreira-Filho et al., 2009). 
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Meal composition can affect post-prandial changes in BP, for example there is little BP 
change following a fructose, compared to a similar energy content, glucose drink, this 
may result from  a flatter insulin response to fructose (Jansen et al., 1987).  It has also 
been shown that there is a greater fall in supine and erect SBP occurs following a high 
simple, compared to high complex, carbohydrate load (Heseltine et al., 1991a). 
Furthermore no significant BP fall is associated with a high fat meal in either the 
supine or erect positions, compared to the post-prandial fall in supine SBP and DBP 
associated with the high protein and high carbohydrate meals (Potter JF, 1989). There 
was no significant post-prandial fall in the upright position for the high protein, high 
carbohydrate or mixed meal, and additionally no post-prandial fall was associated with 
the mixed meal in the supine position (Potter JF, 1989). The actual volume load in 
addition to meal composition can also affect post-prandial BP with larger drink 
volumes of 600ml compared to 200ml being shown to attenuate the fall in BP 
associated with glucose (Jones et al., 2005). Drinking water prior to consumption of a 
meal has been shown to have a pressor response which attenuates the post-prandial fall 
in BP associated in patients with multiple system atrophy (MSA) (Deguchi et al., 
2007). It has also been suggested that the extent of a post-prandial fall in SBP can 
vary, with smaller falls associated with evening meals compared to breakfast or lunch-
time; which were also associated shorter duration of symptoms, and lower frequency 
and severity (Vloet et al., 2003). 
 
 
2.11 Changes in Cardiac BRS with age and disease 
Cardiac BRS relates to the physiological responses to the acute BP changes was found 
to decline during the third and fourth decades, with no evidence of age-related 
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reduction beyond this in those with a normal BP (Dawson et al., 1999), with similar 
results being reported in other studies (Tank et al., 2000). Others have shown a linear 
decline in BRS with increasing age, and a lower BRS in women throughout the age 
range studied (Laitinen et al., 1998) or a large reduction in BRS in those over the age 
of 58 years (Barantke et al., 2008). Studies have shown that cardiac BRS in older 
patients with a history of falls is impaired and may be involved in the underlying 
mechanism of the fall (Boddaert et al., 2004). Increasing age and BP levels have been 
found to be associated with impaired cardiac BRS and therefore there may be a 
common abnormality of cardiovascular homeostasis in hypertension and orthostatic 
hypotension (James and Potter, 1999, Carey et al., 2003, Moreira et al., 1992, James et 
al., 1996, Takeshita et al., 1975). Furthermore even amongst those with orthostatic 
intolerance without OH (i.e. those with symptoms and an increase in HR>30bpm 
within 10 minutes of standing), BRS can be abnormal (Farquhar et al., 2000). 
Similarly those with impaired reflex vasoconstriction without the BP fall, i.e. those 
with the loss of the late phase 2 of the Valsalva, as well as those with OH or borderline 
OH have been shown to have reductions in BRS (Schrezenmaier et al., 2007). Even 
amongst healthy older adults it has been shown that there is reduced heart rate 
variability related to a decline in baroreceptor function on standing compared to 
younger adults who had a larger increase in HR on standing for a similar change in BP 
(Simpson and Wicks, 1988). Thus it can be seen that changes in BRS may have a 
potential role in the pathophysiology of OH and PPH.  
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2.12 Pulse Wave Velocity, Augmentation Index and Arterial 
Stiffness 
2.12.1 Arterial stiffness and disease 
Amongst those with hypertension arterial stiffness is associated with cardiovascular 
disease and aortic stiffness is an independent predictor of primary coronary events 
(Boutouyrie et al., 2002), all cause and cardiovascular mortality (Laurent et al., 2001) 
and fatal stroke (Laurent et al., 2003). The characteristic shape of the arterial pulse 
wave varies according to the site it is detected due to the associated morphology of the 
arterial tree, and also changes with age. The contours of the radial pulse, with 
increasing age in adulthood, shows a progression of a broadening systolic peaks in 
early systole. In the carotid artery the wave shows another peak towards late systole 
and indicates the SBP. As age increases beyond the third decade the two peaks merge, 
with the second one remaining dominant. The femoral pulse also shows a progressive 
increase in the systolic component with an accompanying disappearance of the 
diastolic component with advancing age (Kelly et al., 1989). 
 
Pulse wave velocity (PWV) reflects arterial stiffness which in turn influences BRS, 
and thus a high PWV indicates stiff arteries and impaired BRS (Eveson et al., 2005). 
Augmentation Index  (AIx) has been suggested as a surrogate marker of arterial 
stiffness showing significant correlation with PWV in rabbits (Obara et al., 2009) and 
humans (Yasmin and Brown, 1999). However other studies failed to find AIx 
correlating with PWV in healthy adult humans (Gurovich et al., 2009). Together with 
PWV, AIx is a useful indicator of arterial stiffness, separate from brachial BP 
measurement alone (Wilkinson et al., 1998a). Increases in PWV have been associated 
with higher postural falls in BP, and a higher mean PWV has been found in those with 
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OH. However it should be noted that the difference between mean PWV between these 
two groups was small (around 0.5ms
-1
) and associated with a wide confidence interval 
for the OH group (Mattace-Raso et al., 2006). A relationship between arterial stiffness 
and OH would be suggested by the fact that a higher pulse pressure is associated with 
OH. It has been recently shown in a study of 994 adults (over the age of 80 years, 
mean age 88 ±5 years) that those with OH have a higher augmentation index 
(31.1±SD14.0%) compared to those without (27.2±SD13.6%; p<0.01) (Valbusa et al., 
2012). Although the less direct method of assessing arterial stiffness was shown to be 
higher the more direct carotid-femoral pulse wave velocity was not significantly 
different (Valbusa et al., 2012). Thus it can be seen that arterial stiffness may 
potentially have a role to play in the underlying pathophysiology of OH and PPH. 
 
2.13 Cerebral auto-regulation and ageing 
It has been shown that ageing per se does not alter dynamic CA (dCA), unlike other 
important haemostatic regulatory mechanisms such as cardiac baroreceptor function 
(Carey et al., 2000). Furthermore previous work has been shown that the static and 
dynamic cerebral ARI are not affected by hypertension in middle aged or older people 
within the range studied (systolic 137-206mmHg, diastolic 71-121mmHg) (Eames et 
al., 2003). Profound falls in cerebral blood flow velocities occur with small reductions 
in systemic BP in patients with auto-regulatory failure (Novak et al., 1998). Of note, in 
a small study of five subjects, mean age of 41 years, it was suggested that CA 
dysfunction causing loss of consciousness can occur without the presence of systemic 
hypotension (Grubb et al., 1998). Paradoxical changes in CBFV and cerebrovascular 
resistance during provoked hypotension in patients with recurrent unexplained and 
neurally mediated syncope also suggest abnormal CA.(Grubb et al., 1991a, Schondorf 
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et al., 1997, Folino, 2006) Similarly this has been found in a small TCD study of PPH 
in institutionalised patients (Krajewski et al., 1993).  
 
2.14 Dynamic cerebral auto-regulation and arterial baroreceptor 
sensitivity 
Whilst it is recognised that the baroreflex arc helps maintain systemic BP levels within 
a specific range and that cerebral auto-regulation maintains cerebral blood flow, the 
relationship between CA and BRS is unclear. However it has been shown that in 
young healthy adults that there may be a compensatory mechanism liking BP and 
cerebral blood flow control as those with attenuated dynamic CA had a higher BRS 
(Tzeng et al., 2010). Dynamic CA was measured using both the rate of regulation 
(RoR) and auto-regulatory index from the thigh-cuff release method as well as the 
transfer function of spontaneous oscillations in BP and mean CBFV. Inverse 
relationships between RoR and ARI were found with BRS, whilst a positive 
relationship was found between transfer function gain and BRS (Tzeng et al., 2010). 
 
2.15 Cerebral auto-regulation and symptoms in subjects with OH 
and PPH 
The causes of symptoms associated with a change in posture from supine/sitting to 
standing have been debated (Mader et al., 1987, Low et al., 1995, van Osch et al., 
2005, Khandelwal et al., 2011). It has been suggested that symptoms were simply 
related to cerebral hypoperfusion but others have not shown a definite relationship 
between postural BP changes and associated symptoms. A magnetic resonance 
imaging cerebral perfusion study in symptomatic OH patients has raised the possibility 
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of a link between the high cerebral blood volume (possibly as a result of 
vasodilatation), increases in the mean transit time  of blood flow and a trend towards a 
decrease in CBF in the supine position and the severity of postural falls in BP (van 
Osch et al., 2005). However other work has shown no difference in supine cerebral 
blood flow velocities (CBFV, the surrogate of CBF) between healthy controls and 
those with OH (individuals for which HUT resulted in a fall in SBP ≥30mmHg, DBP 
≥10mmHg or MBP ≥15mmHg) despite the higher resting supine HR and BP (Novak et 
al., 1998). It has been suggested that those with OH can be grouped according to three 
differing auto-regulatory responses based on the relationship between CBFV and BP; 
however this was not correlated with symptoms. The groups include: 1) impaired auto-
regulation and a flat CBFV-BP curve, 2) intact auto-regulation with an expanded auto-
regulatory range and 3) failed auto-regulation with a steep CBFV-BP regression curve 
(Novak et al., 1998). Furthermore a study comparing fifteen patients with OH and 
fifteen matched control participants (mean age 41.8 ±12.9 years and 42.0 ±11.8 years 
respectively) found a significant reduction in CBF amongst those with OH during 
HUT. Furthermore there amongst those with OH, the seven symptomatic patients had a 
significantly greater percentage fall in CBF compared to the eight asymptomatic 
patients (median 38.8, IQR 25.7 to 41.7 versus median 18.7, IQR 9.95 to 23.09) 
(Khandelwal et al., 2011). This suggests that those with OH with HUT have falls in 
CBF and have evidence in CA, and that those with symptoms have a greater fall in 
CBF which may account for symptoms. 
 
Another surrogate marker of CA is the pulsatility index (PI) is defined as the 
difference between the end diastolic and the peak systolic amplitude of cerebral blood 
flow velocity divided by the mean cerebral blood flow velocity i.e. PI= (Peak systolic 
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amplitude CBFV – End diastolic amplitude CBFV)/mean CBFV. A reduced PI is 
found in those with autonomic nervous system dysfunction (pure autonomic failure 
and multiple system atrophy) compared to healthy controls when using lower body 
negative pressure induced by thigh cuff inflation as a depressor stimulus in the supine 
position (Lagi et al., 1994). However others have shown that CA is preserved in 
autonomic failure when a modest 45° head-up-tilt is used as a reactive vasodilatation 
occurs which lowers CBFV and vascular resistance to maintain CBF (Brooks et al., 
1989). This modest HUT is less than the majority of other studies who use a tilt of at 
least 60°. Thus there is conflicting evidence as to how CA and autonomic dysfunction, 
and potentially OH in older people may be linked. Whether it is due to the differing 
methodology of the studies (lower body negative pressure versus HUT), or perhaps a 
variable pathophysiological mechanism needs to be considered. 
 
A small study in institutionalised older people with mean age 84.9 years 
(SD±7.9years) showed that after a mixed meal, the fall in SBP, DBP and mean arterial 
pressure within 55 minutes, was not associated with significant changes in the 
maximum or mean cerebral blood flow velocity. However there was an increase in the 
PI during this period suggesting an increase in arteriolar resistance. In the control 
group where no meal was given, there were no changes in BP, CBFV or PI. 
Participants were in the sitting position throughout. Post-prandial hypotension 
participants had a fall in SBP of mean 32mmHg (SD±15mmHg), whilst the remainder 
had a fall in SBP of 3mmHg (SD±10mmHg) (Krajewski et al., 1993). Thus this 
suggests that if PI as a surrogate of the adequacy of CA, then perhaps symptoms in 
PPH, may also be related to CA, rather than systemic falls in BP. 
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At the time of writing the research protocol for this PhD thesis in late 2009 there had 
been no studies published assessing any potential differences in dCA for those patients 
with and without orthostatic symptoms in relation to actual postural BP changes. 
Although it has been shown that cerebral vasoconstriction even in young healthy adults 
occurs with graded orthostatic stress using lower body negative pressure, and that this 
may potentially worsen any reduction in CBF associated with systemic hypotension 
(Levine et al., 1994). Furthermore another study found that those with symptomatic 
OH have a higher CBF in the supine position compared to controls (van Osch et al., 
2005). However since late 2009, a study of 30 participants (in two groups, 
symptomatic vs. asymptomatic, with similar falls in BP) showed that those with 
symptoms showed a significant fall in cerebral blood flow on 70º HUT within a five 
minute period (p=0.003) compared to baseline whereas the asymptomatic participants 
did not ( baseline: symptomatic group 33.46ml/100ml tissue/min, range 20.38-38.57 
ml/100ml tissue/min vs asymptomatic group 31.30 ml/100ml tissue/min range 24.64-
32.16 ml/100ml tissue/min; 5 minutes HUT: symptomatic group 25.40 ml/100ml 
tissue/min range 21.0-30.76 ml/100ml tissue/min vs asymptomatic group 27.84 
ml/100ml tissue/min, 21.59-32.31 ml/100ml tissue/min) (Khandelwal et al., 2011). 
Furthermore the study also suggested that the decrease in cerebral conductance 
(cerebral flow divided by SBP) amongst those with symptoms implied a loss in auto-
regulation of CBF, whereas those who were asymptomatic had auto-regulation of CBF 
as there was an increase in cerebral conductance over the 5 minutes of HUT 
(Khandelwal et al., 2011). These differences would suggest that there are differences in 
dCA between those with symptoms and those asymptomatic of OH, and those without 
OH who have symptoms suggestive of OH and those who do not. 
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2.16 Summary of the issues 
There are several questions arising from the above discussion. Given that both OH and 
PPH are relatively common, what drug treatments are there available, and what ones 
may be best. Furthermore what remains unclear is why only some patients are 
symptomatic with a drop in BP with posture change or after ingesting a simple 
carbohydrate meal, and yet why others have no systemic BP changes but have 
symptoms suggestive of OH or PPH. Symptomatic individuals may have underlying 
abnormalities in cerebral auto-regulation (CA) and perhaps alterations in autonomic 
function as evidenced by impairment of spontaneous cardiac baroreflex sensitivity 
(BRS) and associated arterial stiffness (Eveson et al., 2005). We do not know if the 
higher prevalence of OH in the older population is a direct reflection of these 
abnormalities, which may in part be related to increasing arterial stiffness per se, or 
additionally due to some other mechanisms affecting CA. Furthermore as some 
patients have OH with other types of syncope (McIntosh et al., 1993), there may be a 
common mechanism for these conditions involving changes in arterial stiffness and 
CA.  
 
Thus the aims of this thesis are: 
o To assess the drug treatment of OH with a systematic review  
o To assess the drug treatment of PPH with a systematic review  
o Orthostatic Hypotension Study - To investigate if there are abnormalities in 
dynamic cerebral auto-regulation, BRS and arterial stiffness in relation to the 
symptoms of orthostatic hypotension in patients with and without a postural BP 
fall 
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o Post-prandial Hypotension Study - To investigate if there are abnormalities in 
cerebral auto-regulation, BRS and arterial stiffness in participants with and 
without a history of symptoms suggestive of post-prandial hypotension. 
 
The hypothesis is: 
Abnormalities in dynamic cerebral auto-regulation explain why some patients have 
postural symptoms independent of changes in arterial blood pressure in both 
orthostatic hypotension and post-prandial hypotension. 
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3 A systematic review of the pharmacological 
management of orthostatic hypotension 
 
This Chapter has been published elsewhere:  
ONG, A. C., MYINT, P. K., SHEPSTONE, L. & POTTER, J. F. 2013. A systematic 
review of the pharmacological management of orthostatic hypotension. Int J Clin 
Pract, 67, 633-46. 
 
3.1 Introduction 
OH is a common condition in older adults (Poon and Braun, 2005, Mader et al., 1987), 
varies in the presence (Lahrmann et al., 2006, Davis et al., 1987) or absence of 
symptoms, and is associated with morbidity and mortality (Davis et al., 1987, Rose et 
al., 2006). The varying controversies around the definition of OH in terms of timing, 
duration and size of BP changes and its multiple causations have been described in the 
previous Chapter (Moya et al., 2009), (Lahrmann et al., 2006, Deegan et al., 2007, 
Freeman et al., 2011, Romero-Ortuno et al., 2010).  
 
Various drug treatments have been tried in the management of OH, although only two 
are recommended in the recent ESC guidelines (Moya et al., 2009), i.e. ﬂudrocortisone 
(Campbell et al., 1975, Decaux, 1979) and midodrine (Jankovic et al., 1993, Hoeldtke 
et al., 2006, Kaufmann et al., 2002). Other agents that have been tried include 
pyridostigmine (Singer et al., 2006) , dihydroergotamine (Bellamy and Hunyor, 1984, 
Bevegard et al., 1976, Fouad et al., 1981), D,L-3,4-threo-DOPS (Birkmayer et al., 
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1983), octreotide (Bordet et al., 1995), yohimbine (Shibao et al., 2010), domperidone 
(Montastruc et al., 1985), Korodin (Belz et al., 2002) along with increasing dietary 
sodium intake (Claydon and Hainsworth, 2004) and non-pharmacological methods, 
e.g. abdominal compression or lower limb bandaging, sleeping head up, drinking 
water, as well as strength training. However, the quality of evidence of beneﬁt from 
these studies has been limited by the fact that many are methodologically ﬂawed, 
lacking randomisation, blinding, a control group and were of short duration. The 
magnitude of the effects of these therapeutic agents in a randomised controlled trial 
setting has not been examined systematically using meta-analysis techniques. Thus, the 
objective of this report was a systematic review of blinded randomised controlled 
studies involving the pharmacological management of OH using a ‘single dose’ and 
‘repeated doses’.
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3.2 Methods 
3.2.1 Study selection 
3.2.1.1 Eligibility and selection criteria  
All single- or double-blind, randomised controlled trials, which compared the efﬁcacy 
of a drug treatment with placebo or another drug in the treatment of OH in humans 
over the age of 18 years, were eligible to be considered. This included ‘single dose’ 
use of a drug (i.e. single-dose studies, or where the effect of a drug on blood pressure 
was measured for up to 24 hours after dosing) and studies where treatment involved 
‘repeated doses’ and where blood pressure (BP) measurements were made over at least 
48 hours. We used the original study authors’ deﬁnition of OH because of the 
considerable variability in the criteria between studies. The causes of OH in the studies 
selected included pure autonomic failure, multiple system atrophy, Parkinson’s 
disease, diabetes mellitus and idiopathic OH. To be eligible, the studies needed to 
report changes in supine or sitting and standing [or head-up-tilt (HUT)] systolic (SBP) 
and diastolic blood pressure (DBP) and/or mean arterial pressure (MAP). The study 
characteristics of eligible longer term studies and short-term studies are shown in 
Table 5 and 8, respectively. 
 
3.2.1.2 Information sources  
OVID SP MEDLINE (1950-Week 7, 2011), OVID SP EMBASE (1980-Week 7, 
2011), CINAHL (Week 7, 2011) were systematically searched on the 28th of February 
2011. Hand-searching of the bibliography of the full-text articles and cross-referencing 
with de-duplicated screened articles was also carried out (Figure 11). 
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3.2.1.3 Search  
Searches were limited to ‘English language’ and ‘humans’. The following individual 
terms were used: ‘orthostatic hypotension.mp. or exp Hypotension, Orthostatic/’, 
‘postural hypotension.mp. or exp Hypotension, Orthostatic/’, ‘ﬂudrocortisone.mp. or 
exp Fludrocortisone/’, ‘exp disease management/or exp medication therapy 
management/’, ‘exp therapeutics/or exp clinical protocols/or exp drug therapy/ or 
patient care/or exp placebos/’, ‘drug treat- ment.mp.’, ‘drug management.mp.’, 
‘droxidopa.mp. or exp threo 3, 4 dihydroxyphenylserine/’, ‘korodin.mp. or exp 
camphor/’, ‘domperidone.mp. or exp Domperidone/’, ‘ergotamine.mp. or exp 
Ergotamine/ ’, ‘octreotide.mp. or exp Octreotide’, ‘salt.mp. or exp sodium chloride/’, 
‘midodrine.mp. or exp Midodrine/’, ‘Pyridostigmine.mp. or exp Pyridostigmine 
Bromide/’, ‘propranolol.mp. or exp Propranolol/’. The ﬁrst two were individually 
combined with each of the subsequent terms. All results were imported by ACLO into 
Endnote X4, de-duplicated, and those relevant to OH were screened for any relevant 
articles for its pharmacological treatment. This included papers on the use of 
erythropoietin amongst others. These full-text articles were then independently 
assessed by three authors (ACLO, JFP and PKM). 
 
3.2.2 Data extraction and synthesis 
3.2.2.1 Data collection  
Data from the studies in Table 5 and Table 8 were extracted by one observer (ACLO) 
on a specially designed form and the data were then independently checked by two 
blinded observers (JFP and PKM). Authors were contacted, where possible, when 
essential data were not available from the published papers. 
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3.2.2.2 Data items 
Information on study participant characteristics (age, sex, and diagnosis), trial 
inclusion/exclusion criteria and drug intervention including dose and duration of 
treatment was extracted. The outcome measures of the responses in SBP and DBP 
and/or MAP including baseline and on treatment for all arms of the study were 
recorded where available. 
 
3.2.2.3 Risk of bias in individual studies  
Eligible trials were reviewed regarding adequacy of randomisation, concealment of 
allocation, blinding and loss to follow up, as well as transparency of reporting based on 
current recommendations (Higgins and Green, 2008). 
 
3.2.2.4 Synthesis of results  
Eligible trials were categorised into ‘repeated doses’ treatment where pharmacological 
agent(s) had been administered for over 24 hours and included more than one dose, 
and the resulting effects on standing or HUT SBP and DBP were examined. For 
‘single dose’ treatment trials, we considered those where a single dose of an agent had 
been given and the subsequent effects on blood pressure assessed. Because of the 
variability in the parameters the papers presented, a meta-analysis was not considered 
suitable. Data are presented as mean ±SD unless otherwise stated. 
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Records identified via EMBASE  
(n =4713), MEDLINE (n = 2709), 
CINHAL (n=168) 
(n = 7590) 
Additional records 
identified via hand-search 
(n =2)  
Records after duplicates removed 
(n = 2834) 
Records screened 
(n = 708 ) 
Records excluded 
from abstract  
(n = 611) 
Full-text articles assessed for 
eligibility 
(n = 97) 
Full-text articles 
excluded as not blinded 
randomised controlled 
trials 
(n = 84) 
Studies where drugs used 
‘Single dose’ 
(n = 8) 
Studies where drugs used 
‘Repeated doses’ 
(n = 5) 
Figure 11 Flow diagram of Orthostatic Hypotension Treatment Systematic Review 
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Study Design Characteristics Inclusion Exclusion Groups Outcome measures 
Fludrocortisone 
Campbell et al 
1975 (UK) 
 
Randomised 
double-blind 
placebo 
controlled 
cross-over trial 
Sex: 6M  
Data for 5 
Age 52.2 (11.4 ) 
years  
Diabetes 
symptomatic OH ≥30mmmHg 
SBP reduction 
Autonomic neuropathy confirmed 
 
Ischaemic heart disease or 
cardiac failure 
3 week control period before and 
between 
Fludrocortisone 0.1mg bd, 3 
weeks 
Versus 
Placebo, 3 weeks 
SBP, DBP and HR 
after 10 minutes 70* 
HUT (mean of 
minute interval 
measurements) 
 
Kaufmann et al 
1988 (USA) 
 
 
Randomised 
double blind  
placebo 
controlled 
crossover trial 
 
Sex: 1M, 6F 
Data for 7 
Age: 59.1 (7.6) 
years 
 
OH due to autonomic failure (1-
15 years duration) 
Severe OH not defined 
 
Peripheral neuropathy 
based on nerve 
conduction studies 
+clinical examination 
2 days washout between drugs 
0.1mg fludrocortisone + placebo, 
1 week  
versus 
0.1mg fludrocortisone + 
midodrine (0.5mg per kg), 1 week 
Upright MAP±SE 
(after 2 minutes 
stand) 
 
MAP=DBP+1/3(SB
P-DBP) 
 
Schoffer et al 
2007 (Canada) 
 
 
Randomised, 
double-blind 
cross-over trial 
(Phase 2) 
Sex: 13M, 4F 
13 in drug part 
of trial 
Age: 69 
(11)years 
Idiopathic P, duration 6.0(4.5) 
years 
Sustained response to PD 
medication, stable during study, 
symptomatic orthostasis 
Postural drop SBP+/or DBP at 
baseline 
Acute Coronary 
Syndrome, unable to 
consent, other cause for 
autonomic failure, 
SBP>200 or DBP >100 
1/52 washout between drugs 
0.1mg fludrocortisone od 
(placebo bd), 3 weeks 
versus 
Domperidone 10mg tds, 3 weeks 
 
Reduction in SBP 
and DBP at 3min, 
5min after 80*HUT, 
mean(SD) 
Midodrine 
Jankovic et al 
1993 (USA) 
 
 
Randomised 
double-blind 
placebo 
controlled 
parallel group 
trial  
 
Sex: 53M, 44F 
Data for 75 only 
 
Mean age: 61 
(range 22-86) 
years 
 
 
OH due to idiopathic OH, DM, 
PD (0.5-10 years duration) 
Moderate-severe OH with 
Autonomic failure + history 
syncope/near syncope 
+SBP reduction ≥15mmHg 
(Supine to stand) or ≥ 2 OH 
symptoms 
Supine hypertension 
>180/110 
Renal/hepatic impairment 
Phaeochromocytoma 
Severe cardiac 
abnormalities 
1/52 single blind placebo run in 
 
Placebo (18) 4 weeks 
versus 
Midodrine (total of 57) 2.5mg 
(17); 5mg (19); 10mg (21) tds 4 
weeks 
 
SBP, DBP and HR  
supine + stand 
(mean±SE) 
 
Fouad-Tarazi et 
al 1995 (USA) 
 
 
Randomised 
double-blind 
placebo 
controlled 
cross-over trial 
Sex: 4M, 4F 
Data for 8 
Age: 60.4 (13.5) 
years 
 
OH due to idiopathic OH, MSA, 
duration 5.9 (4.6)years 
 
OH BP not defined 
 
Unable to tolerate other treatment  
Supine hypertension 
>180/110 
Symptomatic coronary 
disease, Acute/chronic 
renal failure, 
Thyrotoxicosis 
2/7 single blind placebo run in 
 
Placebo 4 days 
versus 
Midodrine titrate 3-5 days, 
maintenance 3-5 days (mean 
SBP, DBP and HR 
supine + stand, 
mean(SD) 
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Significant Liver disease, 
Phaechromocytoma, 
Dementia 
MAOI 
8.4mg tds) 
versus 
Ephedrine titrate 3-5 days, 
maintenance 3-5 days (mean 
22.3mg tds)  
Low et al 1997 
(USA) 
 
Randomised 
double-blind  
placebo 
controlled 
parallel group 
trial 
Sex: 81M, 81F 
Data for 162 
(171 
randomised) 
Age: 60 (1.7) 
years 
(midodrine); 
59(1.7) years 
(placebo) 
 
OH due to idiopathic OH, PD, 
DM  
>15mmHg orthostatic reduction 
with 
symptoms  
Concomitant fludrocortisone + 
compression garments allowed 
45/89 in placebo group, 33/82 in 
midodrine group – no significant 
difference 
Pregnant or lactating 
Supine hypertension 
>180/110 
1/52 single blind placebo run in 
 
Midodrine (40M, 39F) 10mg tds, 
3 weeks 
versus 
Placebo (41M, 42F), 3 weeks 
 
 
SBP and DBP mean 
change (no SD) 
 
 
Other 
Cleophas et al 
1986 
(Netherlands) 
Randomised 
double-blind , 
placebo 
controlled 
cross-over trial 
(Trial 2) 
Sex: unknown 
N=10 
Mean age: 55.1 
(range 28-79) 
years 
Diabetes type 1 >10 years, 
symptoms of 
dizziness/collapses/near collapse 
Other symptoms of autonomic 
neuropathy 
Fall of MAP of ≥10mmHg at 
clinic 
 
Exclusion unclear 1 wk single blind placebo run in 
 
Pindolol 5mg tds, 1 week 
Versus 
Placebo, 1 week 
 
SBP supine + stand 
(mean±SE)  
Kroll et al 2005 
(Germany) 
Randomised 
double blind 
placebo 
controlled 
parallel groups 
trial 
Sex: 22M, 16F 
Data for 38  
Age: 65.6(6.3) 
(Korodin); 
 71.8(8.6) 
(placebo) 
OH on 2 visits, ≥50yrs 
Orthostatic dysregulation = 
reduction SBP ≥20mmg OR 
reduction DBP ≥10mmHg within 
3 minutes in upright position 
Severe hypotension, 
cardiovascular disease 
e.g.myocardial infarction 
≤ 3months, arrhythmia, 
angina, acute autoimmune 
disease, clinically 
significant pulmonary, 
hepatic, gastrointestinal, 
neurological or 
haematological disease or 
cancer 
Korodin 25 drops tds (1 
drop=1mg D-camphor+38.62mg 
cratageus berry extract) (13M, 
8F) 1 week 
versus 
Placebo (9M, 8F) 1 week 
 
MAP supine + stand 
at 3 minutes 
 
Table 5 Summary of study characteristics of ‘Repeated doses’ drug treatment (≥24 hours) DM = diabetes mellitus, F = female, M = male, MSA = multi-system atrophy, OH = orthostatic 
hypotension, PAF = pure autonomic failure, PD = Parkinsons disease; Mean (SD) unless stated
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Study Adequate sequence 
generation 
Allocation concealment Incomplete outcome 
data addressed 
Free of selective 
reporting 
Free of other bias 
Campbell et al 
1975 (UK) 
 
Randomisation method 
unclear  
 
Unclear if recruiter aware 
Double blinded with 
placebo identical to active 
medication 
One patient left study, 
data not available 
Yes, report data intended Patient selected from  clinic – 
potential to introduce selection 
bias; confounding BP medication 
unclear 
Kaufmann et 
al 1988 (USA) 
 
 
Randomisation method 
unclear 
Unclear allocation 
concealment for double 
blinding 
No missing data Unclear, methods state 
supine and stand/sitting 
BP, but results also 
discuss changes in BP. 
Drug provided by pharmaceutical 
company, any other financial 
involvement unclear. 
Schoffer et al 
2007 (Canada) 
 
 
Computer generated 
randomisation of 
random number by 
staff not otherwise 
involved in study 
Other staff used to 
maintain double blinding 
of investigators but was 
aware of group participant 
allocated to.  Assumed that 
staff member did not have 
contact with participants 
 
Patient withdrawal 
within the first week 
13 of 17 patients data 
used for drug phase 
Yes, adverse events 
mentioned 
Recruitment from 2 clinics, 
potential selection bias  
High dropout rate  
Jankovic et al 
1993 (USA) 
 
 
Randomisation method 
unclear 
Unclear concealment 
Medication dispensed in 
double blind fashion 
Some missing BP data 
(12 out of 97 patients 
excluded) 
Missing questionnaire 
responses (63 out of 97 
used) 
Yes, report primary 
outcomes, comment on 
one protocol violation 
Unclear, 18 centres recruited 
unknown if one recruited more 
than others. Observer bias 
potential. Drug company 
distributed medication, but did 
they also provide other financial 
help? 
Fouad-Tarazi 
et al 1995 
(USA) 
 
 
Double-blind, block 
design, crossover, 
randomisation and 
sequence generation  
method unclear  
Unclear method, Double 
blind mentioned  
Missing data ephedrine 
phase  (1 patient out of 8, 
47  out of 48 cells 
analysed) 
Yes, titration and 
maintenance phase 
outcomes 
Some sitting and some standing 
BP 
 
Low et al 1997 
(USA) 
 
Multicentre double-
blind randomised 
parallel group study – 
each centre received 
double-digit number 
Study monitor off site 
ensured centres unaware of 
allocation 
Patient received coded 
containers with medication 
15% missing data due to 
drop out/adverse events 
Yes, report primary 
outcomes. 
Authors report that majority of 
participants came from 3 centres. 
Possible selection bias. Drug 
company financial grant 
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Table 6 Assessment of risk of bias of ‘Repeated doses’ treatment for OH 
and pre-randomised 
codes, unclear method 
of randomisation 
Cleophas et al 
1986 
(Netherlands) 
Block randomisation 
method unclear 
Unclear allocation 
concealment, but double 
blinded with placebo group 
same number of daily 
tablets 
No missing data Unclear (DBP not 
reported) 
Unclear, no financial statement 
Kroll et al 
2005 
(Germany) 
Computer 
randomisation with 
variable block length 
Placebo same colour, 
medication bottled. Pre-
numbered based on 
randomisation. Masking of 
group throughout. 
Good concealment of 
allocation allowing double 
blinding 
 
39 randomised, 1 
unknown treatment 
group thus not evaluated 
Yes Rehabilitation unit clinic and two 
doctor’s practices, potential 
confounders 
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3.3 Results 
3.3.1 Systematic review of ‘Repeated doses’ drug interventions  
Eight repeated doses studies (Campbell et al., 1975, Jankovic et al., 1993, Kaufmann et 
al., 1988, Schoffer et al., 2007, Fouad-Tarazi et al., 1995, Low et al., 1997, Cleophas et 
al., 1986, Kroll et al., 2005) fulﬁlled selection criteria for inclusion in the systematic 
review, their characteristics and risk of bias are shown in Table 5 and Table 6, 
respectively, with the full compilation of results being available online (Supplementary 
Table 1, http://onlinelibrary.wiley.com/doi/10.1111/ijcp.12122/suppinfo). The risk of 
bias was considered moderate, due to the lack of clarity over methods of randomisation 
and concealment of allocation. There was considerable variability between these eight 
studies in terms of what comparable data parameters and respective standard 
deviations were presented making it difﬁcult to carry out a meta-analysis. Table 7 
shows a summary of drug effectiveness. 
 
3.3.1.1 Midodrine studies  
In a 6- to 10-day duration cross-over trial of eight subjects with idiopathic OH or 
multi-system atrophy (mean duration of 5.9 SD ± 4.6 years) who were unresponsive to 
ﬂudrocortisone, support stockings or a high salt diet (Table 5). Fouad-Tarzi et al. 
(1995) compared the effects of midodrine and ephedrine with placebo on the BP 
changes from baseline. They found that a mean titrated dose of midodrine of 8.4 mg 
tds over 3–5 days, with a maintenance dose given for a further 3–5 days signiﬁcantly 
increased standing SBP from a baseline mean of 89 (± 8) mmHg to 106 (± 11) mmHg 
(p < 0.05). Standing SBP on midodrine was signiﬁcantly higher compared with 
placebo (106 ± 11 vs. 87 ±13 mmHg, p < 0.001)) or a mean 22.3 mg tds dose of 
ephedrine (90 ± 13 mmHg, p < 0.001). There was similar signiﬁcant improvement in 
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the standing DBP values after treatment with midodrine (69 ±9 mmHg, p < 0.001) 
compared with placebo (61 ± 9 mmHg) and ephedrine (63 ± 9 mmHg). They 
concluded that midodrine improved standing BP and symptoms. 
 
Jankovic et al. (1993) randomised 75 subjects with OH (mean postural fall SBP 44 ± 
27 mmHg) attributable to autonomic failure of varying aetiologies, in a parallel group 
trial to 4 weeks using stepped doses of midodrine 2.5 mg, 5 mg and 10 mg tds or 
placebo. The 10 mg tds dose increased standing SBP (by 22 ± 4 mmHg) from a 
baseline value of 94 ± 7 mmHg, p < 0.001; however, this was accompanied by a 
signiﬁcant increase in the supine SBP (13 mmHg, no SD reported, p < 0.05) to a mean 
of 174 ±7 mmHg. A subgroup analysis of patients whose mean postural BP fall was > 
15 mmHg pre-treatment, demonstrated that midodrine 10 mg tds improved the 
standing SBP by 31% (p < 0.01) and standing DBP by 15 mmHg (no SD given, p < 
0.05) from a pre-midodrine level of 62 ± 3 mmHg. The authors suggested that 
midodrine was effective for moderate-to-severe OH associated with autonomic failure. 
The randomised, double-blind controlled trial by Low et al. (1997) reported the mean 
change in supine and standing BP for systolic and diastolic components with 
midodrine and placebo, but no accompanying standard deviation, giving only the 
percentage change. They used a parallel group design to administer 3 weeks of placebo 
or midodrine 10 mg tds after a 1-week placebo run-in period. One hundred and sixty-
two subjects with OH resulting from Brad- bury-Eggleston syndrome, Shy-Drager 
syndrome, Parkinson’s disease and diabetes mellitus were studied after 15 days of 
midodrine 10 mg tds or placebo, which resulted in a signiﬁcant standing SBP increase 
compared with placebo (22.4 mmHg, p < 0.01). This was independent of the 
concomitant use of ﬂudrocortisone, compression garments or both, in the midodrine 
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and placebo groups. Thirty three of 82 subjects randomised to midodrine took 
ﬂudrocortisone and 18 compression hosiery compared with 45 of 89 in the placebo 
group who also received ﬂudrocortisone and 17 used compression stockings with no 
signiﬁcant difference between the groups. Midodrine signiﬁcantly improved the 
standing SBP as well as the global evaluation as assessed by both investigator and 
study subject. 
 
3.3.1.2 Fludrocortisone studies  
Fludrocortisone 0.1 mg bd given in a 3-week cross- over study of ﬁve diabetic patients 
with symptomatic OH (7) resulted in a signiﬁcantly higher mean tilted SBP (154 ± 29 
mmHg) compared with after placebo (110 ± 16 mmHg, p < 0.005). There was also a 
signiﬁcant reduction (p < 0.001) in the postural BP fall (supine SBP 180 ± 26 mmHg, 
tilted SBP 154 ± 29 mmHg) on ﬂudrocortisone, compared with placebo (supine SBP 
149 ± 21 mmHg, tilt SBP 110 ± 16 mmHg). The overall conclusion drawn was that 
ﬂudrocortisone was an effective treatment for patients with diabetes and symptomatic 
postural hypotension. Schoffer et al. (2007) found no signiﬁcant reduction in maximal 
drop in BP at 3 minutes of standing, with domperidone 10 mg tds and ﬂudrocortisone 
0.1 mg od compared with baseline. However, the drop in SBP at 3 minutes was similar 
with ﬂudrocortisone (mean 21 ± 24 mmHg), and domperidone (18 ± 23 mmHg) and 
was not signiﬁcantly different from the baseline fall of 35 ± 23 mmHg. For DBP, the 
corresponding mean differences were 8 ± 13 mmHg and 7 ± 15 mmHg, respectively, 
compared with baseline 7 ± 7 mmHg. Although the investigators of the study 
concluded that the symptoms and postural BP fall improved with both domperidone 
and ﬂudrocortisone, the study was omitted as it only reported BP change on tilt rather 
than the actual BP values and no SDs were given. A cross-over study in seven 
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participants, with OH resulting from autonomic dysfunction, by Kaufmann et al. 
(1988) demonstrated a variable response in MAP in individual patients with midodrine 
alone, ﬂudrocortisone alone and the combination of both. In three participants, there 
was a signiﬁcant improvement in MAP between baseline and midodrine, but lower in 
another participant. MAP was signiﬁcantly lower with ﬂudrocortisone in two 
participants, with a signiﬁcant increase in only one participant. In Supplementary 
Table 1 (http://onlinelibrary.wiley.com/doi/10.1111/ijcp.12122/suppinfo) we have 
calculated the change in MAP to give some comparison with other studies. 
 
Other drug interventions Cleophas et al. (1986) reported that pindolol 5 mg tds in 11 
participants with diabetes reduced the postural SBP fall, there being no signiﬁcant 
difference between supine and standing BP after active treatment. Kroll et al. (2005) 
report that the median reduction in MAP was less with Korodin (11.4 mmHg) 
compared with placebo (14.0 mmHg). The box and whisker plots clearly in the 
publication illustrate both a deterioration and improvement in MAP for both single 
dose and with 1 week of application.  
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The following table summarises the repeated doses treatment of OH Table 7. 
 
Study Drug Improve postural 
BP 
Improve symptoms 
Campbell et al 1975 
(UK) 
 
Fludrocortisone Yes Yes 
Kaufmann et al 1988 
(USA) 
 
 
Midodrine Some Some 
Fludrocortisone Some Some 
Schoffer et al 2007 
(Canada) 
 
 
Fludrocortisone Yes Yes 
Domperidone  Yes Yes 
Jankovic et al 1993 
(USA) 
 
 
Midodrine Yes Yes 
Fouad-Tarazi et al 
1995 (USA) 
 
 
Ephedrine 
 
No No 
Midodrine Yes Yes 
Low et al 1997 (USA) 
 
Midodrine Yes Yes 
Cleophas et al 1986 
(Netherlands) 
Pindolol Yes Yes 
Kroll et al 2005 
(Germany) 
Korodin Yes Yes  
Table 7 Overall study conclusions for ‘Repeated doses’ treatment 
 
3.3.2 Systematic review of ‘Single dose’ drug intervention  
Five studies (Bordet et al., 1995, Wright et al., 1998, Kaufmann et al., 2003, Freeman 
et al., 1999, Singer et al., 2006) were eligible for inclusion in the systematic review. 
The study characteristics and risk of bias within these studies are shown in Table 8 and 
9, respectively, with a full compilation of results being available online as 
Supplementary Table 2 
(http://onlinelibrary.wiley.com/doi/10.1111/ijcp.12122/suppinfo).  
 
Table 10 shows a summary of drug effectiveness. Risk of bias was considered 
moderate due to unclear randomisation methods and allocation concealment.
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Study Design Characteristics Inclusion Exclusion Groups Outcome measures 
Wright et 
al 1998 
(USA) 
Randomised 
double-blind 
placebo 
controlled 
cross-over 
trial 
Sex:11M, 14F 
Data for 24 
Age: 62 (38-78) 
years 
Orthostatic hypotension 
with SBP reduction from 
supine to stand of 
≥15mmHg and 
symptoms 
Pregnancy, lactating, supine 
hypertension ≥180/110, 
sympathomimetics/ vasoactive 
drugs, significant systemic, cardiac, 
renal or gastrointestinal disease 
Single dose  
Placebo vs 2.5mg 
midodrine vs 10mg 
midodrine vs 20mg 
midodrine 
Breakfast 2 hours before 
 
Standing SBP after 1 
to 6 hours (mean, SE) 
measured after 1 
minute standing (and 
up to 15 minutes) 
Bordet et al 
1995 
(France) 
Randomised 
double blind 
placebo 
controlled 
cross-over 
trial 
Sex: 3m, 6F 
Data for all 
Age: 71 (6.8) 
years 
MSA 
OH if SBP decreased by 
>30mmHg or DBP by 
20mmHg within 5 
minutes of standing 
symptomatic 
Diabetes, amyloidosis Single dose 
Placebo vs octreotide 
100µg subcutaneous 
injection 
Breakfast 3 hours before 
 
 
SBP, DBP, MBP 
Supine and minimal 
levels on 60◦ HUT  
Kaufmann 
et al 2003 
(USA) 
Randomised 
double blind 
placebo 
controlled 
cross-over 
trial 
Sex: 15M, 4F 
Data for all 
Age: 64 (2)
a
 years 
MSA, PAF 
Symptomatic orthostatic 
hypotension, decrease of 
systolic/diastolic BP 
>20/10mmHg on 
standing (no time period 
specified) 
 
Hypertension >180/110mmHg, 
significant coronary artery, 
cerebrovascular, peripheral vascular 
disease or cardiac arrhythmias 
Single dose  
L-DOPS (200-2000mg) 
vs placebo capsules 
On fludrocortisone 
Breakfast 1 hour before 
Supine MAP, MAP 3 
minutes after 
standing, up to 12 
hours from baseline 
Freeman et 
al 1999 
(USA) 
Randomised 
double blind 
placebo 
controlled 
cross-over 
trial 
Sex: 7M, 3F 
Data for all 
Age: 60 (18.1)
a
 
years 
Age 20-70 years with 
symptomatic neurogenic 
orthostatic hypotension 
SBP decrease ≥20mmHg 
or DBP ≥10mmHg 
within 3 minutes of 
standing 
Other causes of OH, systemic 
illness affecting autonomic 
function, significant coronary 
artery, cerebrovascular or 
peripheral vascular disease or 
malignant cardiac arrhythmias, 
where relevant not on birth control, 
medications affecting vasomotor 
function that could not be 
discontinued (except 
fludrocortisone)  
 
Single dose 
DL-DOPS vs placebo 
Breakfast 1 hour before 
Supine, 60◦HUT 
SBP, DBP up to 8 
hours 
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Table 8 Summary of study characteristics of ‘Single dose’ drug treatment (a standard error reported) 
  
Singer et al 
2006 (USA) 
Randomised 
double blind 
placebo 
controlled 
cross-over 
trial 
Sex: 30M, 28F 
Data for all (BP) 
Age: 59(11) years 
MSA, PAF, autoimmune 
autonomic neuropathy, 
diabetic autonomic 
neuropathy, unspecified 
neurogenic OH 
Reduction in SBP of 
≥30mmHg or mean BP 
reduction of ≥20mmHg 
within 3 minutes of 
standing 
 
Unclear Single dose 
Pyridostigmine 60mg vs 
Pyridostigmine 60mg 
and midodrine 2.5mg vs 
pyridostigmine 60mg 
and midodrine 5mg 
Supine, standing 
SBP, DBP 1 minute 
after standing and 
HR, up to 6 hours 
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Table 9 Assessment of risk of bias for single-dose double blind randomised controlled trial
Study Adequate sequence 
generation 
Allocation concealment Incomplete outcome 
data addressed 
Free of selective 
reporting 
Free of other bias 
Wright et al 
1998 (USA) 
Unclear if computer 
generated. 
Randomisation method –
Latin square design 
Unclear as it appears 
participants were 
substituted for one taking 
in the same sequence, yet 
states double blinded 
Incomplete data 
mentioned for 2 
participants 
Unclear, but appears to 
report primary end 
points, and in addition 
mentions adverse 
reaction. 
Patients who dropped out were 
replaced by patient taking 
medication in the same sequence  
Unclear regarding financial bias, 
but authors state that by using 
product, they are not endorsing 
Bordet et al 
1995 (France) 
Randomisation method 
unclear 
Double blinded but unclear 
method of allocation 
concealment 
Not mentioned if any 
incomplete data 
Unclear as aim was to 
investigate standing BP, 
yet report HUT BP 
changes 
Unclear financial involvement of 
pharmaceutical company beyond 
supplying drug 
Kaufmann et 
al 2003 (USA) 
Randomisation by 
pharmacist at each 
location, and not centrally. 
Unclear method or if 
computer generated. 
Only pharmacist aware of 
allocation, otherwise 
double blinded 
Incomplete data as 
participants not always 
able to stand for period 
required. Mention 
intention to treat, but 
unclear as to data for 
those who could not 
stand. 
Yes, adverse events 
reported 
Yes, pharmaceutical company 
only supplied drug and did not 
provide financial support, design 
study, and not involved in 
collection, analysis of data, or 
writing up or report. 
Freeman et al 
1999 (USA) 
Randomised by pharmacist 
at centre, unclear method 
and if computer used 
Pharmacist aware of 
allocation, but other staff 
double blinded 
Incomplete data not 
mentioned 
Actual SBP and DBP 
reported 
Unclear of pharmaceutical 
financial involvement 
Singer et al 
2006 (USA) 
Randomised by statistician 
involved in study, unclear 
if computer generated 
Other than statistician, 
other study personnel 
blinded. Concern about 
statistician analysing data 
though. 
At least 1 measurement 
missing for 12 patients 
Yes, report data 
specified. No comment 
about adverse events.  
Assuming statistician analysed 
anonymised data, given method of 
allocation 
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3.3.2.1 DL-DOPS  
In a single-dose cross-over study, Freeman et al. (1999) showed that in 10 subjects 
with mixed cause autonomic failure and OH, DL-DOPS signiﬁcantly reduced the 
postural BP fall to tilt compared with placebo 4 to 7 hours post dose, the greatest 
reduction in postural BP fall being at 5 hours, mean 125.3 (SEM ± 12.5) mmHg vs. 
placebo 97.4 (SEM ± 8.9) mmHg, p < 0.05. Similar results for DBP on tilt were also 
seen with an improvement between 2 and 7 hours, but the greatest improvement 
occurred at 5 hours with a mean 68 (SEM ± 4) mmHg compared with placebo mean 57 
(SEM ± 4.0) mmHg, p < 0.05. Kaufmann et al. (2003) demonstrated that L-DOPS 
improved mean standing BP from 60 (SE ± 4) mmHg to 100 (SE ± 6) mmHg with a 
peak effect at 3.5 hours, with a mean dose of 1137 (SE ± 131) mg in 19 patients with 
severe neurogenic OH in a cross- over study. Participants were able to stand for 3 
minutes in 94% of occurrences after active treatment, compared with 84% with 
placebo (p < 0.001). 
 
3.3.2.2 Pyridostigmine and midodrine  
Singer et al. (2006) evaluated the effects of pyridostigmine 60 mg for up to 6 hours 
post administration and showed a signiﬁcant increase in standing DBP, while the 
combination of pyridostigmine 60 mg plus midodrine 5 mg not only signiﬁcantly 
improved the primary end-point of standing DBP fall compared with placebo alone (p 
= 0.002) but also to pyridostigmine alone (p = 0.03). As the primary end-point was fall 
in standing DBP, the study differed from the majority of studies, which reported 
changes in SBP or MAP, and thus was not comparable to other short-term studies. 
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3.3.2.3 Octreotide  
A single injection of octreotide (a synthetic analogue of somatostatin) 100 µg 
subcutaneously in nine patients (Bordet et al., 1995) with OH resulting from MSA 
delayed the time to maximal BP fall during HUT to 43 (SEM ±  5.7) minutes 
compared with placebo 28.5 (SEM ±  6) minutes and increased supine BP [octreotide 
175 (SEM ±  9) mmHg, placebo 150(SEM ±  8) mmHg, p = 0.02]. The minimal SBP 
and DBP on tilt were not signiﬁcantly different between groups were octreotide 94 
(SEM ± 10) mmHg and 45 (SEM ± 5.3) mmHg, placebo 81 (SEM ± 5) mmHg and 37 
(SEM ± 3) mmHg and for the control arm 81 (SEM ± 6) mmHg and 40 (SEM ± 3.7) 
mmHg. A further study using a single dose of midodrine 10 mg improved standing 
SBP at 1 hour 121.9 (SEM ± 8.2) mmHg, and for up to 4 hours with 20 mg (mean 123 
(SEM ±  9.2) mmHg compared with baseline values of 87.6 (SEM ±  5.2) mmHg and 
95.6 (SEM ±  6.1) mmHg (Wright et al., 1998). 
 
Study Drug Improve postural 
BP 
Improve symptoms 
Wright et al 1998  
(USA) 
Midodrine Yes Yes 
Bordet et al 1995  
(France) 
Octreotide Some No information 
Kaufmann et al 2003  
(USA) 
L-DOPS Yes Yes 
Freeman et al 1999  
(USA) 
DL-DOPS Yes No 
Singer et al 2006  
(USA) 
Pyridostigmine Yes Yes 
Pyridostigmine  + 
midodrine 
Yes Yes 
 
Table 10 Overall study conclusions for ‘Single dose’ treatment
 
3.3.3 Bias  
The trials used in this systematic review on the whole had been unclear with regards to 
random sequence generation and concealment of group allocation. Although many 
mention randomisation by e.g. statistician, pharmacist, it was unclear if the method 
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used was using a computer or a toss of a coin. The majority commented on any 
missing results, e.g. because of dropout of participants, but it remained sometimes 
unclear if there was a degree of selective reporting. In several instances, it was also 
unclear if other sources of bias were introduced, whether if one recruitment centre was 
more heavily involved, if there were financial involvement of pharmaceutical 
companies beyond supplying the drug. In one instance (Wright et al., 1998), it 
appeared that if a participant dropped out, another may have been substituted with the 
same drug allocation sequence, raising issues of allocation concealment, and deviation 
from the study protocol. Of course this may simply be unclear reporting. Overall there 
is a moderate risk of bias. 
 
3.4 Discussion 
Although postural hypotension is a common problem in elderly people with signiﬁcant 
morbidity and mortality, there appears to be little high-quality data as to the best 
pharmacological management. We report a systematic review of the results from 13 
blinded heterogeneous RCTs, which examined the effects of drug treatment for OH. Of 
the 708 reports screened, 97 full-text articles were examined, but only 13 ﬁtted our 
entry criteria, eight involving ‘repeated doses’ treatment and ﬁve ‘single dose’ studies. 
There was a general paucity of good quality trials with comparable data parameters, 
which precluded a good quality meta-analysis. There was a considerable difference in 
effect on postural BP fall not only between trials (despite using the same 
pharmacological agent at the same dosages) whether short- or long-term effects were 
studied, but perhaps more predictably between agents. In general, these trials did show 
treatment increased standing or HUT SBP levels, but there was limited evidence of a 
greater clinical beneﬁt of any speciﬁc therapeutic regime.  
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Current guidelines recognise the limited availability of prospective randomised 
controlled trials. The European Federation of Neurological Societies 2006 guidelines 
recommend ﬂudrocortisone as ﬁrst-line treatment and then midodrine, on its own or 
combined with ﬂudrocortisone, after non-pharmacological measures have been tried 
including education and physical measures. They also recommend DOPS 
(dihydroxyphenylserine) and octreotide for the treatment of OH (Lahrmann et al., 
2006), which are also included in the recommendations in the European Handbook of 
Neurological Management in 2011 (Lahrmann et al., 2010). The ESC 2009 guidelines 
similarly recommend non-pharmacological measures in the treatment of OH, including 
adequate hydration and salt intake, as ﬁrst-line management followed by midodrine 
and ﬂudrocortisone along with pyridostigmine (Moya et al., 2009). Other drugs such as 
octreotide were also proposed where hypotension may be as a result of post-prandial 
haemodynamic changes or erythropoietin where anaemia was the underlying cause 
(Moya et al., 2009). Potential confounding factors that may have had a signiﬁcant 
inﬂuence on the effects of the different pharmacological treatments on orthostatic BP 
change, as well as in symptoms, will have been the variation in the aetiology of the OH 
and the differing mechanisms of actions of the various agents. For example, 
ﬂudrocortisone (9-alpha ﬂudrohydrocortisone acetate) acts not only by increasing 
plasma volume by its sodium retaining effects as a synthetic mineralocorticoid thus 
increasing cardiac output but also by potentially increasing sensitivity to sympathetic 
nerve stimulation resulting in an increase peripheral vascular resistance; this latter 
effect being independent of norepinephrine release from the sympathetic nerve endings 
in response to HUT (Hickler et al., 1959). Midodrine is a pro-drug and its active agent 
desglymidodrine is an alpha-1-adrenoceptor agonist, which also increases mean 
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systemic arterial pressure by raising peripheral vascular resistance (Figueroa et al., 
2010).  
 
Future trials should take into account the likely aetiology of OH to select the agent 
with the most appropriate pharmacological proﬁle. This could be aided by classifying 
OH according to changes in total peripheral resistance and cardiac output to determine 
whether OH is resulting from arteriolar, venous or mixed dysfunction (Deegan et al., 
2007). Whether any improvement in the systemic orthostatic BP fall with treatment is 
associated with symptomatic improvement is less well known. We considered carrying 
out a detailed systematic review, but only some of the RCTs attempted to examine the 
effect of pharmacological intervention on symptoms (Shibao et al., 2010); however, 
there was no consistency between these studies in terms of methodology (e.g. 
questionnaire used). Midodrine has been reported to signiﬁcantly reduce the incidence 
of a patient’s inability to stand (Fouad-Tarazi et al., 1995), and improve the global 
postural symptom score (Wright et al., 1998), with good concurrence between patient 
and investigator scores (Figueroa et al., 2010). In the case of ﬂudrocortisone therapy, it 
has also been reported to result in subjective improvement although the studies were 
too small to draw ﬁrm conclusions (Campbell et al., 1975).  
 
Many clinical reviews highlight the beneﬁt of drug therapy (Freeman, 2003) for OH, 
as well as the many non-pharmacological options (Figueroa et al., 2010). ESC 
guidelines of 2009 based the recommendation of the use of midodrine in the treatment 
of OH on three studies (Jankovic et al., 1993, Wright et al., 1998, Low et al., 1997), 
which because of differences in parameters given made it difﬁcult to meta-analyse. 
However, this systematic review, which included small and large studies of varying 
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duration, highlighted that although there is evidence of some beneﬁcial effect of 
treatment in reducing the postural BP fall, the beneﬁts in terms of symptom relief were 
unclear especially as duration of therapy and underlying aetiology of OH differed 
considerably between studies.  
 
The data on the beneﬁts of ‘repeated doses’ of pharmacological treatment of OH are 
limited both in terms of the effects on postural BP changes as well as symptom relief 
and should be weighed against potential side effects and adverse effects including 
cardiac failure, systolic hypertension and stroke (Hussain et al., 1996, Pathak et al., 
2005). There are limitations to this review. There was signiﬁcant variability in the 
deﬁnition of OH between the studies, with some groups including participants with 
only symptoms (in recognition that the actual fall in systemic BP may be limited), 
whilst others requiring in fall in postural BP greater than the current ESC guidelines on 
Syncope (Moya et al., 2009) or the Consensus Statement (Freeman et al., 2011). This 
highlights the suspicion that it may not be the fall in systemic BP that causes 
symptoms, but the failure to maintain cerebral blood ﬂow as a result of impaired auto-
regulation resulting in a fall in cerebral perfusion to the drop in systemic BP that is the 
underlying problem. Thus, treatments that are used solely to increase systemic BP 
levels may be inappropriate for some patients. There was a large variability in end-
point parameters in studies involving the drug treatment of OH, making a meta-
analysis comparing differing drugs and their effectiveness in treating the postural fall 
in BP impossible.  
 
This systematic review included reports that were published in the English language 
only. The studies included were carried out in Western Europe and North American 
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and the results should be interpreted with caution as they may not be generalizable 
across other ethnic groups. Furthermore, the studies included young and older adults 
where the pathophysiology mechanisms may differ, with arterial stiffness and 
baroreceptor function affecting blood pressure with increasing age (Mattace-Raso et 
al., 2006, Protogerou et al., 2008). In addition, the heterogeneity of the participants in 
the studies is high, with varying underlying causes of OH being included even within 
the same study. There is always a possibility of publication bias with only positive 
effects being emphasised in clinical trials to date. Disappointingly, there was a lack of 
reporting of the amount of change in postural BP levels and standard deviations (i.e. 
the difference a drug exerted on the actual change from supine or sitting to standing or 
tilt blood pressure). Most studies did not report the magnitude of effect of drugs on in 
terms of the improvement or reduction (if any) in postural BP drop and more 
importantly none made any detailed comment on patients symptoms or quality of life 
factors. We suggest that future trials should study the improvement in symptoms and 
QOL measures rather than concentrate just on changes in BP measurements. Using the 
ESC deﬁnition of OH in future studies as well as publishing standard deviations for 
changes in postural BP will allow comparison across studies. Of the few studies that 
did comment on the improvement in symptoms of OH with therapy, only Schoffer et 
al. (2007) used COMPASS-OD (questions relating speciﬁcally to OH and part of the 
Mayo clinic autonomic Symptom Proﬁle), which is correlated with part of the 
Composite Autonomic Scoring Scale (CASS) (Low, 1993) in their outcome 
assessment.  
 
The strength of this review is that we used strict selection criteria based on quality of 
methodology as well as reporting and three authors independently reviewed trials to 
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select those eligible. In the absence of ﬁrm clinical evidence of the effect of 
pharmacological intervention for this common condition with its associated higher 
morbidity and mortality, non- pharmacological management may remain as an 
important ﬁrst step towards the management of this condition although the evidence of 
their effectiveness is equally lacking.  
 
At present there is only one open randomised trial of non-pharmacological 
management of OH in older patients to date, which concluded no beneﬁt of a 6-inch 
head-of-bed elevation on BP or symptoms to other non-pharmacological management 
(Fan et al., 2011). A recent systematic review of non-pharmacological management of 
OH identified 23 studies covering eight differing interventions, concluded that 
although physical counter manoeuvres, eating smaller and frequent meals, compression 
of legs and/or the abdomen, as well as functional electrical stimulation with spinal cord 
injuries could be beneficial, further studies would be needed(Mills et al., 2015). It is 
recognised that others have published systematic reviews on pharmacological and non-
pharmacological management of OH. One study only included midodrine, and 
included a total of nine open and blinded studies for meta-analysis, of which four were 
blinded (Parsaik et al., 2013) and included in this systematic review. Like this 
systematic review, the meta-analysis suggests midodrine can improve OH symptoms, 
but the meta-analysis suggests that only standing SBP is improved, the postural change 
was not greatly reduced(Parsaik et al., 2013). Another systematic review which 
included drug treatment, also noted issues of heterogeneity in studies, and included 
studies published in German (Logan and Witham, 2012). They also agree with Parsaik 
et al (2013) regarding the limited benefit of midodrine but suggest that there is limited 
evidence generally that drugs improve OH with many studies including a risk of bias. 
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They also agree with this systematic review that further research needs to be done 
including pharmacological and non-pharmacological methods, to include investigation 
of symptoms as well as postural BP changes.  
 
A useful comparison for future trials could include pharmacological and non- 
pharmacological measures. Participants with OH could be randomised to a drug where 
a crossover of non-pharmacological measures is unsuccessful in terms of symptomatic 
relief and quality of life rather than BP improvement alone. 
 
3.5 Conclusions 
There is limited evidence as to the beneﬁts of pharmacological agents for treatment of 
OH, with only midodrine and ﬂudrocortisone potentially being of use. Well-designed 
double-blind, randomised controlled trials comparing different drug options (and 
dosages) in the treatment of OH and symptom relief need to be conducted. Ideally, this 
should be done in combination with non-pharmaceutical interventions. 
 79 
 
 
4 Pharmacological Treatment of Post-prandial 
Reductions in Blood Pressure: A Systematic Review 
 
This chapter has been published elsewhere: 
ONG, A. C., MYINT, P. K. & POTTER, J. F. 2014. Pharmacological treatment of post-
prandial reductions in blood pressure: a systematic review. J Am Geriatr Soc, 62, 649-
61. 
 
4.1 Introduction 
The definition of PPH and the degree to which BP may change after eating can vary 
and its epidemiology has been discussed in Chapter 1 of this thesis. In essence it is 
common in older adults (Vaitkevicius et al., 1991, Aronow and Ahn, 1994), (Vloet et 
al., 2005), and may or may not be symptomatic (Vloet et al., 2003, Vloet et al., 2005, 
Jansen and Lipsitz, 1995) and may have an associated morbidity (Vaitkevicius et al., 
1991). Post-prandial hypotension (PPH) can be deﬁned as a reduction in systolic blood 
pressure (SBP) of 20 mmHg or more within 2 hours of the start of a meal or if SBP 
falls to 90 mmHg or less within this period if pre-prandial SBP was 100 mmHg or 
greater (Jansen and Lipsitz, 1995).It is unclear as to how best to pharmacologically 
treat post-prandial falls in BP and its associated symptoms where conservative 
measures such eating smaller meals fails. The evidence for treating PPH has not been 
systematically reviewed, and it is unclear as to which drug, if any is of clinical benefit 
in terms of BP or symptoms.  
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It is known that the post-prandial reductions in BP is independent of the presence or 
absence of systemic hypertension (Visvanathan et al., 2005, Jansen et al., 1987, Potter 
JF, 1989) even when anti-hypertensive medication is withdrawn (Lipsitz et al., 1983). 
This post-prandial reduction in BP reﬂects the failure of the normal homeostatic 
mechanisms to maintain BP levels in the face of a reduction in systemic vascular 
resistance due to splanchnic and peripheral vasodilation not being compensated for by 
an increase in cardiac output (Jansen and Lipsitz, 1995, Heseltine et al., 1991b). 
Evidence suggests that caffeine (an adenosine antagonist that blocks splanchnic 
methylxanthine sensitive adenosine receptors) when given after meals can reduce post-
prandial symptoms and reductions in BP, (Heseltine et al., 1991b, Heseltine et al., 
1991c, Sawynok, 1995) indicating that adenosine may have an underlying 
pathophysiological role in inducing this splanchnic vasodilatation.  
 
In addition to some lifestyle measures  several other agents have also been tried in the 
treatment of PPH by addressing possible underlying pathophysiological mechanisms 
(Jansen and Lipsitz, 1995). For example, acarbose reduces complex carbohydrate 
breakdown, delaying gut glucose absorption (Shibao et al., 2007, Gentilcore et al., 
2011). Whereas 3,4- DL-threo-dihydroxyphenylserine (DL-DOPS), is a 
norepinephrine precursor that converts to norepinephrine in the peripheral and central 
nervous system to replace levels of norepinephrine in autonomic failure (Freeman et 
al., 1996). Guar gum reduces post-prandial reductions in BP by delaying gastric 
emptying and glucose absorption in the small intestine (Jones et al., 2001). Other 
agents such as octreotide (which inhibits the vasodilation of the splanchnic vasculature 
by inhibiting vasoactive peptides) given before a meal have been also been shown to 
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have some beneﬁt in preventing PPH in older adults with hypertension (Jansen et al., 
1989), as has midodrine (an α1-adrenergic agonist) administered concomitantly with 
denopamine (a selective β1-adrenergic agonist) (Hirayama et al., 1993). Although there 
is some evidence of these agents being useful in this setting, the magnitude of the 
effects of these therapeutic agents in a randomised controlled trial setting has not been 
examined systematically.  
 
Herein is reported a systematic review of randomised controlled trials involving the 
pharmacological management of PPH and post-prandial reductions in BP. 
 
4.2 Methods 
4.2.1 Eligibility Criteria 
Studies that speciﬁcally investigated the effect of the drug intervention on post-
prandial change in BP were selected. They had to be controlled randomised studies 
that reported supine or erect BP and included administration of a standardised meal or 
glucose (oral or intraduodenal). Because of the nature of some treatments, open and 
blinded studies were included. Individuals being assessed by medical staff for potential 
symptoms related to PPH or under medical care for any reason and healthy volunteers 
were included in the analysis if they were aged 18 and older, as long as the aim of the 
study was to assess the effects of treatment on post-prandial BP changes. 
 
4.2.2 Information Sources  
MEDLINE (1950–), EMBASE (1980–), and CINAHL (1937–) were searched on July 
16, 2013, limited to studies in English and involving human subjects, followed by 
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hand-searching of the bibliographies of the full-text articles to identify potentially 
relevant studies. 
 
4.2.3 Search Terms 
Search terms included “postprandial hypotension.mp.” or “hypotension.mp.” or 
“Hypotension/or hypotension, orthostatic/” and “eating/or meals.mp.” or “food/or 
prandial.mp. or postprandial period/.” Individual drugs were searched, including 
“octreotide.mp. or octreotide/,” “caffeine.mp. or caffeine/,” “NSAIDS.mp. or anti-
inﬂammatory agents, non-steroidal/,” “indomethacin.mp. or indomethacin/,” 
“ﬂudrocortisone.mp. or ﬂudrocortisone/,” “midodrine.mp. or midodrine/,” 
“acarbose.mp. or acarbose/,” “somatostatin.mp. or somatostatin/,” in addition to more 
generic terms, including “drug treatment.mp. or adult/,” “drug therapy.mp. or drug 
therapy/,” “autonomic nervous system diseases/co, et, pp, th [complications, etiology, 
physiopathology, therapy]”. 
 
4.2.4 Data Collection 
Articles were initially assessed for suitability using the Critical Appraisal Skills 
Programme approach for randomised controlled trials (accessed September 7, 2012, 
http://www.casp-uk.net/ﬁnd-appraise-act/), and are shown in the Table 11. Data 
parameters were originally extracted (ACLO) using a standardised form used 
previously to assess article suitability for meta-analysis. The form was developed 
speciﬁcally for the review after piloting with three randomly selected articles in the 
ﬁrst instance to ensure that all relevant data were captured. Articles were 
independently reviewed (ACLO, JFP) and discrepancies resolved (PKM). 
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4.2.5 Data Items 
Information was extracted on study participant characteristics (age, sex, diagnosis), 
trial inclusion and exclusion criteria, and drug intervention, including dose and 
duration of treatment. The outcome measures of SBP and diastolic BP (DBP) or mean 
arterial pressure (MAP) at baseline and with treatment for all arms of the study had to 
be available as individual components of BP, MAP, or a change in these parameters. 
Results are given as mean mmHg ±standard deviation unless otherwise stated. 
 
4.2.6 Risk of Bias in Individual Studies 
Risk of bias for included studies was assessed, including adequacy of sequence 
generation (presence of random component and method), allocation concealment (pre-
assignment), whether missing data were accounted for, and whether there was 
evidence of within-study selective reporting or other bias (Higgins and Green, 2008). 
Other bias, particularly for cross-over studies may include observer bias, as 
participants may attend on differing days or the introduction of confounders which 
may significantly affect outcome parameters. 
 
4.2.7 Summary Measures 
Because of the inconsistencies in outcome measurements and reporting, it was not 
possible to synthesise summary statistics using a formal meta-analytical approach. 
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4.3 Results 
Fourteen randomised studies were included in the ﬁnal selection for systematic review 
(Figure 12). The characteristics of the studies (including population and meal type) are 
shown in Table 11. Overall, the studies were of reasonable quality; the risks of bias in 
these studies are shown in Table 12.  
 
The timing of the intervention depended on the nature of the agent being studied; in the 
majority of studies, drug treatment was given before or with the meal or glucose load, 
and in the remainder, it was given immediately after the meal or glucose load. BP in all 
but two studies (Heseltine et al., 1991b, Heseltine et al., 1991c) was not explicitly 
measured more than once at each time point. The majority of studies used an 
automated oscillometric BP monitor, others used an ultrasonic BP monitor(Lenders et 
al., 1988) or a random zero sphygmomanometer (Heseltine et al., 1991b, Heseltine et 
al., 1991c). Only two studies (Shibao et al., 2007, Lipsitz et al., 1994) were conducted 
in participants with a formal diagnosis of PPH using the deﬁned criteria (Jansen and 
Lipsitz, 1995). The trials reported the haemodynamic responses but not the 
symptomatic relief of PPH. Shorter-term studies investigated the effects of a single 
dose of treatment within a 24-hour period. In repeated dose studies the intervention 
was continued for longer than 24 hours. 
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Figure 12 Flow diagram of post-prandial BP reductions systematic review of drug treatment 
MEDLINE, CINAHL, EMBASE searches 
from Week 4, 2012. 3140 records found 
2759 records after de-duplication 
38 study abstracts examined 
2709 records excluded from 
title 
22 study full papers obtained 
19 studies reviewed 
16 studies excluded from 
abstracts 
3 excluded from paper (not drug 
intervention (1), not post-
prandial (1), only summary (1) 
5 studies excluded from final 
review as not randomised 
14 studies included in systematic review 
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Study  
Author (Year)  
Drug/ 
Intervention 
Meal/Glucose Study Population Known 
PPH 
PPH 
defined in 
study 
Age (years) Number Gender Groups 
Onrot et al. 
(1985)  
Caffeine 
250mg 
capsule 
standard mixed 
meal (kcal not 
given) 
Autonomic failure 
(primary – 11, 
secondary -1) 
No N/A 63.6 (SD ± 
5.9) 
12 6M:6F Meal(12)/ 
Caffeine(12)/ Meal & 
Caffeine (6) 
Lenders et al. 
(1988)  
Caffeine 
250mg 
capsule 
standard mixed 
meal (405kcal) 
Healthy No N/A 75.4 (SD ± 
6.6) 
15 8M:7F Placebo(15)/Caffeine
(15) 
Heseltine et al. 
(1991) 
Caffeine 
200mg coffee 
standard mixed 
meal (585kcal) 
Healthy No N/A 67.4 (range 
64-72) 
7 2M:5F Placebo(7)/ 
Caffeine(7) 
Heseltine et al. 
(1991)  
Caffeine 
100mg coffee 
glucose drink 
(400kcal) 
Post-acute admission 
(CVD, IHD, CCF, 
PVD, DM, COPD, 
PD) 
No N/A 84 (SD ± 5) 20 10M:10F Decaffeinated (20)/ 
Caffeine(20) 
Lipsitz et al. 
(1994)  
Caffeine 
250mg 
capsule 
liquid meal 
(1674kJ) 
Pure autonomic 
failure, Shy-Drager, 
PD, unknown 
Yes ≥20mmHg 
fall 
supine/sea
ted SBP 
≤60mins 
of meal 
79 (SD ± 9) 9 2M:7F Placebo (9)/ Caffeine 
(9) 
Rakic et al. 
(1996)  
Caffeine 60mg 
5 times/day as 
tea/ coffee 
high carbohydrate 
meal 
(unspecified) 
Normotensive 
(62)/treated HTN 
(46)/untreated HTN 
(63) 
No N/A 75.2 (SD ± 
0.7) 
171 41M:127F Decaffeinated/ 
Caffeine 
Shibao et al. 
(2007)  
Acarbose 
100mg 
standard mixed 
meal (414kcal) 
Pure autonomic 
failure (12), PD (1) 
[secondary cause 
excluded] 
Yes ≥20mmHg 
fall in SBP 
≤120mins 
65 (SD ± 2.64) 13 5M:8F Placebo (13)/ 
Acarbose (13) 
Gentilcore et 
al. (2011)  
Acarbose 
100mg 
Intraduodenal 
sucrose 
(6kcal/min) 
Healthy No N/A Median 70 
(range 66-77) 
8 4M:4F No 
acarbose/Acarbose 
Freeman et al. 
(1996) 
DL-DOPS 
1000mg 
standard mixed 
meal (400kcal) 
All Orthostatic 
hypotension 
No N/A 54 (SD ± 13) 11 7M:4F Placebo (11)/ DL-
DOPS (11) 
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(undefined by BP); 
mix of MSA, PD, 
PAF 
Jones et al. 
(2001)  
Guar gum 9g 50g glucose drink Healthy No 30 min 
sustained 
fall SBP 
≥20mmHg 
median 70 
(range 67-78) 
10 5M:5F Guar gum/ No guar 
gum 
Russo et al. 
(2003)  
Guar gum 9g 50g glucose drink Type 2 DM No 30 min 
sustained 
fall SBP 
≥20mmHg 
median 61 
(range 57-69) 
11 8M:3F Guar gum/ No guar 
gum 
O'Donovan et 
al. (2005)  
Guar gum 4g Intraduodenal 
glucose 
(3kcal/min) 
Healthy No N/A 70.3 (SD ± 
3.4) 
8 4M:4F Guar gum/ No guar 
gum 
Jansen et al. 
(1988)  
Octreotide 
50µg SC 
75g glucose drink Normotensive, HTN No No 74 (SD ± 4) 20 unknown Placebo/ octreotide 
Jansen et al. 
(1989)  
Octreotide 
50µg SC 
75g glucose drink Normotensive, HTN No No 74 (SD ± 4) 20 7M:13F Placebo/ octreotide 
Alam et al. 
(1995)  
Octreotide 
1µg/kg SC bd 
(8am,6pm) 
Meal 
(unspecified) 
Symptomatic OH 
(fall ≥30mmHg 
SBP); PAF, Shy-
Drager. [Secondary 
causes excluded] 
No No range 44-73 18 11M:7F Octreotide/ No 
octreotide 
 
Table 11 Study characteristics post-prandial falls in BP treatment systematic review (Key: DM=diabetes mellitus; HTN=hypertension; OH=orthostatic hypotension; PAF=pure autonomic failure; 
MSA=multi-system atrophy; PD=Parkinson disease; CVD=cerebrovascular disease; PVD=peripheral vascular disease; IHD=ischemic heart disease; CCF=congestive cardiac failure; COPD=chronic 
obstructive pulmonary disease) 
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Study  
(Author, Year) 
Adequate sequence 
generation 
Allocation concealment Incomplete 
outcome data 
addressed 
Free of selective 
reporting 
Free of other bias 
Onrot et al. (1985)  Unclear method. Study days 
randomised, consecutive 
patients used. 
Not blinded allocation not 
concealed, controlled. 
No missing data Yes, expected data 
reported 
One patient had a pacemaker, 
potential confounder in small 
study. 
Lenders et al. (1988)  Unclear method, simply 
stated randomised, cross-over 
Unclear how concealment of 
allocation kept, although states 
double blind, controlled 
No missing data Yes, expected data 
reported. 
No obvious other bias. 
Heseltine et al. (1991) Unclear method, simply 
stated randomised, cross-over 
Unclear how concealment of 
allocation kept, although states 
double blind, controlled 
Plasma caffeine 
level not available 
for 5 participants 
Yes expected data 
reported.  No 
adverse event 
reported 
No obvious other bias. 
Heseltine et al. (1991) Unclear method, simply 
stated randomised, cross-over 
Unclear how concealment of 
allocation kept, although states 
double blind, controlled 
No missing data Yes expected data 
reported.  No 
adverse event 
reported 
No obvious other bias. 
Lipsitz et al. (1994)  Unclear method, simply 
stated randomised, cross-over 
Unclear how concealment of 
allocation kept, although states 
double blind, controlled 
Not all 
participants able 
to stand 
Yes expected data 
reported.  No 
adverse event 
reported 
No obvious other bias. 
Rakic et al. (1996)  Unclear method, simply 
stated randomised, cross-over 
Not blinded allocation not 
concealed, controlled. 
No missing data Yes expected data 
reported.  No 
adverse event 
reported 
No obvious other bias. 
Shibao et al. (2007)  Hospital pharmacy 
randomised participants for 
cross-over 
Hospital pharmacy kept the 
blind codes to maintain 
allocation concealment for 
single & double blind 
components, controlled 
No missing data Yes expected data 
reported. No 
adverse event 
reported 
No obvious other bias. 
Gentilcore et al. (2011)  Unclear method, simply 
stated randomised, cross-over 
Unclear how concealment of 
allocation kept, although states 
No missing data Yes expected data 
reported. No 
adverse event 
No obvious other bias. 
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Table 12 Systematic review of treatment Post-prandial reductions in BP - Risk of bias
double blind, controlled reported 
Freeman et al. (1996)  Unclear method, simply 
stated randomised, cross-over 
Unclear how concealment of 
allocation kept, although states 
double blind, controlled 
No missing data Yes expected data 
reported.  No 
adverse event 
reported 
No obvious other bias. 
Jones et al. (2001)  Unclear method, simply 
stated randomised, cross-over 
Not blinded allocation not 
concealed, controlled. 
No missing data Yes, expected data 
reported Adverse 
event reported 
No obvious other bias. 
Russo et al. (2003)  Unclear method, simply 
stated randomised, cross-over 
Not blinded allocation not 
concealed, controlled. 
No missing data Yes, expected data 
reported . No 
adverse event 
reported. 
Type 2 diabetes possible 
underlying delay in gastric 
emptying and thus confounding 
results 
O’Donovan et al. (2005)  Unclear method, simply 
stated randomised, cross-over 
Unclear how concealment of 
allocation kept, although states 
double blind, controlled 
No missing data Yes, expected data 
reported  No 
adverse event 
reported 
No obvious other bias. 
Jansen et al. (1988) Randomised Unclear method, 
simply stated randomised, 
cross-over 
Unclear how concealment of 
allocation kept, although states 
double blind, controlled 
No missing data MAP rather than 
SBP, DBP.  No 
adverse event 
reported 
Publication bias by duplication 
and with differing parameters. 
Jansen et al. (1989)  Unclear method, simply 
stated randomised, cross-over 
Unclear how concealment of 
allocation kept, although states 
double blind, controlled 
No missing data Yes, expected data 
reported.  No 
adverse event 
reported 
Publication bias by duplication 
Alam et al. (1995)  Unclear method, simply 
stated randomised, cross-over 
Not blinded allocation not 
concealed, controlled. 
No missing data Yes, expected data 
reported.  No 
adverse event 
reported 
No obvious other bias. 
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4.3.1 Single dose Studies 
4.3.1.1 Caffeine  
There were six randomised controlled studies (Heseltine et al., 1991b, Heseltine et al., 
1991c, Lenders et al., 1988, Lipsitz et al., 1994, Onrot et al., 1985, Rakic et al., 1996) 
involving caffeine administered in various doses and forms: as tea or coffee or as pure 
caffeine in capsule form (e.g., 60 mg ﬁve times a day, 250 mg capsule single 
intervention); four of these studies were double-blind. (Heseltine et al., 1991b, 
Heseltine et al., 1991c, Lenders et al., 1988, Lipsitz et al., 1994) Only one study 
enrolled participants with conﬁrmed PPH (deﬁned as a reduction in supine or seated 
SBP of at least 20 mmHg within 60 minutes of the meal), with symptoms of weakness 
or dizziness (Lipsitz et al., 1994). Most participants in these trials were regular caffeine 
consumers, and no adverse effects were reported with caffeine consumption. One study 
(Onrot et al., 1985) of six participants with primary or secondary autonomic failure 
who were regular caffeine consumers but who had no history of PPH demonstrated 
that a single 250 mg dose of caffeine before a standardised meal (Table 11) resulted in 
a signiﬁcantly smaller post-prandial reduction in SBP and DBP by 60 minutes (p 
<0.05) than without caffeine. As seen previously, there was no signiﬁcant difference in 
HR changes between the placebo and caffeine phases. Because no participants had a 
history of PPH, symptomatic differences with treatment were not recorded. A study of 
15 healthy participants who regularly consumed caffeine showed no difference in 
change in MAP from baseline between subjects who had a single 250 mg dose of 
caffeine 1 hour before a standardised meal and those who received placebo. HR was 
also unchanged from baseline in the placebo and caffeine phases (Lenders et al., 1988). 
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Another study showed that caffeine (200 mg coffee) reduced the post-prandial fall in 
standing and supine SBP less than placebo in seven healthy older adults who were 
regular caffeine consumers (Heseltine et al., 1991b). Participants in these two studies 
were healthy volunteers with no symptoms of PPH (Heseltine et al., 1991b, Lenders et 
al., 1988). In 20 regular caffeine drinking older adults with various comorbidities, four 
of whom had symptoms suggestive of orthostatic or PPH, 100 mg of caffeine (given as 
coffee) resulted in a signiﬁcantly smaller overall sitting post-prandial reduction in SBP 
than with placebo (decaffeinated coffee) (Heseltine et al., 1991c). No signiﬁcant post-
prandial difference was noted in DBP or standing SBP between placebo and caffeine. 
Three participants were noted to have a reduction in SBP consistent with PPH. 
Caffeine, but not placebo, alleviated symptoms of PPH in two participants (Heseltine 
et al., 1991c). Another study showed that caffeine (250 mg) did not attenuate the 
decline in SBP, DBP, or MAP associated with ingestion of a meal in nine participants 
with autonomic failure who experienced symptomatic PPH (Lipsitz et al., 1994). 
Although this study included individuals with symptomatic PPH, there was no 
reporting of the effect of caffeine on symptoms. 
 
4.3.1.2 Acarbose 
In 13 participants with autonomic failure and PPH randomised to acarbose (100 mg 
capsule) or placebo given 20 minutes before a mixed meal, acarbose reduced the post-
prandial reduction in supine SBP and DBP, with no effect on HR and no adverse 
effects reported  (Shibao et al., 2007). There was no speciﬁc reporting on the effects of 
treatment on symptoms. In another study, eight healthy older participants, randomised 
in a double-blind order to receive 100 mg of acarbose with an intraduodenal sucrose 
infusion (6 kcal/ min) or sucrose alone on 2 separate days, showed a similar 
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attenuation in SBP and DBP, although a rise in HR accompanied this (p<0.05) 
(Gentilcore et al., 2011). 
 
4.3.1.3 DL-DOPS 
The effect of DL-DOPS (1,000 mg) given 3 hours before a meal on post-prandial BP 
was assessed in a cross-over study in 11 participants with autonomic failure(Freeman 
et al., 1996). The greatest BP reduction occurred 30 minutes after the mixed meal, and 
reductions in SBP (p =0 .01) and DBP (p < 0.01) were signiﬁcantly greater after 
placebo than with DL-DOPS. There were no signiﬁcant differences in HR between 
placebo or DL-DOPS and no effect on symptoms reported. 
 
4.3.1.4 Guar Gum 
Three studies compared the effect of guar gum with that of placebo or control on post-
prandial BP in older adults after a 50 g glucose drink or intra-duodenal glucose (Jones 
et al., 2001, Russo et al., 2003, Jones et al., 1998). A randomised cross-over trial in 10 
healthy adults demonstrated that 9 g of guar gum resulted in a signiﬁcantly smaller 
reduction in SBP (p = 0.02), DBP (p < 0.05) and MAP (p = 0.05) 30 minutes post-
prandially than control, with no HR changes (Jones et al., 2001). A randomised 
crossover study of 11 participants with type 2 diabetes mellitus showed that 9 g of guar 
gum resulted in a signiﬁcantly (p <0.05) smaller post-prandial reduction in BP in 
response to a 50-g oral glucose load (Russo et al., 2003). The use of an intra-duodenal, 
rather than oral, glucose load allows observation of changes in BP independent of any 
effects of the intervention on gastric emptying, because the rate of gastric emptying 
inﬂuences the reduction in post-prandial BP (Jones et al., 1998). A signiﬁcantly 
smaller reduction in SBP, but not DBP, was demonstrated with 4 g of guar gum after a 
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50g intra-duodenal glucose infusion in eight healthy adults than with a glucose-only 
infusion (O'Donovan et al., 2005). 
 
4.3.1.5 Octreotide 
Three articles reporting the effect of subcutaneous octreotide on post-prandial BP did 
not include symptomatic PPH, and symptoms of PPH were not considered (Jansen et 
al., 1989, Jansen et al., 1988, Alam et al., 1995) although the data presented in two of 
these articles may have been from the same participant group (Jansen et al., 1988, 
Jansen et al., 1989). These studies (Jansen et al., 1988, Jansen et al., 1989) included 10 
hypertensive and 10 normotensive adults who received a single dose of subcutaneous 
octreotide (50µg) or placebo (saline) in a double- blind randomised fashion together 
with a 75g glucose drink. Both the normotensive and hypertensive groups showed 
signiﬁcant reductions in MAP at 30 and 60 minutes with placebo but showed no 
signiﬁcant reduction after octreotide (Jansen et al., 1988). A signiﬁcant difference 
between placebo and octreotide was shown for SBP (p =0.008), DBP (p <0.001), and 
MAP (p <0.001) in the hypertensive group and for DBP (p=0.005) and MAP 
(p=0.007) in the normotensive group (Jansen et al., 1989). Another study demonstrated 
in 10 participants with autonomic failure and symptomatic orthostatic hypotension that 
octreotide (1 µg/kg of body weight) resulted in a smaller reduction in post-prandial BP 
from 10 to 120 minutes than no treatment (SBP, p <0.01; DBP, p <0.05). There were 
no signiﬁcant differences in HR, and no adverse effects were reported (Alam et al., 
1995). 
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4.3.2 Repeated doses Studies 
4.3.2.1 Caffeine 
In a study of 171 participants (98% regular caffeine drinkers) that included people 
without hypertension and those with treated or untreated hypertension randomised to a 
2-week period of regular caffeine consumption (60 mg ﬁve times daily) or no caffeine, 
baseline reductions in post-prandial supine SBP were greater in those with untreated 
and treated hypertension than in those without hypertension, with similar changes seen 
in standing SBP (Rakic et al., 1996). Coffee resulted in a signiﬁcantly smaller post-
prandial reduction in supine and standing SBP in regular coffee drinkers without 
hypertension and in tea drinkers with treated hypertension. The effects on HR were not 
reported. Those with untreated hypertension who had no caffeine for 2 weeks also had 
a signiﬁcantly smaller reduction in post-prandial supine SBP. The effect of treatment 
on symptoms was not reported. In a study of the longer-term effects of caffeine (Onrot 
et al., 1985), ﬁve participants were administered caffeine as a 250 mg capsule daily for 
7 days. Participants were then randomised to receive placebo or caffeine as a single 
dose. Despite longer-term caffeine, post-prandial BP remained higher after caffeine (p 
<0.05) than with placebo after a standardised meal (Onrot et al., 1985). 
 
4.3.3 Results Summary 
Table 13 shows a summary of the various drug effects on post-prandial reduction in 
BP, although the majority of studies were conducted in participants who did not have a 
diagnosis of PPH with a proven minimal reduction in post- prandial BP or who had 
symptoms suggestive of PPH (Jansen and Lipsitz, 1995). However bias from sequence 
generation and allocation concealment needs to be considered moderate.
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Study (Author, 
Year) 
Participant Group Drug Approximate Mean 
Change in BP Compared 
to Baseline (mmHg) * 
Original Author 
Conclusion 
Our View 
Onrot et al. 
(1985)  
Autonomic Failure Caffeine (250mg 
capsule) 
SBP: -3 
DBP: -6 
Beneficial Although only carried out in a 
small group, it is certainly 
worth considering Control SBP: -23 
DBP: -14 
Lenders et al. 
(1988)  
Healthy participants Caffeine (250mg 
capsule) 
MAP: 0% (maximal increase 
of 12.5%) 
Beneficial  
Control MAP: -6.1% 
Heseltine et al. 
(JAGS, 1991) 
Healthy participants Caffeine (200mg coffee) SBP: 12 Beneficial Improves post-prandial BP in 
healthy older adults Control  SBP: -17 
Heseltine et al. 
(PMJ, 1991)  
Multiple comorbidities 
(4 of 20 had symptoms 
suggestive of PPH or 
OH) 
Caffeine (100mg coffee) Sitting SBP: 2 Beneficial for sitting 
SBP (but not erect) 
Appears to reduce the fall in 
BP despite co-morbidities Control Sitting SBP: -8 
Lipsitz et al. 
(1994)  
Autonomic Failure Caffeine MAP: -31 Not beneficial for 
PPH 
 
Control MAP: -19 
Rakic et al. 
(1996)  
Normotensive/Hypertens
ion/Untreated 
Hypertension 
Caffeine Standing SBP: -8 (UHTN), -
9 (HTN), -3 (NTN) 
Beneficial  
Control Standing SBP: -10 (UHTN), 
-12 (HTN), -8 (NTN) 
Shibao et al. 
(2007)  
Autonomic failure Acarbose SBP: -17 Beneficial for PPH  
Control SBP: -40 
Gentilcore et al. 
(2011)  
Healthy Acarbose SBP: -1 
DBP: -3 
Beneficial  
Control SBP: -8 
DBP: -9 
Freeman et al. 
(1996)  
Autonomic failure DL-DOPS MBP: -13 Beneficial  
Control MBP: -30 
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Jones et al. 
(2001)  
Healthy  Guar gum SBP: -4 
DBP: -6 
MBP: -4 
Beneficial The magnitude of change is 
small. 
Control  SBP: -7 
DBP: -7 
MBP: -8 
Russo et al. 
(2003)  
Type 2 diabetes mellitus Guar gum SBP: -2.5 
DBP: -2.9 
MAP: -6.8 
Beneficial  Perhaps some improvement 
for SBP 
Control SBP: -4.9 
DBP: -5.5 
MAP: -10.2 
O’Donovan et al. 
(2005)  
Healthy Guar gum SBP: -2.5 
DBP: -4 
Beneficial Improves SBP 
Control SBP: -11 
DBP: -5 
Jansen et al. 
(1988)  
Hypertension and 
Normotensive 
Octreotide MAP: 0 (NTN), -2 (HTN) Beneficial Appears to be the case for 
those with hypertension 
Control MAP: -7 (NTN), -14 (HTN) 
Jansen et al. 
(1989)  
Hypertension and 
Normtensive 
Octreotide SBP: 1 (NTN), -1 (HTN) 
DBP: 0 (NTN), 0 (HTN) 
Beneficial Appears to be the case for 
those with hypertension 
Control SBP: -5 (NTN), -12 (HTN) 
DBP: -9 (NTN), -15 (HTN) 
Alam et al. 
(1995)  
Autonomic failure Octreotide SBP: 0 
DBP: -2 
Beneficial Little difference between 
sitting and post-prandial BP 
noted. Control SBP: -3 
DBP: -5 
Table 13 Overall Study Conclusion for Alleviating Post-Prandial Falls in BP or PPH (Key: * Note that many values are estimated from graphs depicted by original authors. 
UHTN= Untreated Hypertension, HTN = Hypertension, NTN = Normotensive)
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4.4 Discussion 
Despite PPH being associated with signiﬁcant morbidity and mortality in older people, 
evidence of the beneﬁts of pharmacological intervention in reducing these BP 
reductions is limited. The studies included in this systematic review had great 
heterogeneity in terms of intervention drug type, dose, and frequency and time of 
intervention relative to type and size of energy load. Another important inﬂuencing 
factor on effect is the heterogeneity in the population studied (e.g., healthy adults vs 
those with hypertension and diabetes mellitus, those with autonomic dysfunction), with 
only one study speciﬁcally investigating the effect on those with symptomatic PPH. 
Thus caution is needed in the interpretation and use of any therapeutic interventions 
based on the ﬁndings of this systematic review, especially in older adults with 
symptomatic PPH.  
 
This systematic review conﬁrms that certain drug interventions may attenuate post-
prandial reductions in BP, whether given as a once only intervention or as a regular 
intervention over a period of time. The time and size of the effects of intervention on 
BP are summarised in Table 13, but the majority of studies did not speciﬁcally include 
participants with symptoms of PPH or who had a conﬁrmed diagnosis of PPH (Jansen 
and Lipsitz, 1995). Some studies tried to overcome this by including those with a 
history of orthostatic hypotension (OH), but the underlying pathophysiology of OH 
and PPH probably differs, although both conditions can exist in the same patient. It is 
therefore difﬁcult to state conclusively which drug is the best for PPH, particularly 
because adverse effects need to be considered, such as supine hypertension with DL-
DOPs (Freeman et al., 1996).  
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Post-prandial hypotension reﬂects the failure to maintain systemic BP levels that fall as 
a result of a decrease in systemic resistance, with blood being diverted into the 
splanchnic circulation (Jansen and Lipsitz, 1995). Thus, potential methods of 
decreasing PPH might focus on delaying the rate of food absorption from the gut or 
reducing local splanchnic bed vasodilation, although the drugs used to attenuate post- 
prandial reductions in BP in this review have many differing mechanisms of action, 
and the effects are likely to be variable, even more so between population groups. 
There is some supportive evidence that caffeine, an adenosine blocker, has a positive 
effect on ameliorating post-prandial reductions in BP in infrequent and regular users, 
although only one small study speciﬁcally examined individuals with symptomatic 
PPH (Lipsitz et al., 1994). When used in individuals with autonomic failure, caffeine 
resulted in a smaller reduction in post-prandial in the group mean SBP (Onrot et al., 
1985). Caffeine increased MAP when given an hour before a meal, although the time 
elapsed between treatment administration and likely maximum post-prandial BP 
reduction may have negated its maximal potential effect on reducing PPH (Lenders et 
al., 1988). The lack of effect on erect SBP (Heseltine et al., 1991c) may have been due 
to the smaller dose of caffeine administered. Given that caffeine is readily available in 
the form of tea and coffee, its use in PPH could simply be part of a lifestyle change, 
although it would appear that a pre-prandial dose of at least 200 mg is needed.  
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DL-DOPS, by increasing noradrenaline (Freeman et al., 1996), and acarbose, by delaying 
gut glucose absorption (Shibao et al., 2007, Gentilcore et al., 2011), were shown to 
attenuate the post-prandial reduction in BP, and acarbose was shown to attenuate PPH in 
those with severe autonomic failure (Shibao et al., 2007). One study of acarbose (Jian and 
Zhou, 2008) in individuals with PPH did not randomise the order in which participants 
underwent the control study or took acarbose (50 mg) and was therefore excluded from this 
systematic review, although it found a statistically signiﬁcantly smaller post-meal 
reduction in SBP (at 60 minutes: 17.8 ± 11.7 to -4.2  ± 13.1 mmHg, p< 0.001), DBP (-7.6 
± 8.5 to -3.9 ± 6.9 mmHg, p < 0.05) and MAP (-10.3 ± 8.4 to -3.3 ± 8.1 mmHg, p < 0.05). 
Guar gum, presumably by delaying absorption, also attenuated post- prandial BP declines, 
although in some instances, the BP changes were small (<5 mmHg) and of doubtful 
clinical signiﬁcance. Octreotide subcutaneously attenuates the post-prandial reduction in 
BP in those with orthostatic hypotension and hypertension, as well as those who are 
classiﬁed as normotensive.  
 
The variability of timing of drug administration relative to the energy load (a glucose 
drink, liquid meal, or standardised mixed meal), as well as which BP parameters were 
recorded, made it difﬁcult to compare studies and include in a meta-analysis. Although 
some reported all BP parameters and HR changes, others reported only MAP values and 
some only the maximal post-prandial BP changes. For a “positive” treatment effect, the 
majority of studies used the lack of a statistically signiﬁcant reduction in BP from baseline 
with the drug intervention, rather than a change that might be clinically signiﬁcant. 
Furthermore, the majority of studies (except two (Heseltine et al., 1991b, Heseltine et al., 
1991c)) did not explicitly measure BP more than once at each time point, although single 
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measurements were made using validated methods. Also of importance and not reported in 
the studies is the effect of treatment on symptoms in those with symptomatic PPH.  
 
The limitations of this systematic review include the fact that only studies reported in 
English were included and that there were only a few studies available for each 
intervention. Furthermore, only studies that were randomised and controlled in some way 
were included, although it was not required that they be blinded because this was difﬁcult 
for the original investigators with some of the interventions. This may be a potential source 
of bias from included studies. The heterogeneity of study design and parameters assessed 
within the studies included in this systematic review prohibited meta-analysis. Overall, the 
pharmacological agents included have been shown to have some effect on the attenuation 
of post-prandial reductions in BP, although only two studies (Shibao et al., 2007, Lipsitz et 
al., 1994) examined the effect of a drug intervention (caffeine and acarbose) on PPH; 
caffeine was found to be ineffective. Thus, future studies should be directed at comparing 
the effect of these drug interventions on PPH with lifestyle changes, including regular 
caffeine consumption in the form of tea or coffee. Consideration should be given to other 
methods of reducing post-prandial reductions in BP such as altering meal composition in 
terms of energy load and carbohydrate type, paying particular attention to their inﬂuence 
on PPH symptoms.  
 
The effects of PPH and its treatment on the blood supply to important organs other than the 
gut (e.g., cerebral blood ﬂow control), which may account for some of the symptoms, also 
justiﬁes further research. The variable nature of the BP parameters measured in the current 
studies and the heterogeneity of the populations studied make it difﬁcult to project the 
results of this systematic review accurately to older adults with symptomatic PPH. The 
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studies reviewed suggest that caffeine may be helpful in attenuating post-prandial 
reductions in BP but may not be useful in those with PPH. The evidence also suggests that 
acarbose may similarly be of some beneﬁt in individuals with PPH. For the clinician 
managing older adults with symptomatic PPH, the most pragmatic approach appears to 
advise that individuals avoid large simple-carbohydrate meals, consume small frequent 
meals instead, and avoid alcohol (and other vasodilators) with meals. In some individuals, 
having regular caffeinated beverages after meals may be of beneﬁt in terms of reduction in 
PPH symptoms. 
 
4.5 Conclusion 
This systematic review highlights the limited data on the pharmacological treatment of 
PPH in terms of attenuating post-prandial reductions in BP and symptom improvement. 
Future studies should investigate the effectiveness of drug treatment and lifestyle changes 
in symptomatic PPH. In the meantime, the best pragmatic advice would be to avoid large 
simple-carbohydrate meals, alcohol, and vasodilators; in some cases, caffeine may also 
reduce symptoms of PPH.
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5 Methodology 
5.1 Introduction 
The limited understanding of the physiological changes underlying orthostatic and 
post-prandial hypotension (2.1 and 2.3) and the limits of current management has been 
outlined in previous sections, with systematic reviews of their drug treatments in 
previous chapters (Chapters 3 and 4). Furthermore the possibility that abnormalities in 
cerebral auto-regulation are associated with these conditions along with important 
changes in other physiological parameters with age e.g. the decline in BRS and 
increase arterial stiffness with age, suggests that a better understanding of the 
underlying pathophysiology is required in order to treat these conditions more 
effectively in future.  
 
The justification for the methodology used in this thesis will be outlined in this chapter 
with particular reference to the role of TCD and dCA, CO2, continuous BP and BRS 
measurement, as well as assessment of arterial stiffness. Details of the study methods 
used for the Orthostatic Hypotension Study and the Post-prandial Hypotension Study 
are outlined in Chapters 6, and specific Methods for OH in Chapter 7 and for PPH in 
Chapter 13. 
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5.2 Assessing autonomic function 
The autonomic nervous system consists of two components, the  sympathetic and 
parasympathetic systems which can be assessed non-invasively using the classical 
methods originally described by Ewing and Clarke (Ewing and Clarke, 1982).  
Spontaneous heart rate variability (Bellavere et al., 1992) and cardiac baroreceptor 
sensitivity (BRS) (Frattola et al., 1997) are considered more sensitive than the classical 
Ewing and Clarke selection of tests, although some do not consider it necessarily better 
at detecting cardiac autonomic neuropathy in older adults with Type 2 diabetes 
mellitus (Tank et al., 2001). Regardless of which methods are used, impaired 
autonomic function is associated with increased mortality in those with diabetes 
mellitus, hypertension or cardiovascular disease(Gerritsen, 2001). Furthermore, the 
classical selection of tests are relatively straightforward for the clinician to carry out, 
and remains a useful assessment of autonomic function in clinical research (Allan, 
2007).  
 
The parasympathetic system can be examined using the heart rate response to the 
Valsalva manoeuvre, variation during deep breathing and the immediate response to 
standing. Similarly the sympathetic system can be assessed using the BP response to 
sustained handgrip or  to standing from supine (Ewing and Clarke, 1982). From these 
five different observations a widely used scoring system allows a score out of 10 to be 
calculated and is shown in more detail in Section 6.7 (Ewing and Clarke, 1982, Ewing, 
1985). Normal function scores zero, borderline function scores one point and abnormal 
function scores two points. However as heart rate variation normally declines with 
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ageing, age per se must be taken into account when assessing if a test is abnormal or 
not  (O'Brien et al., 1986, Piha, 1991). Of course on the other hand it is unclear 
whether these factors in part or as a whole  may be contributory to the increasing 
prevalence of syncope with age (Soteriades et al., 2002) or if there are other important 
mechanisms that may also have an important role. However for this thesis as it has 
been suggested that  postural falls of SBP≥20mmHg are found in even apparently 
“healthy” older people (O'Brien et al., 1986) and thus those without symptoms, the 
original Ewing and Clarke (1982) parameters for what may be considered “normal”, 
“borderline” or “abnormal” were used. For this thesis both the classical Ewing and 
Clarke (1982) assessment was carried out alongside spontaneous cardiac BRS. 
 
5.3 Assessing Arterial Stiffness 
As discussed previously in Chapter 2, not only is there evidence that an impaired 
cardiac BRS is associated with OH (Schrezenmaier et al., 2007), but also increased 
arterial stiffness is associated with impaired BRS (Eveson et al., 2005). Increasing 
arterial stiffness is furthermore associated with an increased risk of OH in older adults 
(Mattace-Raso et al., 2006), including those with a history of falls (Boddaert et al., 
2004). Both pulse wave velocity (PWV) and the augmentation index (AIx) provide 
information on arterial stiffness, however there are some differences and these have 
been outlined in Chapter 2. 
 
There are various methods to measure PWV and AIx including applanation tonometry 
(SphygmoCor, AtCor Medical Pvt. Limited, Sydney, Australia) which uses the 
upstroke during systole to detect the pressure wave and an oscillometric technique  
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(Vicorder™, Skidmore Medical Limited, Bristol, UK) which uses the time point of 
maximal pressure (van Leeuwen-Segarceanu et al., 2010). As previously discussed in 
Chapter 1, the wave morphology varies with location and changes with age (Kelly et 
al., 1989). The Vicorder™ has been shown to give a reliable estimate of central SBP 
when compared to invasive measurements of MAP, and therefore provides a useful 
non-invasive tool for research (Pucci et al., 2013). This is particularly important in that 
it has been shown that the carotid artery waveform was more likely than the peripheral 
brachial BP waveform to show the decline of the wave reflection used in assessing AIx 
(Tabara et al., 2005).  
 
PWV (measured in metres per second) is derived by determining the time it takes for a 
pulse wave to travel between two sites, usually the carotid and femoral artery 
(Wilkinson et al., 1998a), and thus arterial stiffness as determined by PWV is 
intrinsically related to the blood vessel (Laurent et al., 2006). AIx (shown in Figure 13) 
is calculated as the difference between the first and second peak of the pulse upstroke 
(ΔP) as a proportion of the pulse pressure (PP) and is thus reported as a percentage 
(Wilkinson et al., 1998a). Thus a high PWV directly represents increased arterial 
stiffness, whilst the AIx using pulse wave reflections is an indirect surrogate measure 
and index of stiffness (Laurent et al., 2006). Furthermore although AIx is more readily 
affected by HR and BP (Yasmin and Brown, 1999), it can be adjusted for by HR itself 
(Wilkinson et al., 2000), and aortic stiffness itself does not vary by any acute changes 
in HR (Wilkinson et al., 2002). Due to the differences between PWV and AIx and 
arterial stiffness, both PWV and AIx measurements from the previously validated 
Vicorder
TM 
shall be used in this study (Pucci et al., 2010). 
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As HR varies between subjects, and decreases by 3.9% for each increase in HR of 
10bpm (Wilkinson et al., 2000), this shall be adjusted for, and reported at 75bpm (AIx 
(@75)). This correction is given by: 
AIx (@75) = [(mean HR-75) ×0.0039×mean AIx] +mean AIx, 
because 3.9/ (100%x10bpm) =0.0039 takes into account both percentage change and 
per 10bpm change. 
 
5.4 Measuring Blood Pressure 
Several non-invasive methods have been developed as alternatives to invasive intra-
arterial blood pressure to determine beat to beat systemic blood pressure. The 
Finapres
TM
 (and the Portapres
TM
) are examples of the Penáz or Wesseling method 
using a volume-clamp technique which works by maintaining the size of the artery 
constant by changing the pressure of the finger cuff and detects changes in the artery 
size with an infrared plethysmograph. The BP value is automatically computed using 
ΔP 
PP 
Aortic AIx (%) = ΔP/PP x 100 
Figure 13 Augmentation Index (AIx) calculation (adapted from Wilkinson et al., 1998a) 
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an algorithm based on the volume-clamp set-point, being set at zero transmural 
pressure when the cuff pressure is equal to the arterial blood pressure (Langewouters et 
al., 1998).  A summary of both the positive and negative aspects of using the Finapres 
is given here. 
 
The beat-to-beat BP data acquired using Finapres permits the assessment of BP 
variability by using a technique known as power spectral analysis. The BP signal 
recorded consists of several sinusoidal signals each with two components: amplitude 
and phase (in radians), as shown in Figure 14. Each sinusoidal signal will consist of an 
integer multiple of the frequency of the original signal. By breaking down the original 
BP signal which is in the time-domain into its various frequency components, a 
frequency spectrum is created, which is in the frequency-domain (Figure 14). A power 
spectrum can be created by taking the amplitude of these sinusoids and squaring it to 
represent the power of the sinusoid (Panerai et al., 1999). Spectral analysis has been 
used to show that for some frequency bands (i.e. a specific range of frequencies) there 
is some variation between intra-arterial measurements and Finapres recordings, which 
may be explained by peripheral resistance of arterial blood vessels (Pinna et al., 1996). 
However other work suggests that the differences between Finapres measures of BP 
and intra-arterial measures of aortic BP are consistent, and good enough for use in 
estimation of cardiac BRS (Smith et al., 2008). Although low-frequency oscillations of 
SBP could be overestimated by Finapres, it is thought that overall both the frequency 
and time domain components of BP and pulse interval are reasonably accurate as 
compared to intra-arterial BP measurements (Omboni et al., 1993). 
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Although the Finapres can accurately estimate the mean artery pressure and the 
diastolic pressure when compared to intra-arterial measurements, it is less able to do so 
for the systolic pressure (Van Orshoven et al., 2010). In a study on estimating cerebral 
critical closing pressure the difference between Finapres and aortic ABP, data from 27 
individuals was shown to be not significant in SBP 4.3±18.0 (p=0.22) and mean ABP -
2.5±8.4 mmHg (p=0.14) but significant for DBP 3.2±7.0 mmHg (p=0.027) (Panerai et 
al., 2006).  It has also been shown that compared to intra-arterial brachial pressure 
measurements the effects of peripheral vasoconstriction with phenylephrine and 
vasodilation with nitroprusside can be underestimated and overestimated respectively 
(Applegate et al., 1991b). Extrapolating from this, hypothetically changes in PaCO2, 
which in turn may affect peripheral vasoconstriction and vasodilation, could result in 
significant changes in BP being undetected. Using the brachial and radial arteries from 
175 patients across 5 publications it was calculated that the proportion of Finapres 
measurements expected to be ±5, ±10 and ±15mmHg of the intra-arterial pressure was 
48.2%, 72.9% and 90.4% (Silke and McAuley, 1998). Furthermore the average bias 
for the SBP was 2.2±12.4mmHg in 449 participants across 20 publications used in the 
meta-analysis (Silke and McAuley, 1998). Problems with incremental bias has also 
been noted where measurements are continued for a 3 to 4 hour period (Ristuccia et al., 
1997). In addition, very short recordings can also add in errors due to the presence of 
positive and negative transient drifts which last approximately 20 seconds (Lagro et 
al., 2013). These drifts can alter the size of the relative difference between Finapres 
and intra-arterial measurements, resulting to distortions if the period being measured 
coincides with a drift. Therefore BP should be averaged over at least 30 seconds to 
reduce the effect of these drifts in relation to intra-arterial measurements. However 
despite these shortcomings Finapres measurements of BP still provides useful 
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information, in a non-invasive and arguably more participant acceptable manner, on 
the relative beat-to-beat changes in BP, particularly in terms of the actual magnitude of 
responses (Imholz et al., 1998) to HUT and its use in estimating spontaneous cardiac 
BRS (Smith et al., 2008). 
 
For both the OH and the PPH study in dCA, the reproducibility BP recordings over a 
long period is important, not only for a single session, but for the two week period 
required in the case of the PPH study where participants attend for two sessions. It has 
been shown that the changes to HUT in Finapres recorded beat-to-beat SBP, DBP and 
MAP values along with surface ECG to record HR, is highly reproducible over a 12 
month period in healthy men aged 65 to 75 years (Gabbett and Gass, 2005, Omboni et 
al., 1993). Of course whether the reliability of orthostatic responses seen in “healthy” 
older men is applicable to all groups of “healthy” older persons is not clear. However it 
has been shown that stable haemodynamic baseline values can be achieved with the 
Finapres within 5 to 12 minutes of supine rest in older adults (Mehagnoul-Schipper et 
al., 2000). This is important as this study is looking at relative changes in BP during 
the course of a particular session. Although there is some evidence that Finapres can 
overestimate the SBP during HUT (mean 7.2± SE 1.6mmHg) compared to intra-
brachial arterial readings (Van Orshoven et al., 2010) the Finapres remains a useful 
non-invasive method of determining beat-to-beat changes in BP and was therefore 
used in this study. 
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5.5 Measuring carbon dioxide 
How the partial pressure of arterial CO2 can influence CA has been previously 
discussed in Chapter 1. Studies have shown the importance of monitoring CO2 when 
assessing CA because of the potential influence a fall in PCO2 has on CBF. It has been 
shown that  PCO2 levels fall when changing from supine to an upright position due to 
an increase in tidal volume (Gisolf et al., 2003) as well as alterations in lung 
ventilation and perfusion due to gravity (Cencetti et al., 1997, Gisolf et al., 2003). 
However it has since been shown that although this decrease in PCO2 is maintained, it 
only has a transient effect on CBFV within the MCA (Immink et al., 2009). Methods 
to estimate arterial PCO2 in the research setting ideally has to be balanced by accuracy 
and participant comfort. Although an invasive arterial blood sample may provide more 
accurate measurements, this is often not appropriate for the research setting due to 
patient acceptability, and risks associated with invasive measurement. It has been 
shown that capillary sampling is not significantly different from arterial measurements 
(Dar et al., 1995, Pitkin et al., 1994). Furthermore it has been shown that the use of a 
transcutaneous  monitor (TINA, Radiometer, Copenhagen) for the measurement of 
PCO2 closely agreed with that given by capillary earlobe samples (Dawson et al., 
1998).  Thus for this thesis a transcutaneous monitor to record the relative change in 
PCO2 during HUT was used because it balanced the need to monitor PCO2 with patient 
comfort and compliance with an already demanding procedure. 
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5.6 Measuring spontaneous cardiac BRS 
As previously described in Chapter 1 cardiac BRS relates to the change in the duration 
of the inter-beat heart rate interval (R to R interval on the ECG) caused by the change 
in 1mmHg of BP (msec/mmHg) such that an increase in BP will result in a slowing of 
heart rate (Bothová et al., 2010).  Cardiac BRS begins to decrease with normal ageing 
around the age of 30 years but does not significantly change after the 4
th
 decade 
(Dawson et al., 1999). It is more closely associated with BP and is reduced in older 
people with hypertension compared to adults with a normal BP (Shimada et al., 1986, 
McGarry et al., 1983, Dawson et al., 1999). For example, with the Valsalva 
manoeuvre, cardiac BRS amongst adults over the age of 60 years (mean 70 ±1 years) 
with normal BP has been reported as 4.8±0.8 ms/mmHg significantly higher (p=0.02) 
than those with hypertension (2.2±0.5 ms/mmHg) (Dawson et al., 1999). More 
specifically cardiac BRS has been found to be reduced in both combined systolic and 
diastolic hypertension as well as isolated systolic hypertension (James et al., 1996). 
Furthermore it has been suggested that the postural fall in BP during head up tilt in 
older people with hypertension may be due to the reduced cardiac BRS associated with 
hypertension (James and Potter, 1999).  
 
Various methods have been used to calculate BRS (Davos et al., 2002) but the 
spontaneous variations in BP shall be used here (Eveson et al., 2005). The use of 
spontaneous changes in BP and HR to estimate continuous BRS (Oosting et al., 1997) 
have advantages over provoking changes in HR and BP using drugs, such as 
phenylephrine and sodium nitroprusside, or physical manoeuvres e.g. Valsalva (James 
and Potter, 1999). Firstly, vasoactive drugs could potentially affect the baroreflex itself 
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by acting on e.g. receptors (Oosting et al., 1997). It has also been reported that the 
BRS values from using the Valsalva method were lower than those acquired from 
spontaneous BP and HR (Dawson et al., 1997). Furthermore, anything inducing time 
limited changes (drug or mechanical) may in itself introduce error in BP monitoring 
with the Finapres, as it has been shown that transient drifts can last for around 20 
seconds. Thus the beat-to-beat BP data obtained using Finapres in this study was used 
with the simultaneous surface ECG record of R-R intervals to calculate the 
spontaneous BRS.  
 
BRS can be estimated using sequence analysis (time domain) or power spectral 
analysis (Robbe et al., 1987), however  it has been shown that spectral analysis of BRS 
correlates best (Smith et al., 2008), albeit its reproducibility has been considered as 
moderate (Hojgaard et al., 2005). Assessing BRS using power spectral analysis is 
based on the idea that each spontaneous oscillation in BP occurs at the same frequency 
in R-R interval as a result of the baroreflex. It has been shown that using fast Fourier 
transforms (FFT) of BP and ECG recordings to assess cardiac BRS correlates with 
other methods involving pharmacological agents (James and Potter, 1999). FFT 
derived cardiac BRS declines rapidly in the third and fourth decades, and in one study 
of healthy adults with a mean age of 53 years (range 22-82 years) the mean cardiac 
BRS was 13.7±8.3ms/mmHg (Dawson et al., 1999). Figure 15 illustrates the original 
BP signal and the R-R interval in the time and frequency domain, and the resultant 
power density spectrum for these and their coherence. By dividing the spectrum into 
frequency bands, where variations in the low frequency band (<0.07Hz) are thought to 
relate to vasomotor tone (body temperature, task adaptation), medium frequency (0.07-
0.14Hz) variations thought to be from BP regulation, and the high frequency band 
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(0.15-0.40Hz) thought to be parasympathetic, and mostly respiratory (Robbe et al., 
1987). The relationship between BP and R-R interval can be demonstrated by 
assessing the coherence for each frequency, where 1.0 indicates perfect coherence 
between these variables. The gain or modulus is the ration between the change in the 
time duration of the R-R interval and the BP (ms/mmHg) for each frequency. However 
the latter requires that the coherence cannot be low, as it makes it unreliable (Robbe et 
al., 1987). Out of interest there are other methods to look at BRS which negates the 
need for preselecting specific frequencies, the impulse response function. Simply put, 
this function is the output as a result of an impulse as the input (a spike of data) and 
can be obtained by using the inverse FFT of the transfer function between SBP and 
pulse interval (Dawson et al., 1997). Thus by making comparisons with a model 
corresponding to a particular BRS (in ms/mmHg) we can compare patient groups. 
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Power spectral analysis of spontaneous changes in BP and the pulse interval in the low 
frequency bands 0.05-0.15Hz ) or the combined low and high band (0.15-0.35Hz), 
termed  the α value, was assessed using a custom written computer algorithm by Prof 
R Panerai (University of Leicester) to assess the number of oscillatory components,  as 
well as the frequency and the amplitude of the oscillatory parameters, in addition to the 
phase and coherence (Dawson et al., 1999). BRS is the square root of the ratio of the 
pulse interval (R-R interval) power to the BP power in the low frequency band where 
coherence is ≥0.4 (Smith et al., 2008). For this analysis original signals would be low 
pass filtered with an eighth-order Butterworth filter with a cut-off frequency of 20Hz. 
Linear interpolation allowed removal of any ectopic beats. Data sequences were 
rejected if there were more than a few ectopics (>3) present. Fast Fourier transform 
(FFT) using 512 samples with beat-to-beat changes interpolated using a third-order 
polynormial and then resampled with a 0.5 second interval. Power spectra was 
averaged (over three readings) and smoothed (using a 13 point triangular window). 
Thus the baraoreflex sensitivity index (alpha) can be calculated from the mean of the 
square roots of the ratios of the spectral powers of SBP and pulse interval using FFT 
(Dawson et al., 1999).  
 
As mentioned earlier in this subsection, another aspect of BRS which can be compared 
when data are transformed into the frequency domain is the differences in phase at the 
various frequency bands as well as coherence. It has been found that although the low 
frequency band (0.05-0.15Hz) phase did not significantly differ between younger and 
older adults, there were differences in the high frequency band (0.15-0.35Hz) the older 
adults showed a positive phase (+0.0014±0.14 radians) compared to the younger group 
(-0.011±0.14 radians, p<0.001) (Dawson et al., 1999). Coherence relates to the 
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frequency domain and is similar to a squared correlation coefficient in the time 
domain. It is a measure of a linear association between spectral powers of two different 
variables (Omboni et al., 1993).  However because coherence in the high frequency 
bands was low in both age groups (<0.5), it was unclear as whether on this occasion 
the phase difference was due to something else such as signal noise, age-related 
changes associated with BP control external to baroreceptors or another central system 
impacting on control e.g. cerebral vasomotor regulation. (Dawson et al., 1999) 
 
5.7 Estimating cerebral auto-regulation 
5.7.1 Transcranial Doppler Ultrasound 
Transcranial Doppler Ultrasound (TCD) of the cerebral arteries, most frequently the 
MCA is a useful non-invasive method of determining the CBFV, a surrogate measure 
of CBF. It has been suggested that differences in CA may account for why some 
people with falls in BP are asymptomatic whilst others are not (Wollner et al., 1979). 
Static (sCA) and dynamic (dCA) cerebral auto-regulation can now be easily and 
reliably measured using non-invasive transcranial doppler (TCD) ultrasound 
techniques which insonate the cerebral arteries (usually the middle cerebral arteries) to 
record changes cerebral blood flow velocities (CBFV) that occur over a few seconds 
along with beat to beat changes in BP (Bishop et al., 1986, Aaslid et al., 1982 ). It has 
the advantage of not only being non-invasive but relatively straightforward to perform 
with excellent temporal resolution highlighting the advantage over other potential 
techniques such as positron emission tomography (PET) as well as not involving the 
injection of radioactive material (Chen et al., 2008). Magnetic resonance perfusion 
imaging although has better temporal resolution than PET (Chen et al., 2008), is still 
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considered more expensive than TCD and does not have the necessary time resolution 
needed for the assessment of dynamic cerebral auto-regulation. A blocked or tortuous 
MCA or an inadequate temporal bone window may prevent the adequate recording of 
the MCA therefore restricting the assessment of CA (Lorenz et al., 2009). Although 
hypercapnia is known to increase CBF by causing vasodilatation (Valdueza et al., 
1999), small changes in CO2 do not significantly affect the diameter of the MCA (ter 
Minassian et al., 1998) and as previously noted in Chapter 2, there is little difference in 
the regional cerebral vascular response to hypercapnia and hypocapnia (Ito et al., 
2002).  
 
As briefly discussed in Chapter 2 CBFV has been validated as a good surrogate for 
CBF and provides a simple method of reflecting changes in CBF without having to 
directly assess the changes in diameter of the MCA (Newell et al., 1994, Aaslid et al., 
1991). It has also been shown that there is good correlation between sCA and dCA in 
adults (Tiecks et al., 1995). The use of static CA is limited by its relationship with 
CBFV and BP, as in the semi-steady state measures of CBFV and the associated 
cerebrovascular resistance (CVR)  is the outcome or product of a stable BP level, and 
is given by CVR=ABP/CBFV (Tiecks et al., 1995).  In addition as static CA is 
reflected by average long-term changes in BP, its use is limited by the need for 
sustained changes in BP induced by pharmacologically active agents. Dynamic CA 
reflects the changes in CBFV in response to rapid changes in BP (over a few seconds 
such that would occur during standing) hence the need for measurement of beat-to-beat 
changes in BP (van Beek et al., 2008). Thus for the rapid changes in BP provoked by 
head-up-tilt in this study, dCA was assessed.  
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As was noted in previous discussions, there are several methods which researchers 
have used to change systemic BP, in order to assess CA. Although there are other 
methods which can be used to invoke systemic falls in BP e.g. lower body negative 
pressure (Panerai et al., 2001) which may limit movement artefact, it was felt that HUT 
would provide a physiological response more closely representative of HUT in the 
clinical setting, and also provide some control over the period of postural change 
which active standing would not. 
 
 
Sonograms displaying the CBFV over time from Transcranial Doppler Ultrasound 
(TCD) consist of the maximum velocity envelope extracted using a fast Fourier 
transform algorithm on the raw Doppler shift signal to provide a power spectrum at 
each frequency. The Doppler shift signal consists of several frequencies representative 
of the velocities of its scattered components as the original ultrasound signal usually 
from a 2MHz piezoelectric transducer is reflected from the surface of red blood cells 
within blood vessels. A piezoelectric transducer converts electrical energy into sound 
or acoustic energy (Nichols et al., 2011b, Panerai, 2009). The middle cerebral artery is 
insonated usually via the transtemporal window starting at a depth of around 50mm, 
and its identity is confirmed by the fact it is positive on the sonogram with flow 
towards the transducer and it is also traceable in terms of depth (Katz and Alexandrov, 
2003, Gillard et al., 1986). 
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5.7.2 Static CA 
Although static CA (sCA) will not be used in this thesis, it may aid the understanding 
of dynamic CA (dCA). Static CA can be estimated using linear system analysis with 
the change in BP accounting for the associated cerebral blood flow (𝐶𝐵𝐹). In order to 
understand the principles behind dCA, an idea of how sCA is determined is useful. The 
resistance between the BP as the input of the system and the CBFV as the output of the 
systemic can be shown as the cerebrovascular resistance (𝐶𝑉𝑅) using Ohm’s law 
taking into account brain weight. Thus: 
𝐶𝑉𝑅 =
𝐵𝑃𝑚𝑒𝑎𝑛
𝐶𝐵𝐹𝑚𝑒𝑎𝑛
 
However as TCD and the use of CBFV as a surrogate of CBF does not take brain mass 
into account an index of CVR is used (𝐶𝑉𝑅𝑖) to give: 
𝐶𝑉𝑅𝑖 =
𝐵𝑃𝑚𝑒𝑎𝑛
𝐶𝐵𝐹𝑉𝑚𝑒𝑎𝑛
 
(van Beek et al., 2008) 
 
Another estimate of CVR is Gosling’s pulsatility index (PI) (Gosling et al., 1971) 
which is the difference between the systolic and diastolic components of CBFV over 
the mean CBFV. This gives: 
𝑃𝐼 =
𝐶𝐵𝐹𝑉𝑠𝑦𝑠 − 𝐶𝐵𝐹𝑉𝑑𝑖𝑎𝑠
𝐶𝐵𝐹𝑉𝑚𝑒𝑎𝑛
 
Thus CVRi and PI can be described as inversely correlated to CBFV, such that a 
decrease in CBFV is associated with an increase in PI. However this only holds true in 
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stable conditions and thus useful for assessing static CA as it has been found that a 
reduction in CVRi is associated with an increase in PI (Schondorf et al., 1997). 
 
TCD has been shown to be a valid method of measuring static CA according to the 
Fick principle and assuming a constant cerebral metabolism of oxygen (Larsen et al., 
1994). The Fick principle states that the blood flow within a certain period of time is 
equal to the amount of a substance entering the flow within that time frame divided by 
the difference between the concentration upon entering and upon leaving. Therefore, 
 Cardiac Output (L/min) =
O2 consumption (mL/min)
PaO2(mL/min) − PvO2(mL/min)
 
(Nichols et al., 2011a) 
 
Static cerebral auto-regulation can be determined by infusing pressor or depressor 
agents (e.g. phenylephrine or GTN) to provoke an increase/decrease in the mean 
arterial BP (ABP) whilst simultaneously recording the ABP and corresponding CBFV 
over a period of time (t2-t1). Thus the estimated cerebrovascular resistance (CVRe) 
percentage change associated with the relative change in BP and CBFV over time is 
used to calculate the static cerebral auto-regulation as a percentage proportion of the 
full CA potential (Tiecks et al., 1995).  
 
This can be summarised as: 
CVRe =
ABP
CBFV
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% ΔCVR =
(CVR2 − CVR1)
CVR1
  
% ΔABP =
(ABP2 − ABP1 )
ABP1
 
Thus static CA is: 
𝑆𝑡𝑎𝑡𝑖𝑐 𝐶𝐴 =
%∆𝐶𝑉𝑅
%∆𝐴𝐵𝑃
× 100% 
 
This would infer that if no static CA occurred then a fall in ABP would be associated 
with no change in the CVR and thus a reduction in the CBFV. Whereas if a perfect 
static CA of 100% were present then the CVR would compensate for a reduction in 
ABP (Tiecks et al., 1995).  
 
Although CVR and PI may be useful to assess sCA in stable physiological situations, 
they are not ideal for dynamic changes in BP such as during HUT, as CVR relies on 
the direct relationship of a stable BP against CBFV and PI relies on CBFV stability. 
The dCA, gives more information regarding the efficiency of CA over a short time 
period, important in situations such as supine to standing, and the brief periods 
encountered with symptom onset in such situations (Tiecks et al., 1995). 
 
5.7.3 Dynamic CA 
Using TCD to record cerebral blood flow velocity (CBFV) of the MCA, as a surrogate 
of CBF (Newell et al., 1994, Berlowitz et al., 2011, Wilkinson et al., 2000) allows 
exploration of its relationship with real-time systemic BP and CO2 changes. . As 
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previously noted in previous sections of Chapter 2 (2.6, 2.13, 2.14 and 2.15) and the 
preceding section on sCA, dCA relates to rapid changes in CA over a few seconds 
which can be assessed using several different methods though time and frequency 
domains are the most frequently used, and are described below. 
 
5.7.3.1 Rate of recovery in the Time Domain 
The time it takes for the CBFV to return to baseline values following a BP change 
(both pressor and depressor) as stimulus can indicate the efficiency of dynamic CA. 
An increasing time delay would indicate poor dCA.  Thus for normalised changes in 
CVRi with a BP decrease, assuming a CBFV is representative CBF in a particular 
state: 
𝑅𝑎𝑡𝑒 𝑜𝑓 𝑟𝑒𝑐𝑜𝑣𝑒𝑟𝑦 =  
∆𝐶𝑉𝑅𝑖 ∆𝑇⁄
∆𝐵𝑃
 
 Where ∆𝐶𝑉𝑅𝑖 ∆𝑇⁄  relates to the rate at which cerebrovascular resistance changes over 
a defined period of time (∆𝑇). 
(Aaslid et al., 1989) 
   
5.7.3.2 Auto-regulatory Index (ARI) in the Time Domain 
To assess dynamic CA either spontaneous BP transients or an applied stimulus can be 
used to induce a rapid step reduction in ABP (of ≥15mmHg e.g. such as thigh-cuff 
release) or step increase (e.g. cold pressor test or phenylephrine infusion)  in order to 
allow the response of the ABP and CBFV to be simultaneously analysed over a period 
of time, usually less than 1 minute. The time it takes for CBFV to recover and attain its 
original level will vary according to the state of dCA. The mathematically derived 
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model of cerebral auto-regulation as an index (ARI) is one recognised method in which 
dCA can be measured and can be from 0 (no auto-regulatory function) to 9 (perfect 
auto-regulatory response) as shown in Figure 16. It uses the CBFV and ABP responses 
after a sudden BP change (e.g. thigh-cuff release or HUT) to attain a change in CVR 
per second relative to ABP.  
 
The ARI relies on computer modelling based on the actual recorded CBFV response to 
ABP change from the start of the stimulus e.g. the moment of thigh-cuff release over 
30 seconds, from which a theoretical or hypothetical CBFV response based on no 
cerebral auto-regulation would be created. Within this model of zero CA a linear 
relationship between ABP and CBFV is assumed with falls CBFV following a similar 
percentage fall in ABP. A further nine models of other possible CBFV responses are 
made with an increase in the ability of CA being assumed. Thus an actual CBFV 
response can be matched against these models in order to determine best fitting model 
and thus the ARI value (Tiecks et al., 1995). Thus from Figure 16 it can be seen that 
normal cerebral auto-regulation will have an ARI of around 5.  
 
Mathematical models exploiting the spontaneous CBFV-BP relationship such as auto-
regressive moving averages (ARMA) allows estimation of spontaneous fluctuations in 
ARI during HUT or ARMA-ARI (Panerai et al., 2008).  
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Figure 16 Auto-regulatory indices, Tiecks et al. (2005) 
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5.7.3.3 Critical Closing Pressure and Resistance-Area Product from 
instantaneous CBFV-BP relationship 
The critical closing pressure (CrCP) is defined as the point at which for a given level 
of systemic BP CBF ceases (Panerai, 2003) and is estimated from instantaneous ABP-
CBFV changes (Panerai et al., 2011). There are several methods to assess this, most 
common of which is using a linear model where 𝑣(𝑛) is the CBFV signal for the 
cardiac cycle with 𝑁 number of samples, and 𝑝(𝑛) is the associated BP measurement. 
𝑣(𝑛) = 𝑎. 𝑝(𝑛) + 𝑏 
𝑛 = 1,2, … … . 𝑁 
Therefore RAP and CrCP is estimated for each cardiac cycle using 
𝑅𝐴𝑃 =
1
𝑎
 
𝐶𝑟𝐶𝑃 = −
𝑏
𝑎
 
Or where the mean CBFV (𝑉𝑚)and mean BP (𝐵𝑃𝑚) is used where: 
𝑉𝑚 = (𝐵𝑃𝑚 − 𝐶𝑟𝐶𝑃)/𝑅𝐴𝑃 
Then: 
𝐶𝑟𝐶𝑃 = 𝐵𝑃𝑚 − 𝑅𝐴𝑃. 𝑉𝑚 
(Panerai et al., 2011) 
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However it has been recently shown that using the first harmonic (H1), MAP or DBP 
when used in the calculation of the constant 𝑎, were the best suited for both dynamic 
CA assessment, providing similar estimates of CrCP and RAP using non-invasive 
Finapres for BP measurement as with intra-aortic values, and therefore is used in this 
thesis (Panerai et al., 2011, Panerai et al., 2006). 
 
Thus for the H1 method, H1 is fitted to 𝑣(𝑛) and 𝑝(𝑛) with corresponding amplitudes 
for 𝑉1 the CBFV and 𝑃1 the BP. Therefore using the slope 𝑎, 
𝑎 =
𝑉1
𝑃1
 
Or if using (2Pm), calculating, with the mean (𝑉𝑚)and diastolic values (𝑉𝑑)of CBFV 
and those of BP, (𝑃𝑚) (𝑃𝑑)  
𝑎 =
𝑉𝑚 − 𝑉𝑑
𝑃𝑚 − 𝑃𝑑
 
Therefore substituting 𝑎 into  
𝑅𝐴𝑃 =
1
𝑎
 
𝐶𝑟𝐶𝑃 = −
𝑏
𝑎
 
Although RAP and CrCP are not presented in this thesis, they are useful indicators of 
dCA. 
 
 129 
 
5.7.3.4 Power spectral analysis of CBFV and BP and Fast Fourier Transform 
A signal can be separated into its component sine waves, with each sine wave having a 
different frequency, where the frequency is the time for one complete wave cycle to 
complete (F=1/T). Data collected in the time-domain can be converted to the 
frequency-domain to further explore the relationship between BP and CBFV using a 
fast Fourier transform (FFT) method for transfer function analysis (Panerai et al., 
2005). A graphical representation of transfer function analysis is shown below (Figure 
17). 
 
 
 
 
 
  
Figure 17 Principles of Transfer Function Analysis. [The diagram shows two sinuoidal waveforms and within 
the period (T), the phase shift illustrates a delay between solid wave and dotted wave, and an alteration in 
gain] 
 
Transfer function [𝐻(𝑓)] is the ratio between the smoothed cross-spectra [𝐺𝑃𝑉(𝑓)] to 
the autospectra of ABP [𝐺𝑃𝑃(𝑓)] represented as: 
𝐻(𝑓) =  
𝐺𝑃𝑉(𝑓)
𝐺𝑃𝑃(𝑓)
 
(Panerai et al., 2005) 
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Phase and Gain frequency response 
The gain is the change in amplitude between the input and output signal of the transfer 
function and the phase indicates the time delay between the BP (input) and resultant 
CBFV (output) (van Beek et al., 2008). The magnitude of the gain therefore reflects 
whether adequate CA has taken place to buffer the oscillations of BP. The number of 
degrees (or radians) of phase shift is used and so zero degrees i.e. no difference 
between response in BP and CBFV indicates no auto-regulation. So for example if 
there was a phase shift of 90º or π/2  with a period of 10 seconds (0.1 Hz), then there is 
a time gap of 2.5 seconds between BP and CBFV. Similarly if the phase shift was π, 
where the period was 10 seconds, then time delay would be 5 seconds. The amplitude 
and phase response are obtained using the real and imaginary components of 𝐻(𝑓) to 
give: 
Amplitude  |𝐻(𝑓) = [𝐻𝑅 (𝑓)
2 + 𝐻1 (𝑓)
2]1/2 
Phase   𝜑(𝑓) = tan−1 [
𝐻1 (𝑓)
𝐻𝑅 (𝑓)
] 
(Panerai et al., 2005) 
 
However a phenomenon known as aliasing is a limitation which can affect the results. 
Simply put, in order to reduce this, the sampling rate has to be twice the frequency of 
the original function. Inadequately sampled data will result in the incorrect 
reconstruction resulting in aliasing. However this needs to be balanced with the time it 
takes to compute the sampled signal. This is also known as “wrapping” because 
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software when calculating the transfer function use the angle between –π and +π 
radians, which leads to phase shifts of 2π radians. Thus mathematically, a phase delay 
of –π/3 is the same as -7π/3 and so on (2007, Nichols et al., 2011b). 
 
Coherence Function  
The coherence function (similar to that of Figure 15 (E)) indicates the proportion of 
variation in CBFV explained by BP variation in a linear relationship, such that 
coherence of 1.0 indicates that changes in CBFV are directly proportional to those of 
BP. A coherence of zero indicates a non-linear relationship which could be caused by 
blood flow velocity (auto-regulation) or background noise depending on the frequency 
at which the coherence occurs on the spectrum. Therefore the squared coherence 
function is the fraction of the output power linearly determined by the input power and 
is estimated using: 
𝛾2(𝑓) =  
|𝐺𝑃𝑉(𝑓)|
2
𝐺𝑉𝑉(𝑓)𝐺𝑃𝑃(𝑓)
 
(Panerai et al., 2005) 
 
Impulse and Step Response 
The impulse response function can be defined as the temporal response of CBFV to a 
change in ABP, whilst the step response is the impulse response function used to 
predict the CBFV response to ABP, and can be graded in a similar fashion to Tiecks et 
al (1995) model for ARI (Panerai et al., 1998). 
 132 
 
To visualise the impulse and step response an inverse FFT is used to change it from the 
frequency domain to the time domain. The CBFV step response is calculated from the 
integration of ℎ𝑃𝑉 (𝑛), (i.e. the inverse FFT of the impulse response) for positive 
values of time (Panerai et al., 2005). 
 
5.7.4 Limitations of TCD 
Perhaps one significant limitation which needs to be considered is the effect of the 
quality of BP and TCD signals on the evaluation of CA. Transfer function analysis can 
become unreliable at differing frequencies depending on the duration of the missing 
data. For example if there is 5 second loss of data even every 50 seconds, transfer 
function estimates of CA become unreliable at 0.07 to 0.5Hz; whereas if there is a 2 
second loss then only bands above 0.15Hz is affected (Deegan et al., 2011a). 
 
Of course TCD and thus the measure of CBFV has problems which may affect the 
evaluation of CA such as the fluctuations at different frequencies. Firstly, the obvious 
oscillations in CBFV are that related to the BP pulse waves; and secondly the slower 
oscillations in CBFV including respiratory R-waves at 9-20 cycles per minute (cpm or 
0.15 – 0.33Hz), M-waves at 3-9 cpm (0.33 – 0.11 Hz) and low frequency waves at 1 
cpm (1 Hz). It has been shown that the oscillation amplitudes for CBFV can be greater 
than the BP oscillations despite any falls in CBF being due to CA (Diehl et al., 1998). 
It has thus been suggested that spectral analysis of these waves may be an alternative 
method for determining CA as the oscillations in BP, HR and CBFV are present in 
supine and HUT (Diehl et al., 1998).  
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6 General Methods 
There were two components to this thesis. The Orthostatic Hypotension Study and the 
Post-prandial Hypotension Study, with Methods particular to these in Chapter 7 and 
Chapter 13 respectively. Both shared similar general methods in terms of physiological 
measurements and are described here. 
 
6.1 Recruitment 
Recruitment commenced in December 2010 following approval by the Norfolk 
Research Ethics Committee and the Norfolk & Norwich University Hospital Research 
& Development.  
 
Potential participants were identified by medical staff from all Medicine for the 
Elderly out-patient clinics and General Practice (GP) Surgery records as being possibly 
suitable for the study, based on inclusion and exclusion criteria outlined below. These 
clinics included Syncope Clinic, Falls Clinic, General Clinic and TIA Clinic.  For 
example, of the 43.8% non-TIA patients attending a TIA out-patient clinic at NNUH, 
OH was present in 22.3% (de la Iglesia B. et al., 2013). Similarly participant 
information leaflets were distributed via GP Surgeries by seeking the assistance of the 
NIHR Norfolk Primary Care Research Network who contacted surgeries that would be 
interested in assisting with recruitment through patient identification via their practice 
database. Once potential participants aged over 60 years were identified (which 
included search terms such as “orthostatic/postural hypotension), and exclusion criteria 
checked they were given pre-stamped envelopes containing a Participant Information 
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Sheet to send out with a GP surgery cover letter. Furthermore posters were displayed 
in the waiting areas of GP Surgeries who had agreed to assist with recruitment, and a 
local newspaper advertisement (Eastern Daily Press) was placed asking for volunteers 
with and without symptoms. Potential participants were asked to contact Dr Alice Ong 
by telephone if interested and a call back allowed verbal screening to confirm 
eligibility. This allowed further discussion of the study, and what it involved, giving 
potential participants the opportunity to ask questions. A follow-up telephone call was 
made at least 24 hours later, to obtain verbal consent to attend the hospital for 
participation in the study.   
 
6.2 Sample size 
As the main outcome in this study is to investigate differences in cerebral auto-
regulation, a sample size calculation was based on detecting a difference between 
groups of an ARI (auto-regulatory index) of at least 1.5 with 80% power with α=0.05. 
This would similar to the difference seen between stroke patients and controls in 
previous research, (Brodie et al., 2009) where  the sample size for each group is based 
on 45/ΔARI2. Therefore to detect an ARI of 1.5, 20 participants was required for each 
group. OH was classed as being present, with either a SBP or a DBP fall at 1 or 3 
minutes (Moya et al., 2009); and symptoms were classed as present if the score was 2 
or more on the Orthostatic Grading Score or OGS (Schrezenmaier et al., 2005). 
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6.3 Inclusion criteria 
(FOR BOTH STUDIES) 
≥ 60 years of age 
World Health Organisation (WHO) performance status of 0 to 2 (i.e. ambulatory) 
With or without known postural hypotension  (OH Study) or post-prandial hypotension 
(PPH Study) 
With or without symptoms suggestive of postural hypotension (OH Study) or post-prandial 
hypotension (PPH Study) 
 
 
6.4 Exclusion criteria 
(FOR BOTH STUDIES) 
Intra-current acute illness (e.g. pneumonia, myocardial infarction, major surgery) in the 
preceding 4 weeks 
Atrial fibrillation 
Transient ischaemic attack or completed stroke in preceding 3 months (unless normal 
carotid dopplers) 
Carotid stenosis 
Raynaud’s disease 
Terminal cancer with a life expectancy <6 months 
Anaemia where Hb ≤ 9g/dL 
Known autonomic disturbance from any cause e.g. diabetes, Parkinson’s disease 
On drugs known to affect autonomic function 
 
6.5 Consent 
Written and informed consent was obtained from all participants, and participants were 
made aware that they were free to withdraw at any time. 
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6.6 Ethics 
Full ethical approval was been obtained for this study (Norfolk Research Ethics 
Committee) [REC No. 10/H0310/46]. 
Approval was sought from the local Research & Development Office at the Norfolk & 
Norwich University Hospital. [R&D No. 2010MFE12S (142-10-10)] 
This study has also been registered. ISRCTN92525381 - Do abnormalities in the 
control of brain blood flow account for dizziness on standing or after meals in older 
people? http://www.controlled-trials.com/ISRCTN92525381/ 
 
6.7 Measurements 
6.7.1 Clinical Data 
Participants attended in the morning of the study day with an empty bladder having 
had no caffeine since the evening of the previous day, but were permitted a light 
breakfast. Participant age, sex, medical history including history of falls and frequency 
of falls and drug history were recorded. In order to represent real world older patients 
as closely as possible participants were not asked to stop their regular medication. It 
was recognised by the Ethics Committee that those on anti-hypertensives would 
potentially be at increased risk of stroke if discontinued. However those on medication 
known to affect autonomic function such as β-blockers were excluded from the study 
(Section 6.4). Furthermore it was desirable to have a “real world” study.  Their height, 
weight, BMI, baseline sitting BP and HR (using a validated monitor OMRON 705IT) 
and postural change in BP were measured (supine BP lying for 5 minutes) and 
standing BP at 1 and 3 minutes (after both feet touch the floor were recorded) using a 
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BP cuff of the appropriate size to detect initial OH. OH defined as a fall in SBP of at 
least 20mmHg and/or a fall in DBP of at least 10mmHg at 1 or 3 minutes of standing 
(Moya et al., 2009). The presence or absence of orthostatic symptoms and the effect on 
daily life was assessed using the Orthostatic Grading Scale (Schrezenmaier et al., 
2005), with those scoring ≥2 being classed as “symptomatic”. A full clinical history 
and examination was carried with particular attention paid to undiagnosed exclusion 
criteria e.g. those with previously undetected atrial fibrillation, to exclude carotid bruit 
which may indicate carotid stenosis, and to exclude conditions such as benign 
positional vertigo which may cause symptoms of dizziness.  
 
6.7.2 Autonomic Function Tests 
All participants underwent standard autonomic function tests to assess sympathetic and 
parasympathetic function using the methods of (Ewing and Clarke, 1982) the 
Taskforce® Monitor system (Figure 18, Figure 19, Figure 20) was used to record R to 
R intervals, heart rate and beat to beat BP responses.  The beat-to-beat BP reading 
from the finger (Figure 20) is intermittently validated against the brachial BP.  
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Figure 18 Taskforce Monitor Screen showing ECG, beat-to-beat BP and oscillometric BP 
 
Figure 19 Taskforce connections 
 
Brachial BP 
ECG 
Continuous BP 
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Figure 20 Taskforce beat-to-beat BP measurements 
 
Parameters used to obtain the final autonomic function score (out of 10) (Ewing and 
Clarke, 1982) were: 
1) Heart rate response to Valsalva in the sitting position reflects parasympathetic 
function. The Valsalva manoeuvre was carried out by asking the participant to 
seal their lips around the Leur lock end of a clean plastic 20ml syringe and to 
then blow out the plunger. The mean ratio of the longest R-R interval after 
Valsalva to the shortest R-R interval during Valsalva shall be used to score as 
follows.  
Ratio of R-R interval Outcome Score 
≥1.21 Normal 0 
1.11 to 1.20 Borderline 1 
≤1.10 Abnormal 2 
 
2) Heart rate variation during six deep breaths assesses parasympathetic function. 
Deep breathing is carried out at a rate of 6 breaths a minute whilst sitting and 
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timed using the display on the TFM with Dr Alice Ong, counting inspiration 
and expiration. The mean difference between the maximum and minimum heart 
rate (which can be calculated from the RR interval) is used to give a score as 
follows.  
Heart rate variation (bpm) Outcome Score 
≥15  Normal 0 
11 to 14 Borderline 1 
≤10 Abnormal 2 
 
3) BP response to sustained handgrip whilst sitting assesses sympathetic function. 
Participants were asked to handgrip in their “strongest” hand a partly inflated 
soft covered fabric BP cuff bladder and then to maintain 30% of their maximal 
handgrip strength for up to 5 minutes, and ideally for at least 3 minutes.(Figure, 
Greenlight 300). BP is measured at 1 minute intervals and the difference 
between the highest diastolic BP achieved and the mean of three DBP values 
before handgrip is calculated to give a score. 
Diastolic BP change (mmHg) Outcome Score 
≥16 Normal 0 
11 to 15 Borderline 1 
≤10 Abnormal 2 
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Figure 21 Handgrip using Greenlight 300 blood pressure cuff 
 
4) Immediate HR response to standing from supine assesses parasympathetic 
function. The ratio of the longest R-R interval at or around the 30
th
 heart beat 
after the participant starts to stand, to the shortest R-R interval at or around the 
15
th
 beat is calculated to allow scoring as follows. 
 
Ratio 30
th
 beat R-R interval :15
th
 beat R-R 
interval 
Outcome Score 
≥1.04 Normal 0 
1.01 to 1.03 Borderline 1 
≤1.00 Abnormal 2 
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5) BP response to standing from supine reflects the sympathetic function. The 
postural fall in BP is calculated as the difference in the systolic BP from supine 
to stand at 3 minutes to give scores as follows. 
Postural SBP fall (mmHg) Outcome Score 
≤10 Normal 0 
11 to 29 Borderline 1 
≥30 Abnormal 2 
 
By giving each participant a score for each component a maximal score of 10 for 
autonomic dysfunction can be allocated (Ewing, 1985).  
 
6.7.3 Laboratory Data 
The most recent electrolytes, blood glucose and haemoglobin values from the last 3 
months were checked for participant eligibility.  
 
6.7.4 Transcranial Doppler Measurements Generic Procedure 
Participants attended for TCD having only had a light meal and no caffeine on the day 
of attending the study, and were asked to wear comfortable loose fitting clothing. 
Recordings were carried out in a quiet research laboratory with temperature controlled 
to 20-22°C. Patients lay on a padded couch with a footplate to allow the participant to 
be passively placed into the head up tilt position, and a single pillow was provided for 
head support. The participant went from a supine to the 70° HUT position within a 5 
second period. Whilst supine the arms were rested by their side, and when in the 
upright position during tilt, a table was secured to the tilt-table to allow arms to rest at 
the level of the heart, and the participant was secured to the table using straps across 
their body and legs. 
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Simultaneous recording at baseline of: 1) transcutaneous CO2 partial pressure using a 
transcutaneous gas monitor (Figure 22, TINA, Radiometer, Copenhagen)(Dawson et 
al., 1998)  or the end-tidal CO2 level using an infrared capnograph (Capnogard, 
Novametrix, USA), 2) continuous non-invasive beat-to-beat BP measurements with a 
plethysmograph using a Finapres device (Figure 23 and Figure 24, Ohmeda, Colorado, 
USA)(Panerai et al., 2003, Omboni et al., 1993) on the middle finger of the non-
dominant hand with Physiocal being switched on at the start of a ten minute segment, 
3) bilateral middle cerebral artery velocity using TCD as identified according to 
velocity, depth and waveform (DWL Compumedics, Germany and QL Software 
version 2.5) Figure 26, and 4) three lead surface ECG monitoring (Cardiac Monitor 
304, Graseby Medical, England, Figure 25). The middle cerebral artery (MCA) 
velocity analogue signals (Figure 26) and other analogue signals were digitally 
converted at 200 Hz for off-line analysis. All physiological signals were recorded into 
a data acquisition system (Figure 27, Physidas software, Professor Ronney Panerai, 
Medical Physics, University of Leicester). 
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Figure 22 Transcutaneous carbon dioxide sensor (TINA) 
 
Figure 23 Finapres BP finger cuff 
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Figure 24 Finapres BP monitor 
 
Figure 25 ECG signal 
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Figure 26 Doppler signal showing CBFV from Left MCA (A) and Right MCA (B). Doppler signal  (C) 
towards probe (red) and signal away from probe (blue). Left and right CBFV superimposed on each other in 
real time recording (D). 
 
(A)  
(B) 
  ABP 
(C) 
(D) 
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Figure 27 Physidas screen 
 
ECG 
ABP 
RCBFV 
LCBFV 
pCO2 
Marker switch 
 148 
 
Cerebral blood flow velocities in the left and right middle cerebral arteries (Figure 26) 
were simultaneously  obtained by insonation using the standard  trans-temporal 
window in an area superior to the zygomatic arch (Aaslid et al., 1982 ). A 2 MHz 
Transcranial Doppler probe (DWL, Germany) was fitted securely with a custom 
silicon head-band to allow continuous readings to be taken (Figure 28). Participants 
were asked to remain as still as possible to prevent the introduction of artefact as a 
result of either head movement or probe movement. Once transcutaneous CO2 and 
beat-to-beat BP stabilised and after approximately 30 minutes, recordings began when 
there was less than 10% variation in all values.  
 
At the beginning and the end of each 10 minute segment recording  in the supine 
position at baseline and in the HUT position for each of the maximum of three (for 
Orthostatic Hypotension) and six (for the Post-prandial Hypotension)10 minute 
segment recordings a calibration for BP was carried out by using the Finapres device 
to provide a voltage calibration. Thirty minutes of 70º HUT was selected for OH, as 
this seemed to be a reasonable amount of time to reflect initial OH, and to provoke 
symptoms in the older adult (Moya et al., 2009, Carey et al., 2003). Indeed it has been 
proposed that most positive tests occur within 15 minutes (Pitzalis et al., 2002) and 
other researchers have also used 30 minutes (Grubb et al., 1991b). Although some 
research has suggested longer periods of HUT of 45 minutes, this was at a lower 
incline of 60º HUT (Fitzpatrick et al., 1991). Sixty minutes was selected for PPH as 
this also appeared to be a reasonable time period to allow glucose absorption, and BP 
changes to occur in the HUT position (Krajewski et al., 1993). Prior to this the 
Finapres internal calibration of BP or physiocal was switched on to validate the BP. 
The physical is the baseline pressure servo adjust system for the Finapres, and was 
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disabled during the recordings to prevent zero data output periods. CBFV was 
recorded in the supine and 70° HUT positions, recording the systolic, diastolic and the 
mean CBFV for each MCA to allow calculation of the auto-regulatory indices for each 
side off-line. The mean ARI of both hemispheres is the ARI for that one individual as 
it has been previously shown that the auto-regulatory response does not depend on 
which hemisphere is being assessed (Dawson et al., 2000). Auto-regulatory indices 
were taken before tilt at baseline, at 1 and 3 minutes after tilt, the last 3 and 1 minute of 
the tilt before the participant is returned to supine, and at 1 and 3 minutes after return 
to supine using a standard protocol for our laboratory (James and Potter, 1999). 
 
6.7.5 Baroreflex sensitivity 
Continuous baroreflex sensitivity (BRS) whilst supine was derived using Finapres BP 
and corresponding ECG data using spectral analysis as previously discussed earlier in 
this Chapter(Dawson et al., 1997, Youde et al., 2002). In summary this involves 
changing the R-R interval and BP data into the frequency-domain from the time-
domain to give the power spectrum from which the gain or modulus, phase and 
coherence between the R-R interval and BP can be considered. 
 
6.7.6 Pulse Wave Velocity and Augmentation Index 
As previously discussed pulse wave velocity and  augmentation index are two different 
measures of arterial stiffness but can be measured using the same data (Vicorder, 
Skidmore Medical Limited, UK) and were measured in the supine position after 10 
minutes of rest (Wilkinson et al., 1998b, Asmar et al., 1995). The neck cuff (Figure 29) 
was positioned over the carotid artery with the participant at 30° to the horizontal 
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plane, and a thigh cuff (Figure 30) was placed over the proximal part of the right leg 
(to obtain the femoral artery waveform), with both attaching to the Vicorder Unit 
(Figure 31). The distance between the carotid cuff and the centre of the thigh cuffs 
were measured. Three recordings of reasonable quality (when HR showed less than 
10% variation) was taken to calculate the mean PWV and AIx for each participant 
(Figure 32). 
 
 
 
 
 
 
 
TCD  Transducers  
Capnograph mask 
Figure 28 Headband holding transducers (as demonstrated by a colleague) 
Head band 
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Figure 29 Neck cuff of Vicorder 
 
Figure 30 Thigh cuff of Vicorder 
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Figure 31 Vicorder Unit 
 
Figure 32 Vicorder screen showing adequate tracings for carotid and femoral pulses 
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6.7.7 Data analysis 
In summary, data files were cleaned in terms of removing artefact data spikes (e.g. 
when patient inadvertently moved their arm causing a spike in ECG etc.) whilst 
blinded to the subject group. Data files were kept separately from the master file 
linking data file names with the actual participant during this process. Once files were 
cleaned, parameter data were extracted and BRS and CA information were analysed 
using special software (Professor Ronney Panerai, Medical Physics, University of 
Leicester), this data and baseline data were analysed using SPSS software package (v 
21). The digital signal processing software (RP) will be discussed in later sections. 
 
 
6.7.7.1 Baseline continuous data 
The baseline characteristics of the four groups were statistically analysed for any 
significant differences this included the mean ±SD of continuous variables: age, body 
mass index (weight in kg/height in m
2
), baseline SBP, DBP, HR, capillary blood 
glucose, orthostatic grading score (Schrezenmaier et al., 2005), autonomic function 
score, mean augmentation index, mean augmentation index (@75bpm), change in 
SBP, DBP and HR at 1 minute and 3 minutes. BRS in the very low frequency band, 
low frequency band and the high frequency band were also compared. 
 
 154 
 
6.7.7.2 Baseline categorical data 
Categorical data were also examined for differences between the four groups using a 
Pearson Chi-square or Fisher’s exact test where appropriate, and included: sex, 
smoking status, history of blackouts/syncope, hypertension, diabetes mellitus, use of 
diuretics as a group (and sub-groups of loop and thiazide), use of ACEi or AIIRB (and 
as sub-groups of ACEi and AIIRB), calcium channel blocker, alpha blocker, tricyclic 
antidepressant, any BP lowering drugs, and the presence of symptoms on HUT. 
 
6.7.7.3 Assessment of Cerebral Auto-regulation 
After digital signal processing as described below a comparison between the four 
groups of the baseline ARI (Tiecks et al., 1995) in the supine position was made. This 
included direct fitting of Tiecks model, and reporting the mean coherence, mean gain, 
mean phase, mean phase unwrapped in the low, middle and high frequency bands, and 
the percentage step response recovery. In order to permit continuous estimates of 
dynamic CA this was followed by auto-regressive moving averages or ARMA 
modelling of ABP-CBFV followed by least-squares fitting of Tiecks model to give 
ARMA-ARI (Panerai et al., 2008). 
 
Continuous ARI was calculated by using data 1 minute before HUT (data were linearly 
interpolated backwards if this was not the case) and for 2 minutes after. The point of 
HUT was digitally marked where a switch creates a positive voltage gain on a 
recording channel. Similarly, when participants had orthostatic symptoms, or when the 
maximal time of HUT had been reached, this was digitally marked, to allow analysis 
of data 1 minute before returning to supine and for 2 minutes after. Mean (±SD) 
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CBFV, MAP, HR, tCO2 and ARI are calculated. The t-tests of the coherent averages 
were dependent on the f-test statistic, were dependent upon whether unequal (f, 
p<0.05) or equal (f, p>0.05) variances were assumed. The mean (SD) maximal change 
for each group in SBP, DBP at 1 and 3minutes from HUT as well as at onset of 
symptoms was also assessed. 
 
The PWV and ARI for each group were statistically analysed to assess whether there 
was an association between arterial stiffness and ARI.  
 
6.7.7.4 Digital Signal Processing 
A fast Fourier transform method was used to convert the Doppler signals into 
maximum frequency velocity envelopes and to achieve temporal resolution a window 
of 6.25ms. Data from the Finapres, TINA™ and ECG output was converted to 200Hz 
and stored. The BP trace was calibrated, visually inspected and any artefact data spikes 
were mathematically removed using linear interpolation by using special software (RP) 
after being imported into an MS-DOS system. From the ECG tracing the cardiac cycle 
was marked to determine the R to R interval and any ectopics manually marked and 
removed by linear interpolation. Where the peak of the R wave did not have significant 
amplitude which meant the software incapable of detecting the R waves, these had to 
be individually manually marked and saved. Alternatively where there were too many 
incidences in a single recording of this occurring, the process was repeated by using 
BP data instead. For each cardiac cycle an estimate of the mean MCA velocity, mean 
arterial BP, systolic and diastolic BP using spline interpolation for the supine and 
head-up-tilt positions (Dawson et al., 2000).  CBFV signals were subjected to a median 
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filter, and all signals had a low-pass Butterworth filter with a cut-off frequency of 
20Hz applied. Dynamic cerebral auto-regulation was analysed using time domain 
analysis (Tiecks et al., 1995), ARI from velocity step response and transfer function 
analysis of coherence, phase and gain (Smith et al., 2008) . 
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7 Methods - Orthostatic Hypotension Study 
7.1 Aims 
o To investigate if differences in dynamic cerebral auto-regulation, BRS and 
arterial stiffness are related to the symptoms of orthostatic hypotension in 
patients with and without a postural BP fall. 
o The hypothesis was that abnormalities in dynamic cerebral auto-regulation 
explain why some patients have postural symptoms independent of changes in 
arterial blood pressure in orthostatic hypotension i.e. orthostatic symptoms are 
more closely related to abnormalities in dCA then to postural changes in 
systemic BP levels. 
7.2 Methods 
7.2.1 Recruitment 
Details of participant recruitment is given in the General Methods section. Using BP 
and symptom criteria four groups were generated. Symptomatic OH (i.e. those with 
symptoms e.g. dizziness, nausea, diaphoresis, diplopia (Carey et al., 2001) but with an 
OGS≥2 (Schrezenmaier et al., 2005)) and measurable postural drop in BP), 
Asymptomatic OH (i.e. those without symptoms and measurable postural drop in BP), 
Symptomatic No OH (i.e. those with symptoms but no significant postural drop in BP), 
and Asymptomatic No OH (i.e. normal control). 
 
7.2.2 Study Groups 
Based on the sample size calculation explained in the General Methods section, 20 
participants in each of four groups were distributed based on the following: 
a) OH with symptoms i.e. Symptomatic OH 
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b) OH without symptoms i.e. Asymptomatic OH 
c) No OH and postural symptoms i.e. Symptomatic No OH 
d) No OH and no symptoms (control) i.e. Asymptomatic No OH 
7.2.3 Data collection 
Baseline categorical and continuous data was collected as described in the General 
Methods Chapter including BRS, PWV and AIx. 
As described previously, with TCD and its associated recordings of tCO2, BP and HR, 
the participant was initially placed in the supine position with a 10 minute baseline 
recording, then the 70º HUT position for up to 30 minutes or until symptoms were 
provoked whichever was sooner, and then returned to the supine position. Recordings 
were continued until stable. Whether a participant had symptoms during the procedure, 
and the time at which it occurred were noted and electronically marked on the 
recording. The 30 minutes duration of HUT allowed for some consideration of later 
falls in BP as per the current ESC guidelines (Moya et al., 2009).  
 
7.2.4 Data analysis 
Baseline categorical data and continuous data, as well as TCD data for baseline, pre-
HUT, initial HUT (“UP”) and just before the end of HUT (“DOWN”) for the 
Symptomatic No OH, Asymptomatic OH and Symptomatic OH groups were compared 
to the control group (Asymptomatic No OH).  
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8 Results – Orthostatic Hypotension Study - Baseline 
 
8.1 Baseline data 
A total of 103 participants (51 female, 52 male, mean age 73.92±7.11 years) were 
successfully recruited for screening between the 15
th
 of February 2011 and the 22
nd
 of 
July 2013. The final number of participants with at least a unilateral baseline TCD 
signal was 85, and were separated into the four groups based on whether there was a 
significant postural drop in BP (using the recognized definition i.e. a fall in SBP 
≥20mmHg and/or fall in DBP≥10mmHg at 1 and/or 3 minutes of standing using clinic 
measurements) and the Orthostatic Grading Scale score (i.e. a score of ≥2 indicates 
symptoms) (Schrezenmaier et al., 2005). Although the original plan was to recruit 80 
participants, it was difficult to predict how many of those recruited would have an 
adequate TCD signal. Thus as Figure 33 demonstrates, the numbers in each group 
were: the symptomatic OH group n=23, symptomatic no OH group n=18, 
asymptomatic OH group n=20 and the asymptomatic no OH group n=24 which was 
taken as the “control or normal” subjects. The 30 minutes duration of HUT allowed for 
some consideration of later falls in BP as per the current ESC guidelines (Moya et al., 
2009).  
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Figure 33 Flowchart for the Orthostatic Hypotension Study  
Transcranial Doppler signal available for at least one side at baseline: 
n=85 
(38 female, 47 male) 
Screened: n=103 
(51 female, 52 male) 
Excluded: n=8 
(due to medication) 
Eligible & Recruited: n=95 
Withdrew: n=1 
(due to change of mind) 
Excluded: n=9 
(due to inadequate TCD signals) 
OGS≥2 OGS<2 
BP  
Symptomatic Asymptomatic 
Yes 
n=23 
 
Symptomatic 
OH 
Yes 
n=20 
 
Symptomatic 
OH 
No 
n=18 
 
Symptomatic 
No OH 
No 
n=24 
 
Asymptomatic 
No OH 
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8.2 Population summary 
A summary of the OH study participants basic characteristics are presented in Table 
14. Data for the variables were assessed for normality, and either one-way ANOVA or 
the Kruskal Wallis test was used, followed with Student’s t-Tests (with Levenes test 
for equality of variances) or Mann-Whitney U test to compare against the 
Asymptomatic No OH group (which acted as the control group). As participants were 
grouped according to symptoms and changes in BP from the supine to standing 
position, there were the expected statistical differences between groups for OGS and 
postural changes in BP. Of note, the symptomatic OH group were significantly older 
than the asymptomatic No OH group which was taken as the control group (p=0.019).  
Furthermore the autonomic function score (out of 10) compared to the asymptomatic 
No OH (2.21±1.50), was significantly higher in the symptomatic OH group 
(4.78±1.86, p<0.001). However this was not significantly different to the 
asymptomatic OH group (3.00±2.00, p=0.226) nor the symptomatic No OH group 
(2.94±1.92, p=0.271). 
 
In the asymptomatic No OH group (n=24), there were no postural falls in SBP 
(≥20mmHg) or DBP (≥10mmHg) at 1 minute or 3 minutes. In the symptomatic No OH 
group (n=18) there was no significant postural change in DBP and only one fall in SBP 
at 1 minute, but no falls in DBP or SBP at 3 minutes. In the asymptomatic OH group 
(n=20), there were postural reductions for DBP in eleven cases and SBP in ten cases at 
1 minute, four in SBP and ten in DBP at 3 minutes. In the symptomatic OH group 
(n=23) there were fifteen postural reductions in DBP and fourteen for SBP at 1 minute, 
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with seventeen cases of reduction in DBP and SBP at 3 minutes. There were no 
significant changes in HR at 1 and 3 minutes across the groups, as shown in Table 14. 
 
Categorical data are presented in Table 15. The only characteristic that was statistically 
significant (p=<0.05) between the groups was in the use of an ACEI or ARB as anti-
hypertensive agents (p=0.043), being highest in the symptomatic No OH group 
(38.9%) compared to the others (asymptomatic OH group (25%), asymptomatic No 
OH (8.3%) and symptomatic No OH (8.7%).  This may be a potential a confounder. 
Overall there was no difference in the prevalence of hypertension between the groups 
or in diabetes.  
 
8.3 Baroreceptor Sensitivity 
There were no significant differences between the 4 groups in cardiac baroreceptor 
sensitivity calculated in the low frequency spectrum band (0.05-0.15Hz) as shown in  
Table 16. All values were within expected normal ranges for age and BP levels. 
 
8.4 Arterial Stiffness 
There was no significant difference in Pulse Wave Velocity, as a measure of arterial 
stiffness or in Augmentation Index corrected for pulse rate (AIx and AIx @75 
respectively) between groups (Table 17). However the mean AIx and the mean AIx 
corrected for HR@75bpm (p=0.032) were higher in the Symptomatic No OH group 
than the Control group (p=0.03). 
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Participant Characteristic 
 
Asymptomatic 
No OH (24) 
Symptomatic 
No OH (18) 
Mann 
Whitney U 
Test or T-
Test* 
 (p-value) 
Asymptomatic 
OH (20) 
Mann 
Whitney U 
Test or T-
Test* 
 (p-value) 
Symptomatic 
OH (23) 
Mann 
Whitney U 
Test or T-
Test* 
 (p-value) 
Kruskal-
Wallis Test 
or ANOVA* 
(p-value)  
Mean  SD Mean  SD Mean  SD Mean SD 
Age (years) 71.6 5.9 72.1 8.2 0.828* 74.0 7.4 0.243* 76.0 6.6 0.019* 0.181* 
BMI (kg/m
2
) 27.6 3.3 28.3 3.9 0.588* 29.3 4.7 0.189* 26.5 4.4 0.333* 0.085* 
Baseline SBP (mmHg) -supine 136.6 13.4 150.4 23.3 0.017 141.6 16.1 0.283 152.3 24.2 0.032 0.053 
Baseline DBP (mmHg) -supine 86.2 11.3 80.4 14.8 0.333 82.9 11.5 0.262 83.9 11.5 0.782 0.674 
Baseline HR (bpm) -supine 76.8 10.6 72.4 10.4 0.347 74.9 9.1 0.981 76.5 10.9 0.701 0.802 
Capillary Blood Glucose (mmol/l) 6.7 2.4 7.0 2.3 0.611 7.4 2.9 0.066 7.1 3.1 0.991 0.304 
Orthostatic Grading Scale  1.0 0.8 4.6 2.0 <0.001 1.0 0.9 0.871 6.0 2.7 <0.001 <0.001 
Autonomic Function Score 2.2 1.5 2.9 1.9 0.271 3.0 2.0 0.226 4.8 1.9 <0.001 <0.001 
Change in SBP at 1 minute of 
standing (mmHg) 
7.5 13.3 0.9 15.2 0.127 -16.5 13.8 <0.001 -26.5 26.5 <0.001 <0.001 
Change in DBP at 1 minute of 
standing (mmHg) 
11.1 13.0 7.9 13.1 0.394 -11.5 9.5 <0.001 -14.0 19.3 <0.001 <0.001 
Change in HR at 1 minute of 
standing (bpm) 
8.3 11.7 19.0 16.9 0.034 11.3 8.3 0.423 14.6 11.1 0.103 0.097 
Change in SBP at 3 minutes of 
standing (mmHg) 
3.7 12.6 4.3 13.3 0.859 -12.1 19.4 0.002 -23.1 20.2 <0.001 <0.001 
Change in DBP at 3 minutes of 
standing (mmHg) 
5.0 8.3 10.3 15.3 0.353 -10.3 12.8 <0.001 -16.0 13.7 <0.001 <0.001 
Change in HR at 3 minutes (bpm) 6.8 10.0 10.7 9.9 0.445 7.4 8.1 0.741 7.2 18.5 0.856 0.803 
Table 14 Baseline Characteristics of OH participants (Mann Whitney U or T-test to compare each group with the Control, i.e. Asymptomatic No OH; Kruskal-Wallis Test or ANOVA to 
examine for variances across groups) 
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Participant 
Characteristic 
 
Asymptomatic No 
OH (24) 
Symptomatic No OH (18) Asymptomatic OH (20) Symptomatic OH (23) Difference between 
groups 
No. 
participants 
% No. participants % No. participants % No. participants % Test statistic p-value 
Sex Female 13 54.2 9 50 8 40 8 34.8 2.168 0.549* 
Male 11 45.8 9 50 12 60 15 65.2 
Smoker Yes 1 4.2 2 11.1 0 0 0 0 4.648 0.574# 
No 19 79.2 12 66.7 17 85 17 73.9 
Ex 4 16.7 4 22.2 3 15 6 26.1 
Blackout Yes 7 29.2 9 50 8 40 9 39.1 5.467 0.428# 
Pre-syncope 0 0 1 5.6 0 0 2 8.7 
No 17 70.8 8 44.4 12 60 12 52.2 
Hypertension 6 25 8 9 50 8 40 21.7 4.814 0.192* 
Diabetes Mellitus 1 4.2 3 1 5.6 3 15 13 2.137 0.546# 
Diuretics 3 12.5 2 5 27.8 2 10 13 2.054 0.583# 
Furosemide 0 0 0 1 5.6 0 0 13.0 4.346 0.107# 
Thiazide 2 8.3 2 5 27.8 2 10 4.3 4.951 0.159# 
ACEI or ARB 2 8.3 5 7 38.9 5 25 8.7 7.832 0.043# 
ACEI 1 8.3 5 4 22.2 5 25 8.7 5.307 0.146# 
ARB 1 4.2 0 3 16.7 0 0 0 5.320 0.041# 
Alpha Blocker 1 4.2 4 1 5.6 4 20.0 8.7 3.135 0.375# 
Tricyclic Antidepressant 1 4.2 1 0 0 1 5 4.3 1.252 1.000# 
Any BP lowering drugs 7 29.2 11 9 50 11 55 26.1 5.663 0.130* 
Symptoms on HUT 5 20.8 9 4 22.2 9 45 43.5 5.002 0.174* 
Table 15 Categorical characteristics of OH study participants (Key: *Pearson Chi-Square, # Fisher’s Exact Test) 
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 Asymptomatic No OH 
(24) 
Symptomatic No OH 
(18) 
T-test  
(p-
value) 
Asymptomatic OH 
(20) 
T-test  
(p-
value) 
Symptomatic OH 
(23) 
T-test  
(p-value) 
ANOVA  
(p-value) 
Mean BRS 
(ms/mmHg) 
SD Mean BRS 
(ms/mmHg) 
SD Mean BRS 
(ms/mmHg) 
SD Mean BRS 
(ms/mmHg) 
SD 
Low Frequency Band 
(0.05-0.15Hz) 
8.6 5.2 8.1 6.7 0.268 10.5 5.5 0.262 7.7 5.6 0.337 0.559 
 
Table 16 Baseline Cardiac BRS – OH study (T-test to compare each group with the Control, i.e. Asymptomatic No OH; ANOVA to examine for variances across groups) 
 
Participant 
Characteristic 
 
Asymptomatic 
No OH (24) 
Symptomatic No 
OH (18) 
T-test  
(p-
value) 
Asymptomatic 
OH (20) 
T-test  
(p-value) 
Symptomatic 
OH (23) 
T-test  
(p-value) 
ANOVA  
(p-value) 
Mean  SD Mean  SD Mean  SD Mean SD 
Mean Augmentation 
Index (%) 
9.6 16.0 20.2 19.9 0.029 10.7 12.5 0.509 7.8 15.3 0.695 0.085 
Mean HR with 
Augmentation Index 
(bpm) 
78.8 15.8 74.1 8.1 0.056 83.9 15.5 0.579 81.4 14.0 0.555 0.253 
Mean Augmentation 
Index (%, @75bpm) 
9.7 16.3 20.0 19.3 0.032 10.8 12.5 0.528 8.1 15.5 0.720 0.099 
Mean Pulse Wave 
Velocity (ms-1) 
10.1 2.5 9.7 3.1 0.530 9.8 2.4 0.406 9.2 2.2 0.205 0.682 
 
Table 17 Arterial Stiffness – OH study (T-test to compare each group with the Control, i.e. Asymptomatic No OH; ANOVA to examine for variances across groups)  
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8.5 Baseline Supine Cerebral Haemodynamic Measurements 
 
8.5.1 Supine Measurements  
Baseline TCD measurements were taken in the supine position after 10 minutes rest and 
when haemodynamic values varied by <10%, and are shown in Table 18. Left and Right 
CBF velocities of the respective MCA’s were similar across the groups (p>0.05). In the 
Symptomatic No OH group (Table 18), the mean CBFV on the right side was 
significantly lower compared to Controls, (p=0.036), and corresponded to a lower 
diastolic CBFV (p=0.002).  
 
Comparing Left and Right mean CBFVs, values were similar between groups but there 
were statistical differences between sides in the symptomatic OH group (n=22), with the 
left mean CBFV being higher (Wilcoxon signed ranks, p=0.01), but not the other groups 
(asymptomatic no OH (n=16), p=0.98; asymptomatic OH (n=19), p=0.18; symptomatic 
no OH (n=17), p=0.79). As there were some differences between left and right 
hemispheres, data was reported for left and right sides separately in addition to the mean 
of both sides (where data are missing for left or right, then it is that side the recording 
was performed on that is used). 
 
8.5.2 Estimates of supine Dynamic Cerebral Auto-regulation (Tiecks model) 
Baseline measurements did not show any significant differences between groups in 
terms of dCA taken as the ARI and its associated parameters, data are presented for the 
mean of both MCAs (Table 19). For the right and left MCAs individually, please see 
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Appendix Table 37and Table 38 respectively. From Table 19, it can be seen that the 
mean ARI of the combined right and left MCAs were similar across groups.  
 
In addition to the data presented in the tables, the Wilcoxon Signed Rank Test for 
related samples, did not show any significant differences between values for the left and 
right MCA in the Asymptomatic OH, Asymptomatic No OH or the Symptomatic No 
OH groups (p>0.05). Furthermore there was no significant difference between the left 
and right MCAs in the groups for coherence or phase in the low frequency band 
(p>0.05).  This is despite the slight differences in diastolic CBFV, demonstrating that 
dCA is a complex relationship between BP and CBF. 
 
8.5.3 Baseline ARI and ARMA ARI estimates of Dynamic Cerebral Auto-regulation 
To further assess if differences in baseline dynamic cerebral auto-regulation (dCA) in 
the 4 groups existed, data were also analysed using two different methodologies Tiecks 
model (Tiecks et al., 1995) and by auto-regressive moving average (ARMA) (Panerai et 
al., 2008) using spontaneous fluctuations in BP and CBFV for both left and right MCA, 
and the mean of both MCAs (Table 20). Results for all methods showed no significant 
between group differences in dCA during supine rest. This is consistent with the fact 
that those with symptoms are asymptomatic in the supine position and therefore not a 
surprising finding. 
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Asymptomatic 
No OH  
(n=23, Right 
MCA only=5, 
Left only=2) 
Symptomatic 
No OH  
(n=18, Right 
only =1) 
Mann 
Whitney U 
Test or T-
Test* 
 (p-value) 
Asymptomatic 
OH  
(n=20, Right 
MCA only=1) 
Mann 
Whitney U 
Test or T-
Test* 
 (p-value) 
Symptomatic 
OH  
 
(n=23, Right 
only=1) 
Mann 
Whitney U 
Test or T-
Test* 
 (p-value) 
Kruskal 
Wallis Test or 
ANOVA* 
 (p-values) 
Mean SD Mean SD Mean SD Mean SD 
CBFV
1
 Right (cm/s) 44.5 11.0 38.3 8.0 0.834 47.1 12.6 0.284 46.1 14.1 0.036 0.047 
CBFV
1
 Left (cm/s) 44.3 12.2 43.9 10.2 0.875 42.5 13.9 0.942 47.4 16.5 0.991 0.990 
Mean CBFV
2
 (cm/s) 41.6 8.2 44.0 9.8 0.875 46.7 13.4 0.827 44.6 12.1 0.267 0.693 
Systolic CBFV Right (cm/s) 62.8 18.9 58.5 13.8 0.431 69.8 19.3 0.181 69.0 20.4 0.258 0.160 
Systolic CBFV Left (cm/s) 63.5 17.0 66.5 15.9 0.386 65.4 18.0 0.527 70.5 23.2 0.531 0.923 
Mean systolic CBFV (cm/s) 62.2 13.1 63.5 14.3 0.495 69.7 18.9 0.342 67.5 18.0 0.668 0.470 
Diastolic CBFV Right (cm/s) 28.2 8.8 24.0 4.3 0.753 30.5 7.8 0.626 29.9 9.2 0.002 0.009 
Diastolic CBFV Left (cm/s) 30.1 8.7 27.6 5.8 0.854 27.1 10.6 0.559 31.1 11.6 0.386 0.797 
Mean diastolic CBFV (cm/s) 25.4 4.6 29.7 6.9 0.765* 30.4 9.2 0.581* 28.7 8.0 0.055* 0.161* 
SBP (mmHg) 129.2 26.0 141.1 22.4 0.252* 137.6 19.8 0.854* 141.0 26.1 0.780* 0.534* 
DBP (mmHg) 73.8 15.8 74.9 13.5 0.078 71.4 10.0 0.592 67.0 12.3 0.717 0.205 
MAP (mmHg) 91.0 13.8 97.1 14.8 0.581 93.8 13.0 0.697 90.8 16.2 0.267 0.425 
Heart Rate (bpm) 63.7 8.8 67.2 11.8 0.546 65.3 10.0 0.355 61.6 9.3 0.199 0.319 
tCO2 (mmHg) 96.4 63.7 98.9 67.5 0.331 135.7 20.4 0.103 118.2 59.0 0.767 0.330 
 
Table 18 Baseline Transcranial Doppler Measurements in OH participants (Key: CBFV1=mean of systolic and diastolic CBFV for that side, Mean CBFV2=mean of both sides 
calculated by substitution if only one MCA available; Mann Whitney U or T-test to compare each group with the Control, i.e. Asymptomatic No OH; Kruskal-Wallis Test or 
ANOVA to examine for variances across groups)  
  
1
6
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Table 19 Baseline ARI (Tiecks model) Mean of Right and Left Middle Cerebral Artery (Mann Whitney U or T-test to compare each group with the Control, i.e. Asymptomatic 
No OH; Kruskal-Wallis Test or ANOVA to examine for variances across groups) 
 
  
 
Mean of Right and Left 
sides 
Asymptomatic 
No OH (24) 
Symptomatic 
No OH (18) 
Mann 
Whitney 
U Test  
 (p-value) 
Asymptomatic 
OH (20) 
Mann 
Whitney 
U Test  
 (p-value) 
Symptomatic 
OH (23) 
Mann 
Whitney 
U Test  
 (p-value) 
Kuskall 
Wallis 
Test  
(p-
value) 
Mean  SD Mean  SD Mean  SD Mean SD 
ARI 4.5 1.0 4.8 1.5 0.467 4.7 1.3 0.646 4.8 1.6 0.571 0.887 
Coherence Low 
Frequency (<0.07Hz) 
0.41 0.14 0.41 0.13 0.931 0.38 0.16 0.606 0.36 0.15 0.285 0.702 
Gain Low Frequency 
(<0.07Hz) 
0.41 0.18 0.43 0.17 0.908 0.42 0.18 0.989 0.31 0.08 0.051 0.089 
Phase Low Frequency 
(<0.07Hz) (radians) 
0.44 0.26 0.64 0.32 0.009 0.46 0.32 0.770 0.56 0.37 0.285 0.107 
Step Response Recovery 
(%) 
66.5 20.0 74.0 33.8 0.416 67.9 17.7 0.606 67.1 24.3 0.772 0.920 
  
1
7
0
 
 
 
Asymptomatic 
No OH (24) 
Symptomatic 
No OH (18) 
Mann 
Whitney 
U Test  
 (p-value) 
Asymptomatic 
OH (20) 
Mann 
Whitney 
U Test  
 (p-value) 
Symptomatic 
OH (23) 
Mann 
Whitney 
U Test  
 (p-value) 
Kruskal-
Wallis 
Test (p-
value) 
Mean  SD Mean  SD Mean  SD Mean SD 
ARI Right 5.0 3.0 6.0 2.6 0.198 5.2 2.9 0.751 6.2 2.6 0.173 0.441 
ARI Left 5.0 2.7 5.6 2.5 0.588 4.3 3.6 0.478 5.7 3.0 0.371 0.519 
Mean ARI (Left 
and Right) 
5.0 2.4 5.9 2.1 0.248 4.8 2.5 0.733 5.9 2.2 0.125 0.309 
ARMA ARI Right 5.3 2.0 4.9 1.8 0.189 4.5 2.1 0.137 4.9 2.5 0.928 0.411 
ARMA ARI Left 4.6 2.4 5.0 2.2 0.874 4.5 1.9 0.718 4.9 2.3 0.687 0.839 
Mean ARMA ARI 5.0 1.9 4.9 1.7 0.694 4.5 1.7 0.318 4.9 2.0 0.910 0.741 
 
Table 20 Baseline ARMA estimates of ARI
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8.6 Orthostatic Hypotension Study – Summary of Baseline Data 
Results 
In terms of the main outcomes for the study, cardiac BRS was similar in all groups 
(Table 16). The mean AIx (p=0.029) and the mean AIx corrected for HR@75bpm 
(p=0.032) were higher in the symptomatic No OH group than the control group (Table 
17). However the PWV was similar across all groups (Table 17). There were no 
significant differences between groups in supine dCA for either Tiecks model or 
ARMA methodology (Table 20).  
 
However it should be noted that the symptomatic OH group was significantly older than 
the control group, and had a significantly higher baseline supine SBP, as did the 
symptomatic No OH group, compared to the Controls (Table 14). More participants in 
the symptomatic No OH group and the asymptomatic OH group were on ACEi or 
AIIRBs than the control group (Table 15). The baseline right MCA diastolic CBFV 
(Table 18) was statistically significantly lower in the Symptomatic No OH group 
compared to the control group (Asymptomatic No OH), although the combined mean of 
the right and left CBFV was not different across the groups.  
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9 Orthostatic Hypotension Study – Discussion of 
Baseline Data 
 
At baseline, cardiac BRS, PWV and dCA were similar across the groups with other 
small differences noted.  
 
Participants over the age of 60 years were recruited to the study, and included healthy 
volunteers as well as participants using hospital or GP services in the community. 
Therefore it was not surprising that older participants were found in the Symptomatic 
OH group compared to the Asymptomatic No OH (control) group. The association of 
hypertension with OH (Applegate et al., 1991a, Mader et al., 1987), makes it 
unsurprising that the Symptomatic OH group had a higher supine baseline SBP than the 
control group. However it was found that the Asymptomatic OH group had a similar 
baseline SBP to the control group. Therefore there may be a suggestion that a higher 
supine SBP is associated with the symptoms of OH, regardless of whether there is a 
postural drop in systemic BP (Poon and Braun, 2005). Of course, it should be 
remembered that not everyone with postural falls in BP have symptoms (Mader et al., 
1987).  
 
As the Orthostatic Grading Scale and postural changes in BP were used to classify 
participants into their respective groups, it is interesting to note that the autonomic 
function score was significantly lower in the Symptomatic OH group, suggesting a 
degree of autonomic cardiovascular dysfunction in this group as might be expected. 
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However cardiac BRS values were similar in all 4 groups suggesting parasympathetic 
cardiac control, one part of the autonomic nervous system, was not impaired and 
perhaps not responsible for the postural BP fall of production of postural symptoms. 
The presence of some differences in those taking ACEi and AIIRBs (greater in the 
Asymptomatic OH and Symptomatic No OH groups) may of course be a confounding 
factor. For the clinician this is perhaps a useful vignette. It is well documented that both 
age and increasing BP are associated with impaired cardiac BRS, and thus could 
common to both hypertension and OH (James and Potter, 1999, Takeshita et al., 1975, 
Moreira et al., 1992). Abnormal cardiac BRS has also been found in those with 
orthostatic intolerance without OH (i.e. symptoms and increase in HR>30bpm within 10 
minutes of standing) (Farquhar et al., 2000). Thus it would not be unreasonable to 
expect the older group of Symptomatic OH to have impaired cardiac BRS, however like 
the other two groups they had a similar cardiac BRS to the control. 
 
With a higher baseline supine SBP, perhaps as an indicator of arterial stiffness, it might 
be expected to find a higher augmentation index and/or PWV in the Symptomatic No 
OH and the Symptomatic OH groups. However although the Symptomatic No OH 
group had a significantly higher mean AIx than the control, this was not true for the 
Symptomatic OH group. It may be that the sample size was not large enough, or 
perhaps other factors than arterial stiffness accounts for the reason why Symptomatic 
No OH differs to “normal”, but the Symptomatic OH does not differ from the “normal” 
in terms of arterial stiffness. The proportion of those with hypertension was similar in 
all groups. It also follows on from this that drug treatment for hypertension may also 
have a positive effect on arterial stiffness (Boutouyrie et al., 2011). However whilst 
other studies have suggested that higher PWV values (Mattace-Raso et al., 2006) or AIx 
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(Valbusa et al., 2012) may be found amongst those with OH, the latter study did not 
find a significantly higher PWV amongst those with OH (Valbusa et al., 2012). The 
differences in whether or not PWV or AIx may be higher (or not) in those with OH, 
may be partly attributable to the fact that AIx whilst using pulse wave reflections is an 
indirect surrogate measure. Of course PWV itself has its own fallacies, and relies on 
accurate estimation of the distance between two points.  However the PWV values 
found in this study are not dissimilar to other studies for this age group (Mattace-Raso 
et al., 2006, Valbusa et al., 2012, 2010). 
 
It may be that the lack of the expected increase in arterial stiffness associated with a 
higher supine SBP can also be reflected by the higher supine combined mean of systolic 
and diastolic CBFV (right MCA) found in the Symptomatic OH group compared to the 
control. This was also associated with a significantly higher right diastolic CBFV in this 
group compared to the control group. Furthermore in the supine position, there was a 
difference in CBFV between right and left MCAs only in the Symptomatic OH group, 
being higher in the left MCA. The clinical significance of this is difference is unclear 
and although a history of stroke was amongst the exclusion criteria for the study, given 
the age group of the participants.  It is possible that these differences in CBFV may be 
related to asymptomatic cerebrovascular arterial disease leading to a degree of stenosis 
(though this might have been expected to increase rather than decrease CBFV unless a 
critical stenosis was present) of either the internal carotid artery or its intracranial 
arterial branches (no visualisation of the cerebral arterial system was undertaken prior to 
the study).   
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In the supine position at baseline, the ARI values (Tiecks and ARMA-ARI) were 
similar in all groups, suggesting that despite the differences in supine SBP and CBFV 
between the Symptomatic OH group and the control group, in the supine position at 
least, the cerebral auto-regulation system is able to maintain adequate control associated 
with the absence of any postural symptoms. Other work which supports this has shown 
that neither static nor dynamic ARI are affected by hypertension or age (Eames et al., 
2003). 
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10 Orthostatic Hypotension Study – Effects of Head-Up-
Tilt 
 
10.1 Cerebral Blood Flow Velocities and Blood Pressure 
The effects of HUT on the four groups were assessed in two ways: 1) by comparing 
actual mean values, and 2) by examining the changes from baseline between groups.   
 
As previously described in the General Methods, the effects of HUT can be divided into 
the “UP” and “DOWN” periods, where “UP” relates to the beginning of HUT, and 
“DOWN” relates to the end of HUT. The “UP” component includes the pre-HUT phase, 
the initial few minutes of HUT and “DOWN” component includes the end of HUT 
signalled by the end of 30 minutes where participants were asymptomatic, or a shorter 
time period where participants became symptomatic. 
 
10.1.1 Group Measurements 
The duration of HUT for each group was: Asymptomatic No OH 27.4±4.6 minutes, 
Symptomatic No OH 25.2±8.7 minutes, Asymptomatic OH 22.1±9.2 minutes, 
Symptomatic OH 24.4±8.6minutes. There was no statistical difference between the 
latter three groups compared to the Asymptomatic No OH group in tilt duration 
(p>0.05). The number of participants in each group who had HUT terminated early due 
to symptoms were five of 24 in the Asymptomatic No OH, four of 18 in the 
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Asymptomatic OH, nine of 20 in the Symptomatic No OH and ten of 23 in the 
Symptomatic OH groups respectively (Chi Square, p=0.17).  
 
TCD data of high quality suitable for analysis were not obtained in all subjects for sub-
group analysis, resulting in different numbers in each group from baseline numbers. 
 
The values for CBFV, BP and HR prior to HUT were obtained at 1 minute and 3 
minutes following HUT, and for the minute prior to the end of HUT (as determined by 
the onset of symptoms, or the end of the 30 minutes of HUT which ever occurred 
sooner) are shown in the Appendix Table 39, Table 40, Table 41, and Table 42, 
respectively. Friedman’s Two Way analysis of variance across all time points for each 
variable was significant in all groups (p<0.001). 
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10.1.2 Blood Pressure and Heart Rate with HUT 
There were no significant differences across the groups or in any group compared to the 
control group, in BP and HR prior to HUT, at 1 minute or 3 minutes of HUT, or prior to 
end of HUT (see Appendix Table 39, Table 40, Table 41 and Table 42). The effect of 
HUT on SBP, DBP, MAP and HR can be seen in Figure 34, Figure 35, Figure 36 and 
Figure 37 respectively. 
 
With HUT, a brief fall in BP associated with a small rise in HR is expected. In OH, one 
would expect a significant fall of ≥20mmHg in SBP and/or ≥10mmHg in DBP. When 
this fall in BP occurs will depend on the classification of OH. 
  
Figure 34 The effect of HUT on SBP (…. = varying time scale)  
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Figure 35 The effect of HUT on DBP (…. = varying time scale) 
 
 
Figure 36 The effect of MAP with HUT (…. = varying time scale) 
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Figure 37 The effect of HUT on HR (…. = varying time scale) 
 
10.1.3 Cerebral Haemodynamic measurements with HUT 
The effect of HUT on the mean CBFV (the average of left and right side of the mean of 
systolic and diastolic CBFV) and tCO2 is illustrated in Figure 38 and Figure 39. CBFV 
and other parameters during HUT, at 1 minute or 3 minutes of HUT, or prior to end of 
HUT are shown (see Appendix Table 39, Table 40, Table 41 and Table 42).  
 
Prior to tilt (see Appendix Table 39) the symptomatic OH group had a significantly 
lower right MCA CBFV (mean of systolic and diastolic CBFV) and right diastolic 
CBFV compared to the control group (37.4±6.4 cm/s vs. 45.3±12.1cm/s, p=0.038 and 
23.0±3.8 cm/s vs. 29.8±7.9cm/s, p=0.001 respectively).  One would not necessarily 
expect differences in CBFV between hemispheres to account for symptoms. The 
differences may be related to the diameter of the MCA. The mean diastolic CBFV was 
significantly lower (p=0.007) compared to the control group, 24.5±4.6cm/s vs. 
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29.9±7.1cm/s. TCO2 was similar across the groups pre-HUT which is not necessarily 
unexpected. 
 
 
Figure 38 The effect of HUT on mean CBFV 
 
 
Figure 39 The effect of HUT on tCO2 
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At 1 minute during HUT (see Appendix Table 40), the mean CBFV that is the average 
of the left and right sides (mean of systolic and diastolic CBFV) and also the mean of 
the left and right diastolic CBFV were significantly lower in the symptomatic OH group 
compared to the control (p=0.006 and p<0.0001 respectively). This may suggest a delay 
in dCA preventing the maintenance of CBFV to the supine levels. The fall in tCO2 in 
all groups during the first minute of HUT is consistent with a compensatory 
hyperventilation  to promote relative vasoconstriction to improve blood flow.  
 
At 3 minutes of HUT (Appendix Table 41), the mean of both left and right diastolic 
CBFV remained significantly different between groups, being lower in the symptomatic 
OH group compared to the control (p=0.019). 
 
By the end of HUT, there were no differences in mean CBFV between groups but the 
mean (of left and right) diastolic CBFV (p=0.004) remained significantly lower in the 
symptomatic OH group (20.2±6.2cm/s) compared to the control group (25.9±8.3cm/s) 
(Appendix Table 42). It is unclear how this may fit in with the concept of symptoms and 
No OH, but may be relevant to symptomatic vs. asymptomatic OH. The changes in 
tCO2 remained similar in all groups during HUT. 
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10.1.4 Group Changes during HUT 
The differences between groups in the changes between measurements compared to pre-
HUT were compared at 1 minute and 3 minutes following HUT and prior to the end of 
HUT, and are shown in Appendix Table 43, Table 44 and Table 45 respectively. They 
are further illustrates in Figure 40, Figure 41, Figure 42. The relationship between the 
various parameters are further illustrated by groups in Figure 46, Figure 47, Figure 48 
and Figure 49. 
 
10.1.4.1 Changes in Blood Pressure and Heart Rate 
 
The Asymptomatic OH group demonstrated a statistically significant decrease in HR 
compared to the control group (-3.2±-4.4bpm vs. 2.6±-4.8bpm, p=0.001) after 1 minute 
of HUT (Appendix Table 43). There were no other significant changes noted at 1 
minute. At 3 minutes of HUT (Appendix Table 44) there was a significant increase in 
SBP in the Asymptomatic OH group (p<0.001) but not the Symptomatic OH group 
which like the control group showed a fall in SBP. However by the end of HUT (Table 
45), there was a significant fall in SBP (p=0.011) and MAP (p=0.018) in the 
Symptomatic OH group compared to the control group, which one would expect given 
the baseline classification on active standing. Graphs of the mean group changes in 
SBP, DBP and HR are shown in Figure 40, Figure 41 and Figure 42 respectively. 
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Figure 40 The mean group change in SBP during HUT  
 
 
Figure 41 The mean group change in DBP during HUT (The change from pre-HUT to HUT at 1 and 3 minutes, 
and in the minute prior to the end of HUT) 
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Figure 42 The mean group change in HR during HUT (The change from pre-HUT to HUT at 1 and 3 minutes, 
and in the minute prior to the end of HUT) 
 
 
10.1.4.2 Changes in Cerebral and Haemodynamic values during Tilt 
 
The mean change CBFV (combining left and right CBFV values) are shown in Figure 
43, and the mean change in tCO2 is illustrated in Figure 50. These figures illustrate an 
increase in the mean CBFV in the symptomatic group with a greater fall in tCO2 than 
the two asymptomatic groups. This is associated with a return to baseline BP towards 
the end of HUT. This picture suggests CBFV improves with a fall in tCO2. The 
asymptomatic groups had a persistent decline in BP at the end of HUT, associated with 
a persisting decline in mean CBFV and a return to baseline of tCO2. Furthermore for the 
symptomatic groups, the CBFV seemed to mirror changes in BP, which may suggest by 
its direct relationship to each other, that dCA is dysfunctional. CBFV and other values 
are found in Appendix Table 43, Table 44 and Table 45.  Change in systolic and 
diastolic CBFV are shown in Figure 44and Figure 45. 
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Figure 43 The mean group change in CBFV (combined mean of left and right CBFV) during HUT (The 
change from pre-HUT to HUT at 1 and 3 minutes, and in the minute prior to the end of HUT) 
 
 
Figure 44 The mean group change in systolic CBFV (combined mean of left and right CBFV) during HUT 
(The change from pre-HUT to HUT at 1 and 3 minutes, and in the minute prior to the end of HUT) 
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Figure 45 The mean group change in diastolic CBFV (combined mean of left and right CBFV) during HUT 
(The change from pre-HUT to HUT at 1 and 3 minutes, and in the minute prior to the end of HUT) 
 
 
Figure 46 Changes in BP and CBFV during HUT - Asymptomatic No OH (control) group 
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Figure 47 Changes in BP and CBFV during HUT - Symptomatic No OH group 
 
 
Figure 48 Changes in BP and CBFV during HUT - Asymptomatic OH group 
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Figure 49 Changes in BP and CBFV during HUT - Symptomatic OH group 
 
 
Figure 50 The mean group change in tCO2 during HUT (The change from pre-HUT to HUT at 1 and 3 minutes, 
and in the minute prior to the end of HUT) 
 
 
 
-25
-20
-15
-10
-5
0
5
10
HUT 1 min HUT 3 min …. Pre-end
HUT
C
h
an
ge
 in
 B
P
 (
m
m
H
g)
 a
n
d
 C
B
FV
 (
cm
/s
) 
Symptomatic OH Group - Changes in systolic and 
diastolic BP and CBFV during HUT 
SBP
systolic CBFV
DBP
diastolic CBFV
-20
-15
-10
-5
0
5
HUT 1 min HUT 3 min …. Pre-end HUT
C
h
an
ge
 in
 t
C
O
2 
(m
m
H
g)
 
Change in tCO2 during HUT 
Asymptomatic No OH
Symptomatic No OH
Asymptomatic OH
Symptomatic OH
 190 
 
At 1 minute of HUT the reduction in mean values of the left and right MCAs combined 
CBFV (Appendix Table 43),  was greater in the Asymptomatic OH group compared to 
the control (p=0.008). No other statistical differences between the groups were 
demonstrated (p>0.05).  The significance of this is unclear. 
 
With respect to change at 3 minutes (Appendix Table 44) there were statistically 
significant differences (p<0.05) between the groups in the changes in mean CBFV, 
systolic and diastolic CBFV and in transcutaneous CO2. The smallest mean reduction 
seen in these parameters occurred in the Asymptomatic No OH group, who showed 
significant reductions at 1 minute, which may indicate recovery via a more responsive 
dCA system. Only the mean systolic CBFV showed a statistically significantly 
difference at 3 minutes compared to pre-HUT (p<0.05), with the greatest increase being 
seen in the Symptomatic OH group. The Asymptomatic OH group had the greatest 
reduction in mean CBFV, and in particular the systolic component (p<0.05). It is 
unclear why this could be the case. 
 
There were significant differences (p<0.05) in the change between pre-HUT and prior to 
the end of HUT between groups in the mean MCA CBFVs and their systolic and 
diastolic components (Appendix Table 45). The largest increase in the CBFV was seen 
in the Symptomatic OH group, and was statistically greater than the control group 
(p<0.05). This was despite the greatest fall in SBP being seen in this group, and the fact 
that the fall in tCO2 was similar. 
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10.1.5 Time varying estimates of ARI 
Only optimal quality data files were used to assess ARI in the 1 minute prior to HUT, 
the first minute after HUT, and between the second and third minute of HUT. Each 
participant’s data were divided into 100 samples for each 1 minute period. Thus a SD is 
also give for these 100 samples, as well as the group SD. It should be noted that not all 
participants had the required quality of data for the HUT or the end of HUT (where the 
patients is returned to the supine position). As there were differences between left and 
right MCA CBFVs, the ARI has been reported separately. The “UP” components 
include the pre-HUT values, and at 1 and 2 minutes of HUT. The “DOWN” 
components refer to the minute prior to the end of HUT, when symptoms occur or the 
end of the 30 minutes of HUT, and 1 minute and 2 minutes in the supine position, after 
the end of HUT. 
 
Graphs of the time varying ARI for the “UP” and “DOWN” components illustrate the 
mean ARI of the combined left and right MCAs for each group (Figure 51) and for the 
right and left MCA separately (Figure 52 and Figure 53). The parameters extracted 
using this method are shown in Appendix Table 46 to Table 63 for combined right and 
left MCA, right MCA and left MCA. Note that the pre-HUT values use time varying 
estimates, and are not the same as the baseline values. The symptomatic OH group ARI 
is quick to adjust back to normal upon return to the supine position from the pre-end 
HUT state.
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Figure 51 Time varying estimate of the mean ARI (combined left and right) during HUT(Data calculated from time-varying estimates, Pre-HUT value is not always equal to the baseline value) 
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Figure 52 Time varying ARI of Right MCA during HUT (Data calculated from time-varying estimates, Pre-HUT value is not always equal to the baseline value) 
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Figure 53 Time varying ARI of Left MCA during HUT (Data calculated from time-varying estimates, Pre-HUT value is not always equal to the baseline value) 
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10.1.5.1 The “UP” component: Pre-HUT 
 
There were significant differences in the ARI and CBFV between groups taking the 
mean of both of right and left MCAs in the pre and post-tilt period (Appendix Table 
46). The data for the right MCA (Appendix Table 47), and the left MCA (Appendix 
Table 48) are also presented for completeness though the mean of left and right values 
(Appendix Table 46) will be used for analysis. The lowest mean ARI was seen in the 
Symptomatic OH group compared to the highest in the control group (Table 47, 
p<0.001).  
 
10.1.5.2 The “UP” component: HUT 1 minute 
Mean values for ARI and CBFV values differed between groups (Appendix Table 49), 
the right (Appendix Table 50) and left MCAs (Appendix Table 51) in the first minute of 
HUT. The highest mean ARI was found in the control group which was significantly 
higher than for all other groups (p<0.001).  This suggests that in the control group, dCA 
responds rapidly to the change in BP associated with HUT. 
 
10.1.5.3 The “UP” component: HUT 2 minutes  
The mean ARI for both MCAs combined at 2 minutes of HUT is given in Appendix 
Table 52 and for right (Table 53) and left (Table 54) MCA separately and shows that the 
lowest ARI was seen in both Asymptomatic and Symptomatic OH (versus Control 
group, p<0.001) suggesting that these two groups are similar at this time point. 
However the ARI was similar in the Control and Symptomatic No OH group (p=0.233). 
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10.1.5.4 The “DOWN” component: Prior to end of HUT 
This data is from the minute before the end of HUT when either participants were 
symptomatic. Values for ARI and CBFV for the mean of both MCAs (Appendix Table 
55), right (Appendix Table 56) and left (Appendix Table 57) MCAs were significantly 
different between the groups. The mean CBFV was lowest in the symptomatic OH 
group compared to the control (p<0.001), but this group had a higher MAP and ARI 
compared to the control group (p<0.001).  This suggests that despite BP being 
compensated for during HUT, there is evidence dCA is dysfunctional with the lowering 
of the mean CBFV in this symptomatic OH group. The lowest ARI was in the 
symptomatic No OH group was significantly lower than the control group (p<0.001). 
This would suggest that symptoms is associated with poor dCA, consistent with the 
original hypothesis. 
 
10.1.5.5 The “DOWN” component: Post-HUT 1 minute 
This data reflects responses in the first minute of recovery from HUT in the supine 
position. The ARI and CBFV values varied between the groups, for the combined right 
and left values (Appendix Table 58), the right MCA (Appendix Table 59) and the left 
MCA (Appendix Table 60) individually. The mean ARI of both sides was lower in the 
asymptomatic and symptomatic OH groups, but the mean ARI was lowest in the 
asymptomatic OH group.  It is unclear why this may be the case, but may be related to 
the readjustment to the supine. 
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10.1.5.6 The “DOWN” component: Post-HUT 2 minutes 
Similar to the results for Post-HUT at 1 minute there were significant differences at 2 
minutes Post-HUT in ARI and CBFV between the groups, including the mean of both 
MCAs (Appendix Table 61), the right MCA (Appendix Table 62), and the left MCA 
(Appendix Table 63). Mean CBFV was similar in the control and Symptomatic OH 
group, but lower in the Asymptomatic OH and higher in the Symptomatic No OH 
group. Once again it is unclear why this may have occurred but it is likely related to 
dCA making adjustments in cerebral blood flow. 
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10.1.6 The changes in Time varying estimates of ARI 
As there appeared to be differences in the majority of parameters at various time points 
compared to the control group, the changes in the mean of the various parameters 
combined right and left MCAs compared to pre-HUT, were analysed. Firstly, within 
each group the changes were compared with pre-HUT to HUT at 1 minute, at 3 minutes, 
and prior to end-HUT when participants were either symptomatic, or had come to the 
maximum 30 minutes of HUT. The percentage changes for MAP, HR, CBFV, ARI and 
tCO2 are shown in Figure 54, Figure 55, Figure 56, Figure 57 and Figure 58. The actual 
mean changes at 1 minute HUT, 2 minutes HUT and prior to end of HUT are shown in 
Appendix Table 64, Table 65 and Table 66 respectively with the percentage changes in 
Appendix Table 67, Table 68 and Table 69. 
 
10.1.6.1 Changes in Blood Pressure and Heart Rate during HUT 
 
 
Figure 54 Percentage change in MAP from pre-HUT during HUT
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Figure 55 Percentage change in HR from pre-HUT during HUT 
 
All groups showed falls in MAP during 1 and 2 minutes of HUT (Figure 54) compared 
to their pre-HUT values. The greatest reduction in MAP at 2 minutes of HUT were in 
the Symptomatic OH and Symptomatic No OH (12.6% and 10.7%). However by the 
end of HUT, the greatest reduction in MAP was in the Symptomatic OH group (9.3%) 
as one would expect based on the original classification. 
 
There were increases in HR across all groups by the end of HUT (Figure 55), with the 
greatest in the control (17.3%) and the Symptomatic No OH groups (16.5%) and the 
least in the Asymptomatic OH (9.9%) and Symptomatic OH groups (12.1%). However 
all increases in HR were statistically significantly less than the control group (p<0.001). 
0.0
2.0
4.0
6.0
8.0
10.0
12.0
14.0
16.0
18.0
20.0
HUT 1 min HUT 2 min …. pre-End HUT
%
 C
h
an
ge
 in
 H
R
 
% Change in HR during HUT 
Asymptomatic No OH
Symptomatic No OH
Asymptomatic OH
Symptomatic OH
 200 
 
 
10.1.6.2 Changes in dynamic ARI 
 
 
Figure 56 Percentage change in CBFV from pre-HUT during HUT 
 
 
Figure 57 Percentage change in ARI from pre-HUT during HUT 
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Figure 58 Percentage change in tCO2 from pre-HUT during HUT 
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showing very small mean increases of 0.2% and 1.0% respectively (p=0.89). The 
Symptomatic No OH and Asymptomatic OH groups showing large percentage increases 
in ARI (60.1% and 29.3%) significantly different from the control group (p<0.001). It 
may be that the intact dCA in the asymptomatic OH group prevents symptoms which 
might otherwise occur with a postural change. In the minute at the end of HUT 
(Appendix Table 69), the Symptomatic OH group shows a smaller 14.2% rise in the 
mean ARI, significantly different from the increase of 5.4% in the control group 
(p<0.001). Whilst the control group have a normal dCA system, the lack of an increase 
in the ARI in the symptomatic OH is likely to indicate failure for the dCA to 
compensate for systemic BP changes and thus result in symptoms during HUT. There 
were significant differences in the changes from pre-HUT in the Symptomatic No OH 
group (+2.0%, p<0.001) and the Asymptomatic OH groups (+9.9%, p<0.001) compared 
to the control.  However at the pre-end of tilt all 4 groups had similar changes in ARI 
values despite the initial differences in response following tilt, there being little change 
from baseline. 
 
The Symptomatic No OH (19.9%) and Symptomatic OH (20%) groups showed similar 
reductions in tCO2 (Figure 58) prior to the end of HUT, significantly (<0.001) greater 
than the fall seen in the control group (11.2%). The Asymptomatic OH group 
significantly differed from the control (p<0.001), with only a 2.4% reduction from pre-
HUT values. These differences between the symptomatic No OH and OH versus the 
asymptomatic OH and control may suggest that changes in CO2 are central to the 
mechanism by which symptoms are produced. 
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10.2 Sub-Group Analysis of Original Groups with HUT 
10.2.1 Comparing symptomatic versus asymptomatic HUT within original groups 
As it was difficult to predict those who were likely to have a positive HUT based on 
active supine to standing BP and thus group classification, it was decided that it would 
be useful to carry out post-hoc analysis comparing those who were classed as 
symptomatic against those who were asymptomatic during HUT. Thus in the first 
instance the participants of the original four groups were divided into those with and 
those without symptoms during HUT. In order that time varying averaging could be 
used, only good quality data files were used. In these eight groups, Wilcoxon signed 
ranks test demonstrated significant changes (p<0.001) across all variables (including 
left and right MCA individually and combined). Pre-HUT values are given for each 
group (Appendix Table 70, Table 72,Table 74,Table 76). 
 
The changes between the one minute prior to HUT and pre-End HUT (in the one 
minute prior to end of HUT) are shown in Figures (Figure 59, Figure 60, Figure 61, 
Figure 62, Figure 63) and Tables (Appendix Table 71, Table 73, Table 75, Table 77). 
The change in mean of the combined CBFV and ARI, are the mean of right and left 
MCA values. However numbers were very small in some instances, hence a second 
post-hoc analysis was carried out. 
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Figure 59The mean change in MAP during HUT, a comparison of symptomatic and asymptomatic HUT of 
original groups 
 
Figure 60 The mean change in heart rate during HUT, a comparison of symptomatic and asymptomatic HUT 
of original groups 
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Figure 61 The change in the mean ARI during HUT, a comparison of symptomatic and asymptomatic HUT 
of original groups 
 
 
Figure 62 The change in mean of the combined right and left CBFV during HUT, a comparison of 
symptomatic and asymptomatic HUT of original groups 
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Figure 63 The mean change in transcutaneous CO2 during HUT, a comparison of symptomatic and 
asymptomatic HUT of original groups 
 
There were significant statistical differences within each group, between who were 
symptomatic on HUT and those who were not symptomatic on HUT, across all 
parameters including the mean combined ARI. In general there appears to be a fall in 
ARI associated with those who were symptomatic in most of the groups (except for the 
asymptomatic No OH i.e. control group). However the data from the sub-analysis 
needs to be interpreted with caution, as the data considers only 3 participants in some 
instances. Therefore the second post-hoc analysis was carried out as outlined in the 
next section. 
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10.2.2 Comparing symptomatic versus asymptomatic HUT – All groups combined 
This second post-hoc analysis was carried out in order to determine if there were 
differences in dCA between those who were symptomatic during HUT, vs. those who 
were asymptomatic, regardless of their original classification. Pre-HUT values are 
given (Table 21). Given the differences within groups regarding differences in the 
change in ARI, all participants across the four groups were divided into those who 
were symptomatic on HUT and those who were asymptomatic (Table 22). Once again 
the mean combined values of right and left MCA values were used for ARI and CBFV. 
The figures illustrate the mean changes (Figure 64, Figure 65, Figure 66, Figure 67, 
Figure 68).  
 
 
 
 
All original groups combined T-test 
 (p-value) Symptomatic 
HUT (n=23) 
Asymptomatic 
HUT (n=46) 
Mean SD Mean SD 
Mean combined CBFV (cm/s) 48.2 7.9 42.9 2.8 <0.001 
SD time sample 2.3 7.0 10.3 3.3 <0.001 
MAP (mmHg) 93.8 4.8 93.3 3.6 <0.001 
SD time sample 11.5 5.5 13.1 4.3 <0.001 
tCO2 (mmHg) 107.2 15.9 110.8 20.2 <0.001 
SD time sample 56.1 3.7 54.1 8.0 <0.001 
Mean combined ARI  3.4 0.9 4.1 0.8 <0.001 
SD time sample 2.2 0.5 2.7 0.3 <0.001 
Heart Rate (bpm) 68.4 2.5 67.1 3.7 <0.001 
SD time sample 9.9 3.5 11.8 2.8 <0.001 
Table 21 Pre-HUT values of symptomatic versus asymptomatic during HUT with all four groups combined 
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All original groups combined T-test 
 (p-value) Symptomatic 
HUT (n=23) 
Asymptomatic 
HUT (n=46) 
Mean SD Mean SD 
Change in mean combined CBFV 
(cm/s) 
-8.5 4.3 -7.3 1.8 
<0.001 
Change in SD time sample -2.7 5.7 -0.9 3.1 <0.001 
Change in mean MAP (mmHg) -15.1 10.0 -8.9 4.8 <0.001 
Change in SD time sample 9.2 14.2 2.9 3.9 <0.001 
Change in mean tCO2 (mmHg) -4.8 13.9 -9.3 22.5 <0.001 
Change in SD time sample -14.5 18.9 -5.0 8.0 <0.001 
Change in mean combined ARI  -1.2 1.1 0.7 0.9 <0.001 
Change in SD time sample -0.8 0.4 0.1 0.4 <0.001 
Change in mean Heart Rate (bpm) 5.2 5.6 11.2 3.1 <0.001 
Change in SD time sample 2.3 7.0 3.5 3.7 <0.001 
Table 22 Comparison of changes between pre-HUT and pre-End HUT of those who were symptomatic versus 
asymptomatic during HUT with all four groups combined 
 
 
 
 
 
Figure 64 The change in mean MAP during HUT, a comparison of symptomatic and asymptomatic HUT of 
original groups combined 
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Figure 65 The change in mean HR during HUT, a comparison of symptomatic and asymptomatic HUT of 
original groups combined 
 
 
Figure 66 The change in the mean combined ARI during HUT, a comparison of symptomatic and 
asymptomatic HUT of original groups combined 
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Figure 67 The change in the mean combined CBFV during HUT, a comparison of symptomatic and 
asymptomatic HUT of original groups combined 
 
 
Figure 68 The change in mean tCO2 during HUT, a comparison of symptomatic and asymptomatic HUT of 
original groups combined 
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By combining all those who had symptoms during HUT and comparing them against 
those who remained asymptomatic during HUT, it can be seen that there were 
significant differences in ARI with the symptomatic group showing a fall in the mean 
combined ARI from pre-HUT unlike the asymptomatic group who showed a small 
increase. The asymptomatic group showed a statistically significant greater increase in 
the mean HR and a smaller fall in the group mean MAP and combined mean CBFV, as 
well as a greater fall in tCO2. This would indicate that the asymptomatic group had 
adequate dCA, likely mediated by a fall in tCO2 to prevent a sustained fall in CBFV. 
The difference in CBFV is a small figure, but a greater proportion of the pre-HUT 
values. 
  
 212 
 
 
10.3 Orthostatic Hypotension Study – Effects of HUT Results 
Summary 
 
The most interesting data can be found in the post-hoc analysis of those who were 
symptomatic versus those who were asymptomatic by combining the original four 
groups, suggest that there is a fall in ARI associated with symptoms with HUT. On 
further sub-group analysis comparing those with symptoms versus those who remained 
asymptomatic on HUT, there was evidence of a statistical difference in ARI, with a fall 
in ARI in the symptomatic group, and an increase in the asymptomatic group. TCO2 
fell the greatest in the asymptomatic group, with an increase in CBFV suggesting that 
this the fall in CO2 improves dCA to increase CBF. 
 
The main pattern demonstrated during HUT was the small but progressive decline in 
the continuous ARI measurements in the Asymptomatic OH group (Figure 57) 
although just prior to the end of tilt the changes in all 4 groups were very similar. The 
other groups in this study although demonstrated initial increases in ARI compared the 
pre-HUT state, although these increases in ARI progressively got smaller over time. 
This is despite the fact that all groups showed a decrease in CBFV over the duration of 
the HUT (Figure 43).  
 
The greatest increase in HR was seen in the Asymptomatic No OH group, and 
occurred by 1 minute of HUT to continue to the end of HUT. The Symptomatic No 
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OH group also showed a substantial increase in HR, but this was after 2 minutes of 
HUT and persisted to the end of HUT. MAP appeared to fall amongst all four groups. 
The Symptomatic OH showed the greatest proportionate fall compared to pre-HUT 
early on, however by the end of HUT the MAP came up significantly. This differed 
from the Asymptomatic OH group who showed a minimal fall in MAP within the first 
couple of minutes of HUT, but showed the greatest fall by the end of HUT. The fall in 
MAP was associated with a reduction in tCO2.  All groups showed fall in BP and 
CBFV over the course of HUT, however the symptomatic OH group showed an 
increase in CBFV at the end of HUT despite a fall in BP. 
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11 Orthostatic Hypotension Study – Discussion of Effects 
of HUT 
The primary aim of the OH study was to determine if there were differences in dCA 
between those who did or did not have symptoms, whether they had systemic changes 
in BP. HUT was used in this study in order to reduce data artefact from movement, and 
to provide consistency in the duration attaining the changes in posture. Despite the 
classification of participants at baseline being based on postural changes in BP during 
active standing and symptoms, there were no significant differences in duration of 
HUT of the three groups compared to the control group. However it should be noted 
that tilt tests are not always consistently positive (Moya et al., 2009). Thus the post-
hoc analysis combining all of those who were asymptomatic (n=46) during HUT and 
comparing them to those who were symptomatic (n=23) during HUT provided 
interesting results. Firstly, the ARI fell in the symptomatic group, whereas the 
asymptomatic group showed good dCA. Furthermore the asymptomatic group showed 
evidence of a fall in tCO2 perhaps as a result of hyperventilation leading to 
vasoconstriction, with an increase in CBFV noted with this (Aaslid et al., 1989). 
 
The significant difference between the Symptomatic OH group and the control group 
in terms of right, left and the mean of both MCAs in the first minute of assuming a 
passive upright posture, was not associated with a difference in MAP compared to the 
control group as one might expect. The higher proportionate increase in HR early on 
with the Asymptomatic No OH (control) group, may partly explain why the 
participants within the control group did not have symptoms reported using the 
Orthostatic Grading Scale (OGS), whereas the Symptomatic No OH group did not 
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have such a rapid increase in HR on HUT making them more likely to report postural 
symptoms with the OGS. Although it has been well established that older adults do 
have a blunted HR response to HUT (Goldstein and Shapiro, 1990, Hainsworth and 
Al-Shamma, 1988), this study does suggest that those who are symptomatic despite not 
having a postural drop in BP, do have some evidence of failure of the autonomic 
response. Another fact to note, is that systemic vascular resistance increases with age 
(Tahvanainen et al., 2007), and this may account for why the older participants in the 
Symptomatic OH group, did not have a significantly different beat-to-beat MAP to the 
control group at baseline.  
 
At the end of HUT, the only persisting difference is in the diastolic CBFV, being lower 
in both the Symptomatic No OH and Symptomatic OH groups compared to the 
control. However whilst other studies have shown no difference in CBFV compared to 
those with OH in the supine position (Novak et al., 1998), a small study in younger 
patients with OH (mean age 41.8±12.9 years) showed a significant fall in cerebral 
blood flow with HUT, of which CBFV is a surrogate, compared to controls 
(Khandelwal et al., 2011). Although an interesting phenomenon similar to what was 
found here, it should be noted that the sample population is smaller and is different to 
the participants who took part in this study. However it should be noted that an initial 
transient fall in CBFV is found in young healthy volunteers and is not related to 
postural symptoms (Thomas et al., 2009). Amongst those with of orthostatic pre-
syncope (mean age 57 SEM 4 years) there is evidence of a fall in CBFV before MAP 
(Dan et al., 2002). It has been shown that diastolic CBFV is lower in those with OH 
and autonomic dysfunction early in the period of lower body negative pressure (a 
method which causes provokes falls in BP)(Lagi et al., 1994) and this reduction in 
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diastolic CBFV is also found with HUT vasovagal syncope (Grubb et al., 1991a). 
Although both symptomatic groups (No OH and OH) showed lower CBFV compared 
to the control, these two groups differed from each other as a lower ARI value 
compared to control was found in the Symptomatic No OH group, and a higher ARI 
value (vs. control) was found in the Symptomatic OH group. Thus this might suggest 
that not only does a lower CBFV account for postural symptoms in those with or 
without an associated fall in BP, but that those who have symptoms without a postural 
fall in BP, may also have an abnormal dynamic CA accounting for these symptoms.  
Furthermore the symptomatic OH group showed a relative increase in CBFV at the 
end of HUT despite the associated fall in BP. Other groups did not differ from the 
control at baseline, 1 or 3 minutes of HUT in terms of CBFV, BP or HR. The lack of 
changes between groups may be due to the reliance of classifying participants into 
groups based on the postural changes in BP on active standing, rather than the passive 
change with HUT. 
 
The symptomatic No OH and the symptomatic OH groups showed greater reductions 
in CBFV by the end of HUT compared to pre-HUT than the other two groups. This 
was associated with greater reductions in ARI also. Sub-group analysis suggests that 
symptoms is associated with a greater fall in ARI. The HR shows a statistically 
significant increase compared to the fall in HR seen in the control group. The fall in 
CBFV seen at 2 minutes of HUT resolves in the Asymptomatic OH group, but 
becomes evident at the end of HUT in the symptomatic OH group. Thus this study 
confirms that in older people with OH like their younger counterparts with OH 
(although perhaps the latter a different cohort), there is evidence of a reduction in 
cerebral blood flow during HUT (Khandelwal et al., 2011). Despite CBFV being lower 
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in older adults, ARI values in older adults are similar when measured at rest (Carey et 
al., 2003). Once again there is a significant increase in HR at the end compared to pre-
HUT, albeit proportionately less than the control group. The early termination of any 
significant change in CBFV in the Asymptomatic OH group, may be why the 
participants differed from the Symptomatic OH group, with the signs of a falling 
CBFV developing after the first 2 minutes of HUT. This perhaps correlates with the 
ESC classification of OH in terms of time course (Moya et al., 2009).  CO2 levels can 
affect cerebral auto-regulation, with lower levels allowing cerebral blood flow to be 
restored more quickly after a fall in BP (Aaslid et al., 1989). It is likely that the sudden 
reduction in transcutaneous CO2 seen across the four groups, in part reflects this 
physiological change, in order to attempt to maintain CBFV as markedly seen in the 
initial period of HUT. 
 
By using continuous estimates of the mean ARI (left and right MCA) in the minute 
pre-HUT, there was evidence that all groups differed from the control by being higher 
at the end of HUT. This persisted at 1 minute of HUT, but by 2 minutes of HUT, the 
symptomatic No OH group showed no difference in ARI compared to the control. The 
remaining two groups (Asymptomatic and Symptomatic OH) showed persisting 
differences to the control group. However it may be that the unclear changes in ARI 
during passive HUT may be related to the classification of participants at baseline 
being dependent on active standing. 
 
The changes in continuous estimates of ARI showed that at the end of HUT, the 
Symptomatic No OH, Asymptomatic OH and Symptomatic OH groups were different 
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to the control (Asymptomatic No OH) in that they all showed a reduction in the ARI. It 
may suggest that there are some differences in dCA in these groups compared to the 
control group but whether one hemisphere is affected more than another at differing 
time points is variable. Of course one needs to consider the underlying differences 
between these three groups, which makes it difficult to draw definite conclusions. 
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12 Closing Remarks on the Orthostatic Hypotension 
Study 
12.1 Orthostatic Hypotension Study Results Summary 
Abnormal dCA is present in those who are symptomatic during HUT. Participants 
within the four groups had similar characteristics at baseline in terms of BRS, PWV 
and autonomic function. There appears to be differences in the left and right MCA, 
despite all subjects being right-handed with a left hemisphere dominance. In general 
the symptomatic OH group had a lower CBFV throughout. However this group did 
show an increase in CBFV despite a greater fall in SBP during HUT. Compared to the 
asymptomatic No OH groups, the other groups appear to show a time delay in 
response to HUT, with the small increase in ARI only taking place at 2 minutes of 
HUT, instead of at 1 minute. At the end of HUT, there is an decrease in the continuous 
ARI across all groups, although for the Symptomatic OH and Symptomatic No OH 
group, there appears to be a greater relative change in ARI values. Post-hoc analysis of 
combined data suggests that there is a greater reduction in ARI associated with those 
who are symptomatic during HUT. 
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12.2 Discussion of the Orthostatic Hypotension Study 
The goal of this study was to bring new information within the field of OH and 
cerebral auto-regulation by investigating if there were abnormalities in dCA, cardiac 
BRS or arterial stiffness which would account for whether a person has symptoms  or 
not whether they have postural falls in BP or not. Although data during HUT between 
the four groups were unclear at times, by combining all those who were symptomatic 
during HUT and comparing them to those who were asymptomatic during HUT 
regardless of the original grouping showed interesting results, which have not been 
shown elsewhere before with such a large group. Post-hoc analysis demonstrated that 
those who were symptomatic during HUT had a significant decline in their ARI during 
HUT. Those who were asymptomatic showed a significantly greater fall in tCO2 with a 
statistically smaller decline in CBFV, which the latter is likely to be physiologically 
insignificant. 
 
Those in the Symptomatic OH Group had lower CBFV during HUT and this may 
account for symptoms themselves (Novak et al., 1998). The patterns of ARI change are 
similar in the Asymptomatic OH and the Symptomatic OH group suggesting that 
perhaps they may be one single group. The control group (Asymptomatic No OH) 
showed a small steady decline in ARI during the course of the HUT. The Symptomatic 
OH group on the other hand, shows a mirror image pattern to the control group, with 
the initial fall in ARI, steadily increasing with time. This suggests that there may be 
two groups to OH as a condition. Research in a smaller study (n=21, age 61.8±2.4 
years) suggests the possibility of three OH groups. Those who have impaired auto-
regulation with a flat flow-BP curve, those with intact auto-regulation and expansion 
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of the systemic BP range which auto-regulation can function, and lastly a group with 
failure of auto-regulation associated with a steep flow-BP curve (Novak et al., 1998). 
Whilst this study in older people confirms falls in CBFV during HUT with 
symptomatic OH which occurs later in the time course of HUT, it has additionally 
shown that those with asymptomatic OH has an earlier fall in CBFV which then 
improves. Furthermore this study has revealed changes in dCA during HUT in those 
with symptomatic OH, asymptomatic OH and those with symptoms of OH but in the 
absence of postural falls in BP. This suggests that despite maintained CBFV and the 
lack of a postural drop in BP in the latter group, the presence of symptoms is perhaps 
due to an impairment of dCA. Once again this may tie into the theory by Novak et al. 
(1998). Subgroup analysis shows a significant reduction in ARI with HUT amongst 
those with symptoms, and an increase in ARI in those without symptoms. The 
difference between the two groups is 1.9, and greater than the 1.5 which was hoped to 
be detected in this study. However there is evidence of a greater fall in CBFV and 
MAP in those with symptoms. Of course although statistically significant, whether the 
difference in the mean fall in CBFV of 1 cm/s and a fall in MAP of 6mmHg is 
physiologically significant to each individual is unclear. And in the context of a larger 
difference in mean combined ARI, these differences in CBFV and MAP are arguably 
small. Recent preliminary work elsewhere also suggest a reduction in CA as a cause 
for symptoms in older people (Sanders et al., 2014). 
 
In this study cardiac BRS values were similar in all 4 groups suggesting 
parasympathetic cardiac control, one part of the autonomic nervous system, was not 
impaired and perhaps not responsible for the postural BP fall of production of postural 
symptoms. However it is well known that both age and increasing BP are associated 
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with impaired cardiac BRS, and common to both hypertension and OH (James and 
Potter, 1999, Takeshita et al., 1975, Moreira et al., 1992). Furthermore abnormal 
cardiac BRS has also been found in those with orthostatic intolerance without OH (i.e. 
symptoms and increase in HR>30bpm within 10 minutes of standing) (Farquhar et al., 
2000). Thus this study brings contradicting information to current research. However it 
is noted that the age and use of ACEi/AIIRBs were slightly different and does raise the 
possibility of Type 2 statistical error. The fact that there were no differences between 
groups in cardiac BRS, may reflect the long term benefits of drug treatment with ACEi 
and AIIRBs. 
 
Whilst other studies have suggested that a higher PWV (Mattace-Raso et al., 2006) or 
AIx (Valbusa et al., 2012) may be found amongst those with OH, little difference in 
arterial stiffness between the groups was found in this study. However it may be that 
anti-hypertensive treatment accounts for this, as it has been shown that treatment 
reduces arterial stiffness (Boutouyrie et al., 2011). Thus in this thesis, the slightly 
differing numbers of participants taking ACEi and AIIRBs may have been a potential 
confounder in the original four groups. 
 
12.3 Strengths and Limitations 
The strengths of this study include: 1) it is one of the few studies in dCA of this size to 
include older participants (>60 years) with and without OH and with consideration of 
the presence or absence of symptoms, 2) the broad inclusion criteria and limited 
exclusion criteria allowing the results of this study to be transferred to a wider patient 
population in Western society. However it is offset by weaknesses including: 1) use of 
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passive HUT which likely differs from active standing both in the research and clinical 
settings, 2) the duration of HUT meant deterioration of TCD US signals due to contact 
gel drying out which could have a negative effect on data quality in addition to 
inadequate bone windows (Lorenz et al., 2009) and 3) the reliance of participant 
compliance at all times during the study to ensure consistent and adequate measures of 
CBFV, BP and HR. For the latter part of study looking at time-varying measures, this 
required very high quality data files which were sometimes difficult to obtain during 
the physical manoeuvre of HUT and variation in bone windows particularly in this 
older population. 
 
12.4 Future work in the Orthostatic Hypotension Study 
Although participants were originally grouped by methods which would be available 
to the clinician, not all participants remained true to their group during HUT. This in 
part may be due to the difference in active standing versus passive HUT. In future, it 
may be better to allocate participants according to the result of the HUT, as it is 
difficult to predict the response to HUT. 
 
12.5 Conclusion of the Orthostatic Hypotension Study 
This study adds new information in the first of a large study in this area. There appears 
to be differences in dynamic cerebral auto-regulation in the non-normal older 
population with early falls in ARI values in the Symptomatic OH group which may 
account for the symptoms of OH, without the associated postural falls in BP. Sub-
group analysis reveal that those who have symptoms on HUT have evidence of a 
reduction in ARI. 
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13 Methods - Post-Prandial Hypotension Study 
As previously indicated, much of the technical methods used during this section are the 
same as for the Orthostatic Hypotension study, and can be found in the General 
Methods Chapter. 
 
13.1 Aims 
o To investigate if a) cerebral auto-regulation is impaired in patients with post-
prandial hypotension, and b) if it is impaired to investigate if this relates to 
symptoms, and c) investigate any changes in BRS or arterial stiffness 
o The hypothesis was that abnormalities in dynamic cerebral auto-regulation 
explain why some patients have postural symptoms independent of changes in 
arterial blood pressure in post-prandial hypotension. 
 
13.2 Methods 
13.2.1 Participants 
Participants were recruited as previously described (Section 6.1) with the exception of 
the exclusion of those with known diabetes mellitus. Those who had a history of light-
headedness, pre-syncope or syncope or other symptoms suggestive of a fall in BP 
within a 2 hour period of a meal on a consistently regular (daily) basis, which differed 
from postural symptoms were placed in the PPH group.  Participants recruited to study 
2 who were found to have unfasted capillary blood glucose (>7.0) suggestive of 
diabetes mellitus were informed on the day, and asked to see their GP. A letter was 
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sent to their GP surgery informing them of this and participants were offered the 
option to participate in the OH instead. 
 
Based on the sample-size estimate for ARI like for the OH study, for the PPH study it 
was estimated that there would need to be 20 participants in each group: 1) those with 
possible PPH based on clinical history, and 2) 20 controls, those without a history 
suggestive of PPH. 
 
13.2.2 Randomisation 
Participants were allocated to Lucozade™ (containing 50g glucose) and orange 
flavoured sparkling water (placebo) in a double blind, cross-over method using 
computer block randomisation (using blocks of 4) carried out by a colleague not 
involved in the study, such that participants received each on a different day within a 2 
week period.  
 
13.2.3 Data collection 
As for the OH study, both categorical and continuous data were collected, including 
measures of arterial stiffness, BRS and autonomic function. As noted in the General 
Methods section sixty minutes was selected for PPH as this appeared to be a 
reasonable time period to allow glucose absorption, and BP changes to occur in the 
HUT position (Krajewski et al., 1993). It was also likely to be reasonably well 
tolerated in older adults. 
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After a 10 minute period in the supine position where measurements did not fluctuate 
by more than 10%, a 10 minute recording of baseline data was collected. After 
baseline recordings were taken in the supine position, participants were asked to drink 
either 275ml of Lucozade™ energy orange flavour (equating to 50g of glucose) or 
40ml of sugar-free orange flavour diluting juice with 235ml of carbonate water within 
a 3 minute period. This was followed by HUT. In addition to the standard recordings 
as for the OH study previously outlined (Chapter 6), the capillary blood glucose was 
monitored using a finger prick blood test at baseline, and at 30 and 60 minutes of 
HUT. It has been previously shown that these responses to HUT in healthy elderly 
subjects are reproducible up to 6 weeks apart (Youde et al., 2003).  
 
13.2.4 Data Analysis 
Baseline continuous and categorical data were analysed in a similar fashion to the OH 
study, except that as it was a cross-over study, statistical analysis allowed for non-
independent samples. In addition to that described for the Orthostatic Hypotension 
study participants (Section 6.7.7) with possible post-prandial hypotension and controls 
had cerebral auto-regulatory indices compared in terms of both the glucose and 
placebo arms. As for the OH study, baseline and HUT data were analysed. The latter 
was considered as “UP” and “DOWN” components representing HUT and the end of 
HUT respectively.  
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14 Results - Post-Prandial Hypotension Study - Baseline 
14.1 Post-Prandial Hypotension Study Recruitment 
 
There were a total of 40 participants (17 female, 23 male, mean age 73.45 ±7.28 years) 
who were successfully recruited for screening between the 15
th
 of February 2011 and 
the 22
nd
 of July 2013. The final number of participants with at least a unilateral 
baseline TCD signal was 38. Participants were recruited into a symptomatic and 
asymptomatic group based on whether there was a history suggestive of PPH. They 
were subsequently block randomised in a double blind fashion to receive placebo (with 
sugar free orange squash and carbonated water, 280ml) or Lucozade © (equivalent to 
50g glucose, 280ml) prior to HUT on two different occasions within a 2 week period. 
Thus participants could either receive placebo on visit 1 and glucose on visit 2, or 
glucose on visit 1 and placebo on visit 2 as per Section 13.2. 
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Transcranial Doppler signal available 
for at least one side at baseline: n=38 
(16 female, 22 male) 
Screened: n=40 
(17 female, 23 male) 
Excluded: n=0 
(due to medication) 
Eligible & Recruited: n=40  
 
Withdrew: n=1 
(due to change of mind) 
Excluded: n=1 
(due to inadequate TCD signal) 
? PPH ? PPH 
Asymptomatic Symptomatic 
No PPH 
Placebo/Lucozade OR 
Lucozade/Placebo 
n=20 
Double Blind Block Randomisation 
 
PPH 
Placebo/Lucozade OR 
Lucozade/Placebo 
n=18 
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14.2 Baseline data for the PPH Study 
 
14.2.1 Population summary 
A summary of the PPH study participants basic characteristics are presented in Table 
23.  Both groups had similar age and supine BP levels but as expected a difference in 
the Orthostatic Grading Scale, as participants were divided into symptomatic and 
asymptomatic groups based on a history of symptoms suggestive of post-prandial falls 
in BP. 
 
Categorical data are presented in Table 24 and again no significant difference between 
the two groups was found, in particular the Autonomic Function Score.  
 
14.2.2 Cardiac Baroreceptor Sensitivity 
This was assessed in the supine position over a period of 10 minutes, following a 10 
minute resting period in the supine position. There was no significant difference in 
cardiac BRS, between the No PPH and PPH groups, or within these groups by visit 
(placebo vs. glucose phase, Wilcoxon Signed Ranks Test for related samples). See  
Table 25 for the Low Frequency Band.  
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14.2.3 Arterial Stiffness 
Similarly arterial stiffness was assessed in the supine position, after a 10 minute supine 
resting period. PWV was similar between the symptomatic group and the 
asymptomatic group (Table 26), as was AIx and AIx @75 values. 
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Participant Characteristic 
 
No PPH (20) PPH (20) Mann Whitney U 
Test 
(p-value) 
Mean  SD Mean SD 
Age (years) 74.0 7.4 74.3 7.7 0.620 
BMI (kg/m2) 29.3 4.7 27.6 3.5 0.820 
Baseline SBP (mmHg) 147.0 19.5 145.2 15.7 0.904 
Baseline DBP (mmHg) 83.6 10.7 88.0 9.6 0.277 
Baseline HR (bpm) 71.5 5.7 76.6 12.4 0.265 
Baseline Capillary Glucose 
(mmol/l) * 
6.1 1.3 6.1 1.2 
0.874 
Orthostatic Grading Scale  1.7 1.2 5.4 2.5 <0.001 
Autonomic Function Score 3.1 2.0 3.7 2.3 0.496 
Change in SBP at 1 minute of 
standing (mmHg) 
-6.7 17.9 -14.0 22.6 
0.640 
Change in DBP at 1 minute of 
standing (mmHg) 
-1.2 14.7 -5.1 13.9 
0.758 
Change in HR at 1 minute of 
standing (bpm) 
11.0 5.7 13.2 7.2 
0.396 
Change in SBP at 3 minutes of 
standing (mmHg) 
-1.5 12.5 -6.8 19.3 
0.620 
Change in DBP at 3 minutes of 
standing (mmHg) 
-1.2 14.7 -5.1 13.9 
0.758 
Change in HR at 3 minutes 
(bpm) 
8.3 7.1 9.7 9.3 
0.784 
Table 23: Baseline Characteristics of PPH participants (Key: * placebo arm given here) 
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No PPH (20) PPH (20) Difference between 
groups 
No. 
participants 
% No. 
participants 
% Test 
statistic 
p-value 
Sex Female 7 35.0 10 50.0 0.921* 0.523 
Male 13 65.0 10 50.0 
Smoker Yes 1 5.0 0 0.0 1.032# 0.597 
 No 15 75.0 16 80.0 
 Ex 4 20.0 4 20.0 
Blackout Yes 9 45.0 9 45.0 8.25* 0.012 
 Pre-
syncope 
0 0.0 6 30.0 
 No 11 55.0 5 25.0 
Hypertension 7 35.0 4 20.0 1.129* 0.480 
Diuretics 4 20.0 3 15.0 0.173* 1.00 
Furosemide 2 10.0 0 0.0 2.105* 0.487 
Thiazide 2 10.0 2 10.0 0.000* 1.000 
Spironolactone 0 0.0 1 5.0 1.026* 1.000 
ACEi or AIIRB 5 25.0 2 10.0 1.558* 0.407 
ACEi 3 15.0 2 10.0 0.229* 1.000 
AIIRB 2 10.0 0 0.0 2.105* 0.487 
Alpha Blocker 3 15.0 3 15.0 0.000* 1.000 
Tricyclic 
Antidepressant 
1 5.0 0 0.0 1.026* 1.000 
Table 24 Categorical characteristics of PPH study participants (Key: *Pearson Chi-Square, # Fisher’s Exact Test) 
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 Group No PPH (20) Wilcoxon 
Signed 
Rank Test 
(p-value) 
PPH (20) Wilcoxon 
Signed 
Rank Test 
(p-value) 
Mann-
Whitney U 
Test  
(p-value) 
Mean BRS 
(ms/mmHg) 
SD 
(ms/mmHg) 
Mean BRS 
(ms/mmHg) 
SD 
(ms/mmHg) 
Low 
Frequency 
Band (0.05-
0.15Hz) 
Placebo 7.0 6.0 0.167 6.8 6.7 0.535 
 
0.519 
Lucozade 5.1 2.8 5.5 6.4 0.369 
 
Table 25 Baseline BRS of PPH participants (p-values for both independent No PPH vs PPH groups and related samples within groups Placebo vs Glucose days) 
 
Participant Characteristic No PPH (20) PPH (20) Mann-Whitney U 
Test  
(p-value) 
Mean  SD Mean SD 
Mean Augmentation Index (%) 10.3 16.9 10.7 12.7 0.678 
Mean HR with Augmentation Index (bpm) 75.7 14.2 77.4 12.3 0.620 
Mean Augmentation Index (%, @75bpm) 10.1 16.6 10.8 12.9 0.640 
Mean Pulse Wave Velocity (ms
-1
) 10.0 2.2 9.6 2.6 0.369 
Table 26 Arterial Stiffness of PPH participants  
 234 
 
14.3 Baseline Supine Cerebral Haemodynamic values of PPH study 
participants 
As for the OH study, after a 10 minute period in the supine position where 
measurements did not fluctuate by more than 10%, a 10 minute recording of data was 
collected. 
 
14.3.1 Cerebral Haemodynamic Supine Measurements 
Data are reported for the left and right MCA individually (Table 27), and as a mean of 
both sides (where data are missing for left or right, then the available side is used). 
There were no significant differences between placebo or glucose, or between the No 
PPH and the PPH group at baseline in the supine position. In the supine position where 
participants are asymptomatic, it was not expected to find any differences between or 
within the two groups regardless of phase. 
 
14.3.2 Estimates of supine ARI (Tiecks model) 
No significant differences between groups in terms of ARI values were found (or 
anticipated) when calculated for the mean of both right and left MCA (Table 28) or the 
right (Appendix Table 78) and left (Appendix Table 79) MCA individually.  
 
14.3.3 ARI and ARMA ARI estimates 
ARI (calculated using Tiecks model and by the ARMA method) for both left and right 
MCAs, and the mean of both MCAs (Table 29) were similar for the PPH and no PPH 
groups at baseline and between visits. 
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Table 27 Baseline Transcranial Doppler Measurements in PPH participants (Measurements based on a 10 minute baseline recording, Mean CBFV =combined right and left CBFV)  
Participant Characteristic 
No PPH – 
placebo 
(n=20) 
No PPH – 
glucose (n=20) 
Wilcoxon 
Signed 
Rank 
Test 
 (p-values) 
PPH – placebo 
(n=18) 
PPH – glucose 
(n=18) 
Wilcoxon 
Signed 
Rank Test 
 (p-values) 
Mann-
Whitney U 
Test (p-values) 
Mean SD Mean SD Mean SD Mean SD Placebo Glucose 
CBFV Right (cm/s) 44.4 9.5 46.3 6.7 0.852 44.9 9.5 44.3 8.4 0.501 0.912 0.422 
CBFV Left (cm/s) 47.6 7.2 45.7 9.5 0.313 42.8 9.9 45.9 10.8 0.278 0.189 0.863 
Mean CBFV (cm/s) 46.0 7.3 46.0 7.6 0.737 43.8 8.7 45.1 8.7 0.163 0.369 0.789 
Systolic CBFV Right (cm/s) 66.3 14.6 64.7 17.0 0.709 67.1 14.7 67.1 14.7 1.000 0.765 0.741 
Systolic CBFV Left (cm/s) 71.2 11.8 67.6 12.9 0.232 63.3 14.9 63.3 14.9 0.352 0.178 0.863 
Mean systolic CBFV (cm/s) 68.8 11.8 66.1 10.7 0.654 65.2 13.2 66.4 13.2 0.438 0.648 0.863 
Diastolic CBFV Right (cm/s) 29.1 6.3 28.4 8.1 0.823 29.0 6.9 29.0 6.9 0.535 0.718 0.714 
Diastolic CBFV Left (cm/s) 31.0 4.7 30.3 6.8 0.411 28.1 7.3 28.1 7.3 0.255 0.095 0.648 
Mean diastolic CBFV (cm/s) 30.1 4.8 29.4 5.7 0.601 28.6 6.5 29.7 6.1 0.148 0.158 0.789 
SBP (mmHg) 129.6 16.6 129.9 17.8 0.970 132.8 21.8 136.1 22.8 0.234 0.604 0.386 
DBP (mmHg) 70.3 11.4 68.5 11.2 0.455 72.3 12.7 76.1 11.8 0.196 0.539 0.058 
MAP (mmHg) 89.7 12.0 88.7 11.2 0.737 94.1 14.4 97.9 14.9 0.352 0.386 0.072 
Heart Rate (bpm) 63.0 6.4 61.6 6.1 0.179 63.0 4.7 63.4 4.9 1.000 1.00 0.336 
tCO2 (mmHg) 100.8 52.5 96.0 56.5 0.765 114.4 47.6 108.0 56.3 0.796 0.479 0.582 
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Table 28 Baseline ARI (Tiecks model) Mean of Right and Left Middle Cerebral Artery, Mean ARI =combined right and left ARI 
 
  
  
 
 
No PPH - 
placebo 
No PPH - 
glucose 
Wilcoxon 
Signed 
Ranks  
(p-value) 
PPH - 
placebo 
PPH - 
glucose 
Wilcoxon 
Signed 
Ranks  
(p-value) 
Mann Whitney U 
(p-value) 
Mean  SD Mean  SD Mean SD Mean  SD Placebo Glucose 
Mean ARI 4.89 1.36 4.84 1.49 0.199 5.10 1.48 5.23 1.24 0.605 0.621 0.523 
Coherence Low Frequency (<0.07Hz) 0.42 0.14 0.34 0.11 0.076 0.32 0.15 0.30 0.13 0.717 0.042 0.243 
Gain Low Frequency (<0.07Hz) 0.45 0.10 0.38 0.08 0.064 0.36 0.17 0.32 0.13 0.569 0.039 0.161 
Phase Low Frequency (<0.07Hz) (radians) 0.57 0.49 0.57 0.30 0.267 0.61 0.51 0.55 0.24 0.278 0.670 0.857 
Step Response Recovery (%) 72.2 14.8 71.4 26.6 0.231 88.3 29.8 82.7 31.7 0.379 0.117 0.385 
  
 
2
3
7
 
 
 
 
 
No PPH – 
placebo (n=12) 
No PPH – 
glucose (n=12) 
Wilcoxon 
Signed Ranks 
Test  
(p-values) 
PPH – placebo 
(n=12) 
PPH – glucose 
(n=14) 
Wilcoxon 
Signed Ranks 
Test  
(p-values) 
Mann-Whitney U 
Test  
(p-values) 
Mean  SD Mean  SD Mean SD Mean  SD Placebo Glucose 
ARI Right 5.93 2.00 6.16 2.27 0.735 5.09 2.86 4.12 3.32 0.433 0.592 0.067 
ARI Left 5.27 2.39 4.65 3.28 0.735 4.96 3.76 4.75 3.46 0.851 1.000 0.231 
Mean ARI 
(Left and 
Right) 
5.60 2.01 5.40 1.56 0.866 5.03 2.15 4.43 2.17 0.826 0.340 0.060 
ARMA ARI 
Right 
6.91 2.61 5.15 3.69 0.735 3.97 4.16 3.97 3.64 0.784 0.120 0.899 
ARMA ARI 
Left 
6.35 3.08 4.33 3.59 0.866 3.81 3.71 3.67 3.51 0.724 0.083 0.560 
Mean 
ARMA ARI 
5.21 2.66 4.74 2.64 0.368 3.89 3.36 3.82 2.21 0.814 0.432 0.742 
Table 29 ARMA estimates of ARI Mean ARI =combined right and left ARI
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14.4 Post-Prandial Hypotension Study – Summary of Baseline Data 
Results 
There were no statistical differences between the No PPH and the PPH group, in terms 
of baseline characteristics for continuous or categorical data, except for the expected  
presence or absence of symptoms (Orthostatic Grading Score and history of PPH), upon 
which participants were divided into the No PPH versus the PPH groups. Furthermore, 
there were no differences between these two main groups in terms of cardiac BRS in the 
low frequency band, arterial stiffness and CBFV. ARI, using either method for 
assessment (Tiecks and ARMA-ARI), in the supine position was no different on either 
visit 1 or 2 for both the No PPH and PPH group. The only exception to this was a 
difference between groups in the placebo arm, where there was a statistically significant 
difference in the ARI at baseline was in respect of the mean of the right and left MCA in 
the low frequency band gain. The significance of this is unclear. 
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15 Post-Prandial Hypotension Study – Discussion of 
Baseline Data 
The lack of differences between groups at baseline (Van Orshoven et al., 2010, Vloet et 
al., 2005) and in the supine position is not surprising, given that the condition by 
definition requires the consumption of glucose or an alternative test meal to cause a 
significant reduction in BP. In general no differences in groups would be expected at 
baseline, prior to ingestion of either a glucose drink or a placebo drink (Jones et al., 
2005). Furthermore it was not surprising that there were no significant differences 
between the No PPH and the PPH group with respect to postural falls in BP, as only 
38% of older people have been reported to have both PPH and OH (Vloet et al., 2005).  
 
The AIx was actually lower than anticipated, as elsewhere values of 28±9% and 34±9% 
for men and women aged 60-69 years (McEniery et al., 2005, Salvi et al., 2010), 
whereas here it was 10.3±16.9% and 10.7±12.7% for the No PPH and the PPH groups 
respectively. As HR may affect AIx, this was corrected for HR in this study (Wilkinson 
et al., 2000, Yasmin and Brown, 1999).  PWV in this study was similar to that reported 
elsewhere for a similar age group, with the expectation of PWV being over 8 m/s in 
those over 60 years of age (McEniery et al., 2005). Elsewhere PWV of 12.3±4.0 m/s 
have been reported amongst those age>80 years (Salvi et al., 2010). This may suggest 
that AIx is perhaps less reliable as a marker of arterial stiffness in older people than 
PWV.  
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Values for cardiac BRS in the supine position, using spontaneous fluctuations in HR 
and BP  for spectral analysis, were similar to that reported by Dawson et al (1999) using 
similar methodology (Dawson et al., 1999) and for aged matched healthy volunteers 
(Youde et al., 2002). Furthermore it has been recognised that autonomic dysfunction 
alone is not always related to whether older adults have PPH or not (Lagro et al., 2013). 
 
However given the association of PPH with cerebrovascular damage as indicated by 
leukoaraiosis, in patients with hypertension (Kohara et al., 1999), one could expect 
differences in CBFV between the No PPH and the PPH groups. Furthermore there is 
evidence that CBFV measured in the supine position is lower in older adults (49±13 
cm/s) compared to younger adults (61±14 cm/s) with no differences in supine ARI 
(Carey et al., 2003). The results presented in this study for the baseline data for the 2 
showing no significant differences in CBFV or ARI in the supine position are in 
keeping with other studies in older adults (Carey et al., 2003).  
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16 Post-Prandial Hypotension Study – Effects of HUT 
16.1 Duration of HUT 
Head up Tilt (HUT) at 70
0
 was potentially performed for 60 minutes in each group for 
each phase but terminated early with the onset of symptoms. There were no significant 
differences in the duration of HUT in the No PPH group between placebo or glucose 
arms, being 55.4 ±11.2 minutes and 56.8 ±9.6 minutes respectively (Wilcoxon signed 
ranks test, p=0.484). Similarly there were no significant differences in tilt duration for 
the PPH group following placebo 33.6 ±23.6 minutes or glucose 37.5 ±22.9 minutes 
(Wilcoxon signed ranks test, p=0.975). However the duration of tilt was significantly 
shorter for the PPH group than for those with no PPH for both placebo and glucose 
phases (Mann-Whitney U Test p=0.002 and p=0.018 respectively).  
 
For the No PPH group, six and three were terminated early due to symptoms in the 
placebo and glucose phase respectively. For the PPH group the number of early 
termination of HUT was fourteen and nine for the placebo and glucose arm respectively 
(Pearson Chi Square p=0.001). Of those who had a SBP fall ≥20mmHg by the end of 
HUT, there were 7 in the placebo arm  and 4 in the glucose arm of the No PPH group; 2 
in the placebo and 9 in the glucose arm of the PPH group (Pearson Chi Square 
p=0.265). 
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16.2 Capillary blood glucose 
Capillary blood glucose during HUT is shown (Table 30) with changes from baseline 
(Table 31).
There were no differences between or within groups for baseline capillary glucose. An 
increase compared to baseline glucose was seen in the glucose arm of both groups. As 
expected there were significant increases in capillary glucose at 30 and 60 minutes post-
ingestion  of glucose compared to baseline (p<0.001) in both groups, but again there 
was no difference in the increases between groups. Capillary blood glucose during HUT 
is also shown graphically (Figure 69). 
 
 
Figure 69 Capillary blood glucose during HUT
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Time 
(minutes) 
No PPH – 
Placebo 
Blood 
glucose 
(mmol/l) 
No PPH – 
Glucose 
Blood 
glucose 
(mmol/l) 
Wilcoxon 
Signed 
Ranks 
Test  
(p-value) 
PPH – 
Placebo 
Blood 
glucose 
(mmol/l) 
PPH – 
Glucose 
Blood 
glucose 
(mmol/l) 
Wilcoxon 
Signed 
Ranks 
Test  
(p-value) 
Mann-Whitney U 
test  
(p-value) 
 Mean SD Mean SD Mean SD Mean SD Placebo Glucose 
0 6.1 1.3 6.0 0.8 0.686 6.1 1.2 5.7 1.0 0.201 0.874 0.189 
30 6.4 1.5 10.3 1.4 <0.001 6.5 2.8 10.3 2.3 <0.001 0.426 0.814 
60 6.2 1.3 10.0 2.2 <0.001 5.6 0.5 9.8 3.2 0.003 0.099 0.528 
Table 30 Capillary blood glucose during HUT 
 
Time 
(minutes) 
No PPH – 
Placebo 
Blood 
glucose 
(mmol/l) 
No PPH – 
Glucose 
Blood 
glucose 
(mmol/l) 
Wilcoxon 
Signed 
Ranks 
Test  
(p-value) 
PPH – 
Placebo 
Blood 
glucose 
(mmol/l) 
PPH – 
Glucose 
Blood 
glucose 
(mmol/l) 
Wilcoxon 
Signed 
Ranks 
Test  
(p-value) 
Mann-Whitney U 
test  
(p-value) 
 Mean 
Change 
SD Mean 
Change 
SD Mean 
Change 
SD Mean 
Change  
SD Placebo Glucose 
30 -0.2 1.7 4.4 1.6 <0.001 -0.4 1.9 4.6 2.2 <0.001 0.942 <0.001 
60 -0.1 1.4 4.1 2.4 <0.001 0.3 0.7 4.4 3.1 <0.001 0.454 <0.001 
Table 31 Changes in Capillary blood glucose during HUT 
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16.3 Cerebral Blood Flow Velocity and Blood Pressure changes 
CBFV, BP and HR prior to HUT, at 1 minute and 3 minutes of HUT, and prior to the 
end of HUT are shown in Appendix Table 80, Table 81, Table 82 and Table 83 
respectively. At the top of each table, the number of participants included for each 
variable is given as not all participants had an adequate quality data at all time-points. 
 
16.3.1 Blood Pressure and Heart Rate with HUT 
The effect of HUT, with placebo or glucose in both the No PPH and the PPH groups, on 
SBP (Figure 70), DBP (Figure 71), MAP (Figure 72) and HR (Figure 73) are shown.  
There were no significant differences in SBP, DBP or MAP at any of the time points 
between the No PPH and PPH groups (Appendix Table 80, Table 81, Table 82 and 
Table 83). It should be noted from Appendix Table 80, that the heart rate in the No PPH 
group was statistically higher in the placebo arm (Wilcoxon Signed Ranks Test 
p=0.025). Furthermore, the SBP was significantly higher in the PPH group during the 
placebo phase (Mann Whitney U Test, p=0.034, Appendix Table 80). Friedman’s two 
way analysis of variance for related samples demonstrated that there were significant 
changes in SBP, DBP and HR from pre-HUT in all groups (p<0.01). In general one 
would expect a greater fall in BP with glucose in the PPH group compared to placebo, 
and compared to the No PPH group. 
 245 
 
 
Figure 70 The effect of HUT on SBP (… = varying time scale) 
 
Figure 71 The effect of HUT on DBP (… = varying time scale) 
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Figure 72 The effect of HUT on MAP (… = varying time scale) 
 
Figure 73 The effect of HUT on HR (… = varying time scale) 
80
85
90
95
100
105
110
pre-HUT HUT 1
min
HUT 3
mins
…. pre-End
HUT
M
A
P
 (
m
m
H
g)
 
Mean Arterial Pressure with HUT 
No PPH - Placebo
No PPH - Glucose
PPH - Placebo
PPH - Glucose
50
55
60
65
70
75
80
pre-HUT HUT 1
min
HUT 3
mins
…. pre-End
HUT
H
R
 (
b
p
m
) 
Heart rate with HUT 
No PPH - Placebo
No PPH - Glucose
PPH - Placebo
PPH - Glucose
 247 
 
 
16.3.2 Cerebral Haemodynamic responses to HUT 
The effect of HUT on CBFV and tCO2 are shown below (see Figure 74 and Figure 75). 
 
Figure 74 The effect of HUT on the mean of left and right (combined) CBFV (… = varying time scale) 
 
 
Figure 75 The effect of HUT on tCO2 (… = varying time scale) 
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In the glucose phase, the right systolic CBFV was higher in the No PPH group (Mann 
Whitney U Test, p=0.030). It is unclear as to why this may the case. There were few 
significant differences between hemispheres at either 1 or 3 minutes of HUT, nor 
towards the end of HUT (Appendix Table 81, Table 82 and Table 83 respectively).  
 
Towards the end of HUT the tCO2 was statistically higher in the No PPH group of the 
glucose arm than the PPH group (Mann Whitney U, p=0.043), why this was the case is 
unclear but may be related to glucose metabolism. 
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16.4 Group Changes during HUT 
In this section the differences between measurements in the minute prior to HUT were 
compared to those at 1 and 3 minutes of HUT and the 1 minute prior to the end of HUT, 
and are shown in Appendix Table 84, Table 85 and Table 86 respectively. These 
changes are also illustrated in the Figures below. 
 
16.4.1 Changes in Blood Pressure and Heart Rate 
There was a marked fall in SBP at 3 minutes of HUT in the PPH group during the 
placebo arm (Mann Whitney U test, p=0.027). However at the end of HUT there were 
no statistical differences between groups or phases. For the change in HR at 3 minutes 
of HUT (Table 85) there was a statistically significant increase in the HR in the glucose 
arm of the No PPH group (Wilcoxon Signed Ranks test, p=0.028). However there was 
no statistical difference in the change in HR the placebo and glucose phase for the two 
groups, nor between the two groups.  Graphs of the change in SBP (Figure 76), DBP 
(Figure 77) and HR (Figure 78) during HUT are shown below. The changes over time 
were significantly different within each phase of each group (p<0.01). Although the 
graphs illustrate the expected greatest decline in SBP is in the glucose arms of the PPH 
group, with the second greatest decline by the end of HUT being found in the glucose 
arm of the No PPH group. This was not statistically significant. This was associated 
with a similar pattern with DBP, but again not statistically significant. These patterns in 
BP may be partly explained by the smaller increase in HR at the end of HUT with the 
PPH glucose arm, albeit not shown to be significant. 
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Figure 76 The mean group change in SBP during HUT(… = varying time scale) 
 
Figure 77 The mean group change in DBP during HUT (… = varying time scale) 
 
 
Figure 78 The mean group change in HR during HUT(… = varying time scale) 
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16.4.2 Changes in Cerebral Haemodynamic values   
The mean change of the combined left and right MCA is shown in Figure 79. The 
change in the mean systolic CBFV at 1 minute of HUT compared to pre-HUT, was 
greater in the No PPH group, with a statistically significant greater fall seen (Mann 
Whitney U, p=0.023) (Appendix Table 84). Furthermore at 3 minutes of 
HUT(Appendix Table 85) in the glucose arm, the fall in the right systolic CBFV was 
greater in the No PPH group (Mann Whitney U p=0.018). 
 
In the No PPH group when comparing measurements at the end of HUT compared to 
before HUT (Appendix Table 86) CBFV on the right  showed a greater reduction in the 
glucose arm (Wilcoxon Signed Rank test, p=0.020). This was also significant for the 
right MCA systolic and diastolic CBFV components individually (Wilcoxon Signed 
Ranks p=0.011 and p=0.015 respectively). TCO2 (Figure 80) showed greater increases 
in the No PPH group at the end of HUT in the placebo arm (Mann Whitney U, p=0.018) 
as well as the glucose arm where tCO2 was falling at the end of HUT (Mann Whitney 
U, p=0.002). In the PPH group, a relative fall in tCO2 was seen during the glucose 
phase, compared a slight increase in the placebo arm, albeit this increase was smaller 
than the No PPH placebo or glucose phase for end of HUT (Table 86).  This may 
suggest a metabolic effect of glucose on tCO2, and thus CA. 
 
Hypothetically one would perhaps expect a greater fall in CBFV in the PPH group with 
glucose compared to the No PPH group, and similarly one may expect no difference 
between groups with placebo. 
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Figure 79 The mean group change in CBFV (combined mean of left and right CBFV) during HUT (… = 
varying time scale) 
 
 
 
 
Figure 80 The mean group change in tCO2 during HUT (… = varying time scale)
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16.5 Time varying estimates of ARI 
This section uses a mathematical method of calculating time varying estimates of data. 
As such actual values of ARI may differ from the previous sections because only 
optimal very high quality data files were used to assess ARI in the 1 minute prior to 
HUT, the first minute after HUT, and between the second and third minute of HUT. The 
number of participants used are shown at the top of each table.  Each participant’s data 
were divided into 100 samples for each 1 minute period. Thus a SD is also give for 
these 100 samples, as well as the group SD. It should be noted that not all participants 
had the required quality of data for the HUT or the end of HUT (where the patients is 
returned to the supine position). As there were significant differences between left and 
right MCA CBFVs, the ARI and other variables have been reported separately. The 
HUT component as previously discussed in the General Methods section, can be split 
into the “UP” and “DOWN” components. Graphs of the time varying ARI can be found 
between the two “UP” and “DOWN” sections and include the mean of right and left 
MCA (Figure 81), right MCA (Figure 82), and left MCA (Figure 83). 
 
16.5.1 The “UP” component: Pre-HUT 
The mean ARI of both sides i.e. combined value (Appendix Table 87) did not show 
significant differences within the groups, but did for between groups in the glucose arm, 
being lower in the PPH group. This difference is interesting as participants are in the 
supine position. There were significant differences in the ARI and CBFV between the 
No PPH and PPH groups, as well as within the groups (placebo vs. glucose) in the right 
MCA (Appendix Table 88), left MCA (Appendix Table 89) in the minute preceding 
HUT.   
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16.5.2 The “UP” component: HUT 1 minute 
The mean of both the right and left MCA (i.e. combined values) showed a significant 
difference within and between groups (Appendix Table 90) in the first minute of HUT. 
A higher ARI in the No PPH group for placebo, with a lower ARI for glucose, but for 
the PPH group the reverse was true. A statistically significant higher combined CBFV 
in both groups was associated with glucose. This was also true for the differences in the 
ARI and CBFV between and within the groups in the right MCA (Appendix Table 91), 
left MCA (Appendix Table 92). The only exception to this was that the PPH group did 
not show a significant difference in the right MCA ARI with placebo and glucose. 
However at this stage glucose will have yet to be absorbed, and thus any differences 
cannot be attributed to post-prandial falls. 
 
16.5.3 The “UP” component: HUT 2 minutes  
At 2 minutes of HUT (Appendix Table 93), the combined right and left MCA ARI, the 
No PPH group did not show a difference between the placebo and glucose arm. 
However in the PPH group with glucose ARI values were higher and a significantly 
higher ARI was found in the PPH group for both placebo and glucose. There were 
significant differences in the ARI and CBFV between groups in the right MCA 
(Appendix Table 94) and the left MCA (Appendix Table 95). It is likely that any 
differences are attributable to postural changes rather than glucose. 
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Figure 81 Mean of Right and Left MCA Time Varying ARI (… = varying time scale) 
 
 
Figure 82 Right MCA Time varying ARI (… = varying time scale)
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Figure 83 Left MCA Time varying ARI (… = varying time scale) 
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16.5.4 The “DOWN” component: Prior to end of HUT 
There were significant differences in ARI and CBFV between the groups in the minute 
prior to the end of HUT, for the mean of the combined right and left MCA (Appendix 
Table 96) as well as the individual right MCA (Appendix Table 97) and left MCA 
(Appendix Table 98). This time period is perhaps the most interesting when considering 
post-prandial falls, as the PPH glucose arm shows the greatest decline in ARI from the 3 
minute of HUT mark and along with No PPH glucose shows a decline in CBFV. 
 
16.5.5 The “DOWN” component: Post-HUT 1 minute 
Even in the one minute after the end of HUT, there persisted a significant difference in 
ARI and CBFV between the groups (Appendix Table 99), and individually the right 
MCA (Appendix Table 100) and the left MCA (Appendix Table 101). 
 
16.5.6 The “DOWN” component: Post-HUT 2 minutes 
Looking at 2 minutes after the end of HUT, the combined mean of right and left MCA 
values (Appendix Table 102) for ARI and CBFV remained significantly different 
between the groups, as well as in the individual cases of the right MCA (Appendix 
Table 103) and the left MCA (Appendix Table 104).  
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16.5.7 Group Changes during HUT 
16.5.7.1 Blood pressure and Heart Rate 
The actual changes at 1 minute, 2 minutes and at the end of HUT compared to pre-HUT 
are shown (see Appendix Table 105, Table 106, Table 107). The % changes are shown 
in tables (Appendix Table 108, Table 109, Table 110) and are illustrated in graphs 
(Figure 84, Figure 85).  
 
MAP at 1 minute HUT, showed a significant change within the No PPH and the PPH 
group (placebo vs glucose) as well as between these groups for placebo, but not for 
glucose (Appendix Table 105). With glucose (vs placebo), the HR showed a statistically 
significant small fall in both groups (Appendix Table 105).  In general by the end of 
HUT, all groups showed no change or an increase in MAP, surprisingly the greatest 
increase was in the PPH group. 
 
Figure 84 The percentage change in MAP from pre-HUT during HUT (… = varying time scale) 
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Figure 85 The percentage change in HR from pre-HUT during HUT (… = varying time scale) 
 
16.5.7.2 Dynamic Cerebral Auto-regulation 
The actual changes at 1 minute, 2 minutes and at the end of HUT compared to pre-HUT 
are shown (see Appendix Table 105, Table 106, Table 107). The % changes are shown 
in tables (Appendix Table 108, Table 109, Table 110) including graphs of CBFV 
(Figure 86) and ARI (Figure 87). 
 
There were no significant differences in the change of ARI with placebo between the 
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difference when glucose was given, with a small positive change in ARI being seen in 
the PPH group by the end of HUT (Figure 87). The increase in ARI in the PPH group 
may reflect attempts at maintaining CBFV with glucose ingestion. However the fall in 
ARI in the No PPH group may suggest a failure of dCA due to posture, regardless of 
whether in the glucose or placebo phase. It is likely that the general fall in CBFV over 
the period of HUT is more to do with posture, although the glucose arms of both groups 
show a greater decline, which may be metabolically related. 
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Figure 86 The percentage change in CBFV from pre-HUT during HUT (… = varying time scale) 
 
 
Figure 87 The percentage change in ARI from pre-HUT during HUT (… = varying time scale)
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16.6 Sub-group analysis 
This section was limited by the quality of data files required for time varying analysis. 
Like for OH, it was difficult to determine from the original groupings, whether 
participants were likely to have a significant fall in BP with glucose, and thus post-hoc 
analysis was carried out dividing the participants into those who did have a post-
prandial fall in BP and those who did not, firstly based on their original symptomatic 
(i.e. likely PPH) and asymptomatic groups (i.e. No PPH); and secondly with all 
participants combined based on actual HUT irrespective of original groups or phase (i.e. 
both glucose and placebo combined).  
 
16.6.1 Post-prandial fall in BP 
The participants who had evidence of a significant fall in SBP during HUT were 
divided into four. Each individual participant was only represented once. Therefore 
placebo asymptomatic BP decrease (n=5), placebo symptomatic BP decrease (n=6), 
glucose asymptomatic BP decrease (n=10), glucose symptomatic BP decrease (n=2). 
Analysing the change from pre-HUT (Table 32) to end-HUT, those who received 
placebo were compared asymptomatic vs symptomatic, and similarly for glucose; and 
furthermore those who were asymptomatic or symptomatic, were compared placebo 
versus glucose. A further analysis compared those with symptoms and those who 
remained symptomatic regardless of whether placebo or glucose (Table 33). Figure 88 
and Figure 89 illustrate the changes. 
  
2
6
2
 
 
Placebo 
Asymptomatic 
(n=5) 
Placebo 
Symptomatic 
(n=6) 
Placebo 
(Mann-
Whitney, p-
value) 
Glucose 
Asymptomatic 
(n=10) 
Glucose 
Symptomatic 
(n=2) 
Glucose 
(Mann-
Whitney, 
p-value) 
Asymptomatic 
(Wilcoxon 
Signed Ranks, 
p-value) 
Symptomatic
(Wilcoxon 
Signed 
Ranks, p-
value) 
Mean  SD Mean  SD Mean SD Mean  SD 
Combined 
CBFV (cm/s) 
36.4 1.5 38.0 1.8 <0.001 32.7 8.8 34.1 1.9 <0.001 <0.001 <0.001 
SD time sample 11.6 0.5 6.2 1.3 <0.001 5.6 1.1 5.6 0.6 <0.001 <0.001 <0.001 
MAP (mmHg) 75.3 4.1 106.0 2.4 <0.001 84.4 6.4 92.2 3.5 <0.001 <0.001 <0.001 
SD time sample 10.5 1.8 9.4 2.3 <0.001 5.0 0.8 26.8 4.5 <0.001 <0.001 <0.001 
tCO2 (mmHg) 39.4 3.0 57.8 2.0 <0.001 123.6 8.6 56.4 6.1 <0.001 <0.001 <0.001 
SD time sample 51.5 3.9 45.1 1.8 <0.001 47.8 1.5 52.7 6.1 <0.001 <0.001 <0.001 
Combined ARI  5.2 0.3 4.7 0.8 <0.001 3.2 1.7 5.6 0.35 <0.001 <0.001 <0.001 
SD time sample 2.0 0.3 2.5 0.5 <0.001 0.5 0.1 1.0 0.4 <0.001 <0.001 <0.001 
Heart Rate 
(bpm) 
67.9 3.1 69.5 1.1 <0.001 68.4 1.7 72.4 3.9 <0.001 <0.001 <0.001 
SD time sample 11.4 2.7 9.8 1.4 <0.001 6.9 1.2 5.1 3.9 <0.001 <0.001 <0.001 
Table 32 Fall in BP, pre-HUT parameters asymptomatic versus symptomatic with placebo and glucose 
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Placebo 
Asymptomatic 
(n=5) 
Placebo 
Symptomatic 
(n=6) 
Placebo 
(Mann-
Whitney, p-
value) 
Glucose 
Asymptomatic 
(n=10) 
Glucose 
Symptomatic 
(n=2) 
Glucose 
(Mann-
Whitney, p-
value) 
Asymptomatic 
(Wilcoxon 
Signed Ranks, 
p-value) 
Symptomatic 
(Wilcoxon 
Signed 
Ranks, p-
value) 
Mean  SD Mean  SD Mean  SD Mean  SD 
Change in combined 
CBFV (cm/s) 
-9.9 2.1 -9.8 2.8 
<0.001 
2.6 10.1 2.6 2.2 
<0.001 <0.001 <0.001 
Change in SD time sample 3.5 1.0 3.6 1.5 <0.001 8.6 2.5 -2.8 0.6 <0.001 <0.001 <0.001 
Change in MAP (mmHg) 6.6 7.4 -15.6 3.5 <0.001 5.8 7.0 -2.0 4.2 <0.001 <0.001 <0.001 
Change in SD time sample 2.6 3.9 14.3 2.0 <0.001 15.5 2.7 -21.2 4.5 <0.001 <0.001 <0.001 
Change in tCO2 (mmHg) 79.0 8.5 30.7 3.8 <0.001 7.8 7.6 80.0 6.8 <0.001 <0.001 <0.001 
Change in SD time sample -29.0 5.7 -15.4 2.9 <0.001 20.1 2.7 -51.3 6.1 <0.001 <0.001 <0.001 
Change in combined 
ARI  
-0.1 1.0 -1.0 0.8 
<0.001 
1.5 2.6 -1.8 1.1 
<0.001 <0.001 <0.001 
Change in SD time sample 0.7 0.3 -0.2 0.6 <0.001 2.7 0.5 -0.1 0.6 <0.001 <0.001 <0.001 
Change in Heart Rate 
(bpm) 
2.3 6.8 -12.7 2.8 
<0.001 
-1.2 4.4 -1.4 4.0 
<0.001 <0.001 <0.001 
Change in SD time sample -1.1 4.1 23.1 2.5 <0.001 9.3 4.1 -3.7 3.8 <0.001 <0.001 <0.001 
Table 33 Fall in BP, comparing changes in parameters asymptomatic versus symptomatic with placebo and glucose 
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There is evidence that ARI decreases significantly (p<0.001) in those who are 
symptomatic compared to those who are asymptomatic whether they have consumed 
placebo (mean -1.0 vs. -0.1) or glucose (mean -1.8 vs. 2.7) associated with a fall in SBP 
≥20mmHg. It is likely that those who had a fall in BP with placebo had orthostatic 
hypotension. 
 
16.6.2 No post-prandial fall in BP 
Those who did not have evidence of a significant fall in SBP during HUT were 
similarly divided. Thus placebo asymptomatic no significant BP decrease (n=11), 
placebo symptomatic no BP decrease (n=3), glucose asymptomatic no BP decrease 
(n=10), glucose symptomatic no BP decrease (n=6). As for those with a fall in BP, 
analysing the change from pre-HUT (Table 34) to end-HUT was carried out in a similar 
fashion. Those who received placebo were compared asymptomatic vs symptomatic, 
and similarly for glucose; and furthermore those who were asymptomatic or 
symptomatic, were compared placebo versus glucose. In addition further analysis 
compared those with symptoms and those who remained asymptomatic regardless of 
whether placebo or glucose (Table 35). Figure 88 and Figure 89 illustrate the relative 
changes as mean values of combined ARI and combined CBFV. 
  
2
6
5
 
 
Placebo 
Asymptomatic 
(n=5) 
Placebo 
Symptomatic 
(n=6) 
Placebo 
(Mann-
Whitney, p-
value) 
Glucose 
Asymptomatic 
(n=10) 
Glucose 
Symptomatic 
(n=2) 
Glucose 
(Mann-
Whitney, p-
value) 
Asymptomatic 
(Wilcoxon 
Signed Ranks, 
p-value) 
Symptomatic 
(Wilcoxon 
Signed 
Ranks, p-
value) 
Mean  SD Mean  SD Mean SD Mean  SD 
Combined CBFV 
(cm/s) 
36.6 1.5 41.4 2.3 <0.001 37.4 1.8 39.4 2.7 <0.001 <0.001 <0.001 
SD time sample 12.8 0.9 10.2 2.1 <0.001 5.5 1.3 6.7 1.7 <0.001 <0.001 <0.001 
MAP (mmHg) 90.2 2.6 90.8 3.5 <0.001 95.4 1.9 100.1 3.5 <0.001 <0.001 <0.001 
SD time sample 15.8 1.6 18.2 4.4 <0.001 15.0 1.6 15.5 5.3 <0.001 0.006 <0.001 
tCO2 (mmHg) 36.2 1.6 71.4 4.1 <0.001 54.5 1.6 104.5 2.9 <0.001 <0.001 <0.001 
SD time sample 51.4 2.4 48.6 3.4 <0.001 48.8 1.2 53.8 1.8 <0.001 <0.001 <0.001 
Combined ARI  4.5 0.3 5.6 1.0 <0.001 5.7 0.3 4.5 0.7 <0.001 <0.001 <0.001 
SD time sample 3.1 0.2 2.6 0.7 <0.001 2.0 0.5 2.1 0.4 <0.001 <0.001 <0.001 
Heart Rate (bpm) 66.3 2.1 66.8 2.3 <0.001 75.8 2.2 64.6 1.6 <0.001 <0.001 <0.001 
SD time sample 8.4 3.2 2.9 1.9 <0.001 20.0 2.0 4.7 1.7 <0.001 <0.001 <0.001 
Table 34 No fall in BP, pre-HUT parameters asymptomatic versus symptomatic with placebo and glucose 
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Placebo 
Asymptomatic 
(n=11) 
Placebo 
Symptomatic 
(n=3) 
Placebo 
(Mann-
Whitney, p-
value) 
Glucose 
Asymptomatic 
(n=10) 
Glucose 
Symptomatic 
(n=6) 
Glucose 
(Mann-
Whitney, p-
value) 
Asymptomatic 
(Wilcoxon 
Signed Ranks, 
p-value) 
Symptomatic
(Wilcoxon 
Signed 
Ranks, p-
value) 
Mean  SD Mean  SD Mean  SD Mean  SD 
Change in combined 
CBFV (cm/s) 
3.4 1.9 -0.1 3.5 
<0.001 
4.1 1.8 -5.4 3.8 
<0.001 <0.001 <0.001 
Change in SD time 
sample 
-2.8 2.1 -2.2 3.2 
<0.001 
0.9 1.4 0.0 3.8 
<0.001 <0.001 <0.001 
Change in MAP 
(mmHg) 
9.5 2.8 13.0 4.7 
<0.001 
1.6 2.6 -1.8 4.4 
<0.001 <0.001 <0.001 
Change in SD time 
sample 
-5.7 2.4 -15.7 4.7 
<0.001 
-9.9 2.2 -5.6 5.1 
<0.001 <0.001 <0.001 
Change in tCO2 
(mmHg) 
114.6 4.0 -2.8 4.7 
<0.001 
96.7 3.1 -30.4 4.6 
<0.001 <0.001 <0.001 
Change in SD time 
sample 
-36.9 4.2 16.6 3.9 
<0.001 
-43.0 2.3 -3.1 3.5 
<0.001 <0.001 <0.001 
Change in combined 
ARI  
-0.3 0.6 -1.4 1.4 
<0.001 
0.7 0.8 0.9 0.5 
0.016 <0.001 <0.001 
Change in SD time 
sample 
-0.6 0.3 -0.2 1.2 
<0.001 
-0.7 0.8 0.7 0.8 
<0.001 <0.001 <0.001 
Change in Heart Rate 
(bpm) 
-3.1 3.3 0.3 3.2 
<0.001 
-13.8 2.4 9.0 3.5 
<0.001 <0.001 <0.001 
Change in SD time 
sample 
-5.2 3.3 2.4 2.2 
<0.001 
-16.1 3.1 2.8 4.2 
<0.001 <0.001 <0.001 
Table 35 No fall in BP, comparing the changes in parameters asymptomatic versus symptomatic with placebo and glucose
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16.6.3 BP fall versus No BP fall comparison 
Comparing those with and without falls in SBP ≥20mmHg amongst those who were 
Asymptomatic with placebo showed that pre-HUT were significantly different 
(p<0.001) for all parameters, except the combined right and left CBFV (p=0.97). The 
changes in parameters were different between these two groups except for ARI 
(p=0.08) with similar falls in ARI (-0.3 vs. -0.1). With glucose, the pre-HUT 
parameters were different for those with and without falls in BP (p<0.001). However 
there was no significant difference in ARI increase (0.7 vs. 1.5, p=0.62) for the 
asymptomatic glucose group regardless of whether they had a fall in SBP or not. 
Although MAP, HR, CBFV, tCO2 changes differed (p<0.001). 
 
Amongst those who were symptomatic with placebo, there were differences in pre-
HUT parameters between those with and without falls in SBP (p<0.001). The changes 
were also different (p<0.001), except for reduction in ARI, which were similar for 
those with and without a fall in BP (-1.0 vs -1.4, p=0.07). With glucose, in those who 
were symptomatic, the baseline parameters and changes with HUT differed between 
those with and without falls in BP during HUT (p<0.001). ARI was also different 
between those with or without a BP fall (-1.8 vs. 0.9, p<0.001). Figure 88 and Figure 
89 illustrate the changes in ARI and CBFV. 
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16.6.4 Symptomatic versus Asymptomatic combined groups 
As the previous post-hoc analysis suggested possible trends, and the numbers were 
small, further analysis was carried out. Thus in order to determine the influence of 
dCA on symptoms, participants were divided into those who did or not have symptoms 
regardless of whether they received placebo or glucose and regardless of whether they 
demonstrated a significant fall in BP (Table 36). There was evidence of a fall in ARI 
amongst those who were symptomatic regardless of whether placebo or glucose was 
consumed, or whether there was a fall in BP (p<0.001). How this compares to the 
previous sub-group analysis is shown in Figure 88 and Figure 89 (ARI and CBFV 
respectively). 
 
Asymptomatic 
(n=37) 
Symptomatic 
(n=15) 
 Mann-
Whitney, p-
value Mean  SD Mean  SD 
Change in combined 
CBFV (cm/s) 
0.1 7.8 -3.2 5.7 
<0.001 
Change in SD time 
sample 
2.5 4.6 -0.3 3.6 
<0.001 
Change in MAP 
(mmHg) 
5.9 6.1 -1.6 11.0 
<0.001 
Change in SD time 
sample 
0.6 10.1 -7.1 14.2 
<0.001 
Change in tCO2 
(mmHg) 
74.5 41.1 19.4 41.5 
<0.001 
Change in SD time 
sample 
-22.2 25.3 -13.3 25.2 
<0.001 
Change in combined 
ARI  
0.4 1.6 -0.9 1.4 
<0.001 
Change in SD time 
sample 
0.5 1.4 0.0 0.9 
<0.001 
Change in Heart Rate 
(bpm) 
-4.0 7.5 -1.2 8.4 
<0.001 
Change in SD time 
sample 
-3.3 9.8 6.1 10.7 
<0.001 
Table 36 Asymptomatic versus Symptomatic - groups combined 
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Figure 88 The mean changes in ARI - post-hoc analysis 
 
Figure 89The mean changes in CBFV - post-hoc analysis 
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16.7 Post-Prandial Hypotension Study – Effects of HUT Results 
Summary 
There were no baseline differences in any of the haemodynamic (PWV, BRS) or 
cerebrovascular parameters (including dCA) between the PPH and non-PPH groups.  
After the glucose challenge the changes in capillary blood glucose levels peaked at 30 
minutes with a small fall by 60 minutes with little change after placebo but no 
significant differences between the PPH and non-PPH groups. SBP, MAP and CBFV 
declined over the course of HUT, the mean fall with glucose ingestion being 
particularly marked in the PPH group although this did not reach formal statistical 
difference compared to the non-PPH group probably resulting from the large SD for 
the SBP changes when compared to the pre-HUT period. Associated with glucose 
ingestion was an increase in HR noted in both groups whether earlier or later on during 
HUT. Levels of tCO2 remained similar in both groups in either phase in the initial 
post-tilt period but rose in the Non-PPH group prior to the end of tilt.  In the PPH 
group, tCO2 values remained similar throughout the two phases. 
 
During the course of HUT there was a fall in the mean combined CBFV across all 
groups (Figure 79). Continuous estimates of ARI showed that whilst there was no 
difference in the mean values for the combined ARI for pre-HUT between groups, 
differences were evident between the groups for the changes after the glucose or 
placebo drinks from 1 minute post-tilt, with the PPH group showing significantly 
greater increases in ARI after both phases, with no change being seen in the non-PPH 
group.  At 2 minutes post-tilt PPH group, again showed a significantly greater 
proportional increase following glucose and placebo in combined ARI but there was 
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no different between the placebo and glucose phase for the No PPH group.  However 
by the end of tilt there was no difference in ARI between phases for the PPH group, 
but a fall in ARI was significant in the No PPH group.  
 
Further sub-group analysis demonstrated that those who had symptoms whether or not 
they had a fall in BP during HUT, for either the placebo or glucose phase, had a greater 
reduction in ARI compared to those who were asymptomatic.  
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16.8 Post-Prandial Hypotension Study – Discussion of Effects of 
HUT 
It was anticipated that those in the PPH group would have a significant fall in BP with 
glucose, but not with placebo; with the No PPH group, not having a significant fall in 
BP with either placebo or glucose. As it was thought that symptoms with or without 
falls in BP was more to do with dCA, it was hypothesised that those with symptoms 
without a large fall in BP would have impaired dCA. Although this study showed 
evidence of a fall in CBFV during HUT across all groups, it also showed evidence of a 
decline in dCA (i.e. ARI) in those who were symptomatic, regardless of what 
happened to their blood pressure. Changes in CO2, BP and HR although sometimes 
statistically different between groups, clinically they were relatively small. The 
changes in CBFV within each group over the duration of HUT was statistically 
significant, but again, this appeared separate to the changes in dCA. 
 
There is an associated fall in CBFV, during HUT, but the differing behaviour of each 
cerebral hemisphere may be due to undiagnosed significant stenosis of the cerebral 
arteries. A reduction in CBFV during HUT has been found amongst those with 
orthostatic intolerance suggesting prolonged cerebral vasoconstriction but in the post-
prandial this does not appear to be related to changes in systemic BP levels or CO2 
levels (Lin et al., 2011). Even in young adults with initial orthostatic hypotension it has 
been found that there is a reduction in MCA CBFV from baseline when using HUT 
with lower body negative pressure which was also present with pre-syncope (Thomas 
et al., 2009). During HUT (without glucose ingestion) in a normal subject, it would be 
expected that ARI remained the same throughout (Carey et al., 2003). Although there 
were falls in CBFV and BP during HUT, it was the symptomatic not the asymptomatic 
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participants who showed a greater reduction in ARI. This was more evident with sub-
group and further data analysis. 
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17 Summary of Results: Post-Prandial Hypotension Study  
Post-hoc analysis demonstrated abnormalities in dCA amongst those who were 
symptomatic during HUT despite no evidence of differences between the two groups 
(PPH vs. No PPH) at baseline. 
 
The No PPH and the PPH groups were similar in terms of age, BMI, DBP, DBP, HR, 
autonomic function score, postural BP changes or capillary blood glucose at baseline. 
They were also similar in terms of categorical data such as sex, smoking status, drugs 
and a history of hypertension. They did differ in terms of orthostatic grading scale 
score and the presence of pre-syncope, where the PPH group had a higher orthostatic 
grading score and more participants with a history of pre-syncope. This difference was 
likely due to the participant classification and group allocation.  
 
Furthermore there was no difference at baseline within or between groups for both 
phases (placebo and glucose) in terms of cardiac BRS and measures of arterial stiffness 
(PWV and AIx). In the supine position there were no differences between the placebo 
and glucose phase, nor between the No PPH and the PPH groups, for the mean of 
combined right and left MCA: Tiecks model of ARI and ARMA-ARI models, CBFV, 
and these components for right and left MCAs individually. MAP as well as SBP and 
DBP, HR, tCO2 were also no different in the supine position at baseline.  
 
Furthermore as the continuous estimates of dCA (which had to be used in this study as 
other methods of dCA estimation e.g. Tiecks method call for a stable recording 
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situations which while suitable for baseline recordings is not appropriate in a dynamic 
situation such as during post-prandial tilt) relies on the need for exceptionally high 
quality data recordings, this resulted in the recordings from some subjects being 
rejected.  It may be therefore that a Type 2 statistical error may have been present as 
there were insufficient numbers of participants available with such data especially 
given the natural variability of such measurements.  
 
Using continuous estimates, ARI at the end of HUT, when participants were 
symptomatic or at the end of the maximal 60 minute period, were higher in the glucose 
arm in both the No PPH and the PPH group. This was due to a greater fall in the ARI 
in the No PPH placebo arm. However sub-group analysis showed evidence of a 
significant reduction in ARI amongst those with symptoms irrespective of whether 
glucose was consumed or not, or in terms of BP changes.  
 276 
18 Summary of Discussion: Post-Prandial Hypotension 
Study 
It was hypothesised that those who had symptoms of PPH would have abnormalities in 
dCA. This study is the first of its kind and suggests that those who have symptoms 
may have abnormalities in dCA, irrespective of BP changes. The finding of no 
differences between phases or groups in baseline BP  has been found by others (Van 
Orshoven et al., 2010, Vloet et al., 2005, Jones et al., 2005)  Only 38% of older people 
have been reported to have both PPH and OH (Vloet et al., 2005) and therefore it was 
not surprising that there were no differences between the two groups in terms of 
postural changes in BP. PPH amongst those with hypertension has been associated 
with cerebrovascular damage (Kohara et al., 1999), one could expect baseline 
differences in CBFV between the No PPH and the PPH groups. However in the 
population used in this thesis, there were no significant differences in supine BP 
between the two groups, which may account for the absence of a difference in CBFV 
supine position. Other research suggests that although there are differences in supine 
CBFV, there are no differences in ARI in healthy older adults compared to younger 
adults (Carey et al., 2003). AIx in this study was lower than other studies (McEniery et 
al., 2005, Salvi et al., 2010), although PWV was similar. BRS was similar to other 
studies (Dawson et al., 1999). 
 
The absence of a statistically significant difference between groups in terms of changes 
in BP during HUT which one would expect (Krajewski et al., 1993) was perhaps a 
result of participants being classified based on a clinically history suggestive of PPH. It 
is likely that participant classification impacted the measures of ARI and other 
parameters. During HUT (without glucose ingestion) in a normal subject, it would be 
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expected that ARI remained the same throughout (Carey et al., 2003). Where there is 
systemically higher BP, it has been shown that this may be associated with lower 
cerebral blood flow, and thus one could expect this to indicate perhaps failure of 
cerebral auto-regulation (Waldstein et al., 2010). Similarly, postural changes in BP can 
induce falls in CBFV, and if significantly so, can indicate poor CA(Zhang et al., 1998). 
Age itself does not affect dynamic CA, despite a decrease in cardiac BRS being 
associated with ageing(Carey et al., 2000). 
 
18.1 Strengths and Limitations 
This is the largest study in older adults investigating the changes in dynamic CA in 
PPH. It has proven that older adults are willing to participate in studies which could be 
perceived as uncomfortable due to the duration of HUT. Although a reasonable 
number of participants were successfully recruited, one did withdraw due to 
inconvenience; another could not tolerate HUT due to symptoms and did not wish to 
partake further. Transcranial Doppler US signal was a limiting factor. Although 
reasonable quality signals were obtained in the supine position, this was not always the 
case during HUT, particularly at the beginning and oat the end of HUT. This resulted 
in a loss of data, at the critical points which were key to this study. 
 
Classification of subjects into those with post-prandial hypotension and those without 
was based solely on clinical history as there is no universally agreed classification. 
However the general consensus is that there should be a fall in BP within a 2 hour 
period of meal consumption. This can inevitably lead to miss-classification of subjects 
and a separate analysis of those who had and those who did not have a symptomatic 
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BP fall after the glucose phase and not after placebo is possibly statistically 
underpowered in this regard.  Similarly the time to the maximum fall in BP after drink 
ingestion varied considerably so it is perhaps not surprising that there was considerable 
variation in BP and dCA responses within and between groups.   The glucose load 
used in this study (a 50g glucose drink) has been shown by others (Jones et al., 2005)  
to result in a peak glucose level at around 39.0±4.0 minutes (Berry et al., 2003) with an 
associated fall in SBP of around 10 mmHg at around 30 minutes post-ingestion hence 
this this dose and duration of HUT used in this study.  A solid mixed meal has been 
shown to take as long as 67.5± 10.3 minutes to reach peak blood glucose level, with a 
smaller reduction in BP (Berry et al., 2003). In one small study of older people with 
PPH (liquid meal with 40% carbohydrate), it was shown that a statistically significant 
steady fall in BP occurred between 30 and 55 minutes after a meal (Krajewski et al., 
1993).  
 
18.2 Future work 
In hindsight, perhaps it would have been better to ask participants to attend another 
session whereby they were screened for PPH with a glucose load, as originally 
considered. However this would have involved participants attending for three separate 
visits. At the time of planning the study, it was anticipated that recruitment for multiple 
or prolonged visits would increase the difficulty in recruitment. On this basis a 
screening for PPH using physiological measurements and a glucose load was not 
carried out. However several studies looking at the drug treatment of post-prandial 
falls in BP also did not do so either (Russo et al., 2003, O'Donovan et al., 2005, Jones 
et al., 2005, Gentilcore et al., 2011). However this would certainly be considered in 
future, where time scales for recruitment to the study was less limited. There were 
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participants who withdrew after one visit, as they felt it inconvenient and it was a 
challenge recruiting participants who were willing to attend for two visits. There were 
some participants who had already taken part in the OH study, who if they had not 
already taken part in the OH study, perhaps would have been willing to make three 
visits for this study.  
 
Further analysis was based on the tilt result to assess the changes in dynamic CA, BP 
and HR however care must be taken in the interpretation of such post-hoc analyses. 
Given that only four in the glucose arm of the No PPH group and nine in the glucose 
phase of the PPH group had a SBP fall ≥20mmHg, any potential analysis is limited.  
However there was evidence that those who became symptomatic have a fall in 
dynamic cerebral auto-regulation which might explain their symptoms. It may be that 
future studies will need to have adequate screening to carefully randomise participants 
to No PPH and PPH groups, based on actual HUT with a glucose load prior to placebo 
versus glucose randomisation. Another method if time permitted would be to leave 
recruitment as an open and ongoing process until adequate numbers were met for each 
group. This would of course result in unbalanced groups, but if time permitted, then it 
would be one way of dealing with this problem. 
 
18.3 Conclusion 
In conclusion, this novel study adds new information in the area of PPH and dCA, by 
demonstrating no baseline haemodynamic or cerebrovascular differences between 
those with and without symptoms linked to post-prandial hypotension. Following 
glucose or placebo ingestion there was no significant fall in BP during either phase but 
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large individual differences in responses with glucose during HUT were found. 
Dynamic cerebral auto-regulation differed between placebo and glucose phases for the 
No PPH and the PPH groups with a higher ARI associated with glucose. Post-hoc 
analysis demonstrated a fall in ARI amongst any participant with symptoms. 
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19 Thesis Discussion 
Individuals with orthostatic hypotension and post-prandial hypotension, both common 
conditions in older people, have an increased risk of cardiovascular events, falls and 
death.  However not all those who have a fall in systemic BP levels are symptomatic 
(Mader et al., 1987), similarly there are those people who have symptoms of postural 
hypotension or post-prandial hypotension but no associated fall in BP can be detected.   
To date there are few effective treatments for these conditions all of which are directed 
at raising systemic BP levels but if the main cause of symptoms is related to 
abnormalities in brain blood flow control, not changes in systemic BP levels, this may 
be the wrong therapeutic approach.  The main objectives of this thesis were therefore 
1) to review the current treatments for these conditions to assess which therapies were 
effective in reducing symptoms and therefore giving an insight into potential 
underlying pathophysiological mechanisms and 2) most importantly to investigate 
whether abnormalities in brain blood flow control as reflected by differences in 
dynamic cerebral auto-regulation are present in those who are symptomatic with these 
conditions compared to those who are asymptomatic whether or not they have an 
actual fall in systemic BP.  
 
It was hypothesised that an underlying difference in dCA may account for why some 
people have the symptoms associated with OH, but yet do not have the postural fall in 
BP expected. A difference in dCA might also account for why some who have a 
postural fall in BP fail to note any symptoms. Similarly for the Post-Prandial 
Hypotension study it was hypothesised that there are differences in dCA for those with 
a history of PPH compared to those without PPH, and that perhaps glucose can also 
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affect dCA. Other parameters which were investigated included cardiac BRS and 
arterial stiffness. Both of these studies were targeted at the older population and 
includes participants over the age of 60 years of age representative of the Caucasian 
population in Western society where the ageing population is of particular concern.  
 
By understanding the physiological basis for symptomatic orthostatic hypotension and 
post-prandial hypotension it was anticipated that better ways of managing these 
conditions can be developed in the future. It has been shown in the two systematic 
reviews (Chapter 3 and 4) that drug treatment options at the present time are limited 
for both conditions, and the primary emphasis has been on improvements in postural 
BP rather than symptoms. Of the thirteen randomised controlled trials on OH, only 
three considered symptoms in addition to BP changes, two related to midodrine 
(Fouad-Tarazi et al., 1995, Low et al., 1997) and one related to fludrocortisone 
(Campbell et al., 1975). However the method of reporting differed between each study. 
The systematic review carried out on the treatment of OH concluded that both 
fludrocortisone and midodrine may be helpful in improving postural BP. Of the 
fourteen studies included in the systematic review on post-prandial reductions in BP, 
only one study commented on improvements in symptoms as well as BP, and this was 
with caffeine  ingestion (Heseltine et al., 1991c). Furthermore, the majority of studies 
included did not include many with PPH, and thus did not meet the criteria of a fall 
≥20mmHg within 2 hours of a start of a meal or if SBP falls to ≤90 mmHg within this 
period if pre-prandial SBP was ≥100 mmHg (Jansen and Lipsitz, 1995). The body of 
evidence from the systematic reviews was that there were very limited data as to the 
best treatments for these two conditions, all of which concentrated on raising systemic 
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BP levels without assessing the underlying mechanisms or effects on the patient’s 
symptoms. 
 
The second phase of this thesis focussed on the study of dynamic cerebral auto-
regulation in those with and without symptoms related to postural and post-prandial 
hypotension as it was proposed that abnormalities in auto-regulation accounted for the 
symptoms related to these conditions.  The first study concentrated on the mechanisms 
underlying the symptoms related to orthostatic hypotension, where participants were 
classified by whether they had evidence of a postural fall in BP in the clinic setting 
based on the ESC criteria for OH (≥20mmHg fall in SBP and/or a fall ≥10mmHg in 
DBP) (Moya et al., 2009), and had evidence of postural symptoms as recorded by the 
orthostatic grading scale (Schrezenmaier et al., 2005). However one of the main 
limitations with this method of classification is that not all participants who had a 
postural fall in BP on active standing would go on to have a fall on passive HUT and it 
is well recognized that the reproducibility of a postural BP fall with and without 
symptoms on standing or HUT is poor (Cooke et al., 2009). For the second study on 
PPH, participants were divided into two groups based on a history of symptoms of 
cerebral hypo-perfusion within a 2 hour period of a meal, though this classification can 
be inaccurate for several reasons including the accuracy of participant reporting 
symptoms.  
 
The two studies in this thesis both had a sample size calculated to be big enough to 
detect a difference in an index of dynamic cerebral auto-regulation (dCA) i.e. ARI of 
clinical significance (a problem with previous studies, which were too small to detect 
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such a difference). All analyses were conducted blinded to the classification of the 
subject status (ie symptomatic or asymptomatic).   
 
Baseline measures of cardiac baroreceptor sensitivity were similar in all groups of the 
OH study. This would suggest that parasympathetic cardiac control, one part of the 
autonomic nervous system, was not impaired and perhaps not responsible for the 
production of postural symptoms despite the baroreceptor being integral in control of 
systemic BP variation especially to posture. However both age and increasing BP are 
associated with impaired cardiac BRS, and other studies demonstrate that impaired 
BRS are common to both hypertension and OH (James and Potter, 1999, Takeshita et 
al., 1975, Moreira et al., 1992). In contradiction to this thesis abnormal cardiac BRS 
has been found in those with orthostatic intolerance without OH (i.e. symptoms and 
increase in HR>30bpm within 10 minutes of standing) (Farquhar et al., 2000). Cardiac 
BRS values were however similar to other studies using a similar aged population and 
methodology (Dawson et al., 1999). Arterial stiffness, as reflected by pulse wave 
velocity and augmentation index, was similar in all groups of the OH study. However 
other studies have shown an association between higher PWV (Mattace-Raso et al., 
2006) or AIx (Valbusa et al., 2012) and OH in terms of BP changes alone. It is 
unlikely that concomitant anti-hypertensive treatment accounts for this difference 
between studies but cannot be discounted as some, but not all, anti-hypertensive drug 
groups do reduce arterial stiffness (Boutouyrie et al., 2011). The OH study groups did 
not show any differences in supine CBFV between groups whether or not there was a 
postural BP fall and if this produced symptoms. It should be remembered that although 
CBFV is a useful surrogate marker of CBF, it does assume that there is no significant 
change in arterial diameter. Cerebral auto-regulation, as measured by ARI values 
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(Tiecks model and ARMA-ARI), was similar amongst all OH and PPH study groups in 
the supine position. This is consistent with other studies which demonstrated that 
neither static nor dynamic ARI are affected by hypertension or age (Eames et al., 
2003). Furthermore although other research suggests that differences in supine CBFV 
may exist, there are no differences in ARI in healthy older adults compared to younger 
adults (Carey et al., 2003). 
 
For the OH study, those in the Symptomatic OH Group had lower CBFV values during 
HUT which became more marked with the development of symptoms, the latter  
probably resulting from reduced cerebral perfusion  as suggested by others (Novak et 
al., 1998). Postural changes in systemic BP levels should not normally result in a fall 
in brain perfusion if cerebral auto-regulation is intact within the normal physiological 
BP changes seen with standing, but falls in CBFV are evident if there is impaired CA 
(Zhang et al., 1998). However ARI changes were similar in the Asymptomatic OH and 
the Symptomatic OH group suggesting that perhaps they may be one single group. The 
control group (Asymptomatic No OH) showed a small steady decline in ARI during 
the course of the HUT. The Symptomatic OH group on the other hand, shows a similar 
pattern to the control group, with the initial fall in ARI, steadily increasing with time. 
This suggests that there may be two groups to OH as a condition. Research in a smaller 
study (n=21, age 61.8±2.4 years) suggests the possibility of three OH groups. Those 
who have impaired auto-regulation with a flat flow-BP curve, those with intact auto-
regulation and expansion of the systemic BP range which auto-regulation can function, 
and lastly a group with failure of auto-regulation associated with a steep flow-BP curve 
(Novak et al., 1998). Whilst this study in older people confirms falls in CBFV during 
HUT with symptomatic OH which occurs later in the time course of HUT, it has 
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additionally shown that those with asymptomatic OH have an earlier fall in CBFV 
which then improves towards pre-HUT values. This may be related to CO2 changes 
during HUT, with a theoretical reduction in CO2 causing relative vasoconstriction and 
increases in CO2 resulting in relative vasodilatation. Furthermore this study has 
revealed changes in dCA during HUT in those with symptomatic OH, asymptomatic 
OH and those with symptoms of OH but in the absence of postural falls in BP. This 
suggests that despite maintained CBFV and the lack of a postural drop in BP in the 
latter group, the presence of symptoms is perhaps due to an impairment of dCA. Once 
again this may tie into the theory by Novak et al. (1998).  
 
Subgroup analysis of the OH study data showed a significant reduction in ARI with 
HUT amongst those with symptoms, and a relative increase in ARI in those without 
symptoms. The mean difference in ARI value between those with and without 
symptoms during HUT was substantial at 1.9 (a greater difference than is seen between 
controls and stroke patients for example (Eames et al., 2002)). However there was an 
associated greater fall in CBFV and MAP in those with symptomatic HUT, but 
although statistically significant, the difference in the mean fall in CBFV of 1 cm/s 
was small and a fall in MAP of 6mmHg may not be physiologically significant. In the 
context of a larger proportionate difference in mean combined ARI, these differences 
in CBFV and MAP are arguably small. The fall in CBFV and MAP was also seen in 
all groups in the PPH study, and perhaps suggesting that some participants may have 
both OH and PPH (Vloet et al., 2005).  Preliminary work done by another group 
suggest a reduction in CA is also responsible for symptoms in orthostatic intolerance 
in older people (Sanders et al., 2014).  
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With the PPH study, during HUT (without glucose ingestion) in a normal subject, it 
would be expected that ARI remained the same throughout (Carey et al., 2003). 
Although there were falls in CBFV and BP during HUT whether participants 
consumed placebo or glucose in either group, it was the symptomatic not the 
asymptomatic participants who showed a greater reduction in ARI. To date there are 
no known published studies investigating the association between symptoms, glucose 
ingestion and dCA. 
 
Post-hoc analysis of the PPH study data showed evidence that those who became 
symptomatic did have a fall in dynamic cerebral auto-regulation which might explain 
their symptoms. Although care must be taken in the interpretation of such post-hoc 
analyses,  both the OH and the PPH study do provide evidence that symptoms during 
HUT may be due impairment in dynamic CA.  This finding which is new and 
important as it may have important therapeutic implications in that new therapies for 
these conditions should potentially concentrate on treatments that may stop the fall in 
cerebral auto-regulation to prevent the onset of symptoms. 
 
19.1 Strengths of the studies 
The strengths of both the OH and the PPH studies included in this thesis are twofold.  
Firstly both studies are one of the few studies in dCA of this size to include older 
participants (>60 years) with consideration to the cause of symptoms. The relatively 
large participant numbers included compared to many studies published to date adds to 
the power to detect the differences in dCA. Secondly the broad inclusion criteria and 
limited exclusion criteria permit the results of this study to be considered applicable to 
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the general patient population that present to their physician with these common but 
under-researched conditions. 
 
19.2 Limitations of the studies 
However there are weaknesses including: 1) use of passive HUT which likely differs 
from active standing both in the research and clinical settings, 2) the duration of HUT 
meant deterioration of TCD US signals due to contact gel drying out which could have 
a negative effect on data quality in addition to inadequate bone windows (Lorenz et al., 
2009) and 3) the reliance of participant compliance at all times during the study to 
ensure consistent and adequate measures of CBFV, BP and HR. For the latter part of 
study looking at time-varying measures, this required very high quality data files 
which were sometimes difficult to obtain during the physical manoeuvre of HUT and 
variation in bone windows particularly in this older population. Classification of 
participants for the PPH study was not optimal. In hindsight it would have been better 
to ask participants to attend another session whereby they were screened for PPH with 
a glucose load, as originally considered. However this would have involved 
participants attending for three separate visits. However it was already a challenge 
recruiting older participants who were willing to attend for two visits. It may be that 
future studies will need to have adequate screening to carefully randomise participants 
to No PPH and PPH groups, based on actual HUT with a glucose load prior to placebo 
versus glucose randomisation. Another method if time permitted, would be to leave 
recruitment as an open and ongoing process until adequate numbers were met for each 
group. This would of course result in unbalanced groups, but if time permitted, then it 
would be one way of dealing with this problem. The underlying mechanism for the fall 
in ARI amongst those with symptoms, in this thesis was not investigated. However it 
 289 
may be that local changes in CO2, can account for this. High arterial CO2 results in 
vasodilation of the cerebral vessels, increasing cerebral blood flow (Lassen, 1974). 
Thus if CA is abnormal relative vasoconstriction may occur as a result in a fall in CO2 
which then reduces cerebral blood flow resulting in symptoms. Furthermore the 
technical difficulties in acquiring accurate measurements using transcranial Doppler 
ultrasound does pose a problem as regards to the quality of data recorded and may 
potentially affect results unless care is taken, with only acceptance of good quality 
signals for the basis of analysis. Furthermore other factors such as the use of anti-
hypertensives in research participants may mask any underlying differences in 
characteristics between groups. 
 
19.3 Thesis Conclusion 
In conclusion for the OH study, the abnormalities in dynamic cerebral auto-regulation 
were found during HUT, but not in the supine position, in those who were 
symptomatic, regardless of postural changes BP. The PPH study also suggested that 
symptoms were associated with impairment in dCA. However other important 
haemodynamic parameters including cardiac BRS and arterial stiffness were similar in 
those with/without symptoms and no orthostatic hypotension, and in those 
with/without symptoms and orthostatic hypotension; as well as similar in those 
with/without a history of symptoms of post-prandial hypotension. 
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20 Future Work 
Future research should try and objectively assess whether current treatment options for 
both orthostatic and post-prandial hypotension should concentrate not only on reducing 
the fall in systemic blood pressure levels which may precipitate symptom onset but 
also on measures that reduce the fall in cerebral auto-regulation which may prevent 
symptom onset.   It would be useful to determine whether the reduction in ARI and 
associated symptoms demonstrated in this can be reversed in the context of 
improvements in systemic BP. It may be that fludrocortisone and midodrine do more 
than just may small improvements in postural BP, perhaps they reverse the fall in the 
ARI seen with HUT in this thesis. Furthermore, perhaps the small effect in systemic 
BP seen in previous studies with caffeine is only half the story. Caffeine is known to 
improve concentration, and maybe it can improve dCA and prevent the fall in ARI 
amongst symptomatic individuals.  
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21 Appendix  
Herein contains various tables for the OH and PPH study, referred to as “Appendix 
Table” within the main text. 
   
  
2
9
2
  
Table 37 Baseline ARI (Tiecks model) Right Middle Cerebral Artery (Mann Whitney U to compare each group with the Control, i.e. Asymptomatic No OH; Kruskal-Wallis Test to examine 
for variances across groups) 
 
 
 
  
 
Right side 
Asymptomatic No 
OH (24) 
Symptomatic No 
OH (18) 
Mann 
Whitney 
U Test  
 (p-value) 
Asymptomatic 
OH (20) 
Mann 
Whitney 
U Test  
 (p-value) 
Symptomatic OH 
(23) 
Mann 
Whitney 
U Test  
 (p-value) 
Kuskall 
Wallis 
Test  
(p-value) 
Mean  SD Mean  SD Mean  SD Mean SD 
ARI 4.4 1.2 4.7 1.6 0.581 4.7 1.4 0.568 4.6 1.5 0.624 0.924 
Coherence Low Frequency 
(<0.07Hz) 
0.41 0.16 0.41 0.14 1.000 0.41 0.18 0.922 0.36 0.15 0.191 0.583 
Gain Low Frequency 
(<0.07Hz) 
0.42 0.24 0.43 0.17 0.728 0.43 0.20 0.686 0.30 0.09 0.040 0.049 
Phase Low Frequency 
(<0.07Hz) (radians) 
0.43 0.37 0.65 0.32 0.750 0.49 0.30 0.856 0.53 0.37 0.678 0.228 
Step Response Recovery (%) 65.5 25.9 77.8 50.3 0.542 64.8 14.9 0.587 67.5 24.5 0.489 0.859 
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Table 38 Baseline ARI (Tiecks model) Left Middle Cerebral Artery (Mann Whitney U to compare each group with the Control, i.e. Asymptomatic No OH; Kruskal-Wallis Test to examine 
for variances across groups) 
 
 
  
 
Left side 
Asymptomatic No 
OH (24) 
Symptomatic No 
OH (18) 
Mann 
Whitney U 
Test  
 (p-value) 
Asymptomatic 
OH (20) 
Mann 
Whitney 
U Test  
 (p-value) 
Symptomatic OH 
(23) 
Mann 
Whitney 
U Test  
 (p-value) 
Kuskall 
Wallis 
Test  
(p-value) 
Mean  SD Mean  SD Mean  SD Mean SD 
ARI 4.5 1.3 4.9 1.4 0.399 4.6 1.3 0.989 4.9 1.7 0.443 0.792 
Coherence Low Frequency 
(<0.07Hz) 
0.41 0.16 0.40 0.13 0.816 0.36 0.17 0.308 0.37 0.17 0.385 0.680 
Gain Low Frequency 
(<0.07Hz) 
0.41 0.26 0.43 0.18 0.581 0.40 0.20 0.989 0.33 0.09 0.513 0.501 
Phase Low Frequency 
(<0.07Hz) (radians) 
0.44 0.36 0.62 0.37 0.064 0.43 0.43 0.900 0.58 0.43 0.204 0.221 
Step Response Recovery 
(%) 
67.6 24.0 70.1 23.2 0.706 71.0 23.8 0.587 66.8 27.0 0.753 0.952 
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 Asymptomatic No 
OH (21) 
Symptomatic 
No OH (18) 
Mann 
Whitney 
U Test or 
T-Test* 
 (p-value) 
Asymptomatic 
OH (19) 
Mann 
Whitney 
U Test or 
T-Test* 
 (p-value) 
Symptomatic 
OH (23) 
Mann 
Whitney 
U Test or 
T-Test* 
 (p-value) 
Kruskal-
Wallis Test 
or ANOVA 
(p-value) 
Mean  SD Mean  SD Mean  SD Mean SD 
CBFV
1
 Right (cm/s) 45.4 13.4 47.4 14.9 0.686 48.2 11.5 0.361 37.4 6.4 0.038 0.014 
CBFV
1
 Left (cm/s) 45.2 13.7 47.6 14.3 0.666 43.2 14.0 0.936 42.3 11.0 0.518 0.665 
Mean CBFV
2
 (cm/s) 45.3 12.1 47.5 14.0 0.989 45.7 10.4 0.915 39.9 7.3 0.130 0.201 
Systolic CBFV Right (cm/s) 65.9 19.9 70.5 21.4 0.443 71.5 17.8 0.169 57.8 11.4 0.209 0.062 
Systolic CBFV Left (cm/s) 64.9 22.3 70.7 20.2 0.335 67.1 18.2 0.469 65.2 16.4 0.769 0.694 
Mean Systolic CBFV (cm/s) 65.4 19.1 70.6 19.7 0.349 69.3 15.1 0.187 61.5 12.4 0.488 0.174 
Diastolic CBFV Right (cm/s) 29.8 7.9 30.7 10.2 0.945 30.4 6.8 0.573 23.0 3.8 0.001 0.001 
Diastolic CBFV Left (cm/s) 30.1 8.3 31.4 10.5 1.000 27.1 10.6 0.537 26.1 8.3 0.124 0.426 
Mean Diastolic CBFV (cm/s) 29.9 7.1 31.0 10.1 0.922 28.8 7.0 0.649 24.5 4.6 0.007 0.034 
SBP (mmHg) 138.4 22.4 142.2 29.4 0.686 143.0 17.5 0.130 139.7 23.8 0.664 0.739 
DBP (mmHg) 71.9 12.4 68.7 13.1 0.335 72.3 8.2 1.000 74.8 12.5 0.613 0.473 
MAP (mmHg) 93.5 14.3 93.2 18.4 0.950* 95.9 10.0 0.549* 97.3 15.4 0.399* 0.771* 
Heart Rate (bpm) 65.3 10.7 63.0 10.2 0.410 65.5 10.7 0.503 69.0 12.0 0.124 0.290 
tCO2 (mmHg) 106.3 62.3 109.9 67.0 0.989 105.2 65.5 0.728 114.4 56.5 0.630 0.958 
Table 39 Group Measurements pre-HUT CBFV1=mean of systolic and diastolic CBFV for that side, Mean CBFV2=mean of both sides calculated by substitution if only one MCA available; 
Mann Whitney U to compare each group with the Control, i.e. Asymptomatic No OH; Kruskal-Wallis Test to examine for variances across groups)  
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 Asymptomatic No 
OH (21) 
Symptomatic 
No OH (18) 
Mann 
Whitney 
U Test or 
T-Test* 
 (p-value) 
Asymptomatic 
OH (19) 
Mann 
Whitney 
U Test or 
T-Test* 
 (p-value) 
Symptomatic 
OH (23) 
Mann 
Whitney 
U Test or 
T-Test* 
 (p-value) 
Kruskal-
Wallis Test 
or ANOVA* 
(p-value) 
Mean  SD Mean  SD Mean  SD Mean SD 
CBFV
1
 Right (cm/s) 44.3 14.2 42.6 16.5 0.606 41.9 11.4 0.810 35.4 7.2 0.028 0.107 
CBFV
1
 Left (cm/s) 44.0 12.1 44.7 17.6 0.606 36.0 15.6 0.145 33.4 13.2 0.012 0.069 
Mean CBFV
2
 (cm/s) 44.2 12.0 43.7 16.4 0.494 39.8 10.0 0.247 34.4 8.2 0.006 0.043 
Systolic CBFV Right (cm/s) 65.1 21.7 65.1 23.3 0.878 62.7 16.4 0.851 57.5 12.1 0.341 0.675 
Systolic CBFV Left (cm/s) 64.0 21.5 66.6 24.0 1.000 57.0 21.1 0.436 53.9 18.2 0.124 0.352 
Mean Systolic CBFV (cm/s) 64.6 20.1 65.9 22.4 0.878 60.8 15.1 0.830 55.7 12.2 0.118 0.394 
Diastolic CBFV Right (cm/s) 29.4 9.1 28.3 12.5 0.686 27.5 8.6 0.537 21.6 5.8 <0.0001 0.007 
Diastolic CBFV Left (cm/s) 29.4 7.6 30.4 13.0 0.749 23.3 11.7 0.105 20.5 10.2 0.003 0.018 
Mean Diastolic CBFV (cm/s) 29.4 7.3 29.4 12.1 0.530 26.0 7.5 0.178 21.0 6.1 <0.0001 0.004 
SBP (mmHg) 131.2 29.3 124.6 26.0 0.394 126.0 25.7 0.936 118.7 35.8 0.226 0.604 
DBP (mmHg) 72.4 17.7 66.3 15.7 0.192 71.0 13.5 0.810 69.9 15.5 0.296 0.475 
MAP (mmHg) 91.1 20.6 85.3 17.1 0.644* 88.8 16.7 0.695* 84.3 22.5 0.303* 0.654* 
Heart Rate (bpm) 68.0 10.3 67.0 11.5 0.770 70.4 8.8 0.124 74.0 12.9 0.065 0.173 
tCO2 (mmHg) 100.7 61.0 95.6 57.5 0.394 91.7 59.7 0.611 101.6 56.4 0.953 0.883 
Table 40 Groups Measurements at 1 minute of HUT CBFV1=mean of systolic and diastolic CBFV for that side, Mean CBFV2=mean of both sides calculated by substitution if only one MCA 
available; Mann Whitney U to compare each group with the Control, i.e. Asymptomatic No OH; Kruskal-Wallis Test to examine for variances across groups)  
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Asymptomatic No 
OH (21) 
Symptomatic 
No OH (18) 
Mann 
Whitney 
U Test or 
T-Test* 
 (p-value) 
Asymptomatic 
OH (19) 
Mann 
Whitney 
U Test or 
T-Test* 
 (p-value) 
Symptomatic 
OH (23) 
Mann 
Whitney 
U Test or 
T-Test* 
 (p-value) 
Kruskal-
Wallis Test 
or ANOVA* 
(p-value) 
Mean  SD Mean  SD Mean  SD Mean SD 
CBFV
1
 Right (cm/s) 43.7 13.5 41.4 13.4 0.379 40.2 10.4 0.486 36.9 8.2 0.055 0.318 
CBFV
1
 Left (cm/s) 40.7 12.3 41.1 14.4 0.835 36.4 11.2 0.361 38.3 9.1 0.597 0.829 
Mean CBFV
2
 (cm/s) 42.2 11.3 41.3 12.3 0.606 38.3 8.1 0.376 37.6 7.9 0.209 0.618 
Systolic CBFV Right (cm/s) 63.8 21.1 62.7 19.9 0.770 60.0 16.0 0.789 59.7 15.5 0.630 0.967 
Systolic CBFV Left (cm/s) 62.0 19.2 61.7 18.8 0.967 57.3 15.5 0.649 62.5 12.4 0.630 0.678 
Mean Systolic CBFV (cm/s) 62.9 18.1 62.2 16.5 0.791 58.7 14.0 0.592 61.1 11.7 0.681 0.865 
Diastolic CBFV Right (cm/s) 29.7 8.3 27.3 9.2 0.223 26.9 6.8 0.258 23.3 6.0 0.005 0.033 
Diastolic CBFV Left (cm/s) 26.8 11.1 27.4 11.0 0.394 23.7 8.9 0.226 23.4 9.1 0.142 0.466 
Mean Diastolic CBFV (cm/s) 28.3 8.1 27.4 8.9 0.379 25.3 5.4 0.130 23.4 6.8 0.019 0.103 
SBP (mmHg) 122.7 19.5 121.5 30.2 0.891* 126.6 28.1 0.733* 119.0 36.5 0.680* 0.872* 
DBP (mmHg) 70.5 11.4 64.5 17.4 0.204* 72.1 17.7 0.606* 68.0 17.8 0.580* 0.506* 
MAP (mmHg) 86.9 12.3 83.5 19.9 0.519* 89.5 19.3 0.601* 84.7 21.9 0.698* 0.765* 
Heart Rate (bpm) 73.8 10.8 69.4 12.3 0.244* 73.6 9.1 0.953* 74.6 12.3 0.823* 0.490* 
tCO2 (mmHg) 90.6 57.0 92.9 56.8 0.878 95.0 60.9 0.936 99.6 56.7 0.787 0.980 
Table 41 Groups Measurements at 3 minutes of HUT CBFV1=mean of systolic and diastolic CBFV for that side, Mean CBFV2=mean of both sides calculated by substitution if only one MCA 
available; Mann Whitney U to compare each group with the Control, i.e. Asymptomatic No OH; Kruskal-Wallis Test to examine for variances across groups) 
  
  
2
9
7
 
 
 
Asymptomatic No 
OH (22) 
Symptomatic 
No OH (18) 
Mann 
Whitney 
U Test or 
T-Test* 
 (p-value) 
Asymptomatic 
OH (19) 
Mann 
Whitney 
U Test or 
T-Test* 
 (p-value) 
Symptomatic 
OH (23) 
Mann 
Whitney 
U Test or 
T-Test* 
 (p-value) 
Kruskal-
Wallis Test 
or ANOVA* 
(p-value) 
Mean  SD Mean  SD Mean  SD Mean SD 
CBFV
1
 Right (cm/s) 39.1 12.5 41.5 11.3 0.530* 38.7 9.2 0.920* 36.5 10.1 0.452* 0.546* 
CBFV
1
 Left (cm/s) 38.3 13.2 38.6 9.9 0.943* 35.9 11.7 0.548* 33.9 7.6 0.183* 0.452* 
Mean CBFV
2
 (cm/s) 38.7 11.6 40.0 8.9 0.677 37.3 7.5 0.794 34.4 7.3 0.229 0.321 
Systolic CBFV Right (cm/s) 58.3 21.1 64.1 16.9 0.155 60.4 14.2 0.333 55.1 20.5 0.856 0.371 
Systolic CBFV Left (cm/s) 52.8 25.4 58.9 15.0 0.312 58.7 16.4 0.347 52.4 18.0 0.910 0.511 
Mean Systolic CBFV (cm/s) 57.1 20.6 61.5 12.8 0.209 59.6 12.2 0.320 53.8 15.5 0.633 0.250 
Diastolic CBFV Right (cm/s) 26.4 8.3 27.9 7.2 0.677 25.6 6.0 0.497 21.2 8.5 0.013 0.033 
Diastolic CBFV Left (cm/s) 23.8 11.9 26.3 7.0 0.861 23.2 9.1 0.433 19.1 10.8 0.093 0.189 
Mean Diastolic CBFV (cm/s) 25.9 8.3 27.1 6.0 0.798 24.4 5.3 0.333 20.2 6.2 0.004 0.003 
SBP (mmHg) 121.3 24.3 125.9 27.0 0.567* 125.1 31.2 0.662* 132.9 33.3 0.188* 0.602* 
DBP (mmHg) 69.1 14.5 70.6 14.0 0.749* 68.0 18.1 0.836* 74.1 17.4 0.298* 0.621* 
MAP (mmHg) 85.8 16.0 86.9 17.0 0.839* 86.6 22.0 0.896* 92.0 20.8 0.268* 0.689* 
Heart Rate (bpm) 76.0 13.1 76.0 13.8 0.994* 72.9 9.7 0.397* 78.0 14.1 0.627* 0.649* 
tCO2 (mmHg) 102.0 52.0 107.1 51.8 0.545 103.8 53.2 0.875 99.1 63.5 0.964 0.985 
Table 42 Group Measurements prior to End HUT (CBFV1=mean of systolic and diastolic CBFV for that side, Mean CBFV2=mean of both sides calculated by substitution if only one MCA 
available; Mann Whitney U to compare each group with the Control, i.e. Asymptomatic No OH; Kruskal-Wallis Test to examine for variances across groups)
  
2
9
8
 
 
Asymptomatic 
No OH (21) 
Symptomatic No 
OH (18) 
Mann 
Whitney 
U Test or 
T-Test* 
 (p-value) 
Asymptomatic 
OH (19) 
Mann 
Whitney 
U Test or 
T-Test* 
 (p-value) 
Symptomatic 
OH (23) 
Mann 
Whitney 
U Test 
or T-
Test* 
 (p-value) 
Kruskal-
Wallis 
Test or 
ANOVA* 
(p-value) 
Mean  SD Mean  SD Mean  SD Mean SD 
Change CBFV
1
 Right (cm/s) -1.1 -4.4 -4.8 -6.3 0.038* 1.6 -5.8 0.095* -4.2 -9.3 0.168* 0.015* 
Change CBFV
1
 Left (cm/s) -1.1 -4.1 -3.0 -7.8 0.294 1.3 -4.6 0.124 -3.2 -9.6 0.488 0.145 
Change Mean CBFV
2
 (cm/s) -1.3 -3.2 -3.5 -6.2 0.195* -6.1 -7.0 0.008* -0.8 -8.3 0.789* 0.050* 
Change Systolic CBFV Right (cm/s) -0.8 -6.3 -5.4 -8.1 0.078 2.7 -8.1 0.226 -4.9 -10.9 0.148 0.028 
Change Systolic CBFV Left (cm/s) -0.9 -5.3 -4.0 -10.3 0.294 -0.4 -12.0 0.537 -1.9 -16.4 0.418 0.425 
Change Mean Systolic CBFV (cm/s) -1.2 -4.2 -3.9 -7.8 0.204* -9.1 -10.4 0.003* -0.1 -12.3 0.682* 0.014* 
Change Diastolic CBFV Right (cm/s) -0.4 -3.8 -2.3 -6.1 0.349 0.6 -4.8 0.503 -2.2 -8.2 0.318 0.386 
Change Diastolic CBFV Left (cm/s) -0.7 -3.7 -1.0 -6.3 0.686 -0.4 -7.3 0.520 -0.2 -11 0.787 0.803 
Change Mean Diastolic CBFV (cm/s) -0.6 -2.9 -1.7 -5.2 0.450* -2.7 -4.9 0.108* -0.5 -6.2 0.899* 0.455* 
Change SBP (mmHg) -7.1 -15.8 -17.6 -26.4 0.151* -0.6 -21.2 0.272* -12.8 -30.2 0.435* 0.164* 
Change DBP (mmHg) 0.6 -13.4 -2.4 -14.1 0.646 -1.1 -15.8 0.688 -4.1 -19 0.404 0.629 
Change MAP (mmHg) -2.4 -14 -7.9 -16.7 0.266* -0.7 -15.5 0.730* -7.2 -20.1 0.364* 0.462* 
Change Heart Rate (bpm) 2.6 -4.8 3.9 -7.8 0.626 -3.2 -4.4 0.001 3.9 -10.4 0.916 0.004 
Change tCO2 (mmHg) -5.6 -14.6 -14.3 -23.1 0.183 -3.3 -13.1 0.915 -7.3 -25.6 0.751 0.537 
Table 43 Differences between pre-HUT and 1 minute HUT (Negative values indicate a fall from baseline, CBFV1=mean of systolic and diastolic CBFV for that side, Mean CBFV2=mean of 
both sides calculated by substitution if only one MCA available; Mann Whitney U or T-test to compare each group with the Control, i.e. Asymptomatic No OH; Kruskal-Wallis Test or 
ANOVA to examine for variances across groups) 
  
  
2
9
9
 
 
Asymptomatic 
No OH (22) 
Symptomatic No 
OH (18) 
Mann 
Whitney 
U Test 
or T-
Test* 
 (p-value) 
Asymptomatic 
OH (19) 
Mann 
Whitney 
U Test or 
T-Test* 
 (p-value) 
Symptomatic 
OH (23) 
Mann 
Whitney 
U Test 
or T-
Test* 
 (p-value) 
Kruskal-
Wallis 
Test or 
ANOVA* 
(p-value) 
Mean  SD Mean  SD Mean  SD Mean SD 
Change CBFV
1
 Right (cm/s) -1.7 -5.9 -6 -10.9 0.053 7.9 -8.7 <0.001 -0.5 -8.5 0.916 <0.001 
Change CBFV
1
 Left (cm/s) -4.4 -7.4 -6.5 -10.7 0.460 6.7 -7.8 <0.001 -4 -9.4 0.991 <0.001 
Change Mean CBFV
2
 (cm/s) -3.4 -5.1 -5.8 -9.3 0.311* -7.7 -7.2 0.034* -2.3 -7.5 0.593* <0.001 
Change Systolic CBFV Right (cm/s) -2.1 -8 -7.8 -15.4 0.094 11.5 -12.9 <0.001 1.9 -15 0.630 <0.001 
Change Systolic CBFV Left (cm/s) -3 -12 -8.9 -14 0.223 7.3 -16.3 <0.001 -2.7 -10.9 0.991 <0.001 
Change Mean Systolic CBFV (cm/s) -3 -7.2 -7.3 -12.4 0.181* -11.5 -11.1 0.006* -0.5 -10.1 0.362* 0.015 
Change Diastolic CBFV Right (cm/s) 0 -4.2 -3.4 -7.3 0.043 3.5 -5 0.057 0.3 -5.8 0.391 0.004 
Change Diastolic CBFV Left (cm/s) -3.3 -8.6 -4 -8.8 0.477 1.8 -8.2 0.047 -2.6 -9.9 0.565 0.015 
Change Mean Diastolic CBFV (cm/s) -1.8 -5 -3.6 -6.9 0.371* -3.6 -4.2 0.233* -1.1 -6.5 0.702* 0.315 
Change SBP (mmHg) -15.7 -19.6 -20.7 -25.4 0.493* 16.4 -24.4 <0.001* -20.7 -25.8 0.477* <0.001 
Change DBP (mmHg) -1.4 -10.7 -4.2 -11 0.426 0.2 -17.6 0.270 -6.9 -12.1 0.254 0.174 
Change MAP (mmHg) -6.7 -12 -9.7 -14.9 0.443 6.4 -17.7 0.003 -12.6 -15.5 0.296 0.001 
Change Heart Rate (bpm) 8.5 -6.5 6.4 -9.7 0.282 -8.2 -6.6 <0.001 5.6 -5.7 0.148 <0.001 
Change tCO2 (mmHg) -15.8 -26.1 -17 -18.8 0.606 10.3 -18.3 0.002 -14.8 -18.3 0.787 0.001 
Table 44 Differences between pre-HUT and 3 minutes HUT (Negative values indicate a fall from baseline, CBFV1=mean of systolic and diastolic CBFV for that side, Mean CBFV2=mean of 
both sides calculated by substitution if only one MCA available; Mann Whitney U or T-test to compare each group with the Control, i.e. Asymptomatic No OH; Kruskal-Wallis Test or 
ANOVA to examine for variances across groups) 
  
  
3
0
0
 
 
 
Asymptomatic 
No OH (22) 
Symptomatic No 
OH (18) 
Mann 
Whitney 
U Test or 
T-Test* 
 (p-value) 
Asymptomatic 
OH (19) 
Mann 
Whitney 
U Test or 
T-Test* 
 (p-value) 
Symptomatic 
OH (23) 
Mann 
Whitney 
U Test or 
T-Test* 
 (p-value) 
Kruskal-
Wallis 
Test or 
ANOVA* 
(p-value) 
Mean  SD Mean  SD Mean  SD Mean SD 
Change CBFV
1
 Right (cm/s) -5.7 -8.2 -4.2 -12.5 0.659* -9.5 -9.5 0.181* 1.9 -9.5 0.006* 0.001 
Change CBFV
1
 Left (cm/s) -6.2 -11.3 -1.6 -17.6 0.330* -7.2 -10.0 0.754* 11.6 -11.9 <0.001* <0.001 
Change Mean CBFV
2
 (cm/s) -5.9 -8.9 -2.9 -11.9 0.368* -8.4 -6.0 0.325* 6.7 -7.8 <0.001* <0.001 
Change Systolic CBFV Right (cm/s) -6.8 -10.2 -5.5 -15.3 0.563 -11.1 -13.1 0.250 1.5 -15.3 0.008 0.010 
Change Systolic CBFV Left (cm/s) -11.4 -17.3 1.0 -22.6 0.075 -8.4 -16.1 0.937 12.7 -21.4 <0.001 <0.001 
Change Mean Systolic CBFV (cm/s) -9.1 -10.8 -2.3 -11.8 0.064* -9.8 -8.5 0.835* 7.1 -15.3 <0.001* <0.001 
Change Diastolic CBFV Right (cm/s) -2.9 -6.6 -1.9 -8.9 0.737 -4.8 -5.8 0.129 1.1 -7.1 0.097 0.032 
Change Diastolic CBFV Left (cm/s) -5.9 -11.9 1.2 -15.8 0.427 -4 -6.6 0.676 6.9 -9.4 <0.001 <0.001 
Change Mean Diastolic CBFV (cm/s) -4.4 -7.7 -0.3 -9.9 0.153* -4.4 -4.5 0.995* 4 -5.5 <0.001* <0.001 
Change SBP (mmHg) -14.2 -24.3 -3.6 -34.3 0.263* -17.9 -29.5 0.656* 6.8 -28.6 0.011* 0.027 
Change DBP (mmHg) -2.9 -12.8 -2.7 -14.9 0.959* -4.3 -14.5 0.748* 0.7 -13.6 0.369* 0.711 
Change MAP (mmHg) -6.8 -16.2 -3.6 -18.2 0.555* -9.3 -16.8 0.634* 5.3 -16.7 0.018* 0.040 
Change Heart Rate (bpm) 11.4 -6.9 -4.2 -13.2 <0.001* 7.4 -9.2 0.117* -9 -8.3 <0.001* <0.001 
Change tCO2 (mmHg) -2.8 -65.9 6.1 -77.1 0.476 -1.5 -52.1 0.601 15.3 -38.2 0.084 0.184 
Table 45 Differences between pre-HUT and prior to end of HUT (Negative values indicate a fall from baseline, CBFV1=mean of systolic and diastolic CBFV for that side, Mean CBFV2=mean 
of both sides calculated by substitution if only one MCA available; Mann Whitney U or T-test to compare each group with the Control, i.e. Asymptomatic No OH; Kruskal-Wallis Test or 
ANOVA to examine for variances across groups) 
 
  
  
3
0
1
 
 
 
Asymptomatic 
No OH (17) 
Symptomatic 
No OH (16) 
Mann 
Whitney 
U Test  
 (p-value) 
Asymptomatic 
OH (16) 
Mann 
Whitney 
U Test  
 (p-value) 
Symptomatic 
OH (21) 
Mann 
Whitney 
U Test  
 (p-value) 
Kruskal-
Wallis Test 
(p-value) Mean  SD Mean  SD Mean  SD Mean SD 
CBFV (cm/s) 45.4 0.6 47.6 0.5 <0.001 46.0 0.5 <0.001 39.3 0.4 <0.001 <0.001 
SD time sample 13.7 1.5 15.3 0.9 <0.001 12.5 0.4 <0.001 7.1 0.7 <0.001 <0.001 
MAP (mmHg) 92.2 0.7 95.5 0.8 <0.001 95.0 0.9 <0.001 97.5 0.7 <0.001 <0.001 
SD time sample 11.2 0.6 19.7 0.9 <0.001 11.9 0.9 <0.001 15.8 0.8 <0.001 <0.001 
tCO2 (mmHg) 115.1 0.8 123.1 1.5 <0.001 98.3 0.9 <0.001 120.1 1.1 <0.001 <0.001 
SD time sample 52.4 0.8 55.9 0.6 <0.001 66.6 0.8 <0.001 55.1 0.7 <0.001 <0.001 
ARI  5.2 0.2 3.2 0.1 <0.001 3.7 0.1 <0.001 4.8 0.3 <0.001 <0.001 
SD time sample 2.6 0.2 2.8 0.1 <0.001 3.4 0.1 <0.001 3.1 0.1 <0.001 <0.001 
Heart Rate (bpm) 65.7 0.8 64.5 1.2 <0.001 67.0 0.8 <0.001 70.2 0.9 <0.001 <0.001 
SD time sample 10.7 1.2 12.1 0.7 <0.001 10.3 0.6 <0.001 13.2 1.1 <0.001 <0.001 
 
Table 46 Continuous estimates of ARI Pre-HUT (Mean of left and right MCA; Mann Whitney U to compare each group with the Control, i.e. Asymptomatic No OH; Kruskal-Wallis Test to examine 
for variances across group ) 
 
  
  
3
0
2
 
 
Asymptomatic 
No OH (17) 
Symptomatic 
No OH (16) 
Mann 
Whitney U 
Test  
 (p-value) 
Asymptomatic 
OH (16) 
Mann 
Whitney 
U Test  
 (p-value) 
Symptomatic 
OH (21) 
Mann 
Whitney 
U Test  
 (p-value) 
Kruskal-
Wallis Test 
(p-value) Mean  SD Mean  SD Mean  SD Mean SD 
CBFV Right (cm/s) 46.9 0.7 47.7 0.5 <0.001 47.6 0.8 <0.001 38.0 0.4 <0.001 <0.001 
SD time sample 14.3 1.5 14.8 0.7 0.436 10.9 0.4 <0.001 6.2 0.8 <0.001 <0.001 
MAP (mmHg) 93.9 0.8 96.4 0.8 <0.001 96.3 1.1 <0.001 96.9 0.7 <0.001 <0.001 
SD time sample 13.7 1.0 19.7 0.9 <0.001 11.6 1.1 <0.001 16.7 0.9 <0.001 <0.001 
tCO2 (mmHg) 116.7 1.2 124.8 1.4 <0.001 100.9 1.3 <0.001 122.0 0.9 <0.001 <0.001 
SD time sample 56.4 0.7 56.4 0.6 0.674 67.3 1.1 <0.001 51.4 0.7 <0.001 <0.001 
ARI Right 4.4 0.2 3.6 0.1 <0.001 3.8 0.1 <0.001 4.8 0.3 <0.001 <0.001 
SD time sample 3.0 0.1 2.7 0.1 <0.001 3.4 0.1 <0.001 3.2 0.1 <0.001 <0.001 
Heart Rate (bpm) 64.7 0.7 64.6 1.4 0.292 67.5 0.9 <0.001 69.1 0.9 <0.001 <0.001 
SD time sample 10.5 1.1 12.1 1.0 <0.001 10.4 0.7 0.314 12.3 1.1 <0.001 <0.001 
 
Table 47 Continuous estimates of ARI Pre-HUT (Right MCA; Mann Whitney U to compare each group with the Control, i.e. Asymptomatic No OH; Kruskal-Wallis Test to examine for variances 
across group) 
  
  
3
0
3
 
 
 
Asymptomatic 
No OH (14) 
Symptomatic 
No OH (16) 
Mann 
Whitney U 
Test  
 (p-value) 
Asymptomatic 
OH (16) 
Mann 
Whitney 
U Test  
 (p-value) 
Symptomatic 
OH (14) 
Mann 
Whitney 
U Test  
 (p-value) 
Kruskal-
Wallis Test 
(p-value) Mean  SD Mean  SD Mean  SD Mean SD 
CBFV Left (cm/s) 43.9 0.8 47.4 0.7 <0.001 44.4 0.6 <0.001 40.5 0.6 <0.001 <0.001 
SD time sample 13.1 1.6 15.8 1.3 <0.001 14.0 0.5 0.032 8.0 0.8 <0.001 <0.001 
MAP (mmHg) 90.6 0.8 94.6 1.0 <0.001 93.8 1.0 <0.001 98.1 1.0 <0.001 <0.001 
SD time sample 8.7 0.8 19.7 1.1 <0.001 12.1 0.9 <0.001 14.9 1.1 <0.001 <0.001 
tCO2 (mmHg) 113.5 0.8 121.4 1.7 <0.001 95.8 1.2 <0.001 118.2 1.6 <0.001 <0.001 
SD time sample 48.3 1.0 55.4 0.7 <0.001 65.9 1.0 <0.001 58.8 0.8 <0.001 <0.001 
ARI Left 5.9 0.4 2.8 0.1 <0.001 3.7 0.2 <0.001 4.7 0.3 <0.001 <0.001 
SD time sample 2.1 0.2 2.9 0.1 <0.001 3.3 0.1 <0.001 3.0 0.1 <0.001 <0.001 
Heart Rate (bpm) 66.7 1.1 64.3 1.3 <0.001 66.5 1.1 0.083 71.2 1.4 <0.001 <0.001 
SD time sample 11.0 1.6 12.1 0.9 <0.001 10.2 0.9 0.004 14.2 1.2 <0.001 <0.001 
 
Table 48 Continuous estimates of ARI Pre-HUT (Left MCA; Mann Whitney U to compare each group with the Control, i.e. Asymptomatic No OH; Kruskal-Wallis Test to examine for variances 
across group) 
 
  
  
3
0
4
 
 
 
Asymptomatic 
No OH (17) 
Symptomatic 
No OH (16) 
Mann 
Whitney 
U Test  
 (p-value) 
Asymptomatic 
OH (16) 
Mann 
Whitney 
U Test  
 (p-value) 
Symptomatic 
OH (21) 
Mann 
Whitney 
U Test  
 (p-value) 
Kruskal-
Wallis Test 
(p-value) Mean  SD Mean  SD Mean  SD Mean SD 
CBFV (cm/s) 42.3 1.6 44.0 1.7 <0.001 42.1 1.5 0.287 37.7 1.9 <0.001 <0.001 
SD time sample 12.2 1.2 14.2 1.4 <0.001 11.1 0.9 <0.001 8.4 0.8 <0.001 <0.001 
MAP (mmHg) 16.1 1.2 20.4 3.2 <0.001 18.5 1.9 <0.001 22.0 1.1 <0.001 <0.001 
SD time sample 85.1 1.3 87.7 2.3 <0.001 90.4 2.0 <0.001 88.6 1.8 <0.001 <0.001 
tCO2 (mmHg) 105.2 4.5 109.5 6.9 <0.001 93.6 6.8 <0.001 110.2 4.5 <0.001 <0.001 
SD time sample 52.1 3.2 53.9 4.1 0.004 59.7 4.5 <0.001 55.5 1.6 <0.001 <0.001 
ARI  5.7 0.5 3.5 0.4 <0.001 4.2 0.4 <0.001 4.3 0.2 <0.001 <0.001 
SD time sample 2.9 0.2 3.2 0.4 <0.001 3.4 0.3 <0.001 3.2 0.2 <0.001 <0.001 
Heart Rate (bpm) 70.0 1.7 67.3 1.7 <0.001 70.2 1.3 0.571 73.7 2.2 <0.001 <0.001 
SD time sample 12.3 1.0 13.0 1.3 <0.001 11.2 0.8 <0.001 15.0 4.5 <0.001 <0.001 
 
Table 49 Continuous estimates of ARI HUT 1 minute (Mean of right and left MCA; Mann Whitney U to compare each group with the Control, i.e. Asymptomatic No OH; Kruskal-Wallis Test to 
examine for variances across group) 
  
  
3
0
5
 
 
 
Asymptomatic 
No OH (17) 
Symptomatic 
No OH (16) 
Mann 
Whitney 
U Test  
 (p-value) 
Asymptomatic 
OH (16) 
Mann 
Whitney 
U Test  
 (p-value) 
Symptomatic 
OH (21) 
Mann 
Whitney U 
Test  
 (p-value) 
Kruskal-
Wallis Test 
(p-value) Mean  SD Mean  SD Mean  SD Mean SD 
CBFV Right (cm/s) 43.2 2.3 44.7 2.0 <0.001 43.2 2.0 0.951 36.8 1.5 <0.001 <0.001 
SD time sample 13.1 1.6 13.0 1.1 0.651 10.8 1.0 <0.001 8.0 0.9 <0.001 <0.001 
MAP (mmHg) 93.4 3.8 92.1 3.6 <0.001 92.5 4.6 <0.001 91.8 4.2 0.009 0.001 
SD time sample 22.5 4.2 19.8 1.8 <0.001 18.5 5.1 <0.001 22.5 2.1 0.096 <0.001 
tCO2 (mmHg) 108.4 6.5 114.5 6.4 <0.001 92.5 6.5 <0.001 110.8 5.7 0.005 <0.001 
SD time sample 55.8 4.3 52.7 3.1 <0.001 63.2 6.4 <0.001 52.5 1.6 <0.001 <0.001 
ARI Right 5.6 0.6 3.6 0.4 <0.001 3.7 0.5 <0.001 4.1 0.3 <0.001 <0.001 
SD time sample 3.1 0.2 3.2 0.3 0.609 3.5 0.3 <0.001 3.2 0.2 0.001 <0.001 
Heart Rate (bpm) 68.4 2.8 67.3 2.0 0.001 70.5 2.1 <0.001 71.7 2.9 <0.001 <0.001 
SD time sample 12.0 1.1 13.2 1.6 <0.001 11.0 1.2 <0.001 15.2 9.1 <0.001 <0.001 
 
Table 50 Continuous estimates of ARI HUT 1 minute (Right MCA; Mann Whitney U to compare each group with the Control, i.e. Asymptomatic No OH; Kruskal-Wallis Test to examine for 
variances across group) 
 
 
 
 
  
3
0
6
 
 
Asymptomatic 
No OH (14) 
Symptomatic 
No OH (16) 
Mann 
Whitney 
U Test  
 (p-value) 
Asymptomatic 
OH (16) 
Mann 
Whitney 
U Test  
 (p-value) 
Symptomatic 
OH (14) 
Mann 
Whitney 
U Test  
 (p-value) 
Kruskal-
Wallis Test 
(p-value) Mean  SD Mean  SD Mean  SD Mean SD 
CBFV Left (cm/s) 43.0 2.2 44.0 1.3 0.001 39.4 1.8 <0.001 38.4 2.3 <0.001 <0.001 
SD time sample 11.5 1.6 16.6 1.3 <0.001 11.5 1.2 0.977 8.7 1.0 <0.001 <0.001 
MAP (mmHg) 88.5 4.0 88.4 3.0 0.970 88.8 4.2 0.943 94.0 3.2 <0.001 <0.001 
SD time sample 14.1 2.5 19.4 2.8 <0.001 19.3 5.2 <0.001 22.4 2.4 <0.001 <0.001 
tCO2 (mmHg) 105.9 7.0 108.9 6.3 0.011 87.4 6.6 <0.001 109.2 4.0 <0.001 <0.001 
SD time sample 48.1 4.6 50.5 3.2 0.002 61.5 5.8 <0.001 58.5 2.2 <0.001 <0.001 
ARI Left 5.4 0.4 3.5 0.7 <0.001 4.1 0.9 <0.001 4.4 0.4 <0.001 <0.001 
SD time sample 2.9 0.4 2.9 0.4 0.693 3.6 0.3 <0.001 3.2 0.2 <0.001 <0.001 
Heart Rate (bpm) 70.5 2.7 67.0 1.9 <0.001 69.9 2.1 0.089 75.9 2.2 <0.001 <0.001 
SD time sample 12.6 1.6 13.3 1.7 0.009 11.2 1.1 <0.001 14.7 1.3 <0.001 <0.001 
 
Table 51 Continuous estimates of ARI HUT 1 minute (Left MCA; Mann Whitney U to compare each group with the Control, i.e. Asymptomatic No OH; Kruskal-Wallis Test to examine for variances 
across group) 
 
  
  
3
0
7
 
 
Asymptomatic 
No OH (17) 
Symptomatic 
No OH (16) 
Mann 
Whitney 
U Test  
 (p-value) 
Asymptomatic 
OH (16) 
Mann 
Whitney 
U Test  
 (p-value) 
Symptomatic 
OH (21) 
Mann 
Whitney 
U Test  
 (p-value) 
Kruskal-
Wallis Test 
(p-value) Mean  SD Mean  SD Mean  SD Mean SD 
CBFV (cm/s) 41.3 1.0 41.6 1.1 0.009 40.5 0.7 <0.001 35.4 0.8 <0.001 <0.001 
SD time sample 11.0 1.3 14.0 1.4 <0.001 10.0 0.6 <0.001 8.3 0.7 <0.001 <0.001 
MAP (mmHg) 84.9 1.0 85.2 2.3 0.491 90.5 1.6 <0.001 85.3 1.1 0.055 <0.001 
SD time sample 15.0 1.2 20.9 2.2 <0.001 20.1 2.1 <0.001 20.4 0.8 <0.001 <0.001 
tCO2 (mmHg) 99.9 1.8 102.9 4.7 <0.001 88.8 2.9 <0.001 102.0 1.3 <0.001 <0.001 
SD time sample 47.2 1.6 49.8 2.7 <0.001 58.7 3.4 <0.001 53.4 1.1 <0.001 <0.001 
ARI  5.1 0.7 5.1 0.2 0.233 4.8 0.5 <0.001 4.8 0.4 <0.001 <0.001 
SD time sample 2.6 0.1 2.7 0.2 <0.001 2.8 0.3 <0.001 2.9 0.2 <0.001 <0.001 
Heart Rate (bpm) 75.1 1.3 69.8 1.6 <0.001 73.9 0.7 <0.001 76.2 1.2 <0.001 <0.001 
SD time sample 13.1 3.1 12.3 1.2 <0.001 11.2 0.8 <0.001 14.3 1.5 <0.001 <0.001 
 
Table 52 Continuous estimates of ARI HUT 2 minute (Mean of right and left MCA; Mann Whitney U to compare each group with the Control, i.e. Asymptomatic No OH; Kruskal-Wallis Test to 
examine for variances across group) 
  
  
3
0
8
 
 
 
Asymptomatic 
No OH (17) 
Symptomatic 
No OH (16) 
Mann 
Whitney 
U Test  
 (p-value) 
Asymptomatic 
OH (16) 
Mann 
Whitney 
U Test  
 (p-value) 
Symptomatic 
OH (21) 
Mann 
Whitney 
U Test  
 (p-value) 
Kruskal-
Wallis Test 
(p-value) Mean  SD Mean  SD Mean  SD Mean SD 
CBFV Right (cm/s) 41.8 1.0 42.0 1.0 0.194 42.1 0.8 0.047 35.2 0.7 <0.001 <0.001 
SD time sample 11.6 1.5 13.7 1.2 <0.001 9.4 0.7 <0.001 7.5 0.7 <0.001 <0.001 
MAP (mmHg) 84.7 1.5 86.0 3.2 0.142 92.2 1.3 <0.001 83.1 0.9 <0.001 <0.001 
SD time sample 17.4 1.8 20.7 2.9 <0.001 20.7 1.6 <0.001 21.8 1.1 <0.001 <0.001 
tCO2 (mmHg) 100.7 2.0 107.2 2.6 <0.001 89.7 1.4 <0.001 102.1 1.3 <0.001 <0.001 
SD time sample 50.8 1.4 49.3 0.7 <0.001 61.6 1.0 <0.001 51.5 1.2 <0.001 <0.001 
ARI Right 5.1 0.9 5.4 0.5 0.127 4.7 0.7 <0.001 4.9 0.5 0.029 <0.001 
SD time sample 2.7 0.3 2.4 0.3 <0.001 2.8 0.4 0.682 3.0 0.3 <0.001 <0.001 
Heart Rate (bpm) 73.8 1.7 69.5 1.5 <0.001 73.8 0.9 0.781 74.0 1.6 0.369 <0.001 
SD time sample 13.1 3.1 12.4 1.6 0.042 10.7 1.1 <0.001 14.5 2.6 <0.001 <0.001 
 
Table 53 Continuous estimates of ARI HUT 2 minute (Right MCA; Mann Whitney U to compare each group with the Control, i.e. Asymptomatic No OH; Kruskal-Wallis Test to examine for 
variances across group) 
  
  
3
0
9
 
 
Asymptomatic 
No OH (14) 
Symptomatic 
No OH (16) 
Mann 
Whitney 
U Test  
 (p-value) 
Asymptomatic 
OH (16) 
Mann 
Whitney 
U Test  
 (p-value) 
Symptomatic 
OH (14) 
Mann 
Whitney 
U Test  
 (p-value) 
Kruskal-
Wallis Test 
(p-value) Mean  SD Mean  SD Mean  SD Mean SD 
CBFV Left (cm/s) 40.5 1.0 42.5 1.1 <0.001 38.1 0.7 <0.001 35.5 1.0 <0.001 <0.001 
SD time sample 9.7 1.1 15.4 0.9 <0.001 11.0 0.4 <0.001 9.0 1.4 <0.001 <0.001 
MAP (mmHg) 85.0 1.2 82.8 1.9 0.003 90.1 1.1 <0.001 87.5 1.6 <0.001 <0.001 
SD time sample 12.1 2.3 21.3 2.9 <0.001 21.0 1.9 <0.001 19.0 0.8 <0.001 <0.001 
tCO2 (mmHg) 98.1 2.3 102.7 1.8 <0.001 85.1 1.2 <0.001 101.8 1.8 <0.001 <0.001 
SD time sample 42.1 1.6 47.5 1.1 <0.001 59.7 1.0 <0.001 55.2 1.2 <0.001 <0.001 
ARI Left 5.5 0.4 5.0 0.3 <0.001 4.8 0.4 <0.001 4.6 0.6 <0.001 <0.001 
SD time sample 2.4 0.2 2.9 0.2 <0.001 3.1 0.2 <0.001 2.9 0.2 <0.001 <0.001 
Heart Rate (bpm) 76.3 1.4 69.2 1.6 <0.001 73.6 0.9 <0.001 78.4 1.4 <0.001 <0.001 
SD time sample 12.9 1.1 12.5 1.5 <0.001 11.3 1.0 <0.001 14.2 1.6 <0.001 <0.001 
 
Table 54 Continuous estimates of ARI HUT 2 minute (Left MCA; Mann Whitney U to compare each group with the Control, i.e. Asymptomatic No OH; Kruskal-Wallis Test to examine for variances 
across group) 
 
 
  
  
3
1
0
 
 
Asymptomatic 
No OH (16) 
Symptomatic 
No OH (11) 
Mann 
Whitney 
U Test  
 (p-value) 
Asymptomatic 
OH (14) 
Mann 
Whitney 
U Test  
 (p-value) 
Symptomatic 
OH (18) 
Mann 
Whitney 
U Test  
 (p-value) 
Kruskal-
Wallis Test 
(p-value) Mean  SD Mean  SD Mean  SD Mean SD 
CBFV (cm/s) 38.2 0.7 36.3 0.8 <0.001 38.2 0.9 0.618 34.4 1.9 <0.001 <0.001 
SD time sample 10.8 0.7 13.6 0.8 <0.001 10.5 0.7 0.040 9.1 0.6 <0.001 <0.001 
MAP (mmHg) 81.9 1.1 83.1 1.0 <0.001 82.0 1.0 0.289 87.8 3.1 <0.001 <0.001 
SD time sample 15.5 1.0 19.9 0.6 <0.001 24.2 2.6 <0.001 21.3 0.9 <0.001 <0.001 
tCO2 (mmHg) 97.9 1.1 97.5 0.9 0.041 102.5 2.0 <0.001 97.2 1.0 <0.001 <0.001 
SD time sample 48.9 1.6 51.3 0.6 <0.001 49.1 1.9 0.185 61.3 4.4 <0.001 <0.001 
ARI  4.6 0.3 3.4 0.2 <0.001 4.0 0.1 <0.001 5.0 0.3 <0.001 <0.001 
SD time sample 2.9 0.1 3.0 0.1 <0.001 2.6 0.1 <0.001 3.2 0.1 <0.001 <0.001 
Heart Rate (bpm) 77.3 0.9 75.1 0.6 <0.001 73.5 1.5 <0.001 76.4 2.5 0.458 <0.001 
SD time sample 15.3 1.1 15.1 1.0 0.317 12.5 1.2 <0.001 15.9 1.1 0.001 <0.001 
 
Table 55 Continuous estimates of ARI prior to end of HUT (Mean of right and left MCA; Mann Whitney U to compare each group with the Control, i.e. Asymptomatic No OH; Kruskal-Wallis Test 
to examine for variances across group)  
  
3
1
1
 
 
 
Asymptomatic 
No OH (17) 
Symptomatic 
No OH (16) 
Mann 
Whitney 
U Test  
 (p-value) 
Asymptomatic 
OH (12) 
Mann 
Whitney 
U Test  
 (p-value) 
Symptomatic 
OH (20) 
Mann 
Whitney 
U Test  
 (p-value) 
Kruskal-
Wallis Test 
(p-value) Mean  SD Mean  SD Mean  SD Mean SD 
CBFV Right (cm/s) 38.3 0.8 37.8 1.1 0.002 39.6 1.0 <0.001 35.0 0.5 <0.001 <0.001 
SD time sample 10.8 0.8 15.9 0.9 <0.001 10.3 1.3 0.003 8.5 0.9 <0.001 <0.001 
MAP (mmHg) 83.7 0.9 87.3 1.4 <0.001 84.2 1.5 0.013 87.4 1.2 <0.001 <0.001 
SD time sample 15.1 0.8 17.4 1.3 <0.001 28.6 1.2 <0.001 22.4 1.0 <0.001 <0.001 
tCO2 (mmHg) 97.9 1.0 99.9 1.8 <0.001 107.4 2.1 <0.001 90.9 1.0 <0.001 <0.001 
SD time sample 50.6 1.1 51.1 0.8 <0.001 49.9 1.5 <0.001 63.8 1.1 <0.001 <0.001 
ARI Right 4.8 0.1 2.7 0.3 <0.001 4.0 0.4 <0.001 5.2 0.2 <0.001 <0.001 
SD time sample 2.9 0.0 3.0 0.2 <0.001 2.4 0.3 <0.001 3.4 0.1 <0.001 <0.001 
Heart Rate (bpm) 77.1 0.8 77.2 0.9 0.260 71.9 1.3 <0.001 77.1 1.5 0.649 <0.001 
SD time sample 15.6 1.3 16.4 1.8 0.054 11.8 1.2 <0.001 16.2 1.6 0.019 <0.001 
 
Table 56 Continuous estimates of ARI prior to end of HUT (Right MCA; Mann Whitney U to compare each group with the Control, i.e. Asymptomatic No OH; Kruskal-Wallis Test to examine for 
variances across group) 
  
  
3
1
2
 
 
Asymptomatic 
No OH (16) 
Symptomatic 
No OH (11) 
Mann 
Whitney 
U Test  
 (p-value) 
Asymptomatic 
OH (14) 
Mann 
Whitney 
U Test  
 (p-value) 
Symptomatic 
OH (18) 
Mann 
Whitney 
U Test  
 (p-value) 
Kruskal-
Wallis Test 
(p-value) Mean  SD Mean  SD Mean  SD Mean SD 
CBFV Left (cm/s) 38.1 0.4 37.4 1.6 0.551 35.5 1.1 <0.001 33.8 3.9 <0.001 <0.001 
SD time sample 10.6 0.6 15.4 2.1 <0.001 10.9 0.6 <0.001 9.8 1.2 <0.001 <0.001 
MAP (mmHg) 79.6 1.7 82.3 1.0 0.002 79.0 1.0 0.001 88.2 6.3 <0.001 <0.001 
SD time sample 15.7 2.4 22.7 0.3 <0.001 22.9 1.4 <0.001 20.2 1.0 <0.001 <0.001 
tCO2 (mmHg) 99.3 2.0 95.7 0.4 0.001 95.3 1.4 <0.001 103.6 1.8 <0.001 <0.001 
SD time sample 45.3 1.7 53.1 0.6 <0.001 50.7 1.3 <0.001 58.8 8.0 <0.001 <0.001 
ARI Left 3.9 0.2 3.3 0.0 <0.001 4.1 0.2 <0.001 4.8 0.6 <0.001 <0.001 
SD time sample 2.8 0.2 3.3 0.0 <0.001 3.0 0.1 <0.001 3.0 0.2 <0.001 <0.001 
Heart Rate (bpm) 78.3 1.3 75.0 0.5 <0.001 72.8 1.0 <0.001 75.7 4.6 0.003 <0.001 
SD time sample 15.0 1.4 13.7 0.6 0.007 12.8 1.5 <0.001 15.5 1.8 0.261 <0.001 
 
Table 57 Continuous estimates of ARI prior to end of HUT (Left MCA; Mann Whitney U to compare each group with the Control, i.e. Asymptomatic No OH; Kruskal-Wallis Test to examine for 
variances across group) 
 
 
  
  
3
1
3
 
 
Asymptomatic 
No OH (16) 
Symptomatic 
No OH (11) 
Mann 
Whitney 
U Test  
 (p-value) 
Asymptomatic 
OH (14) 
Mann 
Whitney U 
Test  
 (p-value) 
Symptomatic 
OH (18) 
Mann 
Whitney 
U Test  
 (p-value) 
Kruskal-
Wallis Test 
(p-value) Mean  SD Mean  SD Mean  SD Mean SD 
CBFV (cm/s) 40.5 1.1 44.2 0.8 <0.001 41.5 1.6 0.001 38.8 1.5 <0.001 <0.001 
SD time sample 11.2 1.0 13.3 1.5 <0.001 10.7 1.3 <0.001 11.1 1.6 0.479 <0.001 
MAP (mmHg) 84.2 3.4 90.2 2.2 <0.001 84.8 2.9 0.051 90.7 6.2 <0.001 <0.001 
SD time sample 18.3 1.8 19.7 0.6 <0.001 18.3 3.1 0.321 21.9 2.2 <0.001 <0.001 
tCO2 (mmHg) 105.4 4.2 110.3 2.3 <0.001 108.5 3.7 <0.001 103.8 6.5 0.007 <0.001 
SD time sample 51.2 1.9 48.7 0.8 <0.001 45.4 1.5 <0.001 62.9 5.3 <0.001 <0.001 
ARI  4.9 0.2 5.0 0.3 0.269 4.2 0.4 <0.001 4.7 0.6 <0.001 <0.001 
SD time sample 2.7 0.1 2.7 0.2 0.685 2.9 0.1 <0.001 3.1 0.2 <0.001 <0.001 
Heart Rate (bpm) 69.9 2.7 63.6 0.9 <0.001 66.3 2.4 <0.001 72.6 4.1 <0.001 <0.001 
SD time sample 11.4 5.4 12.8 1.5 <0.001 10.8 5.1 0.006 14.7 1.2 <0.001 <0.001 
 
Table 58 Continuous estimates of ARI post-HUT 1 minute (Mean of right and left MCA; Mann Whitney U to compare each group with the Control, i.e. Asymptomatic No OH; Kruskal-Wallis Test 
to examine for variances across group) 
  
  
3
1
4
 
 
 
Asymptomatic 
No OH (17) 
Symptomatic 
No OH (16) 
Mann 
Whitney 
U Test  
 (p-value) 
Asymptomatic 
OH (12) 
Mann 
Whitney 
U Test  
 (p-value) 
Symptomatic 
OH (20) 
Mann 
Whitney 
U Test  
 (p-value) 
Kruskal-
Wallis Test 
(p-value) Mean  SD Mean  SD Mean  SD Mean SD 
CBFV Right (cm/s) 41.6 1.3 43.2 1.4 <0.001 43.3 1.2 <0.001 38.7 1.5 <0.001 <0.001 
SD time sample 12.1 1.1 13.9 2.6 <0.001 10.8 1.8 <0.001 10.2 2.6 <0.001 <0.001 
MAP (mmHg) 86.8 6.1 88.1 3.9 0.236 84.6 3.5 0.031 88.9 5.3 0.004 <0.001 
SD time sample 19.2 2.3 19.5 1.0 0.216 17.9 4.9 <0.001 23.3 3.3 <0.001 <0.001 
tCO2 (mmHg) 105.4 7.0 107.4 4.1 0.041 112.3 6.0 <0.001 99.2 11.0 <0.001 <0.001 
SD time sample 54.7 3.6 49.2 1.3 <0.001 43.2 2.0 <0.001 64.5 3.6 <0.001 <0.001 
ARI Right 5.0 0.3 4.8 0.5 0.221 3.8 0.6 <0.001 4.8 0.7 0.007 <0.001 
SD time sample 2.7 0.2 2.8 0.1 0.015 2.7 0.2 0.639 3.1 0.3 <0.001 <0.001 
Heart Rate (bpm) 69.8 3.7 66.1 1.6 <0.001 66.4 3.0 <0.001 73.6 3.3 <0.001 <0.001 
SD time sample 11.2 1.7 12.2 2.3 0.016 9.3 1.2 <0.001 15.1 1.5 <0.001 <0.001 
 
Table 59 Continuous estimates of ARI post-HUT 1 minute (Right MCA; Mann Whitney U to compare each group with the Control, i.e. Asymptomatic No OH; Kruskal-Wallis Test to examine for 
variances across group) 
  
  
3
1
5
 
 
Asymptomatic 
No OH (16) 
Symptomatic 
No OH (11) 
Mann 
Whitney 
U Test  
 (p-value) 
Asymptomatic 
OH (14) 
Mann 
Whitney 
U Test  
 (p-value) 
Symptomatic 
OH (18) 
Mann 
Whitney 
U Test  
 (p-value) 
Kruskal-
Wallis Test 
(p-value) Mean  SD Mean  SD Mean  SD Mean SD 
CBFV Left (cm/s) 40.3 1.3 44.4 0.9 <0.001 37.8 1.0 <0.001 38.2 2.3 <0.001 <0.001 
SD time sample 11.9 1.1 12.5 0.8 <0.001 8.8 1.1 <0.001 12.1 2.1 0.068 <0.001 
MAP (mmHg) 83.1 6.1 92.3 1.2 <0.001 82.6 3.3 0.766 92.7 8.5 <0.001 <0.001 
SD time sample 18.4 2.9 19.8 0.5 <0.001 17.0 2.0 <0.001 20.7 2.1 <0.001 <0.001 
tCO2 (mmHg) 108.2 7.3 113.2 1.2 <0.001 103.0 5.6 <0.001 108.0 4.0 0.622 <0.001 
SD time sample 48.9 3.0 48.4 0.9 0.561 47.6 1.8 0.002 63.0 8.5 <0.001 <0.001 
ARI Left 5.1 0.6 5.0 0.5 0.066 4.5 0.4 <0.001 4.6 0.5 <0.001 <0.001 
SD time sample 2.5 0.4 2.9 0.3 <0.001 3.0 0.2 <0.001 3.1 0.2 <0.001 <0.001 
Heart Rate (bpm) 70.2 3.3 61.1 1.7 <0.001 68.3 5.3 <0.001 72.8 4.7 0.001 <0.001 
SD time sample 10.9 1.5 13.6 1.9 <0.001 11.7 14.2 <0.001 14.6 1.3 <0.001 <0.001 
 
Table 60 Continuous estimates of ARI post-HUT 1 minute (Left MCA; Mann Whitney U to compare each group with the Control, i.e. Asymptomatic No OH; Kruskal-Wallis Test to examine for 
variances across group) 
 
 
  
  
3
1
6
 
 
 
Asymptomatic 
No OH (16) 
Symptomatic 
No OH (11) 
Mann 
Whitney 
U Test  
 (p-value)) 
Asymptomatic 
OH (14) 
Mann 
Whitney U 
Test  
 (p-value) 
Symptomatic 
OH (18) 
Mann 
Whitney 
U Test  
 (p-value) 
Kruskal-
Wallis Test 
(p-value) Mean  SD Mean  SD Mean  SD Mean SD 
CBFV (cm/s) 41.6 0.8 43.6 0.2 <0.001 41.2 1.1 <0.001 41.7 1.3 0.132 <0.001 
SD time sample 12.0 1.2 11.8 0.5 <0.001 10.5 1.0 <0.001 11.7 1.0 0.001 <0.001 
MAP (mmHg) 97.3 1.6 92.3 0.2 <0.001 90.4 1.2 <0.001 98.8 2.1 <0.001 <0.001 
SD time sample 16.9 1.1 19.6 0.4 <0.001 14.8 0.8 <0.001 19.5 1.1 <0.001 <0.001 
tCO2 (mmHg) 122.7 2.5 112.8 0.3 <0.001 118.1 2.0 <0.001 113.5 4.2 <0.001 <0.001 
SD time sample 56.1 0.9 49.4 0.4 0.025 45.4 0.6 <0.001 62.6 3.7 0.100 <0.001 
ARI  4.9 0.3 4.9 0.1 <0.001 4.1 0.4 <0.001 4.8 0.4 0.051 <0.001 
SD time sample 2.7 0.2 3.0 0.0 <0.001 2.8 0.2 0.613 2.8 0.1 <0.001 <0.001 
Heart Rate (bpm) 64.7 0.8 62.5 0.7 <0.001 62.2 0.9 <0.001 65.5 2.1 <0.001 <0.001 
SD time sample 11.3 0.7 13.0 1.4 0.523 10.5 1.0 <0.001 14.0 1.5 0.087 <0.001 
 
Table 61 Continuous estimates of ARI post-HUT 2 minute (Mean of right and left MCA; Mann Whitney U to compare each group with the Control, i.e. Asymptomatic No OH; Kruskal-Wallis Test 
to examine for variances across group)
  
3
1
7
 
 
 
 
Asymptomatic No 
OH (17) 
Symptomatic No 
OH (16) 
Mann 
Whitney 
U Test  
 (p-value) 
Asymptomati
c OH (12) 
Mann 
Whitney 
U Test  
 (p-value) 
Symptomatic OH 
(20) 
Mann 
Whitney U 
Test  
 (p-value) 
Kruskal-
Wallis Test 
(p-value) Mean  SD Mean  SD Mean  SD Mean SD 
CBFV Right (cm/s) 42.1 0.9 43.6 0.4 <0.001 42.6 0.7 <0.001 40.4 0.6 <0.001 <0.001 
SD time sample 12.0 1.3 11.0 1.0 0.013 12.4 1.4 0.024 10.3 1.7 <0.001 <0.001 
MAP (mmHg) 100.0 1.1 92.3 0.5 <0.001 91.6 1.8 <0.001 102.2 1.0 <0.001 <0.001 
SD time sample 17.4 1.3 19.4 0.6 <0.001 12.8 0.9 <0.001 19.9 1.2 <0.001 <0.001 
tCO2 (mmHg) 122.1 1.8 112.2 0.6 <0.001 123.7 2.8 <0.001 109.3 7.5 <0.001 <0.001 
SD time sample 59.9 1.1 50.6 0.5 <0.001 41.6 0.8 <0.001 72.0 3.2 <0.001 <0.001 
ARI Right 5.0 0.3 5.1 0.1 0.106 3.6 0.4 <0.001 4.9 0.5 0.552 <0.001 
SD time sample 2.7 0.2 2.7 0.1 0.279 2.7 0.3 0.044 2.8 0.1 0.001 <0.001 
Heart Rate (bpm) 64.6 1.0 64.6 1.0 0.890 61.0 1.4 <0.001 67.4 1.5 <0.001 <0.001 
SD time sample 11.2 1.3 11.4 2.2 0.945 10.0 1.0 <0.001 14.2 2.0 <0.001 <0.001 
 
Table 62 Continuous estimates of ARI post-HUT 2 minute (Right MCA; Mann Whitney U to compare each group with the Control, i.e. Asymptomatic No OH; Kruskal-Wallis Test to examine for 
variances across group) 
  
  
3
1
8
 
 
 
 
Asymptomatic 
No OH (16) 
Symptomatic 
No OH (11) 
Mann 
Whitney 
U Test  
 (p-value) 
Asymptomatic 
OH (14) 
Mann 
Whitney U 
Test  
 (p-value) 
Symptomatic 
OH (18) 
Mann 
Whitney 
U Test  
 (p-value) 
Kruskal-
Wallis Test 
(p-value) Mean  SD Mean  SD Mean  SD Mean SD 
CBFV Left (cm/s) 41.5 0.7 44.4 0.9 <0.001 39.0 0.7 <0.001 39.9 0.6 <0.001 <0.001 
SD time sample 12.5 1.2 12.5 0.8 0.264 7.9 0.7 <0.001 14.6 0.6 <0.001 <0.001 
MAP (mmHg) 95.4 1.3 92.3 1.2 <0.001 88.7 1.5 <0.001 101.4 1.4 <0.001 <0.001 
SD time sample 16.2 1.4 19.8 0.5 <0.001 16.4 1.2 0.351 17.8 1.3 <0.001 <0.001 
tCO2 (mmHg) 124.6 1.7 113.2 1.2 <0.001 113.0 2.4 <0.001 126.2 2.3 <0.001 <0.001 
SD time sample 52.5 1.1 48.4 0.9 <0.001 49.7 1.0 <0.001 61.9 1.3 <0.001 <0.001 
ARI Left 4.8 0.5 5.0 0.5 0.003 4.5 0.6 <0.001 4.4 0.6 0.002 <0.001 
SD time sample 2.6 0.4 2.9 0.3 <0.001 2.9 0.3 <0.001 2.9 0.3 <0.001 <0.001 
Heart Rate (bpm) 65.0 1.2 61.1 1.7 <0.001 63.9 1.3 <0.001 67.9 1.4 <0.001 <0.001 
SD time sample 11.7 0.9 13.6 1.9 <0.001 10.3 0.9 <0.001 15.1 2.0 <0.001 <0.001 
 
Table 63 Continuous estimates of ARI post-HUT 2 minute (Left MCA; Mann Whitney U to compare each group with the Control, i.e. Asymptomatic No OH; Kruskal-Wallis Test to examine for 
variances across group) 
 
 
  
  
3
1
9
 
 
Asymptomatic 
No OH (14) 
Symptomatic 
No OH (16) 
Mann 
Whitney 
U Test  
 (p-value) 
Asymptomatic 
OH (16) 
Mann 
Whitney 
U Test  
 (p-value) 
Symptomatic 
OH (14) 
Mann 
Whitney 
U Test  
 (p-value) 
Kruskal-
Wallis 
Test (p-
value) 
Mean  SD Mean  SD Mean  SD Mean SD 
Change in combined CBFV 
(cm/s) -3.1 -1.4 -3.6 -1.6 0.023 -3.8 -1.7 0.003 -1.6 -1.9 
<0.001 <0.001 
Change in SD time sample -1.5 -1.9 -1.1 -2.2 0.102 -1.3 -1.1 0.123 1.3 -1.1 <0.001 <0.001 
Change in MAP (mmHg) -7.2 -1.3 -7.8 -2.3 0.012 -4.6 -2.2 <0.001 -9 -2 <0.001 <0.001 
Change in SD time sample 4.8 -1.4 0.7 -3.3 <0.001 6.6 -1.8 <0.001 6.2 -1.6 <0.001 <0.001 
Change in tCO2 (mmHg) -10.2 -4.2 -13.9 -7.7 <0.001 -4 -8.2 <0.001 -10 -4.8 0.745 <0.001 
Change in SD time sample -0.4 -3.3 -1.7 -4.7 <0.001 -7.4 -4.1 <0.001 0.4 -2 0.071 <0.001 
Change in combined ARI  0.5 -0.5 0.3 -0.4 0.007 0.5 -0.5 0.846 -0.5 -0.3 <0.001 <0.001 
Change in SD time sample 0.4 -0.2 0.4 -0.4 0.892 0.1 -0.3 <0.001 0.1 -0.2 <0.001 <0.001 
Change in Heart Rate (bpm) 4.3 -1.8 2.9 -2.6 <0.001 3.1 -1.4 <0.001 3.5 -2.5 0.020 <0.001 
Change in SD time sample 1.8 -1.5 0.9 -1.2 <0.001 0.9 -1 <0.001 1.7 -4.6 0.010 <0.001 
 
Table 64 Changes in mean time varying estimates at 1 minute of HUT (Mann Whitney U to compare each group with the Control, i.e. Asymptomatic No OH; Kruskal-Wallis Test to examine for 
variances across group) 
  
  
3
2
0
 
 
Asymptomatic 
No OH (16) 
Symptomatic 
No OH (16) 
Mann 
Whitney 
U Test  
 (p-value)) 
Asymptomatic 
OH (16) 
Mann 
Whitney 
U Test  
 (p-value) 
Symptomatic 
OH (14) 
Mann 
Whitney 
U Test  
 (p-value) 
Kruskal-
Wallis 
Test (p-
value) 
Mean  SD Mean  SD Mean  SD Mean SD 
Change in combined CBFV 
(cm/s) -3.9 -1.1 -5.9 -1.3 <0.001 -5.6 -0.8 <0.001 -3.9 -0.7 
0.357 <0.001 
Change in SD time sample -2.6 -2.2 -1.3 -2 <0.001 -2.5 -0.6 0.266 1.2 -1.1 <0.001 <0.001 
Change in MAP (mmHg) -7.6 -1.5 -10.3 -2 <0.001 -4.6 -1.5 <0.001 -12.2 -1.4 <0.001 <0.001 
Change in SD time sample 3.7 -1.4 1.2 -1.8 <0.001 8.3 -1.6 <0.001 4.6 -1.3 <0.001 <0.001 
Change in tCO2 (mmHg) -13.5 -5.3 -20.3 -5.8 <0.001 -9.6 -3.5 <0.001 -18.1 -1.6 <0.001 <0.001 
Change in SD time sample -6.6 -4.7 -6.1 -2.6 0.001 -8 -2.9 <0.001 -1.8 -1.2 <0.001 <0.001 
Change in combined ARI  0 -1 1.9 -0.3 <0.001 1.1 -0.6 <0.001 0 -0.6 0.892 <0.001 
Change in SD time sample 0 -0.3 -0.1 -0.2 <0.001 -0.6 -0.3 <0.001 -0.2 -0.2 <0.001 <0.001 
Change in Heart Rate (bpm) 9.3 -1.6 5.3 -2.5 <0.001 6.8 -1 <0.001 6 -1.6 <0.001 <0.001 
Change in SD time sample 2.5 -3.2 0.2 -1.4 <0.001 0.9 -1 <0.001 1.1 -1.8 <0.001 <0.001 
 
Table 65 Changes in mean time varying estimates at 2 minutes of HUT (Mann Whitney U to compare each group with the Control, i.e. Asymptomatic No OH; Kruskal-Wallis Test to examine for 
variances across group) 
  
  
3
2
1
 
 
 
Asymptomatic 
No OH (17) 
Symptomatic 
No OH (16) 
Mann 
Whitney 
U Test  
 (p-value) 
Asymptomatic 
OH (12) 
Mann 
Whitney 
U Test  
 (p-value) 
Symptomatic 
OH (20) 
Mann 
Whitney 
U Test  
 (p-value) 
Kruskal-
Wallis 
Test (p-
value) 
Mean  SD Mean  SD Mean  SD Mean SD 
Change in combined CBFV 
(cm/s) -7.2 -0.7 -10.9 -0.8 <0.001 -8.3 -1.4 0.001 -7.7 -3.9 
<0.001 <0.001 
Change in SD time sample -2.4 -1.4 -0.9 -0.9 0.003 -2.6 -1.6 <0.001 -0.7 -4.6 <0.001 <0.001 
Change in MAP (mmHg) -11 -2.2 -11.7 -1.1 <0.001 -13.2 -1.1 <0.001 -9.1 -3.7 <0.001 <0.001 
Change in SD time sample 3.9 -1 -0.2 -1.3 <0.001 10.6 -3.2 <0.001 4.4 -2.3 <0.001 <0.001 
Change in tCO2 (mmHg) -12.8 -7.3 -24.4 -1.4 <0.001 -2.3 -11.4 <0.001 -24 -2.4 <0.001 <0.001 
Change in SD time sample -7.2 -6.7 -4.8 -0.8 0.692 -14.6 -6.2 <0.001 6.1 -4.5 <0.001 <0.001 
Change in combined ARI  -0.3 -0.6 0.1 -0.2 <0.001 0.4 -0.2 <0.001 0.7 -0.8 <0.001 <0.001 
Change in SD time sample 0.1 -0.4 0.1 -0.1 <0.001 -0.6 -0.2 <0.001 0.2 -0.2 <0.001 <0.001 
Change in Heart Rate (bpm) 11.4 -1.1 10.6 -1.1 <0.001 6.7 -1.6 <0.001 8.5 -3.3 <0.001 <0.001 
Change in SD time sample 4.6 -1.5 2.9 -1.1 <0.001 1.9 -1.8 <0.001 3.2 -1.4 <0.001 <0.001 
 
Table 66 Changes in mean time varying estimates pre-end of HUT (Mann Whitney U to compare each group with the Control, i.e. Asymptomatic No OH; Kruskal-Wallis Test to examine for 
variances across group)
  
3
2
2
 
 
 
 
Asymptomatic 
No OH (14) 
Symptomatic No 
OH (16) 
Mann 
Whitney 
U Test  
 (p-value) 
Asymptomatic OH 
(16) 
Mann 
Whitney 
U Test  
 (p-value) 
Symptomatic OH 
(14) 
Mann 
Whitney 
U Test  
 (p-value) 
Kruskal-
Wallis 
Test  
(p-value) 
% of 
Mean 
SD % of 
Mean 
SD % of 
Mean 
SD % of 
Mean 
SD 
Change in combined CBFV 
(cm/s) 
-6.8 -3.2 -7.5 -3.4 0.095 -8.3 -3.6 0.006 -4.2 -4.7 <0.001 <0.001 
Change in SD time sample -10.1 -13.7 -6.5 -13.9 0.054 -10.0 -8.9 0.419 20.1 -16.8 <0.001 <0.001 
Change in MAP (mmHg) -7.9 -1.3 -8.2 -2.4 0.101 -4.8 -2.3 <0.001 -9.2 -2.0 <0.001 <0.001 
Change in SD time sample 43.2 -14.6 3.7 -16.7 <0.001 55.7 -16.1 <0.001 40.0 -11.7 0.233 <0.001 
Change in tCO2 (mmHg) -8.9 -3.6 -11.2 -6.1 0.001 -4.0 -8.3 0.002 -8.3 -3.9 0.341 <0.001 
Change in SD time sample -0.8 -6.3 -3.0 -8.3 0.001 -11.1 -6.2 <0.001 0.7 -3.5 0.066 <0.001 
Change in combined ARI  10.4 -9.4 10.0 -13.5 0.690 13.3 -13.6 0.018 -9.8 -6.6 <0.001 <0.001 
Change in SD time sample 15.8 -7.1 14.4 -16.3 0.546 1.6 -9.0 <0.001 4.0 -6.0 <0.001 <0.001 
Change in Heart Rate 
(bpm) 
6.6 -2.7 4.5 -4.1 0.001 4.7 -2.1 <0.001 5.0 -3.6 0.003 <0.001 
Change in SD time sample 17.9 -15.4 7.5 -10.1 <0.001 9.3 -10.3 <0.001 13.6 -34.9 <0.001 <0.001 
 
Table 67 Percentage mean change from pre-HUT at 1 minute of HUT (Mann Whitney U to compare each group with the Control, i.e. Asymptomatic No OH; Kruskal-Wallis Test to examine for 
variances across group) 
  
  
3
2
3
 
 
 
 
 
Asymptomatic 
No OH (16) 
Symptomatic No 
OH (16) 
Mann 
Whitney 
U Test  
 (p-value) 
Asymptomatic OH 
(16) 
Mann 
Whitney 
U Test  
 (p-value) 
Symptomatic OH 
(14) 
Mann 
Whitney 
U Test  
 (p-value) 
Kruskal-
Wallis 
Test  
(p-value) 
% of 
Mean 
SD % of 
Mean 
SD % of 
Mean 
SD % of 
Mean 
SD 
Change in combined CBFV 
(cm/s) 
-8.7 -2.5 -12.5 -2.7 <0.001 -11.7 -2.1 <0.001 -9.9 -1.7 <0.001 <0.001 
Change in SD time sample -18.4 -16.1 -7.8 -12.8 <0.001 -19.1 -5.3 0.196 18.1 -16.5 <0.001 <0.001 
Change in MAP (mmHg) -8.0 -1.4 -10.8 -2.1 <0.001 -5.3 -2.2 <0.001 -12.6 -1.4 <0.001 <0.001 
Change in SD time sample 34.6 -12.4 5.9 -9.4 <0.001 64.3 -20.9 <0.001 29.4 -9.3 0.233 <0.001 
Change in tCO2 (mmHg) -13.1 -1.8 -16.4 -4.5 <0.001 -8.6 -4.7 <0.001 -15.1 -1.3 0.341 <0.001 
Change in SD time sample -9.9 -3.6 -10.9 -4.6 <0.001 -13.7 -6.8 0.100 -3.2 -2.2 0.066 <0.001 
Change in combined ARI  -3.9 -13.3 60.1 -11.4 <0.001 32.7 -18.4 <0.001 0.9 -13.3 <0.001 <0.001 
Change in SD time sample 2.5 -5.8 -3.1 -6.9 <0.001 -17.7 -9.1 <0.001 -5.3 -5.8 <0.001 <0.001 
Change in Heart Rate 
(bpm) 
14.4 -2.5 8.4 -4.0 <0.001 10.3 -1.8 <0.001 8.6 -2.4 0.003 <0.001 
Change in SD time sample 24.4 -28.2 2.1 -11.5 <0.001 11.0 -11.5 <0.001 8.8 -12.6 <0.001 <0.001 
Table 68 Percentage mean change from pre-HUT at 2 minutes of HUT (Mann Whitney U to compare each group with the Control, i.e. Asymptomatic No OH; Kruskal-Wallis Test to examine for 
variances across group) 
  
  
3
2
4
 
 
 
 
 
Asymptomatic 
No OH (16) 
Symptomatic No 
OH (16) 
Mann 
Whitney 
U Test  
 (p-value) 
Asymptomatic OH 
(16) 
Mann 
Whitney 
U Test  
 (p-value) 
Symptomatic OH 
(14) 
Mann 
Whitney 
U Test  
 (p-value) 
Kruskal-
Wallis 
Test  
(p-value) 
% of 
Mean 
SD % of 
Mean 
SD % of 
Mean 
SD % of 
Mean 
SD 
Change in combined CBFV 
(cm/s) -15.8 -1.7 -22.9 -1.8 
<0.001 
-17.8 -3.1 
<0.001 
-17.6 -8.0 
0.680 <0.001 
Change in SD time sample -17.7 -9.1 -5.9 -6.3 <0.001 -19.4 -13.4 0.730 3.8 -45.5 <0.001 <0.001 
Change in MAP (mmHg) -11.9 -2.4 -12.2 -1.1 0.025 -13.8 -1.2 <0.001 -9.5 -3.8 0.008 <0.001 
Change in SD time sample 34.3 -8.8 -1.0 -7.0 <0.001 64.6 -25.5 <0.001 32.5 -15.8 0.320 <0.001 
Change in tCO2 (mmHg) -11.2 -6.3 -20.0 -1.5 <0.001 -2.9 -11.3 <0.001 -22.4 -4.1 <0.001 <0.001 
Change in SD time sample -13.1 -11.7 -8.6 -1.5 0.594 -25.1 -11.6 <0.001 10.1 -7.6 <0.001 <0.001 
Change in combined ARI  -5.0 -12.5 2.0 -7.0 0.001 10.6 -5.1 <0.001 17.3 -21.0 <0.001 <0.001 
Change in SD time sample 3.9 -14.9 5.3 -4.0 0.009 -20.6 -8.3 <0.001 6.4 -5.7 0.183 <0.001 
Change in Heart Rate 
(bpm) 17.3 -1.7 16.2 -1.7 
0.001 
10.3 -2.4 
<0.001 
12.4 -4.9 
<0.001 <0.001 
Change in SD time sample 44.2 -15.5 24.4 -9.0 <0.001 15.8 -15.4 <0.001 28.6 -12.8 <0.001 <0.001 
 
Table 69 Percentage mean change from pre-HUT at end of HUT (Mann Whitney U to compare each group with the Control, i.e. Asymptomatic No OH; Kruskal-Wallis Test to examine for 
variances across group) 
 
  
  
3
2
5
 
 
 
 
 
Asymptomatic No OH (17) Mann 
Whitney 
U Test  
 (p-value) 
Symptomatic 
HUT (n=3) 
Asymptomatic 
HUT (n=14) 
Mean SD Mean SD 
Mean combined CBFV 
(cm/s) 
42.3 1.2 46.1 0.8 
<0.001 
SD time sample 13.8 1.3 13.6 1.7 <0.001 
MAP (mmHg) 95 1.8 89.4 1.2 <0.001 
SD time sample 4.8 2.5 8.9 0.9 <0.001 
tCO2 (mmHg) 87.5 1.8 120.6 1.0 <0.001 
SD time sample 60.0 1.7 41.8 1.2 <0.001 
Mean combined ARI  5.5 0.8 5.0 0.1 <0.001 
SD time sample 2.1 0.5 2.6 0.1 <0.001 
Heart Rate (bpm) 68.4 3.8 66.3 1.3 <0.001 
SD time sample 4.8 2.9 11.8 1.7 <0.001 
Table 70 Pre-HUT values for those who were symptomatic versus asymptomatic during HUT within Asymptomatic No OH group 
 
 
 
  
  
3
2
6
 
 
 
 
 
Asymptomatic No OH (17) Mann 
Whitney 
U Test  
 (p-value) 
Symptomatic 
HUT (n=3) 
Asymptomatic 
HUT (n=14) 
Mean SD Mean SD 
Change in mean combined 
CBFV (cm/s) 
-6.3 3.3 -7.6 0.9 
<0.001 
Change in SD time sample -5.2 2.4 -3.2 1.8 <0.001 
Change in MAP (mmHg) -14.7 4.1 -9.8 1.5 <0.001 
Change in SD time sample 20.8 4.6 2.0 1.3 <0.001 
Change in tCO2 (mmHg) -2.9 2.2 -15.7 1.8 <0.001 
Change in SD time sample 4.0 2.1 -0.8 1.9 <0.001 
Change in mean combined 
ARI  
-2.6 1.3 -0.5 0.3 
<0.001 
Change in SD time sample -0.5 0.5 0.4 0.1 <0.001 
Change in Heart Rate 
(bpm) 
4.8 5.0 13.3 1.6 
<0.001 
Change in SD time sample 10.8 3.0 4.9 2.2 <0.001 
Table 71 Comparison of mean changes between pre-HUT and pre-End HUT of those who were symptomatic versus asymptomatic during HUT within Asymptomatic No OH group 
  
  
3
2
7
 
 
 
 
 
Symptomatic No OH (16) Mann 
Whitney 
U Test  
 (p-value) 
Symptomatic 
HUT(n=6) 
Asymptomatic 
HUT(n=10) 
Mean SD Mean SD 
Mean combined CBFV 
(cm/s) 
59.5 1.4 41.9 0.4 
<0.001 
SD time sample 19.5 1.5 8.4 0.3 <0.001 
MAP (mmHg) 88.0 1.7 95.1 1.2 <0.001 
SD time sample 19.1 1.6 20.1 0.7 <0.001 
tCO2 (mmHg) 99.6 3.1 129.6 1.2 <0.001 
SD time sample 51.0 1.2 52.5 0.7 <0.001 
Mean combined ARI  3.6 0.0 3.0 0.2 <0.001 
SD time sample 3.3 0.2 2.4 0.0 <0.001 
Heart Rate (bpm) 68.7 2.4 62.5 1.1 <0.001 
SD time sample 12.0 0.6 11.0 1.3 <0.001 
Table 72 Pre-HUT values for those who were symptomatic versus asymptomatic during HUT within Symptomatic No OH group 
 
 
 
  
  
3
2
8
 
 
 
 
 
Symptomatic No OH (16) Mann 
Whitney 
U Test  
 (p-value) 
Symptomatic 
HUT(n=6) 
Asymptomatic 
HUT(n=10) 
Mean SD Mean SD 
Change in mean combined 
CBFV (cm/s) 
-14.7 1.5 -7.6 0.9 
<0.001 
Change in SD time sample 3.2 1.1 -3.2 1.8 <0.001 
Change in MAP (mmHg) -28.7 2.5 -6.3 3.1 <0.001 
Change in SD time sample 19.0 2.6 5.8 3.1 <0.001 
Change in tCO2 (mmHg) -25.2 3.7 28.8 4.4 <0.001 
Change in SD time sample -15.0 2.4 -14.4 3.1 0.196 
Change in mean combined 
ARI  
-0.4 0.1 -0.5 0.3 
<0.001 
Change in SD time sample -1.2 0.1 0.4 0.1 <0.001 
Change in Heart Rate 
(bpm) 
-1.3 2.5 8.6 2.4 
<0.001 
Change in SD time sample 3.0 1.2 2.0 2.9 <0.001 
Table 73 Comparison of mean changes between pre-HUT and pre-End HUT of those who were symptomatic versus asymptomatic during HUT within Symptomatic OH group 
  
  
3
2
9
 
 
 
 
Asymptomatic OH (16) Mann 
Whitney 
U Test  
 (p-value) 
Symptomatic 
HUT(n=5) 
Asymptomatic 
HUT(n=11) 
Mean SD Mean SD 
Mean combined CBFV 
(cm/s) 
51.3 0.9 46.1 0.8 
<0.001 
SD time sample 8.8 0.6 13.6 1.7 <0.001 
MAP (mmHg) 100.3 1.0 89.4 1.2 <0.001 
SD time sample 10.7 1.6 8.9 0.9 <0.001 
tCO2 (mmHg) 130.1 1.6 120.6 1.0 <0.001 
SD time sample 58.3 1.2 41.8 1.2 <0.001 
Mean combined ARI  4.2 0.2 5.0 0.1 <0.001 
SD time sample 3.4 0.1 2.6 0.1 <0.001 
Heart Rate (bpm) 68.3 0.9 66.3 1.3 <0.001 
SD time sample 10.2 0.6 11.8 1.7 <0.001 
Table 74 Pre-HUT values for those who were symptomatic versus asymptomatic during HUT within Asymptomatic OH group 
 
 
 
 
  
  
3
3
0
 
 
 
 
 
Asymptomatic OH (16) Mann 
Whitney 
U Test  
 (p-value) 
Symptomatic 
HUT(n=5) 
Asymptomatic 
HUT(n=11) 
Mean SD Mean SD 
Change in mean combined 
CBFV (cm/s) 
-7.4 2.7 -8.8 0.6 
<0.001 
Change in SD time sample -10.4 2.2 3.0 0.6 <0.001 
Change in MAP (mmHg) -12.1 8.3 -4.3 2.0 <0.001 
Change in SD time sample -13.6 4.8 -2.0 2.4 <0.001 
Change in tCO2 (mmHg) 2.4 12.0 -26.7 2.0 <0.001 
Change in SD time sample -44.5 4.4 5.1 1.4 <0.001 
Change in mean combined 
ARI  
-1.1 0.4 1.1 0.6 
<0.001 
Change in SD time sample -1.0 0.3 0.4 0.2 <0.001 
Change in Heart Rate 
(bpm) 
8.9 3.7 14.0 1.7 
<0.001 
Change in SD time sample -7.5 2.9 7.0 2.7 <0.001 
Table 75 Comparison of mean changes between pre-HUT and pre-End HUT of those who were symptomatic versus asymptomatic during HUT within Symptomatic No OH group 
  
  
3
3
1
 
 
 
 
 
Symptomatic OH (20) Mann 
Whitney 
U Test  
 (p-value) 
Symptomatic 
HUT (n=9) 
Asymptomatic 
HUT (n=11) 
Mean SD Mean SD 
Mean combined CBFV 
(cm/s) 
39.8 0.6 38.9 0.6 
<0.001 
SD time sample 8.1 0.9 6.1 0.6 <0.001 
MAP (mmHg) 91.8 1.9 97.9 1.3 <0.001 
SD time sample 11.4 2.1 11.8 0.6 <0.001 
tCO2 (mmHg) 111.7 2.1 115.9 1.8 <0.001 
SD time sample 55.0 1.2 61.6 1.0 <0.001 
Mean combined ARI  4.7 0.3 4.6 0.4 <0.001 
SD time sample 3.2 0.1 2.9 0.1 <0.001 
Heart Rate (bpm) 68.4 2.0 72.1 1.8 <0.001 
SD time sample 12.8 0.6 15.3 1.9 <0.001 
Table 76 Pre-HUT values for those who were symptomatic versus asymptomatic during HUT within Symptomatic OH group 
 
 
 
  
  
3
3
2
 
 
 
 
 
Symptomatic OH (20) Mann 
Whitney 
U Test  
 (p-value) 
Symptomatic 
HUT (n=9) 
Asymptomatic 
HUT (n=11) 
Mean SD Mean SD 
Change in mean combined 
CBFV (cm/s) 
-5.7 0.8 -4.6 0.9 
<0.001 
Change in SD time sample 1.5 0.8 0.5 0.7 <0.001 
Change in MAP (mmHg) -4.7 2.5 -15.2 2.6 <0.001 
Change in SD time sample 10.5 2.1 5.9 1.8 <0.001 
Change in tCO2 (mmHg) 6.5 3.2 -23.6 2.1 <0.001 
Change in SD time sample -2.5 1.5 -9.9 2.5 <0.001 
Change in mean combined 
ARI  
-0.5 0.5 1.6 0.4 
<0.001 
Change in SD time sample -0.5 0.2 0.3 0.1 <0.001 
Change in Heart Rate 
(bpm) 
8.2 3.6 9.0 1.8 
<0.001 
Change in SD time sample 2.7 2.2 0.1 2.3 <0.001 
Table 77 Comparison of mean changes between pre-HUT and pre-End HUT of those who were symptomatic versus asymptomatic during HUT within Symptomatic OH group 
  
  
3
3
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Table 78 Baseline ARI (Tiecks model) Right Middle Cerebral Artery 
 
 
  
 
Right side 
No PPH  
- placebo 
No PPH  
- glucose 
Wilcoxon 
Signed 
Ranks  
(p-value) 
PPH  
- placebo 
PPH  
- glucose 
Wilcoxon 
Signed 
Ranks  
(p-value) 
Mann Whitney U 
(p-value) 
Mean  SD Mean  SD Mean SD Mean  SD Placebo Glucose 
ARI 5.32 0.97 4.78 1.59 0.064 4.98 1.51 5.11 1.55 0.328 0.821 0.361 
Coherence Low Frequency (<0.07Hz) 0.44 0.17 0.34 0.11 0.152 0.31 0.15 0.30 0.15 0.657 0.041 0.239 
Gain Low Frequency (<0.07Hz) 0.44 0.19 0.38 0.07 0.507 0.34 0.14 0.34 0.13 0.859 0.201 0.381 
Phase Low Frequency (<0.07Hz) (radians) 0.70 0.29 0.55 0.36 0.133 0.65 0.29 0.65 0.28 0.929 0.683 0.491 
Step Response Recovery (%) 76.1 13.8 68.4 25.6 0.221 72.8 21.3 80.9 38.4 0.594 0.586 0.468 
  
3
3
4
 
 
 
 
 
 
Table 79 Baseline ARI (Tiecks model) Left Middle Cerebral Artery 
 
  
 
Left side 
No PPH - 
placebo 
No PPH - 
glucose 
Wilcoxon 
Signed 
Ranks  
(p-value) 
PPH - 
placebo 
PPH - glucose Wilcoxon 
Signed 
Ranks  
(p-value) 
Mann Whitney U 
(p-value) 
Mean  SD Mean  SD Mean SD Mean  SD Placebo Glucose 
ARI 4.67 1.60 4.62 2.19 0.777 5.43 2.02 5.34 1.56 0.836 0.154 0.422 
Coherence Low Frequency (<0.07Hz) 0.41 0.18 0.33 0.14 0.215 0.34 0.18 0.30 0.13 0.796 0.135 0.567 
Gain Low Frequency (<0.07Hz) 0.46 0.18 0.38 0.13 0.267 0.40 0.29 0.30 0.16 0.469 0.175 0.142 
Phase Low Frequency (<0.07Hz) (radians) 0.49 0.55 0.55 0.34 0.349 0.67 0.59 0.46 0.35 0.255 0.347 0.403 
Step Response Recovery (%) 70.1 21.2 70.9 40.4 0.647 101.9 57.1 84.5 37.6 0.642 0.036 0.317 
  
3
3
5
 
 
No PPH – 
placebo 
(n=17) 
No PPH – 
glucose (n=17) 
Wilcoxon 
Signed 
Ranks Test  
(p-values) 
PPH – placebo 
(n=12) 
PPH – glucose 
(n=12) 
Wilcoxon 
Signed 
Ranks Test  
(p-values) 
Mann Whitney U 
test (p-value) 
Mean  SD Mean  SD Mean SD Mean  SD Placebo Glucose 
CBFV Right (cm/s) 43.7 8.8 46.4 6.6 0.287 43.3 11.4 42.1 7.1 0.695 0.616 0.166 
CBFV Left (cm/s) 43.4 8.2 45.1 8.4 0.523 44.7 9.1 45.1 9.3 0.875 0.499 0.811 
Mean CBFV (cm/s) 43.5 7.1 45.8 6.5 0.795 44.0 9.0 43.6 7.0 1.000 0.664 0.891 
Systolic CBFV Right (cm/s) 68.5 11.1 72.5 11.1 0.332 68.3 17.4 62.3 10.7 0.272 0.777 0.030 
Systolic CBFV Left (cm/s) 66.9 12.9 69.7 13.5 0.619 64.2 17.2 68.0 16.9 0.754 0.616 1.000 
Mean Systolic CBFV (cm/s) 67.7 9.8 71.1 10.9 0.723 66.3 11.3 65.2 12.2 0.735 0.901 0.784 
Diastolic CBFV Right (cm/s) 27.4 6.5 28.7 4.4 0.227 26.8 9.1 27.3 4.6 0.583 0.499 0.471 
Diastolic CBFV Left (cm/s) 27.3 5.6 28.7 5.8 0.554 24.8 10.2 28.7 5.1 0.272 0.679 0.586 
Mean Diastolic CBFV (cm/s) 27.3 5.4 28.7 4.7 0.723 25.8 7.6 28.0 4.2 0.735 0.757 0.471 
SBP (mmHg) 134.1 16.0 138.2 20.3 0.868 152.2 24.2 139.9 23.5 0.347 0.034 0.744 
DBP (mmHg) 71.8 14.6 73.2 10.5 0.831 81.0 21.3 79.6 17.2 0.638 0.283 0.499 
MAP (mmHg) 92.6 13.0 94.9 11.5 0.723 106.4 20.1 102.4 19.1 0.388 0.053 0.394 
Heart Rate (bpm) 66.2 5.5 61.7 5.3 0.025 62.5 4.4 63.4 5.3 0.638 0.073 0.370 
tCO2 (mmHg) 48.2 63.5 47.3 63.6 0.981 73.4 70.4 101.0 64.3 0.239 0.527 0.053 
Table 80 Group Measurements pre-HUT (i.e.1 minute prior to HUT; For this time point the Wilcoxon Signed Ranks used to compare placebo and glucose phase within each group, Mann-Whitney 
used to compare No PPH and PPH Group for each phase, Mean CBFV =combined right and left CBFV)  
  
  
3
3
6
 
 
 
No PPH – 
placebo (n=17) 
No PPH – 
glucose (n=17) 
Wilcoxon 
Signed 
Ranks Test  
(p-values) 
PPH – 
placebo 
(n=12) 
PPH – 
glucose 
(n=12) 
Wilcoxon 
Signed 
Ranks Test  
(p-values) 
Mann Whitney U 
test  
(p-value) 
Mean  SD Mean  SD Mean SD Mean  SD Placebo Glucose 
CBFV Right (cm/s) 38.6 9.5 41.0 8.9 0.687 40.0 11.9 38.9 9.3 0.875 0.879 0.616 
CBFV Left (cm/s) 39.1 8.5 42.2 8.6 0.407 41.3 7.4 44.8 12.3 0.347 0.303 0.499 
Mean CBFV (cm/s) 38.8 7.8 41.6 8.3 0.554 40.7 8.6 41.9 8.7 0.128 0.494 0.584 
Systolic CBFV Right (cm/s) 59.3 15.0 62.6 12.3 0.492 59.7 15.2 58.8 14.6 0.754 0.948 0.444 
Systolic CBFV Left (cm/s) 59.9 11.7 64.1 11.5 0.246 62.0 10.9 67.2 20.5 0.480 0.556 0.711 
Mean Systolic CBFV (cm/s) 59.6 11.7 63.3 10.9 0.687 60.9 11.4 63.0 14.8 0.237 0.534 0.632 
Diastolic CBFV Right (cm/s) 25.2 7.4 27.1 6.6 0.586 26.8 9.7 25.8 6.0 0.875 0.777 0.679 
Diastolic CBFV Left (cm/s) 25.8 6.4 28.1 6.3 0.309 27.6 6.2 29.3 6.9 0.638 0.394 0.647 
Mean Diastolic CBFV (cm/s) 25.5 6.0 27.6 6.2 0.569 27.2 7.2 27.5 4.9 0.310 0.318 0.811 
SBP (mmHg) 117.2 21.9 123.5 22.5 0.381 129.7 18.1 123.4 30.5 0.308 0.370 0.679 
DBP (mmHg) 75.1 13.4 72.8 17.0 0.586 80.4 24.0 78.6 21.6 0.530 0.419 0.711 
MAP (mmHg) 88.3 14.3 88.6 16.5 0.906 98.0 22.5 95.5 26.1 0.530 0.325 0.647 
Heart Rate (bpm) 70.5 7.2 67.4 6.1 0.227 66.7 6.8 68.6 5.4 0.480 0.195 0.777 
tCO2 (mmHg) 42.6 57.0 44.6 59.2 0.868 58.8 53.2 85.9 54.1 0.272 0.777 0.107 
Table 81 Group Measurements at 1 minute of HUT (For this time point the Wilcoxon Signed Ranks used to compare placebo and glucose phase within each group, Mann-Whitney used to 
compare No PPH and PPH Group for each phase)   
  
3
3
7
 
 
No PPH – 
placebo (n=17) 
No PPH – 
glucose (n=17) 
Wilcoxon 
Signed 
Ranks Test  
(p-value) 
PPH – 
placebo 
(n=12) 
PPH – glucose 
(n=12) 
Wilcoxon 
Signed 
Ranks Test  
(p-value) 
Mann Whitney U 
test  
(p-value) 
Mean  SD Mean  SD Mean SD Mean  SD Placebo Glucose 
CBFV Right (cm/s) 40.0 8.8 39.6 8.7 0.981 38.4 10.1 39.7 10.5 0.875 0.412 0.879 
CBFV Left (cm/s) 40.2 8.5 42.2 10.0 0.381 40.8 6.6 43.0 13.0 1.000 0.877 0.679 
Mean CBFV (cm/s) 40.1 7.2 40.9 8.5 0.868 39.6 7.2 41.3 9.9 0.779 0.710 0.931 
Systolic CBFV Right (cm/s) 62.6 12.3 61.1 12.7 0.723 58.5 13.3 59.5 15.3 0.875 0.276 0.711 
Systolic CBFV Left (cm/s) 61.5 11.9 65.0 15.6 0.554 62.2 10.7 64.9 22.9 0.695 0.842 0.983 
Mean Systolic CBFV (cm/s) 62.0 10.1 63.0 12.6 0.831 60.4 10.1 62.2 16.2 0.889 0.757 0.986 
Diastolic CBFV Right (cm/s) 25.8 8.0 25.6 6.0 0.831 25.1 7.9 26.7 6.9 0.480 0.521 0.616 
Diastolic CBFV Left (cm/s) 26.4 6.7 27.2 6.3 0.523 26.7 5.6 28.6 7.4 0.695 0.774 0.419 
Mean Diastolic CBFV (cm/s) 26.1 6.4 26.4 5.8 0.831 25.9 6.1 27.6 6.1 0.674 0.576 0.931 
SBP (mmHg) 127.4 27.6 129.8 16.6 0.723 126.7 21.8 123.2 24.1 0.754 0.363 0.325 
DBP (mmHg) 71.1 17.7 75.5 16.4 0.868 79.0 23.7 80.3 21.4 0.814 0.707 0.527 
MAP (mmHg) 87.4 17.7 92.1 14.7 0.407 95.6 22.5 95.2 23.0 0.814 0.707 0.711 
Heart Rate (bpm) 69.9 8.4 69.3 6.7 0.906 68.0 7.6 73.3 14.1 0.347 0.550 0.647 
tCO2 (mmHg) 45.0 59.4 42.5 56.2 0.831 59.3 54.5 93.7 58.3 0.099 0.912 0.059 
Table 82 Groups Measurements at 3 minutes of HUT (For this time point the Wilcoxon Signed Ranks used to compare placebo and glucose phase within each group, Mann-Whitney used to 
compare No PPH and PPH Group for each phase) 
  
  
3
3
8
 
 
 
No PPH – 
placebo 
(n=17) 
No PPH – 
glucose (n=19) 
Wilcoxon 
Signed 
Ranks 
Test  
(p-value) 
PPH – 
placebo 
(n=13) 
PPH – glucose 
(n=15) 
Wilcoxon 
Signed 
Ranks Test  
(p-value) 
Mann Whitney U 
test (p-value) 
Mean  SD Mean  SD Mean SD Mean  SD Placebo Glucose 
CBFV Right (cm/s) 38.7 8.2 35.4 7.8 0.124 35.5 6.6 34.5 6.2 0.552 0.320 0.918 
CBFV Left (cm/s) 35.8 10.0 37.1 8.8 0.554 35.0 6.6 37.6 8.4 0.600 0.934 0.681 
Mean CBFV (cm/s) 37.3 8.4 36.3 7.5 0.687 35.3 5.6 36.1 5.2 0.176 0.711 0.973 
Systolic CBFV Right (cm/s) 60.3 11.1 54.9 11.9 0.149 54.9 10.1 55.1 10.1 0.861 0.183 1.000 
Systolic CBFV Left (cm/s) 54.9 13.9 58.7 11.2 0.435 53.4 8.3 59.8 14.1 0.249 1.000 0.681 
Mean Systolic CBFV (cm/s) 57.6 11.1 56.8 10.4 0.723 54.2 7.1 57.5 9.5 0.735 0.509 0.706 
Diastolic CBFV Right (cm/s) 26.4 5.6 24.1 5.0 0.163 23.6 4.8 22.7 5.8 0.552 0.113 0.242 
Diastolic CBFV Left (cm/s) 24.7 7.0 28.1 10.0 0.149 23.9 6.0 24.9 6.9 0.807 0.805 0.286 
Mean Diastolic CBFV (cm/s) 25.6 5.8 26.1 6.3 0.653 23.7 4.7 23.8 5.2 0.063 0.457 0.430 
SBP (mmHg) 121.9 24.9 120.8 19.3 0.906 128.4 31.1 122.9 26.7 0.507 0.385 0.758 
DBP (mmHg) 75.0 15.4 73.2 12.2 0.943 74.8 16.2 73.2 17.1 0.807 0.320 0.560 
MAP (mmHg) 89.3 16.3 88.1 12.9 0.723 93.2 20.2 91.8 15.3 0.507 0.113 0.286 
Heart Rate (bpm) 76.9 10.1 75.7 10.0 0.943 71.7 9.0 74.7 12.3 0.861 0.263 0.202 
tCO2 (mmHg) 117.0 29.9 117.7 21.1 0.984 105.2 52.4 81.9 52.3 0.101 0.869 0.043 
Table 83 Group Measurements prior to End HUT (i.e.1 minute prior to the end of HUT; For this time point the Wilcoxon Signed Ranks used to compare placebo and glucose phase within each 
group, Mann-Whitney used to compare No PPH and PPH Group for each phase))
  
3
3
9
 
 
No PPH – 
placebo (n=17) 
No PPH – 
glucose 
(n=17) 
Wilcoxon 
Signed 
Ranks Test  
(p-values) 
PPH – 
placebo 
(n=12) 
PPH – 
glucose 
(n=12) 
Wilcoxon 
Signed 
Ranks Test  
(p-values) 
Mann Whitney U 
test  
(p-value) 
Mean  SD Mean  SD Mean SD Mean  SD Placebo Glucose 
Change CBFV Right (cm/s) -5.1 6.8 -5.4 5.7 0.492 -3.3 4.5 -3.2 4.9 0.937 0.419 0.325 
Change CBFV Left (cm/s) -4.3 6.9 -3.0 5.7 0.356 -3.4 6.4 -0.3 9.2 0.308 0.616 0.556 
Change Mean CBFV (cm/s) -4.7 6.4 -4.2 5.2 0.795 -3.3 5.0 -1.7 6.3 0.735 0.534 0.179 
Change Systolic CBFV Right (cm/s) -9.2 11.3 -9.8 9.2 0.554 -8.6 9.7 -3.5 7.6 0.239 0.586 0.059 
Change Systolic CBFV Left (cm/s) -7.0 10.8 -5.7 8.9 0.407 -2.2 14.5 -0.9 13.2 0.638 0.679 0.347 
Change Mean Systolic CBFV (cm/s) -8.1 10.8 -7.7 8.3 0.981 -5.4 5.6 -2.2 9.7 0.398 0.951 0.023 
Change Diastolic CBFV Right (cm/s) -2.2 6.3 -1.6 4.4 0.795 0.0 2.8 -1.5 3.2 0.388 0.283 0.983 
Change Diastolic CBFV Left (cm/s) -1.5 5.2 -0.6 4.3 0.795 2.9 10.3 0.6 5.7 0.695 0.211 0.679 
Change Mean Diastolic CBFV (cm/s) -1.9 5.2 -1.1 4.2 0.906 1.4 5.7 -0.4 3.8 0.237 0.147 0.286 
Change SBP (mmHg) -16.9 21.8 -14.6 24.7 0.523 -22.5 20.9 -16.5 22.8 0.433 0.711 0.527 
Change DBP (mmHg) 3.3 12.3 -0.4 12.5 0.758 -0.6 11.8 -1.0 11.9 0.937 0.227 0.556 
Change MAP (mmHg) -4.3 11.6 -6.2 14.1 0.831 -8.3 13.1 -6.9 14.4 0.638 0.471 0.419 
Change Heart Rate (bpm) 4.3 4.6 5.8 4.4 0.227 4.2 7.4 5.2 5.5 0.754 0.913 0.879 
Change tCO2 (mmHg) -5.5 10.8 -2.7 9.7 0.981 -14.6 20.7 -15.2 20.6 1.000 0.394 0.227 
Table 84 Differences between pre-HUT and 1 minute HUT (i.e. The difference between 1 minute prior to HUT and 1 minute HUT; Wilcoxon Signed Ranks used to compare placebo and glucose 
phase within each group, Mann-Whitney used to compare No PPH and PPH Group for each phase) 
  
  
3
4
0
 
 
No PPH – 
placebo 
(n=17) 
No PPH – 
glucose 
(n=17) 
Wilcoxon 
Signed 
Ranks Test  
(p-values) 
PPH – 
placebo 
(n=12) 
PPH – 
glucose 
(n=12) 
Wilcoxon 
Signed 
Ranks Test  
(p-values) 
Mann Whitney U 
test  
(p-value) 
Mean  SD Mean  SD Mean SD Mean  SD Placebo Glucose 
Change CBFV Right (cm/s) -3.7 9.3 -6.8 5.5 0.136 -4.9 4.4 -2.4 5.9 0.272 0.283 0.166 
Change CBFV Left (cm/s) -3.2 9.3 -2.9 6.6 0.758 -3.9 6.1 -2.2 7.1 0.695 0.948 0.744 
Change Mean CBFV (cm/s) -3.4 6.6 -4.9 5.3 0.193 -4.4 4.5 -2.3 5.5 0.735 0.455 0.319 
Change Systolic CBFV Right (cm/s) -5.9 10.1 -11.4 8.9 0.062 -9.8 7.7 -2.9 8.0 0.084 0.245 0.018 
Change Systolic CBFV Left (cm/s) -5.4 14.9 -4.7 12.3 0.093 -2.0 16.5 -3.1 11.2 0.875 0.647 0.647 
Change Mean Systolic CBFV (cm/s) -5.7 9.5 -8.1 9.9 0.795 -5.9 6.9 -3.0 8.3 0.612 0.619 0.147 
Change Diastolic CBFV Right (cm/s) -1.6 8.5 -3.1 5.5 0.210 -1.7 3.5 -0.6 4.4 0.583 0.370 0.283 
Change Diastolic CBFV Left (cm/s) -0.9 6.4 -1.5 5.9 0.758 2.0 11.2 -0.1 4.6 0.695 0.777 0.586 
Change Mean Diastolic CBFV (cm/s) -1.3 5.9 -2.3 5.4 0.102 0.1 6.7 -0.3 4.0 0.735 0.147 0.515 
Change SBP (mmHg) -6.7 18.9 -8.4 17.7 0.723 -25.5 19.5 -16.7 21.6 0.182 0.027 0.394 
Change DBP (mmHg) -0.8 9.4 2.3 10.9 0.687 -2.0 11.9 0.7 10.5 0.583 0.527 0.913 
Change MAP (mmHg) -5.2 10.8 -2.8 12.4 0.619 -10.8 12.4 -7.2 13.1 0.433 0.227 0.647 
Change Heart Rate (bpm) 3.8 4.2 7.6 5.0 0.028 5.5 7.8 9.9 15.3 0.346 0.811 0.499 
Change tCO2 (mmHg) -3.2 6.9 -4.8 10.0 0.538 -14.1 21.2 -7.3 21.0 0.182 0.152 0.499 
Table 85 Differences between pre-HUT and 3 minutes HUT (i.e. The difference between 1 minute prior to HUT and 3 minute HUT; Wilcoxon Signed Ranks used to compare placebo and glucose 
phase within each group, Mann-Whitney used to compare No PPH and PPH Group for each phase) 
  
  
3
4
1
 
 
 
No PPH – 
placebo 
(n=17) 
No PPH – 
glucose 
(n=19) 
Wilcoxon 
Signed 
Ranks Test  
(p-values) 
PPH – 
placebo 
(n=13) 
PPH – 
glucose 
(n=15) 
Wilcoxon 
Signed 
Ranks Test  
(p-values) 
Mann Whitney U 
test  
(p-value) 
Mean  SD Mean  SD Mean SD Mean  SD Placebo Glucose 
Change CBFV Right (cm/s) -5.0 7.6 -12.4 7.4 0.020 -6.1 18.9 -11.0 17.0 0.657 0.919 0.547 
Change CBFV Left (cm/s) -8.3 8.2 -9.0 5.6 0.776 -4.5 12.8 -10.1 22.0 0.477 0.610 0.711 
Change Mean CBFV (cm/s) -6.7 6.1 -10.7 5.6 0.427 -5.3 14.8 -10.5 17.7 0.310 0.209 0.539 
Change Systolic CBFV Right (cm/s) -8.4 10.7 -19.0 13.0 0.011 -9.8 26.1 -14.3 26.9 0.722 0.919 0.378 
Change Systolic CBFV Left (cm/s) -13.4 13.8 -11.8 11.2 0.910 -6.9 20.1 -14.7 37.4 0.477 0.610 0.611 
Change Mean Systolic CBFV (cm/s) -10.9 10.1 -15.4 11.1 0.460 -8.4 21.4 -14.5 29.8 0.612 0.349 0.567 
Change Diastolic CBFV Right (cm/s) -1.0 6.7 -5.6 4.5 0.015 -2.2 13.0 -6.0 10.8 0.424 0.799 0.746 
Change Diastolic CBFV Left (cm/s) -3.0 6.4 -1.1 10.1 0.955 -0.4 8.3 -4.5 13.2 0.328 0.540 0.781 
Change Mean Diastolic CBFV (cm/s) -2.0 5.5 -3.4 6.2 0.955 -1.3 9.8 -5.2 10.6 0.128 0.455 0.838 
Change SBP (mmHg) -11.1 26.0 -17.0 21.3 0.570 -12.1 57.7 -32.7 48.8 0.657 1.000 0.430 
Change DBP (mmHg) 0.8 17.7 0.2 9.6 0.609 5.0 31.7 -11.4 27.4 0.328 1.000 0.353 
Change MAP (mmHg) -4.8 18.5 -6.7 11.5 0.650 -2.0 38.9 -19.0 33.8 0.534 1.000 0.643 
Change Heart Rate (bpm) 10.5 9.7 14.2 9.6 0.100 16.6 19.1 8.1 28.1 1.000 0.574 0.487 
Change tCO2 (mmHg) 80.7 63.5 73.6 68.1 0.460 11.4 70.0 -34.3 84.7 0.155 0.018 0.002 
Table 86 Differences between pre-HUT and prior to end of HUT (i.e. The difference between 1 minute prior to HUT and 1 minute prior to the end of HUT; Wilcoxon Signed Ranks used to compare 
placebo and glucose phase within each group, Mann-Whitney used to compare No PPH and PPH Group for each phase) 
 
  
  
3
4
2
 
 
No PPH - 
placebo 
(n=15) 
No PPH – glucose 
(n=14) 
Wilcoxon 
Signed Ranks 
Test  
(p-value) 
PPH – 
placebo 
(n=12) 
PPH – glucose 
(n=12) 
Wilcoxon Signed 
Ranks Test  
(p-value) 
Mann Whitney U 
Test  
(p-value) 
Mean  SD Mean  SD Mean SD Mean  SD Placebo Glucose 
CBFV (cm/s) 32.9 1.8 43.2 1.6 <0.001 36.0 3.2 39.1 1.2 <0.001 <0.001 <0.001 
SD time sample 7.8 2.2 7.6 1.2 0.587 9.2 2.5 10.9 1.1 <0.001 0.001 <0.001 
MAP (mmHg) 88.1 2.9 95.4 2.6 <0.001 84.0 3.7 86.2 4.9 0.021 <0.001 <0.001 
SD time sample 13.8 3.6 16.8 2.3 <0.001 18.1 2.3 14.2 3.7 <0.001 <0.001 <0.001 
tCO2 (mmHg) 50.5 12.4 50.9 2.1 <0.001 81.7 9.2 89.9 3.9 <0.001 <0.001 <0.001 
SD time sample 61.7 7.9 55.4 3.1 <0.001 33.8 8.0 33.3 5.2 0.390 <0.001 <0.001 
ARI  4.9 1.5 4.9 1.6 0.962 4.7 1.2 4.7 0.6 0.962 0.337 0.003 
SD time sample 2.8 0.4 2.4 0.2 <0.001 2.6 0.4 2.4 0.5 0.001 0.002 0.042 
Heart Rate (bpm) 72.0 1.6 66.3 2.2 <0.001 67.4 2.1 63.5 1.7 <0.001 <0.001 <0.001 
SD time sample 5.8 1.4 13.7 1.0 <0.001 6.5 2.4 5.7 2.2 0.019 0.046 <0.001 
Table 87 Continuous estimates of CBFV, MAP, TCO2 ARI and HR Pre-HUT (Mean of left and right MCA)  
 
  
3
4
3
 
 
No PPH - 
placebo 
(n=15) 
No PPH – 
glucose (n=14) 
Wilcoxon 
Signed Ranks 
Test  
(p-value) 
PPH – placebo 
(n=12) 
PPH – 
glucose 
(n=12) 
Wilcoxon 
Signed 
Ranks Test  
(p-value) 
Mann Whitney U Test  
(p-value) 
Mean  SD Mean  SD Mean SD Mean  SD Placebo Glucose 
CBFV Right (cm/s) 30.7 3.0 42.5 2.2 <0.001 33.7 2.3 36.9 2.0 <0.001 <0.001 <0.001 
SD time sample 8.6 3.1 8.1 1.1 0.171 8.7 3.2 10.6 1.3 <0.001 0.885 <0.001 
MAP (mmHg) 85.4 4.5 87.4 3.3 0.004 86.7 2.3 84.8 2.8 <0.001 0.001 <0.001 
SD time sample 15.0 3.5 18.2 3.9 <0.001 21.9 1.6 11.5 2.5 <0.001 <0.001 <0.001 
tCO2 (mmHg) 47.3 3.6 56.8 1.8 <0.001 65.5 3.7 63.7 3.5 <0.001 <0.001 <0.001 
SD time sample 62.7 6.2 54.2 2.3 <0.001 45.4 3.0 43.1 2.6 <0.001 <0.001 <0.001 
ARI Right 4.9 0.9 4.3 0.9 <0.001 4.5 1.5 5.9 1.0 <0.001 0.001 <0.001 
SD time sample 3.3 0.2 3.2 0.3 0.038 2.6 0.5 2.1 1.0 <0.001 <0.001 <0.001 
Heart Rate (bpm) 71.8 1.9 65.5 2.3 <0.001 67.5 2.5 63.3 3.2 <0.001 <0.001 <0.001 
SD time sample 7.2 1.2 6.4 1.3 <0.001 6.2 2.9 5.6 3.1 0.038 <0.001 <0.001 
Table 88 Continuous estimates of CBFV, MAP, TCO2 ARI and HR Pre-HUT (Right MCA) 
  
  
3
4
4
 
 
 
No PPH - 
placebo 
(n=15) 
No PPH – glucose 
(n=14) 
Wilcoxon 
Signed Ranks 
Test  
(p-value) 
PPH – placebo 
(n=12) 
PPH – glucose 
(n=12) 
Wilcoxon 
Signed Ranks 
Test  
(p-value) 
Mann Whitney U 
Test  
(p-value) 
Mean  SD Mean  SD Mean SD Mean  SD Placebo Glucose 
CBFV Left (cm/s) 34.3 2.7 43.8 1.7 <0.001 41.4 1.9 40.7 1.4 <0.001 <0.001 <0.001 
SD time sample 6.7 3.1 7.2 2.1 0.043 9.0 1.6 11.4 1.4 <0.001 0.077 <0.001 
MAP (mmHg) 89.8 4.2 103.5 4.9 <0.001 77.3 3.0 93.0 4.4 <0.001 <0.001 <0.001 
SD time sample 11.5 5.1 15.4 5.1 <0.001 11.0 3.0 20.3 3.4 <0.001 0.006 <0.001 
tCO2 (mmHg) 45.4 3.6 45.0 3.1 0.468 109.6 4.5 118.8 6.4 <0.001 <0.001 <0.001 
SD time sample 64.5 6.1 56.7 4.3 <0.001 12.1 4.4 28.9 2.8 <0.001 <0.001 <0.001 
ARI Left 5.3 2.3 5.4 2.4 <0.001 4.1 0.7 3.4 1.2 <0.001 <0.001 <0.001 
SD time sample 2.3 0.8 1.6 0.6 <0.001 2.7 0.4 2.7 0.5 0.105 <0.001 <0.001 
Heart Rate (bpm) 73.0 1.2 67.2 2.8 <0.001 66.4 2.9 63.6 2.2 <0.001 <0.001 <0.001 
SD time sample 3.8 1.1 21.0 1.6 <0.001 6.4 3.5 6.0 2.9 0.735 <0.001 <0.001 
Table 89 Continuous estimates of CBFV, MAP, TCO2 ARI and HR Pre-HUT (Left MCA) 
 
  
  
3
4
5
 
 
No PPH – 
placebo 
(n=13) 
No PPH – 
glucose (n=13) 
Wilcoxon 
Signed Ranks 
Test  
(p-value) 
PPH – placebo 
(n=11) 
PPH – glucose 
(n=12) 
Wilcoxon 
Signed Ranks 
Test  
(p-value) 
Mann Whitney U 
Test (p-value) 
Mean  SD Mean  SD Mean SD Mean  SD Placebo Glucose 
CBFV (cm/s) 35.0 2.5 40.7 1.2 <0.001 38.1 1.8 38.5 2.3 <0.001 <0.001 <0.001 
SD time sample 10.6 1.7 5.7 1.1 <0.001 6.7 1.2 9.7 1.2 <0.001 <0.001 <0.001 
MAP (mmHg) 86.7 2.1 96.8 3.9 <0.001 89.5 2.7 89.5 1.8 0.004 <0.001 <0.001 
SD time sample 11.0 1.3 18.8 4.4 <0.001 16.7 2.7 13.0 1.5 <0.001 <0.001 <0.001 
tCO2 (mmHg) 55.9 4.8 49.6 1.4 <0.001 83.8 14.3 112.7 12.2 <0.001 <0.001 <0.001 
SD time sample 58.0 4.9 54.2 1.8 <0.001 37.4 8.7 24.0 8.0 <0.001 <0.001 <0.001 
ARI  5.5 1.5 4.0 1.2 <0.001 4.7 1.1 5.4 0.5 0.155 <0.001 <0.001 
SD time sample 2.1 0.3 2.1 0.2 0.216 2.2 0.5 2.0 0.5 0.988 0.100 0.805 
Heart Rate (bpm) 69.2 2.9 68.7 1.0 0.171 67.9 2.0 67.2 3.9 0.053 <0.001 0.014 
SD time sample 6.5 2.4 5.8 1.2 0.015 6.3 2.2 9.6 5.3 0.006 0.940 0.003 
Table 90 Continuous estimates of CBFV, MAP, TCO2, ARI and HR HUT 1 minute (Mean of right and left MCA)  
  
3
4
6
 
 
 
No PPH – 
placebo (n=13) 
No PPH – 
glucose (n=13) 
Wilcoxon 
Signed 
Ranks Test  
(p-value) 
PPH – placebo 
(n=11) 
PPH – glucose 
(n=12) 
Wilcoxon 
Signed Ranks 
Test  
(p-value) 
Mann Whitney U 
Test  
(p-value) 
Mean  SD Mean  SD Mean  SD Mean  SD Placebo Glucose 
CBFV Right (cm/s) 32.4 1.6 40.8 2.5 <0.001 42.6 1.7 36.5 1.6 0.001 <0.001 0.024 
SD time sample 8.4 3.2 3.8 1.9 <0.001 6.5 1.7 8.7 1.4 <0.001 0.001 <0.001 
MAP (mmHg) 92.7 1.2 104.3 6.3 <0.001 82.8 1.8 87.5 2.7 0.041 <0.001 <0.001 
SD time sample 9.4 1.0 17.1 5.7 <0.001 9.9 2.1 5.5 2.4 0.030 <0.001 0.001 
tCO2 (mmHg) 48.2 1.2 44.0 1.8 <0.001 116.6 2.5 70.3 3.4 <0.001 <0.001 <0.001 
SD time sample 69.0 1.8 55.5 2.5 <0.001 11.5 3.0 47.6 2.4 <0.001 <0.001 <0.001 
ARI Right 0.7 0.6 3.3 1.2 <0.001 4.8 0.5 6.7 0.4 0.276 <0.001 <0.001 
SD time sample 1.1 0.5 2.2 0.4 <0.001 1.7 0.5 1.3 0.4 0.441 <0.001 <0.001 
Heart Rate (bpm) 73.0 0.6 68.2 1.4 <0.001 67.2 3.3 64.4 4.6 0.267 <0.001 0.017 
SD time sample 3.5 0.9 3.9 2.1 0.244 7.2 3.6 5.5 4.9 0.005 0.015 0.523 
Table 91 Continuous estimates of  CBFV, MAP, TCO2, ARI and HR HUT 1 minute (Right MCA) 
 
 
 
  
  
3
4
7
 
 
 
No PPH – 
placebo (n=13) 
No PPH – 
glucose (n=13) 
Wilcoxon 
Signed 
Ranks Test  
(p-values) 
PPH – placebo 
(n=11) 
PPH – glucose 
(n=12) 
Wilcoxon 
Signed 
Ranks Test  
(p-values) 
Mann Whitney U 
Test  
(p-value) 
Mean  SD Mean  SD Mean SD Mean  SD Placebo Glucose 
CBFV Left (cm/s) 36.5 2.7 40.9 1.1 <0.001 36.8 2.0 31.9 1.0 <0.001 <0.001 <0.001 
SD time sample 9.1 2.7 7.3 0.9 <0.001 7.9 2.7 14.8 1.7 <0.001 <0.001 <0.001 
MAP (mmHg) 81.1 1.8 92.9 3.9 <0.001 90.6 1.2 98.6 1.4 <0.001 <0.001 <0.001 
SD time sample 17.2 2.4 18.8 4.9 <0.001 22.1 2.0 14.0 2.2 <0.001 <0.001 <0.001 
tCO2 (mmHg) 42.6 1.5 55.1 1.8 <0.001 68.3 2.1 126.7 1.7 <0.001 <0.001 <0.001 
SD time sample 60.7 1.9 53.0 2.0 <0.001 48.7 1.3 22.8 2.8 <0.001 <0.001 <0.001 
ARI Left 3.9 1.7 4.7 0.4 <0.001 4.2 1.0 6.9 0.9 <0.001 <0.001 <0.001 
SD time sample 3.1 0.5 2.3 0.2 <0.001 3.6 0.2 1.4 0.6 <0.001 <0.001 <0.001 
Heart Rate (bpm) 71.8 2.0 69.9 1.3 <0.001 67.1 2.5 73.6 3.8 <0.001 <0.001 <0.001 
SD time sample 7.4 1.9 8.4 1.4 0.026 5.2 3.4 18.3 5.5 <0.001 <0.001 0.910 
Table 92 Continuous estimates of CBFV, MAP, TCO2, ARI and HR HUT 1 minute (Left MCA) 
 
  
  
3
4
8
 
 
No PPH – 
placebo 
(n=13) 
No PPH – 
glucose (n=13) 
Wilcoxon 
Signed Ranks 
Test  
(p-values) 
PPH – placebo 
(n=11) 
PPH – glucose 
(n=12) 
Wilcoxon 
Signed Ranks 
Test  
(p-values) 
Mann Whitney U Test 
(p-value) 
Mean  SD Mean  SD Mean SD Mean  SD Placebo Glucose 
Combined CBFV 
(cm/s) 
35.3 1.8 42.0 1.9 <0.001 40.9 1.5 34.4 0.7 <0.001 <0.001 <0.001 
SD time sample 9.2 1.9 6.5 1.0 <0.001 6.3 1.4 12.1 1.1 <0.001 <0.001 <0.001 
MAP (mmHg) 83.8 1.5 100.8 5.8 <0.001 85.9 1.3 92.7 1.1 <0.001 <0.001 <0.001 
SD time sample 13.2 2.7 17.9 6.3 <0.001 17.6 1.8 9.7 1.6 <0.001 <0.001 <0.001 
tCO2 (mmHg) 51.6 6.0 51.0 1.9 0.156 91.2 2.8 100.4 3.3 <0.001 <0.001 <0.001 
SD time sample 59.8 5.1 56.3 2.6 <0.001 32.5 2.3 36.2 3.2 <0.001 <0.001 <0.001 
Combined ARI  4.3 0.7 4.6 0.9 0.310 5.4 0.7 7.0 0.3 <0.001 <0.001 <0.001 
SD time sample 2.4 0.7 2.5 0.4 0.200 2.6 0.2 1.3 0.1 <0.001 0.038 <0.001 
Heart Rate (bpm) 70.8 2.6 69.2 1.3 <0.001 66.9 2.4 69.2 2.7 0.001 <0.001 0.116 
SD time sample 5.7 1.3 6.2 1.6 <0.001 5.8 2.1 11.6 3.6 <0.001 0.864 <0.001 
Table 93 Continuous estimates of ARI HUT 2 minute (Mean of right and left MCA)
  
3
4
9
 
 
 
No PPH – 
placebo 
(n=13) 
No PPH – 
glucose (n=13) 
Wilcoxon 
Signed Ranks 
Test  
(p-values) 
PPH – placebo 
(n=11) 
PPH – glucose 
(n=12) 
Wilcoxon 
Signed Ranks 
Test  
(p-values) 
Mann Whitney U 
Test  
(p-value) 
Mean  SD Mean  SD Mean SD Mean  SD Placebo Glucose 
CBFV Right (cm/s) 36.5 2.7 40.9 1.1 <0.001 36.8 2.0 31.9 1.0 <0.001 0.713 <0.001 
SD time sample 9.1 2.7 7.3 0.9 <0.001 7.9 2.7 14.8 1.7 <0.001 0.002 <0.001 
MAP (mmHg) 81.1 1.8 92.9 3.9 <0.001 90.6 1.2 98.6 1.4 <0.001 <0.001 <0.001 
SD time sample 17.2 2.4 18.8 4.9 0.076 22.1 2.0 14.0 2.2 <0.001 <0.001 <0.001 
tCO2 (mmHg) 42.6 1.5 55.1 1.8 <0.001 68.3 2.1 126.7 1.7 <0.001 <0.001 <0.001 
SD time sample 60.7 1.9 53.0 2.0 <0.001 48.7 1.3 22.8 2.8 <0.001 <0.001 <0.001 
ARI Right 3.9 1.7 4.7 0.4 <0.001 4.2 1.0 6.9 0.9 <0.001 0.117 <0.001 
SD time sample 3.1 0.5 2.3 0.2 <0.001 3.6 0.2 1.4 0.6 <0.001 <0.001 <0.001 
Heart Rate (bpm) 71.8 2.0 69.9 1.3 <0.001 67.1 2.5 73.6 3.8 <0.001 <0.001 <0.001 
SD time sample 7.4 1.9 8.4 1.4 <0.001 5.2 3.4 18.3 5.5 <0.001 <0.001 <0.001 
Table 94 Continuous estimates of ARI HUT 2 minute (Right MCA) 
  
  
3
5
0
 
 
No PPH – 
placebo 
(n=13) 
No PPH – 
glucose (n=13) 
Wilcoxon 
Signed Ranks 
Test  
(p-values) 
PPH – placebo 
(n=11) 
PPH – glucose 
(n=12) 
Wilcoxon 
Signed Ranks 
Test  
(p-values) 
Mann Whitney U 
Test  
(p-value) 
Mean  SD Mean  SD Mean SD Mean  SD Placebo Glucose 
CBFV Left (cm/s) 31.4 1.4 43.0 3.4 <0.001 45.0 1.9 36.7 1.1 <0.001 <0.001 <0.001 
SD time sample 9.2 2.6 5.7 1.9 <0.001 4.6 1.3 9.5 1.0 <0.001 <0.001 <0.001 
MAP (mmHg) 85.5 1.6 108.8 8.5 <0.001 81.1 1.5 87.2 1.3 <0.001 <0.001 <0.001 
SD time sample 16.2 1.6 17.1 8.2 0.074 13.0 1.7 4.0 2.0 <0.001 <0.001 <0.001 
tCO2 (mmHg) 48.5 1.1 46.9 2.7 0.025 114.6 2.1 72.5 1.9 <0.001 <0.001 <0.001 
SD time sample 69.7 2.2 59.5 3.7 <0.001 16.0 3.1 49.5 1.5 <0.001 <0.001 <0.001 
ARI Left 2.4 0.6 4.4 1.9 <0.001 6.7 0.8 7.1 0.5 <0.001 <0.001 <0.001 
SD time sample 2.4 0.6 2.8 0.8 0.310 1.7 0.3 1.2 0.5 <0.001 <0.001 <0.001 
Heart Rate (bpm) 74.1 0.9 68.4 1.8 <0.001 66.8 3.4 65.5 3.0 0.014 <0.001 <0.001 
SD time sample 4.2 0.8 4.1 2.5 <0.001 6.5 4.2 4.2 2.7 <0.001 <0.001 0.920 
Table 95 Continuous estimates of ARI HUT 2 minute (Left MCA) 
 
  
  
3
5
1
 
 
No PPH – 
placebo 
(n=13) 
No PPH – 
glucose (n=13) 
Wilcoxon 
Signed Ranks 
Test  
(p-values) 
PPH – placebo 
(n=11) 
PPH – glucose 
(n=12) 
Wilcoxon 
Signed Ranks 
Test  
(p-values) 
Mann Whitney U Test 
(p-value) 
Mean  SD Mean  SD Mean SD Mean  SD Placebo Glucose 
Combined CBFV 
(cm/s) 
35.1 0.8 38.8 4.4 <0.001 37.5 1.0 39.7 2.9 <0.001 <0.001 0.335 
SD time sample 12.6 1.0 8.4 1.3 <0.001 7.5 1.3 9.0 0.9 <0.001 <0.001 0.030 
MAP (mmHg) 89.3 1.6 94.3 2.3 <0.001 99.7 5.6 95.9 4.0 <0.001 <0.001 0.021 
SD time sample 14.2 0.9 16.4 2.4 <0.001 17.0 1.6 12.8 1.3 <0.001 <0.001 <0.001 
tCO2 (mmHg) 127.9 1.3 115.7 1.7 <0.001 119.0 3.8 102.5 4.0 <0.001 <0.001 <0.001 
SD time sample 24.5 0.8 38.1 4.7 <0.001 46.4 10.7 47.0 9.7 0.003 <0.001 <0.001 
Combined ARI  4.4 0.4 4.9 0.3 <0.001 4.8 0.5 5.0 0.5 0.001 <0.001 0.073 
SD time sample 2.9 0.1 3.1 0.2 <0.001 2.9 0.2 3.0 0.2 0.004 0.122 <0.001 
Heart Rate (bpm) 60.0 1.1 67.8 2.8 <0.001 64.8 2.0 67.5 1.8 <0.001 <0.001 0.681 
SD time sample 21.3 0.5 7.1 0.8 <0.001 14.5 3.1 10.2 1.8 <0.001 <0.001 0.111 
Table 96 Continuous estimates of CBFV, MAP, TCO2, HR and ARI prior to end of HUT (Mean of right and left MCA)
  
3
5
2
 
 
No PPH – 
placebo (n=13) 
No PPH – 
glucose (n=13) 
Wilcoxon 
Signed Ranks 
Test  
(p-values) 
PPH – placebo 
(n=11) 
PPH – glucose 
(n=12) 
Wilcoxon 
Signed Ranks 
Test  
(p-values) 
Mann Whitney U 
Test  
(p-value) 
Mean  SD Mean  SD Mean SD Mean  SD Placebo Glucose 
CBFV Right (cm/s) 32.7 1.7 37.6 0.6 <0.001 39.0 0.7 37.1 1.6 <0.001 <0.001 <0.001 
SD time sample 15.8 1.7 7.2 0.5 <0.001 6.7 0.7 8.2 1.0 0.188 <0.001 <0.001 
MAP (mmHg) 89.4 3.0 98.2 1.3 <0.001 101.5 1.0 83.8 2.4 <0.001 <0.001 <0.001 
SD time sample 14.4 1.5 11.6 1.0 <0.001 18.0 1.3 16.3 2.5 <0.001 <0.001 <0.001 
tCO2 (mmHg) 122.0 2.4 93.8 1.6 <0.001 114.1 1.4 118.5 3.0 <0.001 <0.001 <0.001 
SD time sample 28.9 1.1 55.7 1.2 <0.001 52.8 0.8 18.9 3.3 <0.001 <0.001 <0.001 
ARI Right 3.3 0.6 4.9 0.6 <0.001 4.9 0.3 4.3 0.7 <0.001 <0.001 <0.001 
SD time sample 3.0 0.2 2.7 0.1 <0.001 3.0 0.1 3.3 0.2 <0.001 0.335 <0.001 
Heart Rate (bpm) 59.9 2.1 67.5 1.6 <0.001 64.7 1.6 68.1 3.8 <0.001 <0.001 0.931 
SD time sample 19.8 1.0 11.8 2.5 <0.001 11.7 1.5 9.9 2.3 0.709 <0.001 <0.001 
Table 97 Continuous estimates of CBFV, MAP, TCO2, HR and ARI prior to end of HUT (Right MCA) 
  
  
3
5
3
 
 
No PPH – 
placebo (n=13) 
No PPH – 
glucose (n=13) 
Wilcoxon 
Signed Ranks 
Test  
(p-values) 
PPH – placebo 
(n=11) 
PPH – glucose 
(n=12) 
Wilcoxon 
Signed Ranks 
Test  
(p-values) 
Mann Whitney U Test  
(p-value) 
Mean  SD Mean  SD Mean SD Mean  SD Placebo Glucose 
CBFV Left (cm/s) 37.8 0.6 35.3 2.0 <0.001 33.7 1.1 47.7 1.7 <0.001 <0.001 <0.001 
SD time sample 10.1 1.0 11.2 2.4 <0.001 6.2 1.0 10.7 0.4 <0.001 <0.001 0.272 
MAP (mmHg) 88.2 1.6 84.0 1.8 <0.001 108.7 1.4 101.4 2.6 <0.001 <0.001 <0.001 
SD time sample 13.9 1.1 13.9 2.6 0.591 18.6 1.9 14.2 2.0 <0.001 <0.001 0.400 
tCO2 (mmHg) 132.0 2.6 117.0 2.3 <0.001 116.8 2.3 108.8 3.3 <0.001 <0.001 <0.001 
SD time sample 19.6 1.9 15.7 3.7 <0.001 61.5 0.9 54.9 1.9 <0.001 <0.001 <0.001 
ARI Left 4.7 0.9 4.8 0.5 <0.001 5.4 0.5 5.7 0.6 <0.001 <0.001 <0.001 
SD time sample 2.7 0.2 3.1 0.5 0.003 3.1 0.2 3.0 0.5 <0.001 <0.001 0.246 
Heart Rate (bpm) 60.9 1.6 69.9 4.1 <0.001 68.6 1.3 66.0 2.3 <0.001 <0.001 <0.001 
SD time sample 22.9 0.6 7.0 3.2 <0.001 11.4 1.0 8.8 2.4 <0.001 <0.001 0.001 
Table 98 Continuous estimates of CBFV, MAP, TCO2, HR and ARI prior to end of HUT (Left MCA) 
 
  
  
3
5
4
 
 
No PPH – 
placebo 
(n=13) 
No PPH – 
glucose (n=13) 
Wilcoxon 
Signed Ranks 
Test  
(p-values) 
PPH – placebo 
(n=11) 
PPH – glucose 
(n=12) 
Wilcoxon 
Signed Ranks 
Test  
(p-values) 
Mann Whitney U Test 
(p-value) 
Mean  SD Mean  SD Mean SD Mean  SD Placebo Glucose 
Combined CBFV 
(cm/s) 
36.6 1.5 44.6 0.9 <0.001 37.7 0.6 37.8 1.6 0.525 <0.001 <0.001 
SD time sample 12.7 1.2 10.0 0.5 <0.001 6.4 0.8 8.7 1.5 <0.001 <0.001 <0.001 
MAP (mmHg) 91.7 0.8 96.1 1.0 <0.001 105.0 2.1 95.6 2.4 <0.001 <0.001 <0.001 
SD time sample 16.2 0.7 12.6 0.6 <0.001 17.9 1.0 11.6 1.0 <0.001 <0.001 <0.001 
tCO2 (mmHg) 128.2 1.2 117.4 1.1 <0.001 116.6 2.2 104.8 6.1 <0.001 <0.001 <0.001 
SD time sample 24.3 1.2 34.5 1.0 <0.001 55.8 4.5 41.1 9.2 <0.001 <0.001 <0.001 
Combined ARI  4.8 0.7 5.5 0.4 <0.001 4.3 0.6 4.8 0.4 <0.001 <0.001 <0.001 
SD time sample 2.6 0.4 2.9 0.5 <0.001 2.9 0.2 2.5 0.2 <0.001 <0.001 <0.001 
Heart Rate (bpm) 58.6 0.8 65.0 1.3 <0.001 65.9 1.4 66.9 1.1 <0.001 <0.001 <0.001 
SD time sample 21.1 0.4 7.1 0.8 <0.001 11.5 1.4 8.5 2.2 <0.001 <0.001 <0.001 
Table 99 Continuous estimates of CBFV, MAP, TCO2, HR and ARI post-HUT 1 minute (Mean of right and left MCA)  
  
3
5
5
 
 
No PPH – 
placebo 
(n=13) 
No PPH – 
glucose (n=13) 
Wilcoxon 
Signed Ranks 
Test  
(p-values) 
PPH – placebo 
(n=11) 
PPH – glucose 
(n=12) 
Wilcoxon 
Signed Ranks 
Test  
(p-values) 
Mann Whitney U 
Test  
(p-value) 
Mean  SD Mean  SD Mean SD Mean  SD Placebo Glucose 
CBFV Right (cm/s) 35.9 2.6 40.3 1.5 <0.001 39.6 0.7 37.5 0.5 <0.001 <0.001 <0.001 
SD time sample 14.7 2.4 9.5 0.8 <0.001 6.9 0.4 7.2 0.4 <0.001 <0.001 <0.001 
MAP (mmHg) 93.7 0.8 88.2 0.8 <0.001 102.7 0.8 99.5 1.0 <0.001 <0.001 <0.001 
SD time sample 18.0 1.2 12.6 0.6 <0.001 17.5 0.8 11.2 0.6 <0.001 <0.001 <0.001 
tCO2 (mmHg) 122.3 1.0 125.0 1.4 <0.001 116.3 1.2 94.5 1.1 <0.001 <0.001 <0.001 
SD time sample 27.9 1.3 12.8 1.3 <0.001 53.2 0.8 56.7 0.9 <0.001 <0.001 <0.001 
ARI Right 3.9 0.9 5.5 0.8 <0.001 4.5 0.7 5.0 0.1 <0.001 <0.001 <0.001 
SD time sample 3.0 0.4 2.6 0.4 <0.001 2.8 0.3 2.4 0.1 <0.001 <0.001 <0.001 
Heart Rate (bpm) 58.8 1.1 63.1 0.9 <0.001 64.4 1.3 67.4 1.7 <0.001 <0.001 <0.001 
SD time sample 19.4 0.4 7.3 0.8 <0.001 11.2 0.9 10.8 2.4 0.307 <0.001 <0.001 
Table 100 Continuous estimates of CBFV, MAP, TCO2, HR and ARI post-HUT 1 minute (Right MCA) 
  
  
3
5
6
 
 
No PPH – 
placebo (n=13) 
No PPH – glucose 
(n=13) 
Wilcoxon 
Signed 
Ranks Test  
(p-values) 
PPH – 
placebo 
(n=11) 
PPH – glucose 
(n=12) 
Wilcoxon 
Signed Ranks 
Test  
(p-values) 
Mann Whitney U Test  
(p-value) 
Mean  SD Mean  SD Mean SD Mean  SD Placebo Glucose 
CBFV Left (cm/s) 37.4 0.9 38.0 3.3 0.396 35.6 1.0 49.0 1.3 <0.001 <0.001 <0.001 
SD time sample 10.7 0.7 11.2 2.9 0.481 5.8 1.2 10.5 0.5 <0.001 <0.001 0.187 
MAP (mmHg) 89.7 1.1 88.9 1.6 0.042 108.3 0.7 103.9 1.6 <0.001 <0.001 <0.001 
SD time sample 14.3 0.9 12.1 2.0 <0.001 18.4 1.1 12.5 1.1 <0.001 <0.001 0.232 
tCO2 (mmHg) 134.1 1.7 122.0 1.6 <0.001 116.0 1.0 109.7 1.4 <0.001 <0.001 <0.001 
SD time sample 20.8 1.6 14.6 2.7 <0.001 60.5 0.9 56.2 1.4 <0.001 <0.001 <0.001 
ARI Left 5.7 0.6 4.5 0.8 <0.001 4.1 0.8 5.6 0.7 <0.001 <0.001 <0.001 
SD time sample 2.2 0.7 2.5 0.4 <0.001 3.1 0.3 3.2 0.6 0.032 <0.001 <0.001 
Heart Rate (bpm) 59.2 0.9 66.5 1.3 <0.001 67.9 1.1 65.7 1.8 <0.001 <0.001 0.002 
SD time sample 22.9 0.7 4.7 1.5 <0.001 11.2 0.7 7.0 1.4 <0.001 <0.001 <0.001 
Table 101 Continuous estimates of CBFV, MAP, TCO2, HR and ARI post-HUT 1 minute (Left MCA) 
 
  
  
3
5
7
 
 
 
 
No PPH – 
placebo 
(n=13) 
No PPH – 
glucose (n=13) 
Wilcoxon 
Signed Ranks 
Test  
(p-values) 
PPH – placebo 
(n=11) 
PPH – glucose 
(n=12) 
Wilcoxon 
Signed Ranks 
Test  
(p-values) 
Mann Whitney U Test 
(p-value) 
Mean  SD Mean  SD Mean SD Mean  SD Placebo Glucose 
CBFV (cm/s) 37.6 0.8 43.4 2.5 <0.001 37.3 0.5 38.5 3.4 0.132 0.050 <0.001 
SD time sample 10.9 0.9 8.7 0.8 <0.001 6.7 1.0 8.7 1.3 <0.001 <0.001 0.057 
MAP (mmHg) 92.4 1.1 95.9 1.5 <0.001 103.8 2.4 95.4 3.2 <0.001 <0.001 <0.001 
SD time sample 16.9 1.1 13.9 1.5 <0.001 17.6 2.5 11.8 1.5 <0.001 0.002 <0.001 
tCO2 (mmHg) 128.3 1.5 117.6 1.3 <0.001 113.3 3.7 107.7 5.2 <0.001 <0.001 <0.001 
SD time sample 24.3 1.4 35.9 1.0 <0.001 53.4 4.8 39.7 9.6 <0.001 <0.001 <0.001 
ARI  5.4 0.5 5.3 0.6 0.006 4.6 0.3 5.0 0.9 <0.001 <0.001 <0.001 
SD time sample 2.7 0.2 2.5 0.3 <0.001 3.0 0.2 2.7 0.4 <0.001 <0.001 <0.001 
Heart Rate (bpm) 58.3 1.0 64.8 1.2 <0.001 66.1 1.3 66.5 1.3 0.069 <0.001 <0.001 
SD time sample 21.0 0.8 7.7 1.2 <0.001 11.7 1.7 8.6 1.7 <0.001 <0.001 <0.001 
Table 102 Continuous estimates of CBFV, MAP, TCO2, HR and ARI post-HUT 2 minute (Mean of right and left MCA) 
  
  
3
5
8
 
 
No PPH – 
placebo (n=13) 
No PPH – 
glucose (n=13) 
Wilcoxon 
Signed Ranks 
Test  
(p-values) 
PPH – 
placebo 
(n=11) 
PPH – glucose 
(n=12) 
Wilcoxon 
Signed Ranks 
Test  
(p-values) 
Mann Whitney U 
Test (p-value) 
Mean  SD Mean  SD Mean SD Mean  SD Placebo Glucose 
CBFV Right (cm/s) 38.1 1.3 41.3 0.9 <0.001 38.6 0.8 37.3 0.6 <0.001 0.014 <0.001 
SD time sample 11.3 1.5 8.2 1.3 <0.001 7.6 1.1 7.5 0.5 <0.001 <0.001 <0.001 
MAP (mmHg) 94.7 0.9 89.5 1.3 <0.001 101.9 1.3 98.2 1.1 <0.001 <0.001 <0.001 
SD time sample 19.3 0.6 13.7 0.8 <0.001 16.7 1.1 11.2 1.1 <0.001 <0.001 <0.001 
tCO2 (mmHg) 122.3 1.2 126.6 1.8 <0.001 113.6 2.4 93.2 0.9 <0.001 <0.001 <0.001 
SD time sample 27.2 1.3 16.4 2.3 <0.001 51.3 1.3 55.7 0.7 <0.001 <0.001 <0.001 
ARI Right 5.6 0.6 4.6 0.8 <0.001 4.6 0.4 5.8 0.3 0.543 <0.001 <0.001 
SD time sample 2.8 0.5 2.8 0.2 0.264 3.0 0.2 2.4 0.3 <0.001 0.122 <0.001 
Heart Rate (bpm) 58.0 1.3 63.8 1.2 <0.001 64.6 1.1 67.2 1.5 <0.001 <0.001 <0.001 
SD time sample 19.1 0.5 7.7 0.9 <0.001 11.2 1.0 11.4 2.2 0.613 <0.001 <0.001 
Table 103 Continuous estimates of CBFV, MAP, TCO2, HR and ARI post-HUT 2 minute (Right MCA) 
  
  
3
5
9
 
 
 
 
No PPH – 
placebo (n=13) 
No PPH – glucose 
(n=13) 
Wilcoxon 
Signed Ranks 
Test  
(p-values) 
PPH – placebo 
(n=11) 
PPH – glucose 
(n=12) 
Wilcoxon 
Signed Ranks 
Test  
(p-values) 
Mann Whitney U Test 
(p-value) 
Mean  SD Mean  SD Mean SD Mean  SD Placebo Glucose 
CBFV Left (cm/s) 37.0 0.6 36.7 3.0 0.389 36.1 0.7 48.5 1.5 <0.001 <0.001 <0.001 
SD time sample 10.6 0.6 9.5 1.9 <0.001 5.6 0.8 10.1 0.9 <0.001 <0.001 <0.001 
MAP (mmHg) 90.3 1.8 90.1 1.5 0.953 106.4 3.4 101.1 1.7 <0.001 <0.001 <0.001 
SD time sample 14.5 2.1 11.8 1.5 <0.001 18.6 4.5 12.7 1.9 <0.001 <0.001 0.001 
tCO2 (mmHg) 134.3 2.3 123.0 2.5 <0.001 111.7 4.5 107.3 1.5 <0.001 <0.001 <0.001 
SD time sample 21.4 2.6 17.0 2.6 <0.001 57.5 4.1 54.7 1.3 <0.001 <0.001 <0.001 
ARI Left 5.3 0.6 3.5 0.8 <0.001 4.2 0.7 6.9 0.5 <0.001 <0.001 <0.001 
SD time sample 2.7 0.4 3.2 0.3 <0.001 3.0 0.4 2.1 0.3 0.844 <0.001 <0.001 
Heart Rate (bpm) 58.7 1.4 66.1 1.8 <0.001 67.9 1.5 65.3 1.6 <0.001 <0.001 <0.001 
SD time sample 22.8 1.4 6.5 2.0 <0.001 11.5 1.3 6.5 1.4 <0.001 <0.001 0.572 
Table 104 Continuous estimates of CBFV, MAP, TCO2, HR and ARI post-HUT 2 minute (Left MCA) 
 
  
  
3
6
0
 
Table 105 Changes in time varying estimates at 1 minute of HUT  
 
No PPH – 
placebo (n=13) 
No PPH – glucose 
(n=13) 
Wilcoxon 
Signed Ranks 
Test  
(p-values) 
PPH – placebo 
(n=11) 
PPH – glucose 
(n=12) 
Wilcoxon 
Signed Ranks 
Test  
(p-values) 
Mann Whitney U Test 
(p-value) 
Mean  SD Mean  SD Mean SD Mean  SD Placebo Glucose 
Change in CBFV 
(cm/s) 
2.2 3.2 -2.4 1.9 <0.001 2.2 3.2 -29.6 1.6 <0.001 <0.001 <0.001 
Change in SD time 
sample 
2.9 2.8 -1.9 1.6 <0.001 -2.5 2.6 27.2 2.9 <0.001 0.279 <0.001 
Change in MAP 
(mmHg) 
-1.2 3.8 1.4 4.9 <0.001 5.6 3.0 -0.1 4.0 <0.001 <0.001 0.443 
Change in SD time 
sample 
-2.6 3.5 2.0 4.6 <0.001 -1.4 2.4 -3.0 2.5 0.622 <0.001 <0.001 
Change in tCO2 
(mmHg) 
6.9 11.7 -1.3 2.5 <0.001 2.1 10.0 20.4 15.1 <0.001 <0.001 <0.001 
Change in SD time 
sample 
-4.4 6.3 -1.3 3.7 <0.001 3.6 6.5 -12.4 6.9 <0.001 <0.001 <0.001 
Change in ARI  0.5 2.6 -0.9 2.6 <0.001 0.0 2.1 1.2 0.5 0.658 0.098 0.001 
Change in SD time 
sample 
-0.8 0.5 -0.3 0.4 <0.001 -0.4 0.8 -0.8 0.6 0.363 0.352 <0.001 
Change in Heart 
Rate (bpm) 
-2.9 3.7 2.3 2.0 <0.001 0.5 2.8 3.7 4.1 0.010 <0.001 0.001 
Change in SD time 
sample 
0.9 2.8 -7.9 1.5 <0.001 -0.1 3.2 4.0 6.3 0.006 <0.001 <0.001 
  
3
6
1
 
 
No PPH – 
placebo (n=13) 
No PPH – glucose 
(n=13) 
Wilcoxon 
Signed Ranks 
Test  
(p-values) 
PPH – placebo 
(n=11) 
PPH – glucose 
(n=12) 
Wilcoxon 
Signed Ranks 
Test  
(p-values) 
Mann Whitney U Test 
(p-value) 
Mean  SD Mean  SD Mean SD Mean  SD Placebo Glucose 
Change in CBFV 
(cm/s) 
2.4 2.6 -1.2 2.4 <0.001 4.9 3.6 -4.9 1.1 <0.001 <0.001 <0.001 
Change in SD time 
sample 
1.4 3.2 -1.2 1.4 <0.001 -2.9 2.3 0.7 1.6 <0.001 <0.001 <0.001 
Change in MAP 
(mmHg) 
-4.3 3.7 5.4 6.2 <0.001 1.9 3.9 3.1 3.7 0.238 <0.001 0.028 
Change in SD time 
sample 
-0.6 3.2 1.1 5.8 <0.001 -0.5 2.0 -6.4 2.5 <0.001 0.723 <0.001 
Change in tCO2 
(mmHg) 
-1.2 12.5 -0.1 3.1 <0.001 -9.6 8.8 -8.0 5.9 <0.001 <0.001 <0.001 
Change in SD time 
sample 
-1.9 8.4 -0.8 4.0 <0.001 -1.3 7.4 -0.3 4.2 0.001 0.988 0.497 
Change in ARI  -0.6 2.0 -0.3 1.7 0.167 0.7 1.5 2.9 0.5 <0.001 <0.001 <0.001 
Change in SD time 
sample 
-0.4 0.8 0.1 0.4 <0.001 0.0 0.5 -1.5 0.1 <0.001 <0.001 <0.001 
Change in Heart 
Rate (bpm) 
-1.1 3.4 2.8 2.4 <0.001 -0.5 3.4 5.9 2.9 <0.001 0.178 <0.001 
Change in SD time 
sample 
-0.1 1.9 -7.5 2.3 <0.001 -0.7 4.0 5.9 4.1 <0.001 0.125 <0.001 
Table 106 Changes in time varying estimates at 2 minutes of HUT 
  
  
3
6
2
 
 
No PPH – 
placebo (n=13) 
No PPH – glucose 
(n=13) 
Wilcoxon 
Signed Ranks 
Test  
(p-values) 
PPH – placebo 
(n=11) 
PPH – glucose 
(n=12) 
Wilcoxon 
Signed Ranks 
Test  
(p-values) 
Mann Whitney U Test 
(p-value) 
Mean  SD Mean  SD Mean SD Mean  SD Placebo Glucose 
Change in combined 
CBFV (cm/s) 
1.9 1.7 -4.4 5.5 <0.001 1.5 2.7 0.6 3.5 0.081 0.034 0.167 
Change in SD time 
sample 
6.1 2.3 0.7 1.4 <0.001 -1.6 3.1 -1.9 1.2 0.485 <0.001 <0.001 
Change in MAP 
(mmHg) 
1.2 4.5 -1.2 2.5 0.001 15.8 4.2 9.7 7.9 <0.001 <0.001 <0.001 
Change in SD time 
sample 
-0.9 3.5 -0.5 3.3 0.009 1.1 2.4 -1.4 4.1 0.534 0.192 <0.001 
Change in tCO2 
(mmHg) 
80.7 4.5 64.8 2.9 <0.001 37.4 8.1 12.6 4.2 <0.001 <0.001 <0.001 
Change in SD time 
sample 
-40.0 7.1 -17.3 5.5 <0.001 12.6 9.6 13.8 13.0 0.137 <0.001 <0.001 
Change in combined 
ARI  
-1.8 0.6 0.0 1.4 <0.001 0.1 1.2 0.3 0.7 0.080 <0.001 0.001 
Change in SD time 
sample 
0.3 0.2 0.7 0.4 <0.001 0.3 0.5 0.5 0.6 <0.001 0.758 0.027 
Change in Heart 
Rate (bpm) 
-11.3 1.6 1.5 4.4 <0.001 -2.6 2.3 4.0 2.6 <0.001 <0.001 0.732 
Change in SD time 
sample 
16.2 1.4 -6.6 1.2 <0.001 8.0 4.3 4.5 2.9 <0.001 <0.001 <0.001 
Table 107 Changes in time varying estimates at end of HUT 
  
  
3
6
3
 
 
 
 
No PPH – 
placebo (n=13) 
No PPH – 
glucose (n=13) 
Wilcoxon 
Signed 
Ranks Test  
(p-values) 
PPH – placebo 
(n=11) 
PPH – glucose 
(n=12) 
Wilcoxon 
Signed 
Ranks Test  
(p-values) 
Mann Whitney U 
Test (p-value) 
% of 
Mean 
SD % of 
Mean 
SD % of 
Mean 
SD % of 
Mean 
SD Placebo Glucose 
Change in combined CBFV 
(cm/s) 
-7.4 5.9 -5.5 4.3 <0.001 6.8 10.4 -74.8 4.2 <0.001 <0.001 <0.001 
Change in SD time sample -26.5 24.7 -23.5 19.2 0.199 -22.9 21.6 242.9 45.5 <0.001 0.424 <0.001 
Change in MAP (mmHg) 1.6 5.6 1.5 5.1 0.121 6.7 3.8 0.4 4.4 <0.001 <0.001 0.495 
Change in SD time sample 17.7 35.0 13.6 28.2 0.001 -7.2 13.9 -16.8 13 0.065 <0.001 <0.001 
Change in tCO2 (mmHg) -2.4 5.2 -2.4 4.8 0.039 2.4 12.5 25 15.5 <0.001 <0.001 <0.001 
Change in SD time sample -2.3 6.3 -2 6.5 0.050 12.7 24.3 -37.6 18.3 <0.001 <0.001 <0.001 
Change in combined ARI  -1.4 61.3 1.6 65.2 0.100 9.2 39.2 28.4 10.6 0.854 0.046 0.001 
Change in SD time sample -9.9 15.0 -10.6 16.6 0.089 -10.5 30 -29.6 20.8 0.831 0.397 <0.001 
Change in Heart Rate 
(bpm) 
3.3 2.8 3.6 3.1 <0.001 0.8 4.1 6.5 6.5 0.003 <0.001 <0.001 
Change in SD time sample -146.4 43.2 -57.7 9.5 <0.001 9.9 51.2 110.9 143 0.002 <0.001 <0.001 
Table 108 Percentage change from pre-HUT at 1 minute of HUT (-% = negative percentage change from pre-HUT) 
  
  
3
6
4
 
 
 
 
No PPH – 
placebo (n=13) 
No PPH – 
glucose (n=13) 
Wilcoxon 
Signed 
Ranks Test  
(p-values) 
PPH – placebo 
(n=11) 
PPH – glucose 
(n=12) 
Wilcoxon 
Signed 
Ranks Test  
(p-values) 
Mann Whitney U 
Test (p-value) 
% of 
Mean 
SD % of 
Mean 
SD % of 
Mean 
SD % of 
Mean 
SD Placebo Glucose 
Change in combined CBFV 
(cm/s) 
7.7 8.1 -2.6 5.6 <0.001 14.6 12.1 -12.4 2.6 <0.001 <0.001 <0.001 
Change in SD time sample 29.6 53.5 -13.7 16.8 <0.001 -28.5 19.6 7.5 15.0 <0.001 <0.001 <0.001 
Change in MAP (mmHg) -4.8 4.1 5.7 6.5 <0.001 2.5 4.7 3.6 4.3 0.140 <0.001 0.075 
Change in SD time sample -0.9 22.3 7.0 32.1 0.036 -1.7 11.9 -38.8 12.0 <0.001 0.777 <0.001 
Change in tCO2 (mmHg) 6.0 20.1 0.5 6.1 0.022 13.2 13.7 8.9 6.9 0.001 0.024 <0.001 
Change in SD time sample -1.6 14.6 1.8 7.5 <0.001 0.2 18.4 -0.2 11.4 <0.001 0.146 0.719 
Change in combined ARI  2.3 50.2 6.4 43.5 0.088 23.4 37.2 69.2 15.5 <0.001 <0.001 <0.001 
Change in SD time sample -12.5 28.8 6.1 16.8 <0.001 5.5 23.1 -52.3 3.9 <0.001 <0.001 <0.001 
Change in Heart Rate 
(bpm) 
-1.5 4.8 4.4 3.7 <0.001 -0.6 5.0 9.3 4.7 <0.001 0.208 <0.001 
Change in SD time sample 3.2 31.7 -53.8 13.4 <0.001 4.3 67.8 124.5 100.6 <0.001 0.069 <0.001 
Table 109 Percentage change from pre-HUT at 2 minute of HUT  
  
3
6
5
 
 
 
 
No PPH – 
placebo (n=13) 
No PPH – 
glucose (n=13) 
Wilcoxon 
Signed 
Ranks Test  
(p-values) 
PPH – placebo 
(n=11) 
PPH – glucose 
(n=12) 
Wilcoxon 
Signed 
Ranks Test  
(p-values) 
Mann Whitney U 
Test (p-value) 
% of 
Mean 
SD % of 
Mean 
SD % of 
Mean 
SD % of 
Mean 
SD Placebo Glucose 
Change in combined CBFV 
(cm/s) 
6.0 5.5 -13.8 16.5 <0.001 4.0 7.2 -4.3 3.9 <0.001 0.001 <0.001 
Change in SD time sample 110.6 61.6 9.9 16.8 <0.001 -21.2 42.2 -31.6 14.9 0.012 <0.001 <0.001 
Change in MAP (mmHg) 1.5 5.3 -1.3 2.7 0.001 18 5.7 15.2 10.8 0.006 <0.001 <0.001 
Change in SD time sample -2.4 20.7 -1.6 25.4 0.120 -6.1 14.4 18.3 29.7 <0.001 0.068 <0.001 
Change in tCO2 (mmHg) 171.9 22.7 129.1 21.9 <0.001 58.9 15.6 15.4 6.0 <0.001 <0.001 <0.001 
Change in SD time sample -61.7 3.9 -31.3 12.2 <0.001 35.4 34.1 35.7 35.9 0.956 <0.001 <0.001 
Change in combined ARI  -29.0 9.2 -8.2 32.2 0.254 6.6 31.5 8.4 18.2 0.271 <0.001 <0.001 
Change in SD time sample 12.8 7.3 25 14.2 <0.001 9.7 18.8 19.5 22.2 <0.001 <0.001 <0.001 
Change in Heart Rate 
(bpm) 
-15.8 2.1 1.9 6.2 <0.001 -3.8 3.4 2.1 4.0 <0.001 0.067 <0.001 
Change in SD time sample 332.0 78.7 -82.1 33.8 <0.001 79.6 43.0 145.3 77.7 <0.001 0.158 <0.001 
Table 110 Percentage change from pre-HUT at end of HUT
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